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Abstract:  
“High density CHO cell cultures; improved productivity and product 
quality”-Karen Byrne 
Continual growth in the biopharmaceutical industry in recombinant protein production has 
resulted in an ever increasing demand for optimised production processes, particularly in the 
area of upstream mammalian cell culture bioprocessing. The inefficient energy demands of 
mammalian cells in culture persists as a limiting factor for optimisation of cell culture 
processes. The Process Analytical Technology (PAT) framework initiative, put forward by 
the FDA in 2001, outlines measures for the strict monitoring and control of critical process 
parameters (CPP-s) affecting cell growth, productivity and product quality. The identification 
of CPP-s affecting protein quality (namely glycosylation and/or aggregation) has never been 
more important in seeking recombinant protein drug approval. A project was designed aimed 
at addressing the issue of CPP identification in high density CHO cell cultures producing the 
recombinant protein IgG1. Initial studies identified the importance of L-glutamine for cell 
growth and productivity, but also for increased complexity of the glycoform on the IgG1 
protein. This was identified by comparing cultures containing 4 mM L-Glutamine to cultures 
containing 0 and 4 mM L-glutamate. Interestingly this study also identified that the impact of 
the by-product ammonia on recombinant protein quality may be over-estimated by 
investigating such effects through the incorporation of high initial ammonia concentrations 
(~15 mM). In addressing the title of the project, encapsulation as a mode of cultivation for 
suspension adapted mammalian cells was also investigated, with significantly increased 
yields in cell (3.7-fold) and product titres being achieved for batch encapsulated cultures in 
comparison to suspension cultures. Research to date has failed to identify if encapsulation 
may have implications on protein quality. Initial studies identified that the quality of the 
protein harvested at the end of the stationary growth period in both batch and suspension 
cultures was relatively similar. In order to further increase the maximum cell yields and 
product titres obtained in an encapsulated culture, a control-fed perfusion strategy was 
designed and applied to the encapsulated cells. Further increased cell yields, 10-fold higher 
than that which was achieved in a suspension batch cultures were noted. The volumetric titre 
of recombinant protein in the control-fed perfusion cultures was determined to be ~2.65- fold 
higher than that achieved in the batch encapsulated cultures. The rIgG1 had a higher degree 
of complexity at the end of the extended growth period in the control-fed perfusion culture in 
comparison to batch encapsulated cultures. The importance of monitoring cell viability and 
optimising the rate of perfusion was noted by the occurrence of a decrease in glycan 
complexity, associated with the accumulation of dead cells and glycosidase release. 
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Chapter 1: Thesis Introduction: High Density CHO Cell Cultures: Improved 
Productivity and Product Quality; A Literature Review 
 
Abbreviations: 
ADCC     antibody-dependant cell cytotoxicity  
APA     alginate-poly-L-lysine-alginate 
Asn      aspargine 
BHK      baby hamster kidney 
CHO      Chinese hamster ovary 
CMP-NANA     Cytidine-5′-monophospho-N-acetylneuraminica 
CO2      carbon dioxide 
CPP      critical process parameter 
CQA      critical quality attribute 
Cys      Cysteine 
DNA      deoxyribonucleic acid 
DHFR     di-hydrofolate reductase 
DO      dissolved oxygen 
Dol-P      dolichol phosphate  
Dol-P-Glc     dolichol phosphate glucose 
Dol-P-Man     dolichol phosphate-mannose 
DOT      dissolved oxygen tension 
ER      endoplasmic reticulum 
EPO      erythropoietin 
FDA      Food and Drug Authority 
FSH      follicle stimulating hormone 
FPP      farnesyl pyrophosphate 
GA      golgi apparatus 
GalNAc     N-acetlygalactosamine  
GDP-Man     Guanosine DiPhosphate mannose 
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GFAT      glutamine;fructose-6-P amidotransferase 
GlcNAc-PP-Dol     N-acetlyglucosamine-phosphate 
GlcNAc-1-phosphotransferase  N-acetlyglucosamine-1-phosphotransferase 
Gluc I      α-1,2 glucosidase I 
Gluc II      α-1,3 glucosidase II  
GnT      N-acetylglucosaminyl transferases 
GP2      Glycoprotein 2 
GS      glutamine synthase 
HEK      human embryo kidney 
IgG1      Immunoglobulin G1 
IFN-β      interferon-β 
IR     Infrared spectroscopy 
IPP      isopentenyl pyrophosphate 
LH      LH series 210 
Man I      mannosidase I 
Man II     mannosidase II  
NADH     nicotinamide adenine dinucleotide 
NANA     N-acetyl-neuraminic acid 
NBS      New Brunswick Scientific  
NaOH      sodium hydroxide 
NGNA     N-glycolyl-neuraminic acid  
Poly-P-P     polyprenyl pyrophosphate 
O2      oxygen 
OST      oligosaccharyl transferase 
OTR      oxygen transfer rate 
OUR      oxygen uptake rate 
SASA      solvent accessible surface 
TNF-α     tumor necrosis factor alpha  
t-PA      tissue plasminogen activator 
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TGN      trans golgi network 
UDP-Gal     uridine di-phospahte galactose 
UDP-GlcNAc    uridine di-phosphate-N-acetlyglycosamine  
UDP-GNAc     uridine di-phosphate N-acetlyhexosamine 
UTP      uridine tri-phosphate  
 
1.1: Emergence of mammalian cells for recombinant protein production 
Biopharmaceutical products have been described as clinical reagents, vaccines, and 
drugs produced using modern biotechnology for in vivo diagnostic, preventive and 
therapeutic uses (Zhu, 2012). The first biopharmaceutical for medical use, insulin (humulin), 
was produced and approved in 1982. Since then the biopharmaceutical industry has matured 
rapidly (Walsh, 2010). Recombinant deoxyribonucleic acid (DNA) and hybridoma 
technologies are extensively employed to engineer biological systems to produce various 
classes of proteins including: 1) recombinant forms of natural proteins (e.g. human growth 
hormones), 2) derivatives of natural proteins and living systems (e.g. viral like vaccines and 
IgG fusion proteins, 3) viral vectors and plasmid vectors which act as carriers for vaccination 
or gene therapy, 4) in-vivo diagnostic and therapeutic monoclonal antibodies. Since the 
approval of humulin, it has been reported that the Food and Drug Authority (FDA) have 
approved more than 100 new recombinant protein therapeutics and more than 300 non 
recombinant biopharmaceuticals (Zhu, 2012).  
A wide array of biological systems for the production of the above pharmaceuticals exists 
including, microbial cells, insect cells and transgenic animals and plants. However 
mammalian cells exist as the host cells of choice for the commercial production of 
therapeutic proteins (Kim et al., 2012). According to FDA information, among the 27 latest 
approved biopharmaceuticals approved (January 08-June 11), 18 are recombinant proteins 
using cells, organisms or animals. Of the 18 recombinant proteins approved, 12 are produced 
in mammalian expression systems.  It has been estimated that two third of the revenue 
generated in the biopharmaceutical industry comes from products manufactured using 
mammalian systems (Zhu et al., 2012). 
Mammalian cells possess the cellular organelles and enzymes required for performing the 
post translational modification necessary for production of proteins in an active form. 
Pharmaceutical proteins do not consist of a polypeptide chain only. During protein 
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biosynthesis they usually undergo a series of co- and posttranslational modifications. 
Carbohydrate groups are covalently attached to the polypeptide backbone. Glycosylation, 
which involves the introduction of carbohydrate chains to proteins, is desired from a 
regulatory point of view (Nahrgang, 2002). A protein molecule is often defined in terms of its 
carbohydrate structures. Such post translational modifications were not previously possible 
when microbial cells were used as expression vectors. Microbial cells do not also display the 
capabilities to produce high molecular weight proteins but rather small proteins (Vives et al., 
2003; Sakai et al., 2002). 
Stably transfected mammalian cells were first generated by non-viral gene delivery in the 
early 1980’s. The first therapeutic protein produced from a recombinant mammalian cell line 
to gain market approval was human tissue plasminogen activator (t-PA) (tPA, Activase; 
Genentech, S. San Francisco, CA, USA) (Kim et al., 2012). The expression system for this 
therapeutic was a Chinese hamster ovary (CHO) cell line derived from partial inbred female 
Chinese hamster (De Jesus and Wurum, 2011). Since then there has been a marked increase 
in the use of mammalian cells for the production of recombinant therapeutic proteins. Among 
the capable mammalian cells used, those documented as being of commercial importance 
include baby hamster kidney (BHK), mouse myeloma-derived NS0, human embryonic 
kidney (HEK)-293 and the human retina-derived PerC6 (Kim et al., 2012; Chon and Zarbis-
Papastoitsis, 2011; Wurum, 2004; Barnes et al., 2003). It is however estimated that nearly 70 
% of all recombinant therapeutic proteins produced today use CHO cell expression systems 
(Kim et al., 2012). 
CHO cells are deemed the optimal mammalian cell line of choice for the production of new 
recombinant therapeutic proteins due to a number of desirable qualities: 1) CHO cell lines 
have been used as expression systems for the production of approved therapeutic recombinant 
proteins over the past 2 decades establishing them as safe hosts. Their safe host status makes 
them an attractive choice of expression system due to the associated ease of regulatory 
approval for new therapeutic proteins produced in these cell lines. 2) Mammalian cells, 
including CHO cells, have traditionally been associated with low specific productivity of 
recombinant proteins. Reliable and efficient gene amplification systems, including 
dihydrofolate reductase (DHFR)-mediated and glutamine synthase (GS)-mediated systems 
for CHO derived cell lines have overcome this drawback. 3) Mammalian cells in general are 
an attractive expression system due to their ability to perform post-translational modifications 
for production of proteins in a stable and active form. CHO cells in particular have the 
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capacity to efficiently produce recombinant proteins with glycoforms that are both 
compatible with and bioactive in humans. CHO cells possess genes for 99 % of the human 
glycosylating enzymes. It has been determined that 141 of these genes are not active during 
typical exponential growth (Butler and Meneses-Acosta 2012). However the glycoproteins 
produced by this cell line are deemed to be sufficiently similar to human forms. 4) CHO 
derived cell lines have been successfully adapted for growth in regulatory-friendly serum-free 
suspension cultures. Their ability to grow in suspension makes them the preferred candidate 
for large-scale culture in bioreactors (Kim et al, 2012; Butler and Meneses-Acosta 2012). 
Since the emergence of the biopharmaceutical industry and CHO cells as expression hosts, a 
vast amount of research has gone into optimising growth and recombinant protein production 
of these cells in culture. With reported increases in the biopharmaceutical market of 35 % 
since 2001, the popularity of CHO cells as the host of choice for commercial production of 
therapeutic proteins is likely to continue (Kim et al., 2012). Optimisation of recombinant 
protein yields using a mammalian cell line, such as CHO, may be achieved through a variety 
of host cell engineering strategies (Hammond et al., 2012). Both the manipulation of single 
genes and clonal selection for desirable traits have proven to be successful applications in the 
progression towards product titre optimisation using CHO cell lines (Xu et al., 2011).  Up 
until recently the genome sequence of CHO cell lines has been unavailable as a necessary 
tool for the application of genome-scale techniques for the generation of hyper productive 
cell lines. As of December 2011, the CHO genome database contains information of the 
ancestral CHO-K1 genome (Xu et al., 2011) and is accessible at http://www.chogenome.org. 
The availability of the CHO genome sequence represents another “tool in the bioprocessing 
toolbox” facilitating the 1) the design of targeted genetic manipulations 2) aid the revelation 
of components of poorly characterised phenotypes and 3) allow for a more thorough 
utilisation of ‘omic tools for CHO cell lines (Xu et al., 2011). The publication by Xu et al., 
2011 has demonstrated how the availability of the CHO genome allows for insights into 
protein glycosylation capabilities and viral susceptibility of the CHO-K1 cell line. The CHO 
genome database has accommodated a movement of the CHO community (both academic 
and industrial) into the genome era facilitating the rapid output of information expected to 
emerge from efforts in the research community to sequence individual CHO cell lines 
(Hammond et al., 2012).  
Alternative to or in combination with the manipulation of host cell genome for improved 
recombinant protein expression, manipulation and optimisation of upstream cell culture 
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conditions has also proven successful. Over the past 2 decades, a more than 100-fold yield 
improvement of titres in CHO cell culture has been largely attributed to the development of 
upstream cell culturing techniques (Jain and Kumar, 2008). Any parameter which affects the 
behaviour of mammalian cells at the upstream level may be termed a critical process 
parameter (CPP). The behaviour of cells covers all cellular activities including cell growth, 
metabolism, recombinant protein productivity and recombinant protein quality. The CPP’s 
affecting the cell growth and recombinant protein yields at the upstream level include 
temperature, pH, dissolved gases (oxygen (O2) and carbon dioxide (CO2)), medium 
osmolality and composition, feeding strategy employed etc. All of such parameters have been 
extensively investigated and their implications on cell growth and productivity reviewed 
(Section 1.2).  
 
1.2 Factors effecting high cell density growth and high productivity of cells 
 
1.2.1 Temperature 
Early studies investigating the effects of temperature on CHO cell growth and 
productivity were primarily concerned with optimising the maximum specific growth rate of 
the cells in culture. Kurano et al. (1990) conducted studies assessing the effects culture 
temperature may have on the specific growth rate of CHO cells. The optimum temperature 
for growth was documented as being 37 °C. Although the main focus of the study was to 
demonstrate an optimum temperature for cellular growth, such an initial study did give some 
indication that the cells did not display maximum specific productivity rates at this optimum 
growth temperature.  
Subsequent studies therefore focussed on the effect culture temperature may have on a range 
of cellular characteristics such as the growth, viability and the specific productivity of the 
cells. Furukawa and Ohsuye (1997) conducted studies, involving the cultivation of a CHO 
cell line at temperatures of 30, 32, 33.5, 35, 36 and 37 °C. As previously demonstrated 
maximum cell growth occurred at high temperatures such as 36 and 37 °C. It was however 
demonstrated that maximum productivity occurred at 32 °C. Similar research however, 
carried out on different mammalian cell lines, did not indicate the same beneficial effects of 
low temperature cultivation regarding the productivity of cells in culture. Wiedemann et al. 
(1994) demonstrated that low culture temperature had no effect on the productivity of 
recombinant BHK cells producing antithrombin III.  
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This study and similar studies have led to the development of a “biphasic process” with 
“temperature shift optimisation” as demonstrated by Fox et al. (2003). During a biphasic 
process cells are typically cultured at 37 °C for a period of time. During this time high growth 
rates are demonstrated thus yielding high cell numbers capable of producing the recombinant 
protein. After high cell numbers have been achieved, the cultivation temperature is shifted to 
a lower temperature, 30-32 °C, thus inducing maximum specific productivity in the cells. 
Furukawa and Ohsuye (1999) demonstrated the beneficial effects of biphasic cultivation by 
shifting culture temperature from 37 °C to 32 °C during mid-exponential phase of growth. 
Recombinant protein production by the cells improved by 1.7-fold and 2-fold in comparison 
to the results obtained when the culture temperatures were remained at 32 °C and 37 °C, 
respectively, for the duration of the culture period. 
The focus of subsequent studies, moving forward from research published by Furukawa et al. 
(1997 & 1999), has been to determine an optimum time frame for which to shift the 
temperature. Such studies have been completed by Fox et al. (2003), which focused on 
predicting a model for an optimum time to shift the culture temperature in order to maximise 
the production of the recombinant protein IFN-γ. It was demonstrated that shifting the culture 
temperature from 37 °C to 32 °C after 3 days, an increase in volumetric productivity of 40 % 
and 90 % was achieved compared to when the cells were cultured at 32 °C and 37 °C, 
respectively, for the entire cultivation period. It was noted that the vast majority of the 
recombinant protein was produced during the second half of the culture when the cell density 
was highest as expected. 
 Fox et al. (2003) have however demonstrated that this biphasic model for optimisation of 
productivity in CHO cells does seem to be cell line specific and that some cell lines, such as 
those demonstrated by Wiedemann et al. (1994) demonstrate no increase in productivity at 
lower culture temperatures, 30-32 °C. There has therefore been an interest portrayed in the 
adaption of CHO cell lines to hypothermic growth so as that the culture may be maintained at 
low cultivation temperatures for the entire cultivation process. Mammalian cells have showed 
an ability to improve their growth when subjected to changing environmental conditions. 
Yoon et al. (2006) established a study which would exploit this characteristic and alleviate 
growth suppression of CHO cells at low culture temperatures. The adaptation of two CHO 
cell lines to growth and productivity at 32° C was investigated. After adaptation of the two 
cell lines to low temperature growth the specific growth rates of the cell lines were increased 
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by 7 3% and 20 % respectively. However the specific productivities were decreased by 49 % 
and 22 % respectively. 
Sunley et al. (2005) have conducted studies investigating the effects of a combination of cell 
adaptation as well as biphasic cultivation on cell growth rates and productivity. Cells adapted 
to hypothermic growth were grown under low temperature conditions in batch mode for 10 
days and demonstrated enhanced growth rates yielding a 6-fold increase in cell numbers 
compared to non-adapted cells grown under similar culture conditions. When adapted cells 
were subjected to biphasic cultivation a 4-fold increase in cell number was demonstrated by 
the adapted cells compared to the non-adapted cells. Adapted cultures produced a 2.6-fold 
increase and a 3-fold increase in specific productivities when grown in batch cultures and 
biphasic cultures respectively in comparison to non-adapted cultures. 
A biphasic mode of operation allows for the generation of high cell numbers in the culture. 
Once high cell numbers are achieved it allows for the conditions to be shifted to provide an 
environment which allows the cells to exhibit maximum specific production rates resulting in 
a high concentration of recombinant protein product at the end of the culture period. 
 
1.2.2 pH 
Another important environmental factor which influences the behaviour of CHO cells 
in culture is the pH of the environment in which they are growing in. Early studies conducted 
by Kurano et al. (1990) investigated the effect of pH on cell proliferation and concluded that 
cellular growth may occur between a pH range of 7.0 to 7.9 with maximum growth occurring 
at pH 7.6. No focus however was given in this early study as to determining an optimum pH 
at which cellular productivity is at a maximum. It was determined by Trummer et al., (2006), 
that the optimum pH for growth of the cell line was 7.10. In terms of productivity, the 
specific production rate remained unchanged at different pH levels. However the maximum 
amount of product produced by the cell line occurred at pH 6.8 where the maximum 
concentration of the product produced was 1.8-fold higher than that at 7.1. This is due to the 
fact that increased cultivation time was observed at pH 6.8. Again it may be noted that the 
optimum pH for achieving high cell numbers is somewhat different to the optimum pH for 
product production. Similar results were noted from studies completed by Yoon et al. (2004). 
It was noted from such studies that a pH shift may also be incorporated into biphasic 
cultivations illustrating temperature shift optimisation. The implication of shifting the 
temperature to 33 °C and the pH to 6.9 after 3 days of culturing the cells at standard 
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conditions resulted in achieving the highest maximum viable cell concentration. These results 
were put forward in comparison to controls in which the temperature and pH remained at 
standard levels, as well as other cultures in which temperature was decreased and pH was 
increased. 
It does appear that pH only effects CHO cell growth and productivity when the temperature 
of the culture is varied. It is therefore possible to suggest that optimum CHO cell growth 
occurs at pH levels varying around neutral and that culture temperature effects optimum 
growth and productivity of the cells to a greater extent (Borys et al., 1993). 
 
1.2.3 Osmolality and concentration of dissolved carbon dioxide 
Carbon dioxide may be described as a waste product produced by actively respiring 
cells in culture due to catabolic reactions. For every 1 mole of oxygen consumed, 
approximately 1 mole of carbon dioxide is released into the medium (Kimura & Miller, 
1996). Carbon dioxide is also required to some extent by actively growing cells for the 
synthesis of pyrimidines, purines and fatty acids by the cells. As carbon dioxide is released 
by the cells it becomes dissolved in the culture media and causes a decrease in the pH of the 
culture media due to the following reaction. 
 
 CO2 + H2O H2CO3 H
+
 + HCO3
-
 (1.2.3.1) 
 
The adverse effects of decreased pH on cell growth and productivity have been noted above. 
If however the pH is controlled by the addition of base, such as sodium hydroxide (NaOH) a 
subsequent increase in osmolality often occurs (deZengoitia et al., 1998). A physiological 
range between 31-54mm Hg of dissolved carbon dioxide is acceptable for maintaining the pH 
of the medium at an appropriate level and thus the necessity for increasing the osmolality of 
the medium due to NaOH addition is avoided (deZengoitia et al., 1998). Various studies have 
as such been carried out investigating the detrimental effects increased concentrations of 
dissolved carbon dioxide and increased osmolality may have on cultured CHO cells. It must 
be noted that cell culture medium is typically designed to have an osmolality between 260-
320 mOsm/kg (Ozturk and Palsson, 1991). 
deZengotita et al., (1998) have conducted studies which investigated the effects of various 
combinations of dissolved carbon dioxide levels and varying levels of osmolality on the 
growth rate of hybridoma cells producing monoclonal antibodies. The studies indicated that 
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higher dissolved carbon dioxide levels were associated with inhibition of cell growth and the 
onset of cell death. Such results were much more severe when there was no compensation 
made to the osmolality of the original media for increases in osmolality due to pH 
adjustments. Studies completed investigating the effects of osmolality alone with controlled 
dissolved carbon dioxide levels demonstrated a decrease in the growth rate of the cells by 
86% in comparison to the growth rate observed for cells cultured in medium at an osmolality 
of 342 mOsm/kg. Kimura and Miller (1996) however demonstrated that increased osmolality 
had an insignificant effect on the growth rate of CHO cells in the presence of controlled 
dissolved carbon dioxide levels. 
The study conducted by deZengotita et al. (1998) also indicated that the specific productivity 
of the cells was not in actual fact affected by elevated dissolved carbon dioxide or osmolality 
levels. One interesting observation made was the tendency towards higher specific 
productivity rates by the cells at elevated osmolality levels when the carbon dioxide level 
remained at 36 mm Hg. Kimura and Miller (1996) demonstrated that when the osmolality 
was permitted to change as the dissolved carbon dioxide level increased, the specific 
productivity remained the same or even increased for dissolved carbon dioxide levels of 195 
and 250 mm Hg. 
The general acceptance is that increased levels of osmolality do lead to increases in the 
specific productivity of the cells. However more recently Zhu et al. (2005) have documented 
that the increased rate of productivity of the cells at higher osmolality levels does not lead to 
an increase in the concentration of the product produced. This is due to the suppressed growth 
levels demonstrated by cells under conditions of high osmolality. The reduced specific 
growth rate of the cells at higher osmolalities has lead to a reduction in the total number of 
viable cells producing the recombinant protein product. Subsequently when the specific 
productivity was seen to increase at higher osmolalities, no changes were evident in the 
concentration of product produced. 
 
1.2.4 Concentration of dissolved oxygen 
As with all other environmental cultural conditions, the concentration of dissolved 
oxygen (DO) in a cell culture medium has been demonstrated to be essential for optimising 
cell growth and productivity. Trummer et al. (2006) conducted studies investigating the 
effects of DO concentrations ranging from 10-100 % air saturation. It was noted that growth 
and viability were not broadly affected by the varying DO levels in the media and that the 
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specific rate of productivity of the cells also remained fairly constant within such a range. 
However it was noted that the viable cell density of the cells was reduced at lower DO 
concentrations such as 10 % due to the limited amount of oxygen available in the medium for 
growth and metabolism. Other studies have also demonstrated that when the DO 
concentration of a culture medium drops to zero, cellular growth ceases (Shi et al., 1993). 
The reduced viable cell concentration would result in the generation of a lower concentration 
of the recombinant protein due to the reduced numbers of cells producing the recombinant 
protein. 
The % DO is determined by the efficiency at which oxygen may be transferred from the 
surrounding environment into the culture medium. All culture environments are aerated either 
through the contact of the surface of the medium with air, or through the sparging of the 
culture medium with bubbles containing air. The rate at which oxygen is transferred from the 
gaseous phase into the liquid medium is termed the oxygen transfer rate (OTR) and is 
denoted by the following equation: 
       (1.2.4.1) 
 is the rate of oxygen transfer per unit volume of fluid,  is the liquid-phase phase mass 
transfer coefficient,  is the gas-liquid interfacial area per unit volume of fluid,  is the 
concentration of oxygen in the broth and  is the oxygen concentration in the broth in 
equilibrium with the gas phase. It is the difference between  which acts as the 
driving force in order for oxygen to dissolve in the media (Doran, 1995). 
As noted from the equation above, the volumetric mass transfer coefficient is of great 
importance in determining the OTR. This coefficient may be influenced by some of the 
parameters which have previously been demonstrated in this review to affect the productivity 
of cells in a culture medium. Such parameters include the temperature of the medium, the 
osmolality of the medium, medium composition and cell numbers present. Analysis of the 
above equation does indicate that the gas-liquid interfacial area is an important factor in 
determining the volumetric mass transfer coefficient. It is desirable that the method of 
aeration used to increase the DO concentration in the culture medium maximises the 
interfacial area in order to maximise the OTR. As indicated previously, many culture 
mediums are aerated by spargers. Different types of spargers may be employed to produce 
different sized air bubbles which are as such broken up by the impeller and dispersed 
throughout the culture medium. The formation of small bubbles is desirable as they have 
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been noted to increase the interfacial area (Doran, 1995). Micron-sized bubbles have been 
demonstrated to induce a 10-20 fold increase in the OTR in comparison to larger bubbles up 
to 5mm in diameter (Zhang et al., 1992). 
The OTR is also influenced by media components as they may affect the way in which 
bubbles behave in a culture medium. When small bubbles collide they may join 
together/coalesce to form larger bubbles, thus decreasing the interfacial area and the overall 
volumetric mass transfer coefficient. The inclusion of salt in culture media has been noted to 
prevent bubbles from coalescing (Doran, 1995). Oxygen transfer coefficients have been noted 
to be higher in 0.8 M salt solutions as oppose to just water alone (Zhang et al., 1992). The 
OTR however has been noted to decrease with increasing medium complexity. Antifoam may 
be incorporated into cell culture media in order to reduce the build up of foam in culture 
systems. Foam may be caused under agitation by the presence of proteins, polysaccharides 
and fatty acids in the culture medium. Antifoaming agents have been noted to reduce the 
surface tension of the bubbles, thus reducing the bubbles size and increasing the interfacial 
area. This principle however has not always lead to increases in the oxygen transfer rate as 
antifoam also reduces the mobility of the bubbles which subsequently reduces the mass 
transfer coefficient (Doran, 1995). 
Temperature affects both the volumetric mass transfer coefficient and also the solubility of 
oxygen in the culture medium. Increasing the temperature has been noted to decrease the 
mass transfer driving force, , which in turn decreases the OTR. However 
increased temperature has been demonstrated to increase the diffusivity of oxygen in the 
liquid film surrounding the bubble and thus increasing . There is therefore a variable effect 
of the two on the OTR depending on the temperature (Doran, 1995). The OTR in water has 
been demonstrated to remain constant over a varying temperature ranges due to the different 
effects different temperatures may have on decreasing the mass transfer driving force and 
increasing the volumetric mass transfer coefficient (Vogelaar et al., 2000). In regards to 
culture media, in general a temperature of 10-40 °C increases the OTR, whereas above 40°C 
the solubility of oxygen is affected decreasing the driving force for oxygen transfer. The 
presence of cells in the culture medium also influences the OTR by a process referred to as 
interfacial blanketing. Cells may adsorb at gas-liquid interfaces which reduces the area 
available for contact between the gas and the liquid (Doran, 1995). 
 In order for the cells to avoid a situation in which their growth may be affected by a limited 
supply of oxygen as demonstrated by Trummer et al. (2006), it is necessary to ensure that the 
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rate at which oxygen is utilised by the cells is equal to or less than the OTR. The rate at 
which oxygen is utilised by the cells is referred to as the oxygen uptake rate (OUR) (Doran, 
1995). Although animal cells have been noted to have a lower specific OUR than that noted 
by microbial cells in culture, the oxygen demand of mammalian cells in culture has been 
illustrated to increase understandably when the cell concentration increases and also when the 
culture scale increases (Zhang et al., 1992). The OUR is therefore determined by the specific 
oxygen uptake rate of the cells as well as the number of cells present in the culture.  This 
statement may be summarised by the following equation: 
  xqQ oO        (1.2.4.2)
 
Culture states may be defined in terms of the level of dissolved oxygen, or % air saturation, 
which has been transferred into the culture medium. Due to the fact that the OTR must be 
greater than the OUR, a critical level of oxygen must be contained within the culture medium 
at all times, which is referred to as critC . If the oxygen concentration in the medium is below 
the level of critC , oxygen supply to the cells is limited and hypoxia/anoxia conditions exist. 
The desirable value for critC  depends on the particular type of organism being cultured; 
however it usually lies at a level of 5-10 % air saturation (Doran, 1995). Normal or normoxic 
conditions exist when 100% air saturation exists. It has been demonstrated that no differences 
exist in the OUR demonstrated by the cells when the DO level varies from 10-150 % air 
saturation (Jan et al., 1997). However it has also been demonstrated that the OUR becomes 
supply-dependent below critC  (Lin and Miller, 1992).  The OUR may also be sensitive to the 
type of substrate present as an energy source in the medium. Glucose is consumed more 
rapidly than other sugars or carbon energy sources and thus the OUR is higher when glucose 
is used. Supplementation of a culture medium with glutamine or a mixture of amino acids 
resulted in no increase in the OUR being demonstrated by the cells. However when the 
culture medium was supplemented with glucose or the cells were re-suspended in fresh 
culture medium, the OUR increased by 40 % (Jan et al., 1997). As expected the OUR has 
also been demonstrated to increase when the cells are engaging in maximal productivity. Link 
et al. (2004) demonstrated that the maximum specific rate of productivity was achieved by 
the cells at 40 % DO. The OUR was at a maximum at this particular point in comparison to 
when the DO concentration was 5, 60 or 95 % and specific productivity was not at a 
maximum. 
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1.2.5 Concentration of essential nutrients and metabolic by-products 
Animal cells require many essential nutrients for growth and survival in culture. Such 
nutrients include glucose, glutamine, essential amino acids, vitamins and serum components. 
The absence of one or more essential nutrient may result in cell death and therefore a 
decrease in the accumulation of the recombinant protein product (Xie and Wang, 2006). A 
basic medium for animal cell growth is Eagle’s minimal essential medium. However due to 
the fact that over 30 essential nutrients are necessary for cell survival, many experiments 
have been carried out in order to fortify this basic medium to ensure that all nutrients are of a 
sufficient concentration so as that no one nutrient is depleted, which may result in cell death 
(Xie and Wang, 1997). Most of the literature investigating optimisation of nutrient 
components in animal cell culture media has focussed on the depletion of glucose and 
glutamine from the culture medium. Glucose is often present in cell culture media as the 
carbon energy source and glutamine is present as the nitrogen source (Xie and Wang, 2006; 
Kurano et al., 1990). 
The concentration of glucose present in commercially available cell culture media ranges 
from 1-10 g/L (Sigma Aldrich, 2012). Of the commercially available cell culture media 
formulated for CHO cell growth in particular, the typical glucose concentration varies in the 
range of 3-5 g/L (Sigma Aldrich, 2013). When glucose concentrations are high, aerobic cells 
undergo glycolysis at higher rates than normal. Such an activity has been documented to 
result in the production of high levels of nicotinamide adenine dinucleotide (NADH) as well 
as the organic substrate pyruvate. The large amounts of NADH generated cannot be 
reoxidised and therefore the NADH may be utilised by the cells to drive the reduction of 
pyruvate to lactate in order to maintain homeostasis in the cell. The enzyme which catalyses 
this reaction is the lactate dehydrogenase enzyme (Matthews et al., 2000). The production of 
lactate from pyruvate may be summarised in Figure 1.2.5.1. 
Typical concentrations of L-GLN in mammalian cell cultures vary in the range of 1-7 mM, 
depending on cell type and line (Freshney, 1987; Hayter et al., 1991). The utilisation of L-
GLN involves both anabolic, located in the cytosol, and catabolic reactions (glutaminolysis), 
the latter of which occurs in the mitochondria (McKeehan, 1986). Anabolic metabolism is 
required for the generation of the building blocks for biomass and product formation, thus 
allowing L-GLN to serve as a protein constituent. Catabolism is mainly concerned with the 
generation of energy in the form of adenosine tri-phosphate (ATP) and is associated with the 
accumulation of ammonia in culture media (Vriezen et al., 1997). 
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The catabolism of L-GLN, summarised in Figure 1.2.5.1 below, initiates with the enzymatic 
removal of the amido group of L-GLN, yielding glutamate (L-GLU) and 1 mole of ammonia. 
This reaction is catalysed by the phosphate-dependent enzyme glutaminase. An alternative 
pathway for the amido group involves the purine and pyrimidine biosynthetic pathway in 
which it serves as an amino group donor for enzymes involved in such reactions. However, 
its catabolic fate lies in the production of α-ketogluterate through cleavage of the α-amino 
group catalyzed by two possible enzymes, glutamate dehydrogenase and aminotransferase. 
The action of glutamate dehydrogenase yields a second mole of ammonia. The resulting α-
ketogluterate subsequently enters the citric acid cycle, where it is completely oxidised to 
carbon dioxide or partly oxidised to aspartate via transamination of oxaloacetate. Other 
possible outputs from the citric acid cycle include alanine and lactate, through the 
transformation of malate to pyruvate, brought about by the action of malate dehydrogenase. 
The action of the aminotransferase enzyme results in the yield of aspartate or alanine mainly 
through the transfer of the amino group to an α-keto acid, such as pyruvate or oxaloacetate 
(Schneider et al., 1996). 
The theoretical yield of ammonia resulting from the catabolism of 1 mole of L-GLN is 2 
moles. However due to the alternative possible pathways for both the amido group and amino 
group described above, the actual yield is ammonia may be lower (Vriezen et al., 1997). It 
must also be considered that the fate of L-GLN nitrogen is dependent upon the cell line and 
concentration of other metabolites in the culture such as glucose and other amino acids. 
Mammalian cell lines are derived from different species and organs and so therefore differ in 
specific enzymatic and metabolic patterns, as reviewed by Schneider et al., (1996).  
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Figure 1.2.5.1: Overview of the metabolic fates of glucose and glutamine in mammalian 
cells, from Teixeira et al., (2005).  
The irreversible chemical degradation of L-GLN to form pyrrolidonecarboxylic acid in 
aqueous solutions, such as cell culture media, also results in the build up of ammonia in 
cultures. The reaction follows first order kinetics and is characterised as an intramolecular 
SN2 reaction in which the free electron pair of the α-amino nitrogen attacks the carbonyl 
carbon of the final amido group. After the formation of a tetraedric transition state, the amido 
nitrogen is released as ammonia with the formation of pyrrolidonecarboxylic acid. For every 
one mole of L-GLN degraded, one mole of ammonia is released. The reaction is dependent 
upon a number of factors including solution temperature, pH and other components in the 
solution (Schneider et al., 1996). 
In an effort to reduce the accumulation of ammonia in the culture media, a number of 
strategies have been employed. Schneider et al., (1995) reviewed methods to physically 
remove accumulated ammonia such as (1) the use of gas-permeable, hydrophobic porous 
membranes; (2) application of non-porous ion-exchange membranes; (3) use of ion-exchange 
resins; (4) electro dialysis. However the application of such methods is limited in that the 
materials are selective for ammonia removal only. More biological compatible approaches 
involve reducing the concentration of ammonia accumulated in the culture environment. This 
may be brought about by designing culture feed-strategies which allow for lower initial L-
GLN concentrations thus avoiding chemical breakdown of excess L-GLN present in cultures 
(Wong et al., 2005, Wang et al., 2002). More recently efforts have been made to establish 
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CHO cell lines which are able to grow in completely L-GLN free medium (Taschwer et al., 
2012).  
Various studies have documented the negative effects of ammonia and lactate on cell growth 
and productivity. These effects include an increase (ammonia) or a decrease (lactate) in the 
pH of the medium (Miller et al., 1987). Ammonia has been illustrated to permeate the cell 
wall and partition into cellular compartments, disrupting the internal pH which also has 
adverse effects on cellular growth and productivity (Bibila and Robinson, 1995). The 
accumulation of ammonia limits the growth and productivity enhancement possibilities of 
high L-GLN concentrations. Canning and Fields, (1983); Hansen and Emborg, (1994); Yang 
and Bulter, (2000) have all reported a negative effect of an ammonia concentration as low as 
2 mM on cell growth and recombinant protein production. High lactate concentrations, 
induced by the addition of 60 mM sodium lactate have been noted to inhibit growth in CHO 
cells by 25 % (Lao and Toth, 1997). At the end of the cultivation period in hybridoma 
cultures, the concentration of lactate was noted to be 63 mM which was thought to be 
associated with the onset of cell death (Zhang et al., 2004). 
 
1.2.6: Feeding strategy 
 Four major methods of cultivation of animal cells have been documented, depending 
on the methods of providing culture medium containing nutrients to the cells: batch, fed-
batch, continuous and perfusion (Xie and Wang, 2006). Batch cultivation of mammalian cells 
is considered one of the simplest modes of cultivation and is particularly effective when 
protein expression is growth associated (Gugerli, 2003). The persistent use of such a mode of 
cultivation is facilitated by the continuous development of high producing cell lines, 
developments in media formulations satisfying the metabolic demands of cells in culture, and 
also the ease of scalability (Bonham-Carter and Shevitz, 2011). Batch operations offer high 
flexibility, lower risk of contamination and more efficient process development and 
validation (Gugerli, 2003). One trait of mammalian cells in culture which is not satisfied by a 
batch mode of cultivation is the highly deregulated metabolism demonstrated by mammalian 
cells exposed to common culture conditions. When cells are extracted from animal tissue, 
where they are found in a highly controlled environment, and exposed to common culture 
conditions in bioreactors, they characteristically display consumption rates of the main 
carbon and energy sources, far above rates strictly required to give support to cell metabolism 
(Sanfeliu et al., 1997). The highly deregulated metabolism of the cells under such conditions, 
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results in rapid exhaustion of the culture medium, accumulation of toxic metabolic by-
products (namely lactate and ammonia), resulting in the consequent initiation of programmed 
cell death or apoptosis very shortly after the attainment of maximum cell number. As a result 
of low cell numbers achieved and the rapid onset of cell death, low product titres and poor 
volumetric productivity are normally achieved (Leelavatcharamas et al., 1999). Fed-batch 
processes have been described as the most common modes of cultivation utilised for 
recombinant protein production in mammalian cell cultures and have been operated up to 
20,000 L working volume, as reviewed by Chon and Zarbis-Papastoitsis, (2011). The fed-
batch strategy seeks to avoid early complete depletion of key media components, common to 
batch cultivation, by feeding highly concentrated nutrient feeds to the culture at set points. 
Two methods for the optimisation of the concentration of nutrients in the feed medium have 
been proposed and reviewed. The first method is described as an iterative method in which 
cultivation begins in a near optimal basal medium. Concentrated nutrient solutions are 
subsequently added to the culture according to the requirements of the growing cells. Such 
requirements are determined by analysing the spent medium and determining cellular kinetics 
of growth and metabolite consumption and production. The second method is characterised 
by the addition of concentrated nutrient feed of complete medium and/or standard amino acid 
and glucose and glutamine as supplementation feed (Jain and Kumar, 2008). Once the culture 
reaches a pre-determined criteria, (e.g. culture time, percent viability, nutrient or metabolite 
concentration etc), the culture is terminated and the broth is processed to purify the desired 
recombinant protein (Chon and Zarbis-Papastoitsis, 2011). One of the major advantages 
associated with fed-batch cultivation is the relatively high concentration of final product 
present in the media at the point of culture termination (Hu et al., 2011). Therefore the yield 
of product in the medium is higher than that which would be observed in continuous or 
perfusion cultures. Fed-batch processes have been optimised to maximise parameters such as 
viable cell density, culture time, specific productivity, which determine the final 
concentration of protein in the media (Bibila and Robinson, 1995). However, as with any 
mode of cultivation, there are disadvantages associated with this method. The high cost of 
concentrated media, the expertise required and intensive laborious nature of the process are 
notably some (Jain and Kumar, 2008). Results are not assured and even after intensive 
optimisation of the process, only little benefit has been seen. Feeding strategies involving the 
addition of nutrients (such as glucose and glutamine) in highly concentrated formulations 
incorporates the risk of excessive medium osmolality which may inhibit culture productivity. 
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The addition of high concentrations of glucose may induce a Crabtree effect resulting in a 
shift to fermentative metabolism of the cells, resulting in increased lactate yields, limiting cell 
growth and productivity due to premature stress on cells (Jain and Kumar, 2008). However 
one of the major causes for concern is the residence time of the recombinant protein in the 
culture environment increasing the risk of the protein being exposed to proteases and 
glycosidase enzymes (Gramer and Goochee, 1993).  
The problems associated with fed-batch modes of cultivation may be alleviated with the 
progression to a continuous or perfusion feeding strategy. The main advantages of 
continuous/perfusion modes of cultivation are that they can avoid nutrient limitation, while 
reducing the concentration of growth inhibitory metabolites (Yang et al., 2000 and 
Konstantinov et al., 1996). Product quality and purity may be enhanced, not only due to the 
reduced by-product concentration, but also as an effect of the continuous withdrawal of 
protein containing spent media form the culture environment, thus reducing the overall 
residence time of the protein in the culture environment in which it may be exposed to 
proteases and glycosidase enzymes. (Rastilho et al., 2002; Ryll et al., 2000). 
In a continuous culture fresh medium is continuously fed while the spent medium is removed, 
thus maintaining the cells in a relatively optimal biochemical environment (Chon and Zarbis-
Papastoitsis, 2011). The requirements of a continuous process have been outlined and include 
(1) the ability to reach a high cell density, (2) control of cell proliferation and (3) the 
prevention of apoptosis during the maintenance phase (Gugerli, 2003). 
Continuous cultures are regulated by two main parameters (1) the feed rate or perfusion rate 
and (2) the bleed rate, which has been described as the flow rate of the cell-containing stream 
outgoing the reactor. A continuous culture is governed by the following  equations: 
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where P is the perfusion rate, PF the cell free outgoing stream, BF  the cell-containing 
outgoing stream, V the reactor volume, BD  the bleed rate,  , the growth rate, tN  the total 
cell number, VN  the viable cell number and dk  the death rate (Gugerli, 2003). 
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Cell concentration typically increases constantly until it becomes limited by the high cell 
population density. The high cell density attained leads to high volumetric productivity. If 
high cell density is accompanied by low viability, the overall result in an accumulation of 
dead cells. Therefore the key process parameters specific to the continuous culture are the 
feed and bleed rate, as well as feed composition (Jain and Kumar, 2008). 
If BDP   the system is referred to as a conventional chemostat culture and is characterised 
by a growth rate which is equal to the dilution rate. The maximum cell concentration is 
subsequently governed by the following equation (Gugerli, 2003): 
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Continuous chemostat cultures have been documented to sustain steady state operations over 
extended periods of time (Birch et al., 1987; Frame and Hu, 1991). However one of the short 
comings of this proposed method is the relatively low cell concentrations attainable at steady-
state due to the necessary bleed rate (Vits and Hu, 1992). It is true that a bleed stream is 
necessary for not only removal of dead cells, but also to enable control of the culture and 
prevent overgrowth. However, continuous processes can only compete economically with 
batch cultures if a higher cell density and high protein concentrations can be reached. Cell 
concentration and volumetric productivity can be effectively increased by cell recycle or 
partial or complete cell retention Coupling a cell retention device to a continuous bioreactor, 
in what is frequently called a perfusion bioreactor, can lead to a 5-10 fold increase in cell 
concentration (Vits and Hu 1992). A diverse set of devices have been developed over the 
years which enable the retention of cells in bioreactors, while minimising damage to the cells. 
Devices may be based on the principle of filtration, sedimentation and/or centrifugation. 
Some of such devices work better than other and have been extensively reviewed by Gugerli, 
(2003), Chon and Zarbis-Papastoitsis, (2011), Bonham-Carter and Shevitx, (2011) and 
Voisard et al., (2003). 
In theory if cells are completely retained, no steady state should be reached and the cell 
concentration should go towards infinity. In practice, however, Gugerli, (2003) described 
how cells grow until one or several nutrients become limiting. This occurs when the nutrient 
feed rate is no more able to cope with the consumption rate required by the cells for either 
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growth or maintenance, resulting in the onset of apoptosis. A steady-state viable-cell 
concentration will be reached where the death rate equals the growth rate resulting in an 
accumulation of dead cells (Jain and Kumar, 2008). In the case where a constant perfusion 
rate is used and the bleed rate is 0, Gugerli, (2003) described the characteristic behaviours of 
cells, summarised as 4 distinct phases: (1) a first exponential growth phase due to excess 
nutrients (2) a second linear growth phase limited by the feed rate, (3) a decrease in growth 
due to insufficient nutrient feeding (4) slow cell death due to apoptosis. Therefore, once a 
suitable retention device has been proposed, the next issue is maintaining the high cell 
concentration over an extended period of time. In general it is understood that perfusion 
cultures usually approach steady state more rapidly than chemostat cultures without cell 
retention (Miller et al.,1988; Hiller et al., 1993) mainly because of much higher perfusion 
dilution rates due to greater cell concentrations. 
The main criteria for consideration in a perfusion culture with retention are therefore: 1) the 
time point at which the perfusion is initiated 2) The magnitude of the perfusion rate applied 
3) the extent to which the cells should be retained. Up until 2 decades ago, little information 
for the selection of such criteria was available (Vits and Hu 1992). Dowd et al., (2001) 
investigated the importance of perfusion initiation time on the success of a perfusion culture. 
It was found that when starting the perfusion at a time point when glucose was not limiting 
(8.5 mM), there was a 3-fold decline in cell specific productivity. It was assumed that even 
though glucose was not yet limiting, the culture was approaching a batch like stationary 
phase. When perfusion was initiated at an earlier time point (glucose concentration was ~ 14 
mM), the same drop off in the cell specific production rate was not observed. In regards to 
the rate of perfusion, it is now understood that the main method for operating a perfusion 
culture is to adjust the perfusion rate in order to maintain the concentration of both key 
nutrients and by-products at a level suitable for the particular cell line used (Wang et al., 
2002; Konstantinov et al., 1996; Goldman et al., 1998). 
Meuwly et al., (2004) have proposed 3 approaches for consideration, which seek to achieve 
optimal medium perfusion rate: 1) operation of the culture with a fixed perfusion rate during 
the entire culture production run. This enables the system to run in a robust and defined 
manner in regards to medium costs. 2) perfusion rate is adjusted in response to either cell 
number or key nutrient (glucose and glutamine) consumption. This method is difficult to 
operate for cases where cell bleeding is not possible (such as immobilisation) and therefore 
may possibly result in an overgrown, out of control culture. 3) the final method consists of a 
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combination of 1) and 2) in which the culture is divided into two phases. The first phase, 
termed the growth phase, in which the perfusion rate is adjusted with cell growth, is followed 
by a shift in some other parameter to slow cell growth and reduce metabolism.  According to 
a review by Bonham-Carter and Shevitz, (2011), it is due to these advances in manufacturing 
and perfusion culture operation that perfusion is the preferred method of operation for 
recombinant protein production, followed closely by fed-batch processes due to the 
advantage that have been listed above. 
 
1.2.7: Immobilisation of mammalian cells for enhanced cells densities and higher 
productivities 
The immobilisation of mammalian cells has found widespread application in many 
biotechnological fields. Microencapsulation was first used in the treatment of diabetes, in 
which pancreatic islet cells were first immobilised in alginate and delivered in vivo without 
the occurrence of a rejection reaction (Lin and Sun, 1980). Since then mammalian cell 
immobilisation has been used for various applications including the encapsulation of 
recombinant cells containing genes encoding therapeutic proteins. Injection in vivo of the 
cells contained in the capsules results in delivery of such gene products to the host. 
Genetically engineering cells delivering biologically active human factor IX (Liu et al., 
1993), human growth hormone (Chang et al., 1993) and human adenosine deaminase 
(Hughes et al., 1994) have all been encapsulated successfully in alginate microcapsules to 
deliver the recombinant gene product (Awrey, et al., 1996). It is a promising strategy for the 
controlled localised and long term in vivo delivery of therapeutic proteins to the host (Ma et 
al., 2006). 
Microencapsulation of mammalian cells has found widespread application in large scale cell 
cultures for the production of therapeutic proteins in vitro. Animal cells have a natural 
tendency to aggregate and so the immobilisation of cells in microcapsules to provide optimal 
shear-stress free conditions is considered a promising technique (King et al., 1987). Based on 
the first encapsulation of pancreatic islet cells in alginate beads, Lim and Moss, (1981) 
improved this method for the production monoclonal antibodies on a large scale. These initial 
reports suggested a 10-fold increase in monoclonal antibody (mAb) yield in immobilised 
hybridoma cultures in comparison to suspension cultures due to an increase in cell densities 
achieved in cultures, as reviewed by Selimoglu and Elibol, (2010). Mammalian cells are only 
protected by a membrane and in comparison to yeast and bacteria are fragile. As a result high 
23 
 
cell densities in suspension are limited by the mechanical and shear forces resulting from 
agitation and aeration in large scale bioreactors (Papoutsakis, 1991). Encapsulation creates a 
protective microenvironment for these fragile cells and is associated with a number of 
advantages over the cultivation of cells as free suspension cells, including (1) protection from 
damaging stresses induced by mechanical agitation and/or air sparging systems, (2) provision 
of a retention system for the application of perfusion strategies. Microcapsules/beads 
entrapping the cells are 50-1000 times larger than free-suspended cells and so do not clog 
conventional filter systems. (3) Higher local cell concentration and overall cell yield in the 
culture, in the order of 10
7
 cells/ml, can be achieved, resulting in high volumetric 
productivities and reduced capital costs (Lee et al., 1993). Focusing on the concentration of 
cells within the microenvironment, a number of advantages have been associated with high 
localised cell densities leading to increased recombinant protein production. Information 
originating from a cell can easily be communicated to other cells which are in close 
proximity. The concentration of autocrine factors would be locally higher inside the 
immobilisation matrix, as opposed to being diluted in the surrounding media when cells are 
present in suspension. (Yamaguchi et al., 1997). Farrell et al., (1994) recognized that 
endogenous proteins derived from hybridoma cells contributes to increased mAb 
productivities. In particular the cytokine interlukin-6 (IL-6) stimulates mAb production in a 
number of hybridoma cell lines (Makishima et al., 1990). The immobilisation of cells in a 
matrix induces a physical limitation of space available for cell proliferation. Therefore 
reduced specific growth rates observed in immobilised cultures have been associated with 
higher specific rates of recombinant protein production. Yamaguchi et al., (1997) reported 
increased mAb production from baby hamster kidney (BHK) cells immobilised in collagen 
gel particles in the late stage of the culture due to a slower cellular growth rate. However 
mAb production was also enhanced at early culture stages when cellular growth rates 
remained high, in comparison to suspension cultures. Increased mAb production was 
associated with increased communication of cells locally. This hypothesis was verified by a 
separate study in which the concentration of production stimulating autocrine factors was 
increased in the media, and no significant increase in mAb production was observed. 
Mammalian cell immobilisation has achieved a combination of higher cell densities and 
higher volumetric productivities than those which would be achieved for suspension cultures 
for various authors ((Sinacore et al., 1989; Lee and Palsson 1990; Ma et al., 2006; Breguet et 
al., 2007; Selimoglu et al., 2012). 
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Immobilisation of mammalian cells in culture may be in the form of immobilisation on macro 
porous microcarriers and hollow fibre membranes or encapsulated within a gel matrix. 
Enhanced growth and viability have been associated with the application of macroporous 
microcarriers (Griffiths, 1990), but have been demonstrated to present diffusion limitations 
(Ng et al., 1995). The encapsulation of cells within porous microcapsules provides for the 
microenvironment needs of the cells (Breguet et al., 2007) and eliminates diffusion 
limitations associated with large capsules (>1 mm) (Glacken et al., 1983; Robitaille et al., 
1999). 
Various polymers such as chitosan, alginate and polyamino acids have been used in the 
formation of microcapsules (Zhang et al., 2007). An ideal immobilisation material should be 
(i) biocompatible and non-toxic (ii) allow for the sufficient diffusion of oxygen, metabolites 
and their waste products, secreted proteins (if secretion is desired), while preventing cells 
from leaking (iii) must be chemically and mechanically stable in the somewhat harsh large 
scale culture environment for long term processing, as reviewed by Selimoglu and Elibol, 
(2010). Alginate-poly-L-lysine-alginate (APA) microcapsules are reportedly the most widely 
studied microcapsules applied to mammalian cell cultures for enhanced recombinant protein 
production (Zhang et al., 2007). Alginate is a polysaccharide extracted from seaweed and is 
composed of homopolymeric regions of 1,4 linked β-D-mannuronic acid (M-blocks) and α-L-
guluronic acid (G-blocks) residues. The M- and G-blocks vary widely in composition and 
sequence, depending on the organism and tissue they are located from. (Selimoglu and Elibol, 
2010; Peirone et al., 1998). Alginate serves as the polymer of choice in many 
microencapsulation applications as it has already been licensed by the US Food and drugs 
authority (FDA) for application as a pharmaceutical excipient, a viscosity modifier in food 
and as a wound dressing (Bohari et al., 2011). It is formed under mild conditions and so is 
biocompatible and biodegradable (Selimoglu and Elibol, 2010).  
The application of alginate in the formation of 3-D microcapsules containing actively 
growing mammalian cells involves the gelation of the polymer due to interchain chelation of 
divalent cations such as Ca
2+
 and Ba
2+
. These cations competitively bind to preferentially G-
blocks by an exchange of sodium ions from the G-blocks with the divalent cations. 
(Selimoglu and Elibol, 2010; Peirone et al., 1998). Each alginate chain can dimerize to form 
junctions with many other chains and as a result a gel network is formed, as oppose to 
insoluble precipitates. Ca
2+
 is the most suitable ion in relation to biocompatibility of 
mammalian cells to the ion and also affinity for the sodium alginate. The gelled bead size and 
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strength are related to both the molecular weight and concentration of the alginate used. 
Molecular weight determines the intrinsic viscosity of the sodium alginate. Using low 
viscosity alginates requires a high concentration for the formation of a convenient bead 
structure. Stabler et al., (2001) suggested a sodium alginate concentration between 1 and 1.5 
% in order to provide sufficient mechanical stability with optimum mass transfer between the 
extra capsular environment and the cells found inside the gel. Capsules are predominately 
made from a concentration of 1.5 % w/v sodium alginate crosslinked with 1.1% (0.1 M) Ca
2+
. 
The immobilisation of mammalian cells in alginate beads is brought about by the extrusion of 
a homogeneous sodium alginate solution containing a certain density of mammalian cells 
through a nozzle of known diameter. The application of vibrational technology to the nozzle 
results in the formation of universally sized spherical droplets, which become immersed in a 
batch of Ca
2+
 solution. The result is the formation of a gelled bead containing evenly 
distributed mammalian cells immobilised within the matrix. The beads are coated by a layer 
of poly-L-lysine (PLL) followed by a second layer of alginate, usually of lower concentration 
(0.03 %). PLL is a polycation, homopolymer. The alginate bead becomes coated with PLL 
due to the electrostatic attraction forces between the PLL and sodium alginate (Leick et al., 
2011). PLL, with a range of molecular weights may be used, and subsequently determines the 
molecular weight cut-off of the microcapsule membrane. The purpose of the additional 
coating with 0.03 % alginate is to neutralise any un-reacted PLL on the surface of the gelled 
bead and improve the biocompatibility of the beads (Wang et al., 2005). The resulting solid 
bead structure containing the immobilised cells may be liquefied with sodium citrate or semi-
liquefied, brought about by further incubation in Ca
2+
. Liquefaction occurs through 
incubation in sodium citrate due to the subsequent chelation of the Ca
2+
 ions in the gel core 
(Selimoglu and Elibol, 2010). The results of such liquefaction are that cells float freely 
around the interior of the capsule (Gugerli, 2003). Alginate has been shown to support the 
growth of a range of different cell types including pancreatic islets, fibroblasts and myoblasts 
and is associated without a drastic loss of viability after immobilisation. It supports high cell 
seeding densities and remains stable and intact throughout long cultivation processes, 
therefore making APA microcapsules suitable for the expansion of high cell numbers in 
bioreactors in vitro (Bohari et al., 2011).  
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1.3: Quality of produced recombinant proteins 
Over the past two decades a vast amount of progress has been made in the 
identification of culture conditions affecting cell growth and productivity. State of the art 
processes yield up to 6 g/L IgG, which represents a significant improvement from 1 g/L 
observed less than a decade ago. However, product yield should not be the sole parameter 
used for the optimisation of upstream processes. Attention must be paid to the fact that 
increased production levels may compromise the posttranslational modification machinery of 
the cell, yielding high levels of product with reduced activity, lower stability, and/or 
decreased batch-to-batch consistency (Van Berkel et al., 2009). The subsequent lack of rapid 
commercialisation of protein drug candidates in the biopharmaceutical may be attributed to 
the necessity to monitor and control a vast range of CPP’s which have been demonstrated to 
affect not only recombinant protein production but also the quality (Wang, 2005). The main 
critical quality attributes (CQA) determining the biological activity of a recombinant 
therapeutic protein are the glycosylation and aggregation state of the protein. 
As stated above, all proteins consist of a polypeptide chain. During protein biosynthesis these 
polypeptide chains usually undergo a series of co- and post-translational modifications. One 
such modification that plays an important role in the efficacy of therapeutic proteins is 
glycosylation (Jones et al., 2005) Glycosylation may be defined as an enzymatic process by 
which sugars (known as glycans) are chemically attached to proteins to form what are known 
as glycoproteins. While the proteome is coded in the genome, unlike the synthesis of 
proteins, these post-translational modifications are not directed by a template (An et al., 
2009). They are very much dependent upon the influence of environmental factors on the 
activity of glycosylation enzymes (glycosyltranferases) and the availability of glycosylation 
precursors. As a result, glycoproteins are produced as pools of different glycoforms with 
varying glycan structures attached to the polypeptide backbone. Glycoproteins are therefore 
normally heterogeneous in nature. Macroheterogeneity refers to variation in the site 
occupancy of the attached glycans. Microhetergeneity refers to variations in the structure of 
the attached glycans (Jones et al., 2005; Butler, 2005). 
A vast amount of research has gone into glycomics; controlling the pool of glycan structures 
that occupy a recombinant protein (Butler, 2006). The production of a recombinant protein as 
a biopharmaceutical product requires that a consistent glycosylation profile is maintained 
between batches. Therefore an understanding of the culture parameters affecting the 
glycosylation profile of a specific recombinant protein is essential. However before 
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understanding how to control the glycosylation profile of recombinant proteins, it is first 
essential to understand the biosynthesis of these nucleotide sugars and how they are attached 
to protein polypeptide chains (Butler, 2005). 
 
1.3.1: N-glycan biosynthesis: 
There are three known ways by which a glycan structure may be covalently attached 
to a polypeptide backbone: 1) via the NH2 group of an aspargine residue, 2) via the OH-
groups of usually serine or threonine, 3) or through an ethanolamine phosphodiester (Jenkins 
et al., 1996). The most common form of recombinant protein glycosylation is N-
glycosylation and for that reason N-glycans are the most widely studied structural form of 
glycosylation (Hossler et al., 2009). 
N-Glycans formation 
All N-glycans produced by mammalian cells typically consist of a core pentasaccharide 
(Man3GlcNAc2) attached via an N-glycosidic bond to an Aspargine (Asn) residue of a 
consensus amino acid sequence. To be recognised, the Asn residue must be part of a 
tripeptide sequence Asn-X-Ser/Thr, where X can be any amino acid except proline. The 
tripeptide sequence is the consensus amino acid sequence and is often referred to as a sequon. 
The position of the sequon in the polypeptide chain exerts an influence on the glycosylation 
of the protein. Seqouns positioned in close proximity to the amino or carboxyl-termini have a 
tendency to be less efficiently glycosylated (Opdenakker et al., 1993). 
 
 
 
 
 
 
 
 
Figure: 1.3.1.1: Core N-glycan structure (Butler, 2006) 
 
N-glycan biosynthesis and the occupation of a sequon occur co-translationally in the 
endoplasmic reticulum (ER). The process is initiated with the enzymatic transfer of a pre-
synthesized 14-mer oligosaccharide structure (Glc3Man9GlcNAc2) from a dolichol-linked 
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pyrophosphate donor to an Asn residue on the consensus polypeptide backbone of the 
protein.  
Dolichol is formed as an end product of the prenol biosynthesis pathway. It is described as a 
polyisoprenoid lipid with 80-100 carbons or 16-20 isoprene units and includes a saturated α-
isoprene subunit. Dolichol synthesis is catalysed by cis-penyl transferase. The enzyme is 
involved in the elongation of the soluble unsaturated pyrophosphate, farnesyl pyrophosphate 
(FPP) to the correct length using isopentenyl pyrophosphate (IPP). The result is the formation 
of a hydrophobic fully unsaturated polyprenyl pyrophosphate (Poly-P-P), which is embedded 
in the ER membrane. Dephosphorylation and reduction of the α-isoprene unit of the Poly-P-P 
culminates with the formation of the lipid glycosyl carrier, dolichol phosphate (Dol-P) (Jones 
et al., 2005). On the cytosolic side of the ER, the 14-mer oligosaccharide structure is 
synthesised through the step-wise addition of nucleotide sugars (e.g. uridine di-phosphate-N-
acetlyglycosamine (UDP-GlcNAc) and Guanosine DiPhosphate mannose (GDP-Man)) or 
lipid intermediates (e.g. dolichol phosphate-mannose (Dol-P-Man) and dolichol phosphate 
glucose (Dol-P-Glc)) to Dol-P to form N-acetlyglucosamine-phosphate (GlcNAc-PP-Dol) 
(Butler, 2006). This reaction is catalysed by a membrane-associated glycosyl transferase, N-
acetlyglucosamine-1-phosphotransferase (GlcNAc-1-phosphotransferase). Another GlcNAc 
and five mannose units are then transferred to GlcNAc-PP-Dol to form the intermediate 
Man5GlcNAc2-PP-Dol. This intermediate is then transferred to the luminal side of the ER 
where it is further extended by the sequential addition of four more mannose residues and 
three glucose residues (Jones et al., 2005). 
The enzyme involved in the recognition of the Asn residue of a sequon and the subsequent 
transfer of the oligosaccharide is referred to as oligosaccharyl transferase (OST). This 
enzyme exists as a complex of several subunits which are bound to the ER membrane 
approximately 65 amino acid residues from the ribosome P-site. The entire N-glycosylation 
processing method can be seen in the figure below, right from the occupation of a sequon to 
complex glycan processing in the Golgi apparatus (GA) giving rise to glycan heterogeneity 
(Butler, 2006). 
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Figure: 1.3.1.2: N-glycan precursor attached to dolichol carrier (Butler, 2006). 
 
1.3.1.1: N-glycan trimming in the ER 
Glucosidases and Mannosidases located in the ER membrane engage in a process 
known as trimming of this native N-glycan structure. The trimming process is initiated by the 
enzyme α-1,2 glucosidase I (Gluc I) which is responsible for the removal of the terminal 
glucose unit on the 14-mer oligosaccharide structure. (S1) The next two glucose units are 
sequentially removed in a reaction catalysed by the enzyme -1,3 glucosidase II (Gluc II). 
Finally the glycan structure is trimmed to a Man8GlcNac2 structure through the action of 
mannosidase I (Man I) before being translocated to the cis compartment of the GA 
(Opdenakker et al., 1993; Butler, 2006). 
 
1.3.1.2: N-glycan processing in the golgi 
In the GA, Man I activity continues, yielding a high mannose, Man5GlcNAc2, 
structure. This trimmed glycan structure under goes complex processing in the GA as a result 
of the variable activity of a series of enzymes. A series of transferase enzymes are responsible 
for the sequential addition of monosaccharide’s including GlcNAc, galactose, fucose and 
sialic acid resulting in elongation of the N-glycan structure. The first of these enzymes are the 
N-acetylglucosaminyltransferases (GnT). They are responsible for the conversion of the high 
mannose structure into a complex structure through the introduction of variable antennarity 
onto the core structure. Their actions also allow for bisecting GlcNAc to occur between two 
antennae. As seen in Figure 1.3.1.2.1, GnTI transfers GlcNAc residues from the nucleotide 
sugar donor UDP-GlcNAc to the α1,3 mannose arm of the high mannose structure. The 
resulting hybrid structure is converted to a Man3 hybrid structure by the action of a 
mannosidase II (ManII) enzyme. GnTII then transfers a GlcNAc residue to the free α1,6 
mannose arm of the hybrid structure. The resulting structure is a complex biantennary glycan. 
Before elongation of the complex glycan through the action of galactosyl transferase and 
sialy transferase enzymes, other GnT’s may introduce further branching in the glycan, as 
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illustrated in figure below. The combined activity of GnTIV and GnTV leads to a tetra-
antennary structure denoted by M3Gn4, Figure 1.3.1.2.2 (Butler, 2006). 
The action of the GnT enzymes is followed by fucosylation of the complex biantennary 
glycan. This reaction is catalysed by the enzyme α1,6 fucosyltransferase, which is a type II 
transmembrane protein. It is responsible for the transfer of fucose from the fucose donor 
GDP-fucose to the Asn-linked GlcNAc residue. Following fucosylation, the N-Glycans are 
transported to the trans compartment of the GA where the emerging glycan structure is 
subjected to the action of galactosyl and sialy transferase enzymes (Butler, 2006).  
Sialyation is the last intracellular stage of the glycosylation process. The sialylation process 
involves the transfer of sialic acid from the nucleotide sugar precursor, Cytidine-5′-
monophospho-N-acetylneuraminic acid (CMP-NANA), to galactose residue on the glycan 
structure. This reaction is catalysed by the sialy transferase enzyme.18 different types of sialy 
transferase enzymes have been cloned from animals thus giving rise to various terminal 
linkages between the sialic acid and the galactose residues. The two most important linkages 
for human glycoproteins are the α2,3 and the α2,6 linkages. These two reactions are catalysed 
by α2,3 and α2,6 sialy transferases respectively. The α2,6 sialy transferase enzyme is absent 
in hamsters and so CHO cells produce glycoproteins with α2,3 terminal sialic acid residues 
only (Butler, 2005; Jenkins et al., 1996). 
Following sialylation in the trans part of the GA, the glycoproteins are transported to the trans 
golgi network (TGN) from which they emerge in vesicles to transport the assembled 
glycoprotein to its target (Nahrgang, 2002). 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3.1.2.1: Glycosylation pathway for N-glycans (Butler, 2006). 
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Figure 1.3.1.2.2: Production of tri- and tetra-antennary structure 
1.3.1.3: O-linked glycans 
O-linked glycans are smaller structurally than N-linked glycans and are added post-
translationally to a fully folded protein (Butler, 2006). O-linked glycosylation differs to N-
linked glycosylation in that may be initiated in either the ER or the GA. N-linked 
glycosylation has been noted to begin in the ER only. (Hossler, 2009). The most common 
type of O-linked glycans are the mucin type. O-linked glycosylation of proteins begins with 
the transfer of N-acetlygalactosamine (GalNAc) from UDP-GalNAc to the hydroxyl group of 
a specific serine or threonine residue through an O-glycosidic bond. This reaction is catalysed 
by the enzyme GalNAc transferase (Jones et al., 2005). No consensus sequence for O-linked 
glycosylation has been identified. It has however been noted that it often occurs in regions of 
the protein with high proportions of serine, threonine and proline. These residues are thought 
to enable the region of the protein to assume a conformation that is accessible to the GalNAc 
transferase enzyme (Butler, 2005). 
Initial attachment of the GalNAc residue to the folded protein is preceded with elongation of 
the glycan leading to a number of large structures. They are synthesised by various 
glycosyltranferases cumulating in 8 different core structures. These core structures may be 
further modified by sialylation, fucosylation, sulfation, methylation or acetylation. The most 
common core structure found on glycoproteins produced in CHO cells is the core 1 structure 
(Galβ1-3GalNAc) (Butler, 2005). 
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Figure 1.3.1.3.1: Processing of O-linked glycans in CHO cells (Butler, 2006). 
 
1.3.2:  Biological properties of glycosylation 
Recent developments in functional glycomics have broadened our understanding as to 
the physiological function of specific carbohydrate groups attached to proteins (Butler, 2005). 
Several biological properties of recombinant therapeutic proteins rely on the possession of a 
specific glyco-form. Such properties include pharmacokinetics, secretion, in vivo clearance, 
solubility, receptor recognition and antigenicity (Hossler et al., 2009). 
Bioactivity: Fucosylation is a key part of glycan processing in the GA, resulting in the 
transfer of  a core α1,6 fucose residue from the fucose donor GDP-fucose to the Asn-linked 
GlcNAc residue. However little is known regarding the function of this core fucose residue. It 
is understand that fucose plays a role in the removal of glycoproteins from the blood into the 
liver through the binding of fucose to receptors present on the surface of macrophage, 
initiating phagocytosis (Butler, 2005). However studies have shown that fucose has a key role 
in defining the oligosaccharide confirmation needed to allow for protein-carbohydrate 
interactions. In immunoglobulin G1 (IgG1) α1,6 fucose is important for antibody function as 
it determines the binding capacity of the protein to Fc receptors and is involved in antibody-
dependant cell cytotoxicity (ADCC) (Hossler et al., 2009; Sethuraman and Stadheim, 2006). 
IgG-mediated ADCC can be modulated by varying the N-glycan composition. Also, during 
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glycan processing in the GA, GnT enzymes are responsible for the introduction of variable 
antennarity onto the core structure.  The resulting N-glycan antennarity subsequently 
determines the level of terminal glycosylation which in turn may significantly impact the 
activity of the glycoprotein. E.g. In erythropoietin (EPO), it was specifically determined that 
tetrasialyated tetra-antennary N-glycans increased in vivo bioactivity in comparison to 
biantennary N-glycans (Hossler et al., 2009). N-glycan occupancy at a specific site on a 
glycoprotein has been demonstrated to essential for the activity of therapeutic proteins. t-PA 
has three potential glycosylation sites at Asn117, 184 and 448. Occupancy at Asn-184 
modulates its binding affinity for lysine, a critical functional element in the activity of the 
protein (Jones et al., 2005). 
Efficacy and pharmacokinetics: It has been reported that pharmacokinetic variability 
displayed by tumor necrosis factor alpha (TNF-α) antagonist is solely dependent on terminal 
GlcNac levels and independent of terminal galactose and sialic acid levels (Hossler et al., 
2009). The number of N-glycan attachments to a recombinant therapeutic protein may also 
impact the efficacy of the protein. This has been demonstrated in EPO in which an increase in 
the number of N-glycan attachments resulted in an increase in the efficacy and in vivo 
activity of the protein (Jones et al., 2005). 
Half-life and in vivo clearance: Complete glycosylation of recombinant proteins is usually 
associated with maximisation of galactosylation and sialylation. Often the processes are 
incomplete and this gives rise to considerable glycan structural variation (Butler, 2005). High 
levels of terminal sialylation of glycoproteins is important in order to avoid the affects of 
asialoglycoprotein receptors. These receptors are present in the liver and on the surface of 
macrophages and are responsible for the removal of glycoproteins from circulation, thus 
reducing their half life (Butler, 2006). The importance of high terminal sialylation has been 
noted however to vary between therapeutic proteins. Varying levels of terminal sialylation of 
monoclonal IgG1 antibodies have shown no significant differences in the clearance ratio 
(Hossler et al., 2009). However for non-antibody therapeutics such as EPO, the removal of 
sialic acid groups resulted in a significantly reduced half life (Butler, 2005).  
The presence or absence of an N-glycan structure on a therapeutic protein may also affect the 
molecules half-life. E.g. N-glycan occupancy at Asn-117 on t-PA is known to affect its 
clearance from circulation. The addition of N-glycosylation sites to follicle stimulating 
hormone (FSH) increased the half life of the therapeutic protein (Jones et al., 2005). 
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Immunogenicity: Variations in the structure of sialic acid residues have been noted between 
species. N-glycolyl-neuraminic acid (NGNA) is found in goat, sheep and cows, whereas N-
acetyl-neuraminic acid (NANA) is the sialic acid residue found in humans. The ratio of 
NANA to NGNA is dependent upon both the cell line and culture. NGNA is the predominant 
sialic acid found in mice. CHO cells however produce glycoproteins which typically contain 
NANA. However, up to 15 % of the sialic acid residues present on glycoproteins produced in 
CHO cells have been NGNA (Butler, 2006). The presence of high levels of NGNA on CT4-
IgG fusion protein have been demonstrated to elicit an immune response (Hossler et al., 
2009). Galactose monosaccharides have also been demonstrated to impact the 
immunogenicity of recombinant therapeutic proteins. α1,3-linked galactose is known to be 
immunogenic (Butler, 2006). Incomplete processing of N-glycans may result in glycoproteins 
containing hybrid mannose structures which may elicit an immune response. In some cases 
this is a desired property and may be exploited for targeted drug delivery. E.g. Cerezyme, 
which is used in the treatment of Gaucher disease, has mannose sugars which facilitate 
macrophage recognition via the cell surface mannose receptors (Hossler et al., 2009). 
 
1.3.3: Aggregation and glycosylation  
Glycosylation plays a key role in determining the bioactivity of recombinant 
therapeutic proteins, primarily through the binding of the oligosaccharide residues to 
receptors at targeted areas, as described above. Effector function is not however the sole 
biological purpose for the existence of glycan structures on protein molecules. Sufficient 
evidence also exists suggesting that glycosylation has a stabilising effect on protein structure, 
thus reducing the likelihood of protein aggregation occurring (Pace, 1990; Karpusas et al., 
1998; Sola and Griebenow, 2009).  
Large molecule drugs offer a range of favourable properties as therapeutics such as higher 
target specificity and pharmacology potency, to name but a few, in comparison to the more 
conventional small molecule drugs which previously dominated the market. However one 
drawback of these macromolecular drugs is their higher levels of protein structure, required 
for therapeutic efficacy, which result in instability issues due to their noncovalent nature. 
Large molecule drugs display structural complexity and diversity that was never an issue with 
small molecule drug candidates. The challenge therefore lies in the long term stabilization of 
protein pharmaceuticals. Proteins exhibit only a marginal difference in thermodynamic 
stability between their folded and unfolded states. As a result of their colloidal nature, 
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proteins are prone to pH, temperature and concentration dependent precipitation, surface 
adsortption and non native supramolecular aggregation.  
The instabilities of proteins are both chemical (proteolytic degradation, oxidation and 
chemical crosslinking) and physical (precipitation, chemical denaturation, thermal 
denaturation, kinetic inactivation and aggregation) in nature. Various strategies have been put 
in place to with the aim of overcoming the above instabilities and achieving long term 
stabilisation of protein pharmaceuticals. These include the use of stabilizing excipients 
(amino acids, sugars, polyols) and internal stabilisation by altering structural characteristics 
of the protein through chemical modifications e.g. mutations, glycosylation, pegylation (Sola 
and Griebenow, 2009). 
The above strategies have all displayed a series of limitations in the stabilisation of protein 
therapeutics while maintaining complete effector functions of the drug molecule with the 
exception of glycosylation. It has been extensively reported that through manipulation of key 
glycosylation parameters including glycosylation degree, glycan size, and structural 
composition, the stability of the protein may be engineered as desired. Glycosylation has 
been demonstrated to curb all of the major chemical and physical instabilities in a variety of 
therapeutic proteins, as reviewed by Sola and Grienbenow, (2009). 
 
1.3.3.1: Chemical instabilities 
Proteins are highly susceptible to proteolytic degradation, before they even reach their 
targeted areas. Proteolytic stability may be engineered into proteins through alteration of 
glycan structures. Enzymatic glycosylation of end-terminal glycan structures (GlcNAc, 
galactose and sialic acid) in IgG-like antibodies resulted in greater proteolytic stability in the 
presence of papain(Raju and Scallon, 2007). The presence of the glycans provided steric 
hindrance around the peptide backbone of amino acids adjacent to the glycosylation site thus 
conferring the protein with proteolytic stability. Oxidation of various amino acid side chains 
during storage of proteins has been associated with loss in bioactivity. The protein drug 
Erythropoietin (EPOGEN® Amgen, Ortho) is susceptible to tryptophan oxidation. 
Comparison of oxidative susceptibility between glycosylated and deglycosylated forms of the 
protein demonstrated  that glycosylation diminished oxidation rates of the tryptophan (Sola 
and Griebenow, 2009). The existence of disulphide and non-disulphide crosslinking pathways 
in proteins allow for the formation of covalent dimmers and oligomers, resulting in a loss of 
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bioactivity. Chemical glycosylation has been noted to suppress the self-association of protein 
into dimmers and oligomer species in insulin. (Baudy et al., 1995). 
 
1.3.3.2: Physical instabilities 
Protein stability is inversely proportional to it’s concentration. The specific 
concentration at which a protein will become unstable and precipitate out of solution is 
dependent upon the solutions pH, temperature, ionic strength, and excipient concentration. 
Glycosylation has been demonstrated to increase the solubility of many proteins. The 
solubility of the commercially available enzyme peroxidise has been shown to have a linear 
dependence with the degree of glycosylation. A logical explanation for such an observation 
would lie in the principle that glycans have a higher affinity for aqueous solvents than 
polypeptide chains. (Tams et al., 1999). However the increase in solubility of the protein is 
due to an overall greater molecular solvent accessible surface (SASA) caused by the presence 
of the glycans (Sola and Griebenow, 2009). 
Environments of extreme pH disrupt internal electrostatic forces and charge-charge 
interactions in proteins leading to partial unfolding of the protein. This partial unfolding in 
turn causes a reduction in local charge density , followed by a further decrease in the 
electrostatic free energy of the protein which cumulates with global unfolding of the protein. 
Glycosylation has been documented to maintain conformational stability of Penicillin G 
acylase by up to 13 fold at pH 3 and 10 fold at pH 10 when compared to the unglycosylated 
form. Thermal denaturation of proteins has also been extensively studied. Coincidently this is 
one of the most fundamental biophysical properties which becomes altered for proteins once 
they become glycosylated (Kim et al., 2004; Joao et al., 1992; Wormald and Dwek, 1999).  
 
1.3.3.3: Protein aggregation 
The tendency for proteins to formed condensed phases (mainly amorphous 
aggregates) falls under the umbrella of physical instability issues affecting the vast majority 
of large molecule drug products (Sola and Griebenow, 2009). As with all other protein 
instabilities, glycosylation has been outlined as a promising solution to protein aggregation 
which is a significant problem during each stage of production and storage. Aggregation is 
responsible for decreases in yields at every stage of the production process including protein 
expression, upstream bioprocessing, purification, downstream processing and fill finish 
(Manning et al., 2010). 
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Protein aggregation is described as the condensation of proteins to form amorphous solids. 
These amorphous solids may exist as soluble or sub-visible aggregates in solution or phase 
separate and sediment to the bottom of the solution container thus being completely visible. 
Depending on the mechanism by which aggregates form, the aggregation may be reversible 
or irreversible (Philo and Arakawa, 2009). There are 5 main mechanisms by which 
aggregation may occur: 
(1) Self association: This process is characterised by the formation of protein aggregates 
even when the protein is in its native conformation and under thermodynamically 
favourable conditions without stress. This form of aggregation is reversible and its 
potential to occur may be measured by determining the osmotic second viral 
coefficient (B22). Negative B22 measurements indicate predominant protein-protein 
interaction potential, while positive measurements are indicative of protein-protein 
repulsion (Chi et al., 2003). 
(2) Aggregation through unfolding intermediates: Post-translational modification steps in 
protein synthesis involve the folding of protein in tertiary structures which acquire a 
stable conformation. However the process of protein folding may be incomplete and 
result in the presence of partially folded proteins. Hydrophobic patches on the surface 
of such proteins make them prone to aggregation (Fink, 1998). 
(3) Chemical modification: As described above, the macromolecule structure of proteins 
makes them susceptible to chemical instabilities such as oxidation, demerization, 
deamination, and hydrolysis. Such chemical modifications to proteins often promote 
the subsequent aggregation of the protein as they often result in changes in the 
hydrophobicity of proteins as well as their secondary and tertiary structures (Philo 
and Arakawa, 2009). 
(4) Nucleation dependent: The existence of preformed aggregates in protein solution 
reduces the overall energy barrier required nucleation and subsequently accelerates 
the process of aggregation. This process is referred to as homogeneous nucleation. 
The energy barrier may also be reduced by the presence of impurities or 
contaminants as oppose to preformed aggregates. This often results in heterogeneous 
nucleation (.Hamada and Dobson, 2002; Come et al., 1993). 
(5) Surface induced: Hydrophobic interactions between proteins and air-liquid interfaces 
and electrostatic interactions between proteins and surfaces of containers may result 
in aggregation of the protein in those specific areas (Manning et al., 2010). 
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1.3.3.4: Aggregation problems at upstream level 
To date, therapeutic protein aggregation resulting from biopharmaceutical production 
processes has been considered a downstream processing issue (Manning et al., 2010), with 
the implications of upstream processing on aggregation being overlooked. The aggregation of 
proteins during downstream processing has been widely studied and extensively reviewed 
(Manning et al., 2010). However an examination of the full bioprocess of protein aggregation 
from cell culture to fill finish is essential. Protein aggregates may have a similar size and 
density as many other components in a cell culture environment including cell debris and also 
the cells themselves. As with all other chemical and physical instabilities noted for 
therapeutic proteins, various examples so exist in which protein aggregation has been 
prevented or induced due to the persistence of a specific glycoform.  
Baudys et al., (1995) showed how the physical stability of insulin could be improved by 
reducing its aggregation kinetics through the chemical attachment of small sized glycans. The 
positive impact this had on aggregation was related to the transamidation crosslinking 
reaction which suggests a stabilising mechanism involving steric intermolecular repulsion 
phenomena. Ioannou et al., (1998) showed that glycosylation of α-galactosidase A at Asn 215 
prevents aggregation by reducing the exposure of a surface hydrophobic patch on the protein. 
Similarly the deglycosylation of interferons promotes aggregation of the proteins due to the 
exposure of hydrophobic regions on the polypeptide chain. E.g. The primary structure of 
interferon-β (IFN-β) contains a high number of surface exposed hydrophobic residues (Phe-
70, Phe-154, Trp-79, Trp-143), which are all in the vicinity of the glycosylation site. The 
large carbohydrate moiety of the glycans usually shields this area from the environment. 
Deglycosylation of the protein therefore exposes the hydrophobic residues, promoting 
aggregation of the protein. The deglycosylated form of the commercially available 
recombinant protein thyroid stimulating hormone (THYROGEN®: Genezyme) has also been 
demonstrated to be more prone to aggregation (Weintraub et al., 1983). Increased colloidal 
stability of the glycosylated form of phytase has also been observed  (Hoiberg-Nielsen et al., 
2006). This increased in stability was thought to be due to increased steric hindrance brought 
about by the attached glycan as oppose to being dependent upon the hydrophilic related 
properties of the glycans (Sola and Griebenow, 2009). The recombinant protein EPO has 
three N-linked glycosylation sites at Asn-24, Asn-38 and Asn-83 and one O-linked 
glycosylation site at Ser-126. The enzymatic or chemical deglycosylation of EPO was shown 
to induce aggregation of the protein (Dube et al., 1988). Kayser et al., (2011) compared the 
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stability and temperature induced aggregation of glycosylated and aglycosylated forms of 
human IgG1. It was demonstrated that at higher temperatures, the aglycosylated form of the 
IgG1 aggregated more rapidly than the glycosylated form.  
All of the studies above suggest a mechanism in which protein aggregation is prevented due 
to the presence of a glycan on the protein surface (Sola and Griebenow, 2009). The size and 
heterogeneity of the glycan has also been demonstrated to play a significant role in the 
aggregation potential of a protein. Glycosylation is not a completely reproducible process and 
often results in a pool of different glycoforms of the protein being produced in a protein 
solution. Although glycosylation has been noted to have a stabilising effect on recombinant 
proteins, alterations in the glycan structure can be expected to alter both the solution and 
structural stability of the protein. Gomes and Herr, (2006) showed that aggregation of 
proteins could not prevented by smaller sized glycans, independent of the amount of glycan 
attached to the protein. Human IgA has an O-linked glycosylation site in the hinge region. 
Undergalactosylation and undersialylation of this glycan structure have been linked to 
aggregation of the IgA molecule in a hinge specific manner. Undergalactosylation lead to 
increased adhesion of the molecule to extracellular matrix proteins. 
Glycosylation has proven itself important for both bioactivity and effector function of 
recombinant therapeutic proteins, as described in, Section 1.3.2. The impact which 
glycosylation may have on the stability of the protein at both the upstream and downstream 
production levels give rise to the placement of further emphasis on the optimisation of culture 
conditions for efficient and correct glycosylation of recombinant proteins. Culture conditions 
which effect glycosylation, and in doing so which may affect the aggregation state of the 
protein have been investigated 
 
1.3.4: Culture conditions affecting glycosylation.  
The impact of various culture conditions on the growth and productivity of 
mammalian cell expression systems has been extensively researched. However as cells grow 
and produce recombinant proteins, the activities of the enzymes involved in the attachment of 
sugar residues onto emerging polypeptides, may also be influenced by the culture 
environment. Culture conditions affecting the glycosylation of recombinant proteins may in 
turn subsequently influence the bioactivity and in some cases the stability of the recombinant 
proteins. 
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The glycoform profile of recombinant glycoproteins has been reported in literature to be 
affected by various parameters including: the host cell line expressing the protein, the protein 
structure itself and the extracellular culture environment (Jenkins et al., 1996). 
1.3.4.1: Host cell and protein structure 
Choice of expression system for recombinant protein production include bacterial 
cells, yeast cells, plant cells, insects, transgenic animals and plants and mammalian cells such 
as rodent derived or human derived. One of the key requirements of any host cell line lies in 
it’s ability to perform the post-translational modifications (including glycosylation) of the 
protein, thus enabling the protein to perform effectively as an FDA approved therapeutic. The 
above expression systems all vary in their abilities to perform glycosylation of therapeutic 
proteins and also to produce the correct glycoforms for therapeutic function, as reviewed by 
Jenkins et al., (1996). 
Common bacterial expression systems such as E. coli have traditionally had no capacity to 
glycosylate proteins in neither N- or O-linked conformations. Lower eukaryotic cells such as 
yeast and fungi are typically associated with the production of hypermannosylation of 
recombinant proteins produced in such expression systems. The high mannose structures are 
typically released from the cells as end-products of glycosylation (Butler, 2006). The few 
studies which have been completed in plant cell systems have been primarily N-glycan 
structures lacking in sialic acid residues. Insect cells, another conventional host cell choice, 
are limited to produce only simple oligomannose-type oligosaccharides such as 
Man9GlcNAc2 (Jenkins et al., 1996). Mammalian cells exist as the host cells of choice for the 
commercial production of therapeutic proteins (Kim et al., 2012). Given that species which 
are mammals are phylogenetically closer to humans, it is expected that the glycosylation 
characteristics of recombinant proteins produced would be common to that of proteins 
produced by human cell lines and so increase the bioactivity of the potential drug candidate 
in humans through alleviating the possibility for immunogenic response.  
However, as noted in Section 1.3.1, the entire process of glycosylation involves the transfer 
of oligosaccharide structures from nucleotide sugar donors onto the peptide backbone of 
newly synthesised polypeptide chains. These reactions are catalysed by a range of transferase 
enzymes present in the ER and GA of the cell producing the protein. This process is therefore 
not only influenced by the availability of a pool of nucleotide sugar donors in the cell, but 
also on the activity of a series of transferase enzymes. Variations in the activity of these 
enzymes across various mammalian cell lines have been responsible for variations in the 
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attached glycans onto protein. Some variations are independent of the conditions under which 
the host cell is grown (Butler, 2006). 
The activity of GnT enzymes involved in the complex processing of high mannose 
intermediates into complex type glycans has been noted to vary in activity between 
mammalian cell lines. In particular GnT(III), the enzyme responsible for the transfer of β1,4 
bisecting GlcNAc residue, is absent in CHO cells. Glycoproteins produced in these cells 
usually lack β1,4 bisecting GlcNAc (Butler, 2006). Sialyation of glycoproteins has been 
noted to be particularly varied between host cell lines. In section biological structures, two 
possible forms of sialylation (NANA and NGNA) found on mammalian cell proteins, and 
their importance in terms of effector function and immunological response were identified 
and discussed. NGNA levels have been shown to be more prevalent in recombinant proteins 
derived from mouse or human-mouse hybridoma (Jenkins et al., 1996). Most CHO cell lines 
used for recombinant protein production have an inactivated gene for α1-3-
galactosyltransferase and therefore make low levels of NGNA in comparison to NANA. 
However CHO cells have been noted to lack a functional α2,6-sialytransferase enzyme and so 
are solely involved in the synthesis of α2,3-linked terminal sialic acid via α2,3-
sialytransferase. Both sialytransferase enzymes are present in mouse and human cell lines 
(Jenkins et al., 1996; Hossler et al., 2009). 
The primary, secondary or tertiary structure of the recombinant protein is also an important 
factor affecting its glycosylation. The presence of a consensus sequence on an emerging 
polypeptide backbone does not guarantee the glycosylation of the protein. It is estimated that 
only approximately 65 % of all potential glycoprotein sequons become occupied by a glycan. 
Glycosylation proceeds folding of the protein and so it is proposed that often the 
inaccessibility of the sequon to the OST enzyme on the fully folded protein may be 
responsible for a lack of glycosylation of the protein (Butler, 2006). E.g. Di-sulphide bridge 
formation is a co-translational modification noted to cause inaccessibility of glycosylation 
enzymes. The elimination of a disulphide bond between Cysteine (Cys) 45 and Cys 51 in the 
protein interleukin-6 increases the efficiency with which Asn 46 is glycosylated (Weply, 
1991). The position of a sequon is related to the primary structure of the protein. It has 
commonly been reported that the frequency of non-glycosylated sequons increases 
approximately 60 amino acid residues from the C-terminus (Opdenakker et al., 1993). 
Related to both the host cell line and also the cultivation process parameters employed is the 
growth rate of the cells. As noted above, culture conditions allowing for high cellular growth 
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rates and high specific productivities are often employed. This may however have 
implications for the glycosylation of the produced recombinant protein. The growth rate of 
the cells and the rate of synthesis of the protein determine the extent of the time period in 
which the N-glycan is exposed to the OST enzyme. Site occupancy of a polypeptide chain is 
in fact dependent upon the elongation rate. The CHO produced recombinant protein t-PA has 
3 N-glycan sites, one of which is variable at Asn-184. Anderson et al., (2000) showed that 
site occupancy at Asn-184 could be correlated with the fraction of cells in G0/G1 phase of the 
cell cycle. Furthermore, a temperature induced reduced growth rate of the t-PA producing 
CHO cell line resulted in increased site-occupancy at Asn-184. Therefore lowering the rate of 
protein translation improved glycosylation. In regards to the complex processing of 
intermediate glycan structures, residence time in the GA has also proven to be significant. 
Wang et al., 1991 demonstrated that it was possible to decrease the flow of glycoproteins 
through the GA by incubating the cells at 21 °C. The results were significant in that the 
GlcNAc content of the newly synthesised glycans increased by 100 %. In contrast however, 
Bulleid et al., (1992), showed that lowering t-PA synthesis in CHO cells had little effect on 
protein glycosylation. 
 
1.3.4.2: Process conditions 
Host cell line and cellular growth rate should be optimised in order to achieve the 
desired glycosylation profile of the recombinant protein for enhanced stability and 
bioactivity. Once the host cell line has been chosen, the cell culture conditions should be 
optimised in order to minimise glycoprotein heterogeneity and prevent deterioration of 
product quality, thus assuring the production of a certain range of glycoforms or even a 
specific glycoform (Jenkins et al., 1996). Normally changes in the glycosylation due to 
culture conditions are limited to the relative expression of glycoforms out of a pool of 
structures characteristic for a certain glycosylation site of a given protein. In order to 
maintain product quality it is essential to understand the parameters that cause variation in 
glycosylation macro- and micro-heterogeneity. The process conditions affecting the 
glycosylation of proteins are similar to those which affect other cellular activities such as 
growth and specific production rate. 
1.3.4.2.1 Physical parameters 
Biphasic cultivation methods employing temperature shift optimisation for enhanced 
cellular growth rate (phase I) and maximised specific productivities (phase II) are routinely 
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applied in recombinant protein bioprocessing (Fox et al., 2003). However changes in the 
temperature throughout the cultivation period may significantly affect the glycosylation 
profile of the recombinant protein produced. Trummer et al., (2006) demonstrated a reduction 
in the ratio of sialic acid to glycoprotein when the temperature was decreased from 37 °C to 
30 °C for the CHO produced recombinant protein EPO-Fc. In the same study, a decrease in 
sialylation of 20 % and 44 % was noted when the temperature was reduced from the optimum 
to 33 °C and 30 °C respectively. Similarly, Rodriguez et al., (2010) also reported a lower 
degree of sialylation of β-IFN after the application of temperature shift from 37 °C to 32 °C 
in comparison to culture that remained at 37 °C. A decrease in glycan site occupancy was 
also reported for the temperature shift culture in comparison to the 37 °C culture. However 
other studies appear to contradict these findings on the effect of temperature shift on the 
degree of site-occupancy of glycoproteins. Anderson et al., (2000) reported an increase in N-
glycan site-occupancy of t-PA when biphasic cultivation temperature shift from 37 °C to 32 
°C was applied. Gawlizek et al., (2009) tested a broader range of temperatures for CHO cells 
producing the recombinant protein enzyme Glycoprotein 2 (GP2) and reported increased site 
occupancy of 2.3 % and 4 % when temperature shift to 33 °C and 31 °C was applied 
respectively. Moore et al., (1997) investigated the effect of temperature on nucleotide pools 
in CHO cell cultures. After the application of temperature shift from 37 °C to 30 °C, a sharp 
decrease in the pool of uridine tri-phosphate (UTP) was observed. A decrease in UTP as a 
result of changes in culture conditions is often coupled with an observed increase in the 
concentration of activated amino sugars such as UDP-GlcNAc and GalNac, which this study 
reported. An increased ratio UDP-GlcNAc is thought to compete with the nucleotide sialic 
acid donor CMP-NANA for transport into the Golgi. It may therefore be proposed that the 
resulting decreases in the level of sialyation reported by Anderson et al., (2000) and 
Rodriguez et al., (2010) may be due to the increased concentration of UDP-GlcNAc in the 
GA at lower cultivation temperatures (Butler, 2006). 
As stated in Section 1.2.2, There has been a limited amount of investigations to date as to the 
effect the pH of the external environment may have on cellular functions. It is considered that 
adverse external pH changes will in turn alter the pH of the Golgi. If the pHi is altered 
outside the optimum range for the glycosylation enzymes, a decrease in activity and 
subsequent glycan processing may be observed (Butler, 2006). It is generally reported that a 
pH range of 6.9-8.2 does not have a dramatic effect on the glycosylation profile of 
recombinant proteins expressed in CHO cells. Underglycosylation outside of this range was 
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reported (Jenkins et al., 1996). Trummer et al., (2006) reported a maximum sialic acid to 
glycoprotein ration at pH 7.0 for the CHO produced EPO-Fc. This ratio was noted to 
decrease when conditions were altered above or below this pH. The external pH of the culture 
environment was also noted to have implications for N-glycan site-occupancy. Gawlitzek et 
al., (2009) showed a decrease in N-glycan site occupancy of the recombinant protein enzyme 
GP-2 with increasing external pH from 7.05 to 7.15. A similar trend was also noted for the 
level of terminal sialylation of the N-glycan. It was deduced that the level of terminal 
sialylation could be related to site-occupancy. Higher site-occupancy provided increased N-
glycan substrate for the 2,3 sialytransferase to attach sialic acid residues to the terminal 
galactose residue.  
One of the main components of a cells culture environment is the medium in which they 
grow. Due to the fact that over 30 essential nutrients are necessary for cell survival and that 
the requirements of the cell are very much dependent on cell type and process conditions, 
many different forms of culture media have become commercially available. The variation in 
the concentrations of nutrients in such media does in itself have extensive implications on cell 
growth, productivity and importantly recombinant protein quality. Irrespective of nutrient 
concentration, the osmolality of the medium has also been demonstrated to affect the 
glycosylation profile of recombinant proteins.  As noted above in Section 1.2.3 cell culture 
medium is typically designed to have an osmolality between 260-320 mOsm/kg (Ozturk and 
Palsson, 1991). However throughout the culture period, the osmolality of the medium may 
change, e.g. through the addition of base (NaOH) for pH control. Pacis et al., (2011) 
conducted studies using a CHO cell line producing the recombinant protein IgG1 which 
proved indicative of decreased glycan processing at osmolalities outside of the acceptable 
ranges. Increased osmolality of 1250 mOsm/kg resulted in a 23-27 % increase in the level of 
intermediate Man5 glycoforms in comparison to the 750 mOsm/kg control culture. The 
increase in Man5 glycoforms was related to a decrease noted in complex galactosylated 
glycoforms at the elevated osmolality level. Other cell lines followed a similar trend but with 
different absolute levels of Man5. 
The detrimental effects of increased CO2 levels in culture coupled with increases in medium 
osmolalities have been discussed above, also in Section 1.2.3. The glycosylation profile of 
recombinant protein may also be altered at elevated pCO2 levels. Kimura et al., (1997) 
investigated the glycosylation profile of the CHO produced recombinant protein t-PA at an 
elevated pCO2 concentration of 250 mmHg at medium osmolality levels of 210 and 376 
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mOsm/kg. No changes in the sialic acid content or the content of other monosaccharide 
(mannose, galactose, and fructose) were found for the glycoprotein. However the % of 
NGNA in comparison to NANA was lower 60 % lower at 250 mmHg pCO2 in comparison to 
control cultures. Two mechanisms were proposed for these findings. The first coincides with 
a reduction in the activity of the enzyme CMP-NANA-hydroxylase which is responsible for 
the conversion of CMP-NANA to CMP-NGNA in the cytosol. It was predicted that 
alterations in the pHi of the cell brought about by the increased pCO2 levels affected activity 
of the enzyme. CO2 is nonpolar and diffuses across the cell membrane where it hydrates and 
dissociates into H
+
 and HCO3
-
 ions causing increasing in the pHi of the cell. The cell attempts 
to counteract this effect by increased activity of Na
+
/H
+
 and/or HCO3
-
/Cl
-
 antiporters. Such 
activities do not however assure that the pHi returns to it’s original value, thus affecting the 
activity of a range of glycosylation enzymes such as CMP-NANA-hydroxylase. The second 
mechanism proposed for the reduction in CMP-NGNA is related to alterations in cellular 
metabolism brought about by elevated pCO2 levels. pCO2 may affect NADH supply through 
affecting glucose or glutamine consumption or oxygen consumption. NADH is utilised in the 
biosynthesis of CMP-NGNA. 
In relation to the concentration of dissolved gases present in cell culture medium, the effect 
which the level of DO has on the glycosylation profile of recombinant therapeutic proteins 
has been extensively reviewed. Varying results have been published suggesting that the effect 
of DO on the glycosylation of recombinant proteins varies between cell lines and the protein 
produced and may also depend on the cell culture technique employed, amongst other 
variables (Restelli and Butler 2002). It may be recalled from Section 1.2.4, that Normal or 
normoxic conditions exist when 100 % air saturation exists. Under mild hypoxia conditions 
Lin et al., (1993) showed that a minimal effect on the glycosylation of CHO produced t-PA. 
However similar conditions were demonstrated to increase the levels of sialylation of FSH 
also produced by CHO cells (Choitigeat et al., 1994). In such studies it was deduced that the 
increases in the level of sialylation were due to increases in the activity of the sialytransferase 
enzyme. In contrast to this report, Trummer et al., (2006) documented that the maximum 
sialic acid to glycoprotein ratio may be observed at 50 % air saturation for the recombinant 
protein EPO-Fc produced in CHO cells. The level of DO has also been noted to have 
implications on the galactosylation of recombinant proteins. Kunkel et al., 1998 reported a 
decrease in digalactosylated glycans from 30 % at high DO levels to 12 % at low DO levels. 
In a similar study a reduction in the level of galactosylation of N-glycan chains at lower DO 
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levels was reported for a murine hybridoma cell line producing mAb (Kunkel et al., 2007). 
This was denoted by increases in the relative amounts of agalactosyl chains and a decrease in 
the relative amounts of digalactosyl chains. Various mechanisms by which galactosylation 
may be affected by the DO level of the culture environment have been proposed. One of 
which suggests that varying levels of DO may reduce the availability of uridine di-phosphate 
galactose (UDP-Gal) due to reduced transportation in the lumen. The second mechanism 
proposed is based on the principle that low DO levels may affect the redox environment in 
the golgi which in turn alters the pathway for inter-chain disulphide bond formation on 
recombinant proteins. The altered pathway may be associated with early formation of such 
inter-heavy chain disulphide bonds. A relationship has been noted between the level of Fc 
galactosylation and the timing of formation of the disulphide bonds (Rademacher et al., 1996. 
The fucosylation of N-glycan structures attached to recombinant proteins has been illustrated 
to be effected by the level of DO in the culture environment. Restelli et al., (2006) observed 
that maximum core-fucosylation (80%) of recombinant human EPO produced in CHO cells 
occurred at 50 % DO. Higher or lower DO resulted in reduced fucosylation. The decreased 
fucosylation at such extreme levels was related to decreased activity of the Golgi enzyme 
α1,6 fucosyltransferase. 
As noted in Section 1.2.4, the level of DO in a culture environment is very much dependent 
upon the balance between the OTR and the OUR displayed by the cells. However irrelevant 
of this balance, a gradient in the level of DO throughout the bioreactor environment may be 
observed which is solely based on reactor design and mixing. Zhang et al., (2010) recently 
reviewed the expected gradients in the level of DO in a 8m
3
 scale reactor with a 2/0 rush ton 
turbine. Dependent on the OUR and mixing times, differences in oxygen concentration 
throughout the bioreactor may be seen resulting in non-consistent dissolved oxygen tension 
(DOT). Serrato et al., 2004 (Scaling 5) investigated the effect of such oscillations in DOT, in 
the range of 800-12800, on hybridomas producing mAbs. The main finding portrayed that 
mAb produced under the oscillating conditions had a higher amount of triantennary and 
sialyated glycans. Increasing the oscillation period to 12,800 s decreased the percentage of 
ungalactosylated glycans and also glycans containing only one galactose unit by 14 %. 
Glycans containing 3 galactose residues and sialyated glycans increased by 23 %. It was 
deduced that the oscillations did change the redox potential of the cell and also affected the 
folding of the mAb protein which in turn resulted in increased galactosylation. The result do 
to some extent contradict the predictions proposed by Rademacher et al., (1996) in that 
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galactosylation was increased verifying the initial statement that results are cell line and 
recombinant protein dependent. 
In relation to bioreactor design and mixing, shear stress created through agitation and aeration 
have been noted to impact on the glycosylation of recombinant proteins, specifically site-
occupancy. Senger and Karim, (2003) reported that maximum levels of damaging shear stress 
were required in order to reduce the extent of Asn-184 site occupancy in t-PA produced from 
CHO cells. Under conditions of shear stress it was presumed that the protein spent less time 
in the ER, resulting in the reduced attachment of glycostructures. Comparisons have also 
been made between the glycosylation profiles of recombinant proteins produced in different 
culture vessels. Wang et al., (2002) demonstrated variable terminal sialylation of N-glycans 
present on recombinant EPO produced from CHO cells cultivated in T-flasks, stirred tank 
bioreactors and cytopilot fluidised bed bioreactors. The effect of various culture conditions 
outlines above may also vary depending on the cultivation vessel. Kunkel et al., 2000 saw a 
difference in the effect of DO on the galactosylation of mAb produced from a murine 
hybridoma cell line in two different bioreactors, the LH series 210 (LH) and the New 
Brunswick Scientific (NBS) CelliGen. The reduction in galactosylation at high DO was noted 
to be less pronounced in NBS in comparison to LH. mAb proteins harvested from the NBS 
bioreactor contained higher levels of sialyated glycans in comparison to those harvested from 
the LH reactor. The differences in glycosylation patterns were explained by differences in 
oxygen supply and control strategies between the two bioreactors. 
1.3.4.2.2 Chemical parameters 
The environmental culture parameters noted to impact on the glycosylation profile of 
the recombinant therapeutic protein may be described as physical cultural conditions. The 
most important chemical cultural environment is the media in which the cells are cultures. 
Cellular growth and productivity is affected by the depletion of a number of nutrients from 
the culture media and the subsequent release of metabolic by-products into the media over the 
course of the culture period. The most predominant nutrients which have been noted to 
impact on the quality of the recombinant proteins are glucose, glutamine and their 
corresponding by-products, lactate and ammonia. 
It has been reported for some time that glucose starvation decreases glycosylation efficiency 
(Baumann and Jahreis 1983, Chapman and Calhoun 1988) resulting in alterations in the 
degrees of site-occupancy of glycans on recombinant proteins. Hayter et al., (1992) illustrated 
that glucose deprivation resulted in the increased production of non-glycosylated gamma-
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interferon. A number of studies have been completed investigating the resulting decreases in 
glycosylation efficiency. Glucose starvation may result in an intracellular depletion or a 
shortage of glucose-derived precursors of glycans. This concept was first proposed by 
Rearick et al., (1981). It was illustrated that under glucose deprived conditions, CHO cells 
rapidly cease to synthesize the 14-mer oligosaccharide glycosylation precursor 
Glc3Man9GlcNAc2 and alternatively accumulate Man5GlcNAc2 which is subsequently 
glucosylated and transferred onto the polypeptide backbone. The shift from synthesis of 
Man9GlcNAc2 to Man5GlcNAc2 was thought to be due to a decrease in cellular Dol-P-Man as 
the first 5 mannose residues in the oligosaccharide come from GDP-mannose and the last 4 
come from Dol-P-Man. It was concluded that the enzyme that adds the 6
th
 mannose residue is 
very sensitive to small changes in Dol-P-Man concentration. In this case glycosylation did 
still occur, through a different pathway. This study does therefore not propose a mechanism 
as to how site-occupancy is affected by glucose starvation. Nyberg et al., (1999) proposed 
that reduced site-occupancy under glucose starvation conditions was due to a decrease in the 
synthesis of UTP, the precursor for UDP-GlcNAc. It was hypothesised that during glucose 
limitation, available carbon is preferentially utilised for energy production and subsequently 
leads to reduced nucleotide biosynthesis. Under conditions of glucose starvation the declines 
in nucleoside triphosphates such as UTP could not be explained by increases in mono- and 
diphosphates as all nucleosides were being depleted. It was proposed that the nucleosides 
were continually consumed for RNA synthesis under conditions of glucose starvation. This 
concept was proven through the inhibition of protein and RNA synthesis, by which it was 
observed that the decline in nucleosides was alleviated. Lower levels of nucleoside 
triphosphate pools in turn cause lower levels of nucleotide sugar pools resulting in lower 
levels of glycosylation site occupancy. The results presented above so however again appear 
to be cell line and recombinant protein specific. Wong et al., (2004) found that in cases of 
glucose and glutamine limitation, only 6-9% of the recombinant protein IFN-γ was 
unglycosylated. It was concluded that extreme starvation was required in order for a 
significant impact on site-occupancy to occur. 
Wong et al., (2004) also investigated the effect of glucose limitation on the 
microheterogeneity of glycan structures attached to Asn-25 and Asn-97 of IFN-γ. Glucose 
deprivation in the presence of glutamine control affected the complete processing of high-
mannose types to full complex glycans resulting in a greater number of hybrid type glycans at 
both sites. Similarly to above, it was proposed that the presence of the high mannose type 
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glycan was due to limitations in the availability of uridine di-phosphate N-acetlyhexosamine 
(UDP-GlcNAc). The elimination of glucose deprivation may be achieved through the 
implication of fed-batch mode of cultivation. However in order to define feeding strategies it 
is necessary to determine the critical glucose concentration at which glycosylation is affected. 
Xie et al., (1997) compared fed-batch cultures containing initial glucose concentrations of 
2.25 mM with batch cultures in which the initial glucose concentration was 20 mM. Dynamic 
glycosylation efficiency was noted to be effected when the glucose concentration reached 0.6 
mM which was indicated by a 67 % reduction in glycosylated species present. Glycosylation 
efficiency was however recovered when the glucose concentration was brought back to 2.34 
mM. The results therefore indicate that exposure to low glucose concentrations for a short 
period of time does not permanently damage the glycosylation machinery. 
Glutamine is an amino acid which is utilised by cells that have high energy demands and 
synthesise large amounts of protein and nucleic acids in favour or in conjunction with glucose 
as a carbon energy source. The metabolic fates of glutamine in mammalian cells have been 
extensively documented and reviewed (Vriezen et al., 1997 and Schneider et al., 1996). 
Typical concentrations of glutamine in mammalian cell cultures vary in the range of 1-7 mM 
(Freshney, 1987). Starvation of glutamine brought about by a limitation in the culture media 
has also been noted to have implications for the glycosylation of produced recombinant 
proteins. Glutamine starvation has been proposed to result in a decrease in the galactosylation 
of glycan structures on a newly emerging polypeptide chain. Nyberg et al., (1999) provided a 
mechanism by which this may occur. During glutamine starvation, amino sugar formation 
limits UDP-GNAc synthesis, since glutamine is the ammonia donor in this reaction. The 
glutamine;fructose-6-P amidotransferase (GFAT) enzyme responsible for amino sugar 
formation transfers an ammonia group from glutamine to fructose-6-P to form glucosamine-
6-P. The rate of the reaction depends upon glutamine conc. Limited glutamine supply for 
amino sugar formation can explain low UDP-GNAc. Ryll et al., (1994) explained why 
feeding with amino sugars such as glucosamine or galactosamine leads to accumulation of 
UDP-GlcNAc. The excess amino sugars are converted into hexosamine phosphates, 
acetylated, and reacted with UTP to make UTPGlcNAc. As the GFAT reaction is not 
reversible, the majority of hexosamine formed accumulates as nucleotide sugars. Glutamine 
limitation in cultures has also been associated with the prevalence of high mannose structures 
and reduced terminal sialylation. Wong et al., (2004) studies the effect of glutamine and 
glucose limitation and feeding on glycan microheterogeneity. Microheterogeneity of glycans 
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at Asn25 and Asn97 of IFN-γ were relatively unaffected by glutamine limitation. They did 
however see an increase in hybrid types at both glycosylation sites and one extra high 
mannose type at Asn25 that were not present in batch cultures were glutamine was not 
limited. Such results illustrate that glutamine limitation can affect complete processing of 
high-mannose types to full complex types resulting in hybrid types. Additional glucose 
control resulted in a greater num of high-mannose type glycans at both glycan sites. It was 
concluded that in all cases the presence of high mannose types were due to limitations of 
UDP-GlcNAc cause by limited glutamine and glucose. The effect of glutamine limitation of 
terminal sialylation was also investigated. Limiting the glutamine concentration to 0.5 mM in 
control cultures, in comparison to a concentration of 4 mM in batch cultures, did not affect 
sialylation. However at concentrations of 0.3 mM and 0.1 mM sialylation decreased by 17 
and 23 % respectively. It was proposed that this was due to impaired sialytransferase activity 
or a low concentration of substrate or donor CMP-NANA. Also UDP-GlcNAc is essential for 
formation of ManNac which is a precursor of CMP-NANA. UDP-GlcNAc has been well 
documented to be reduced in glutamine and glucose limited cultures. 
Typically yield concentrations up to 5 mM ammonia are expected for typical concentrations 
of glutamine added to cultures (Hayter et al., 1991). The impact of increasing ammonia 
concentrations in culture on recombinant protein glycosylation has also been investigated. 
The overall effect of ammonium ions on recombinant protein glycosylation include increases 
in glycan antennary (Gawlitzek et al., 1998) and reduced levels of sialyated glycans (Hossler 
et al., 2009; Jenkins et al., 1996). Overall, two main mechanisms for the inhibition of 
sialylation by ammonia have been proposed. The first mechanism outlines how ammonium 
ions induce increased glycan antennary and decreased sialyation. Enhanced incorporation of 
ammonia into glucosamine increases the ration of UDP-GlcNAc/UTP ratio. Glucosamine is a 
precursor for UDP-GlcNAc. This mechanism has been described for a number of cell lines 
including BHK, CHO, Ltk929 and hybridoma and contributes to the formation of more 
complex glycans through the transfer of glucosamine and galactose units from the increased 
concentration of nucleotide donors, onto the glycan chain (Gawlitzek et al., 1998). In the 
presence of 30 mM NH4Cl, the UDP-GNAc pool accounted for 60 % of the total nucleotide 
pool in comparison to 9.2 % for standard culture conditions (Yang and Butler, 2002). 
Although increased pools of UDP-GNAc describe the effect of ammonia on increased glycan 
antennary, it has also been suggested as a plausible mechanism for the decreased sialyation 
observed under high ammonia concentrations. Pels Rijcken et al., (1995) described how 
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increased pools of UDP-GNAc and their subsequent increased transfer into the trans-golgi 
may impair the transport of Cytidine 5’ –monophospho-N-acetyl neuraminic acid (CMP-
NANA) into the golgi resulting in decreased sialyation due to lack of available sialic acid 
donors.  This nucleotide sugar competes with CMP-NANA for transport into the golgi and 
therefore decrease the amount of CMP-NANA available for sialylation. The second 
mechanism suggests that ammonia raises the pH of the golgi thereby shifting the optimal pH 
of the sialy transferase enzymes (Butler, 2006; Hossler et al., 2009; Jenkins et al., 1996). 
Ammonium ions act as a weak base, which accumulate in the slightly acidic trans-golgi 
compartment, altering the pH outside of the range for optimal sialy transferase activity 
(Anderson and Goochee, 1995; Gawlitzek et al., 2000).  This concept is supported by the 
findings of Barasch et al., (1991) in which it was reported that defective acidification of 
intracellular organelles in the cells of cystic fibrosis patients resulted in reduced sialyation of 
glycoproteins and lipids brought about by reduced sialytransferase activity. A pH of 7.0 in the 
trans golgi results in a 2-fold decrease in the activity of these enzymes (Anderson and 
Goochee, 1995). Jenkins et al., (1996) reported increasing ammonium ion concentrations, 
above 2 mM, may compromise sialytransferase present in GA. This resulted in reduced α 2,6-
linked sialic acid in G-CSF produced in CHO.  In the study increases in ammonium ions also 
reduced extent of recombinant placental lactogen N-glycosylation by CHO cells, but was 
dependent on pH.  The interaction of ammonia on glycosylation genes has also been more 
recently investigated as a plausible mechanism for alterations in glycosylation at increased 
ammonia concentrations (Chen and Harcum, 2006). 
Although it was stated above that the most important medium components to affect the 
glycosylation profile of recombinant protein are glucose and glutamine, a significant amount 
of research has also been completed assessing the effect of other media components on 
protein glycosylation. The inclusion of sodium butyrate in culture media has been associated 
with increasing the specific productivity of the cells while decreasing the cellular growth rate 
by up regulating apoptosis mechanisms (Hossler et al., 2009). Although the inclusion of the 
small molecule medium component has beneficial effects on growth and productivity, studies 
conducted by Sung et al., (2004) suggest that an overall decline in product quality is to be 
expected. CHO DUKX-B11 cultured in shake flasks under varying concentrations of sodium 
butyrate resulted in a product displaying increased microheterogeneity and reduced levels of 
sialylation. Other studies have assessed the effect of medium fortification with amino acids 
on recombinant protein quality. Crowell et al., 2007 reported an increase in the level of 
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sialylation by supplementing with amino acids which had been depleted from the culture at 
earlier stages. The inclusion of nucleoside-sugar precursors such as glucosamine has also 
been investigated as these precursors affect the intracellular nucleotide sugar pools and the 
subsequent resulting sialylation and antennary levels. Yang and Butler, (2002) demonstrated 
that the incubation of recombinant EPO producing CHO-K1 cells in a concentration greater 
than 10 mM glucosamine resulted in a 37 % decrease in the sialylation on tetrasialyated 
glycans. It was determined that the intracellular pool of UDP-GlcNAc was at least 2-fold 
higher due to glucosamine addition. As explained above, the resulting decrease in terminal 
sialylation may be due to the decreased pool of CMP-NANA resulting from increased levels 
of UDP-GlcNAc. As well as influencing the nucleotide sugar pools, many other medium 
components can influence the activities of the glycosyltransferase enzymes. Manganese for 
example is a metal ion cofactor of the GnT enzymes. Pacis et al., (2011) reported an ~ 10 % 
decrease in the level of intermediate high mannose structures on recombinant IgG1 upon 
supplementation of the media with 1.0 μM McCl2. It was deduced that the addition of 
appropriate concentrations of MnCl2 to culture media, in the range of 0.25-1.0 μM may be 
beneficial in reducing undesirably high levels of high mannose hybrid glycans and achieving 
more complex glycans as a result of GlcNAc addition by GnT enzymes. Gawlitzek et al., 
(2009) tested the effect of additional manganese in the range of 10 nM – 100 μM for 
increased site occupancy of N-glycans on t-PA. Site occupancy was increased by 2.5 % in 
comparison to other cultures. . It was proposed that the increased site occupancy was as a 
result of increased OST activity resulting from the manganese.  No specific changes in site 
occupancy were noted between 100 nM and 100 μM. 
 
1.4: Glycosylation of rIgG1 
 The basic structure of an IgG molecule is of four polypeptide chains, two heavy 
chains (molecular weight 50 kDa) and two light chains (molecular weight 25 kDa). The 
heavy chain has one variable region and three constant regions. The light chain has one 
variable region and one constant region. The variable regions are responsible for antigen 
binding (Conroy et al., 2009). Through the formation of covalent (16 for IgG1 and IgG4, 8 
for IgG2) and noncovalent bonds, the two heavy and light chains form three independent 
protein moieties connected through a flexible linker known as the hinge region (Beck et al., 
2008). Two of these regions are known as the Fab regions. They are identical and contain the 
variable, antigen binding, regions. The third region is referred to as the Fc region is a 
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homodimer and consists of three domains; CH1, CH2 and CH3. The CH2 domains have a 
highly conserved N-glycosylation site at aspargine-297 (Asn-297) (Jefferis 2005). IgG Fc N 
glycans are usually biantennary complex type structures and usually contain a conserved 
heptasccharide core composed of 2 GlcNAc, 3 mannose and 2 GlcNAc residues that are β-1,2 
linked to α-6 mannose and α-3 mannose, forming 2 arms (Beck et al., 2008). 
Most of them are core-fucosylated and are characterised by low levels of galactosylation and 
sialylation. The largest variation in the glycosylation of rIgG1 has been noted in the level of 
galactosylation with biantennary core fucosylated structures containing, two, one or no 
galactose residues (Huhn et al., 2009). The rIgG1 glycoform produced by CHO cells can vary 
widely from clone to clone and are also very much dependent upon cultivation conditions. 
IgG antibodies produced in mammalian cells generally contain low levels of high mannose 
Glycoforms (Man5-9), because most glycoproteins are processed to complex Glycoforms 
G0F, G1F, and G2F. (van Berkel et al., 2009). 
Cell lines producing rIgG1 should be selected based on the production of the IgG with 
fucosylation, galactosylation, and/or sialylation depending on the desired effector 
mechanisms, containing minimal levels of oligomannose-type glycans and putative antigenic 
and/or immunogenic glycan structures (van Berkel et al., 2009). 
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Figure 1.4.1: IgG1 structure containing one consensus N-linked glycosylation site as 
Asn297. 
 
1.5: Objectives of the PhD thesis 
The demand for increased yields in recombinant therapeutic proteins from 
mammalian cell culture systems is constantly rising, requiring cheaper, more efficient, cost 
effective process optimisations than those which currently exist. The biotechnological 
industry has responded to this need with advances being made in cultivation systems and 
their capacities, allowing for the upscaling of mammalian cell cultures resulting in reported 
increased volumetric productivities of 100-fold over the past decade (Jain and Kumar, (2008). 
Scale-up of cultures to large volumes in continuous stirred-tank reactors requires continuous 
monitoring and control of various parameters such as temperature, pH, concentration of 
dissolved gases etc, which have been noted in the above review to affect cellular activities 
across all scales. With the introduction of the Process Analytical Technology (PAT) 
framework initiative by the Food and Drugs Authority (FDA), in 2001, measures have been 
outlined for the strict monitoring and control of the above process parameters. PAT may be 
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defined as “a system for designing, analysing, and controlling manufacture through timely 
measurements (i.e. during processing) of critical quality and performance attributes of raw 
and in-process materials and processes with the goal of insuring final product quality” (Food 
and Drug Administration 2009). This initiative outlines the requirement for a more efficient 
online monitoring system of the entire production process with the key term “quality by 
design” coming to the fore. Therefore in seeking FDA approval for recombinant proteins as 
therapeutic drugs, it is first necessary to identify the CPP’s affecting the mammalian cells in 
culture, with particular attention being paid to the CQA of the recombinant protein produced. 
Once such CPP’s have been identified, monitoring and control systems may be designed and 
put in place enabling the entire production process as well as the product quality to be 
monitored throughout the entire production process as oppose to at the end of the process 
(Lopes et al., 2004). 
Taking into account the ever increasing demand for higher cell and recombinant protein 
yields and also emphasising the strict necessity for monitoring and controlling recombinant 
protein quality, a project was designed entitled “High density CHO cell cultures: improved 
productivity and product quality”. The project was designed with the following aims and 
objectives. 
 
Aim 1: Determination of the effect of ammonia, L-glutamine and L-glutamine substitutes on 
rIgG1 glycosylation and aggregation 
 
Background: One of the CPP’s affecting the quality of recombinant proteins is the metabolic 
profile of the cells in culture. Nutrients, such as glutamine not only provide the energy for 
cell growth but are also necessary for the synthesis of nucleotide sugar donors which act as 
precursors for efficient glycosylation of the produced proteins. The metabolism of nutrient 
components such as glutamine results in the production of metabolic waste products which 
effect cell growth and productivity. The quality of the protein may in turn be outwardly 
affected by changes in cell growth and productivity rates. There is also cause for concern that 
the presence of metabolic by-products also affects protein glycosylation. It has been reported 
that the inefficient energy metabolism of mammalian cells in culture is still a major limiting 
factor for improvements in large scale high cell densities and recombinant protein production. 
The PAT initiative has also placed focus on the necessity to monitor and control nutrients as 
CPP’s in mammalian cell processes. Extensive research in PAT has focused on the 
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development of tools for monitoring and controlling such metabolites in cell culture, 
including infrared spectroscopy (IR) (Foley et al., 2012). Therefore in an initial investigation 
into the progression towards high density CHO DP-12 cell cultures it was first necessary to 
define the window with which cell growth, productivity and product quality could potentially 
be optimised through the alteration of critical media components such as l-glutamine and 
ammonia. 
  
Objective: Varying the concentration of L-glutamine in the culture media will enable the 
determination of the suitable L-glutamine concentration required for achieving high cell 
densities using the above cell line. In addition to high cell densities, product yield and quality 
will also be critical factors used for determining the ideal concentration. While varying the 
concentration of L-glutamine, it is expected that a range of concentrations of ammonia will 
accumulate in the different cultures. The impact of an accumulation of specific ammonia 
concentrations on cellular activities may also be indirectly investigated. L-glutamate will also 
be investigated as a possible carbon source allowing for cell growth and productivity of this 
cell line, in the presence of reduced ammonia concentrations. The experiments will be 
conducted at small scale in a 1 L shake flask platform, allowing for efficient identification of 
suitable L-glutamine concentrations for optimised cell and product yields. The majority of 
research conducted to date investigating the effect of ammonia on protein quality (i.e. 
glycosylation) has involved the introduction of varying ammonia concentrations at the 
beginning of the culture period. The effects on protein glycosylation have been primarily 
concerned with the effects of ammonia on terminal sialylation, i.e. the last step of IgG1 
glycosylation. Through a collaboration with the NIBRT based Dublin-Oxford Glycobiology 
group, a range of N-glycan structures may be identified from rIgG1 samples harvested from 
cultures. Therefore a more dynamic outlook of the effects of ammonia on the glycosylation 
profile of rIgG1 produced in the CHO DP-12 cell line may be obtained. As previous studies 
conducted investigations through the means of high initial ammonia concentrations, it is 
impossible to determine if the reports regarding the affect of ammonia on glycosylation do to 
some extent over-estimate the impact. Another objective of this study is to therefore to 
determine if the effect of ammonia on glycosylation may be different when high ammonia 
concentrations accumulate as a result of cellular metabolism or chemical breakdown of L-
glutamine in comparison to when high initial ammonia concentrations are added to the 
culture. A range of ammonia concentrations will be added initially to cultures. The effect 
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such additions have on cellular activities may be compared and contrasted to those L-
glutamine cultures which gave rise to similar ammonia concentrations by means of 
accumulation. The aggregation state of the protein harvested from all of the cultures will be 
identified. Any alterations in the aggregated state will be compared to alterations in the 
heterogeneity of the glycosylation of the protein with the hope in identifying a link between 
the presence of a specific glycoform and aggregation of the protein. 
 
Aim 2: Scale-up of shake flask cultures to 1.7 L minifors reactor: Investigation of alterations 
in metabolism of rIgG1 glycosylation and or aggregation. 
 
Background: In order to enhance cellular yields and volumetric productivities in mammalian 
cell cultures, the biotechnological sector is continuously developing new methods for the 
scale-up of cultures. The continuing platform of choice for industrial production of 
recombinant proteins from mammalian cell lines is the stirred tank bioreactor. Although 
scale-up does provide a mechanism for the enhancement of volumetric productivities, in 
comparison to typical yields achieved at small scale in shake flask platforms, the 
phenomenon of shearing brought about by mechanical agitation and sparging for aeration can 
have detrimental effects on cell and product yields. 
Objectives: Once the optimal L-glutamine concentration for optimised cell yields, 
productivity and product quality have been identified at small scale, it is necessary to scale-
up such cultures to a bench top stirred tank reactor platform. A dynamic analysis of the 
effects of scale-up on all cellular activities such as growth, metabolism, productivity and 
glycosylation, will be carried out. Any alterations in the cellular glycosylation profile of the 
rIgG1 from scaled-up cultures in comparison to shake flask cultures may be linked to 
alterations in the activities of the cells due to the influence of shearing brought about by 
mechanical agitations and aeration through sparging. Aggregation analysis will also be 
completed on the rIgG1 harvested from the minifors reactor cultures with the aim of 
identifying an effect of scale-up and/or glycan heterogeneity on aggregation of the protein. 
Aim 3: Encapsulation of CHO-DP12 cells in alginate-poly-L-lysine-alginate microcapsules: 
Implications on rIgG1 quality. 
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Background: The CHO DP-12 cell line used in this project typically grows in suspension. 
High cell densities in suspension cultures are however impeded by mechanical and shear 
forces resulting from agitation and aeration schemes in large scale industrial bioreactor. Cell 
immobilisation has been suggested as a vehicle to protect cells for sustained viability and 
enhanced productivity Animal cells have a natural tendency to aggregate and so the 
immobilisation of cells in microcapsules to provide optimal shear-stress free conditions is 
considered a promising technique. 
Objectives: In the quest to produce a high density CHO DP-12 cell culture, the CHO DP-12 
cell line will be cultured in alginate-poly-L-lysine-alginate (APA) microcapsules under batch 
cultivation conditions. All cellular activities will be compared to those observed when the 
cells were cultured in suspension. It is hypothesised that enhanced growth and productivity 
may be achieved due to protection from shear stresses the capsule environment provides. 
Growth may also be promoted by the presence of high concentrations of growth promoting 
autocrine factors in the immediate vicinity of the immobilisation matrix. The quality 
(glycosylation and/or aggregation) of the rIgG1 protein harvested from the encapsulated 
cultures will also be determined. A thorough investigation of the effect of encapsulation as a 
technique on recombinant protein quality is yet to be completed. Protein glycosylation may 
be affected by possible different growth and production activities displayed by the cells. 
Depending on the permeability of the microcapsules to the rIgG1 protein, aggregation of the 
protein may be affected through the association of high concentrations in the immobilisation 
matrix. The results of the encapsulation experiments may in turn outline different CPP’s 
required for monitoring and controlling in encapsulated cultures in comparison to suspension 
cultures. 
Aim 4: Design of an appropriate perfusion system for encapsulated cultures: Implications on 
rIgG1 quality 
Background: The complete colonisation of microcapsules with encapsulated cells has a 
number of limitations, including the prevalence of the immobilisation matrix in the core of 
the capsule. For liquid core microcapsules, such as the APA microcapsules, space limitation 
is not an associated issue. It is hypothesised that cell growth and capsule colonisation may 
also become limited due to nutrient depletion which typically occurs during batch cultivation 
schemes. The APA microcapsules themselves fulfil the one main requirement of any 
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effective perfusion system in that they provide a simple and efficient mechanism for cell 
retention inside the culture vessel and subsequently allow ease of perfusion of fresh and spent 
media to and from the culture. 
Objectives: Based on the results of the batch encapsulated cultures, and also the metabolic 
knowledge gained in Aim 1, a suitable perfusion system will be designed for such cultures 
enabling the addition of growth limiting nutrients and the removal of toxic, inhibitory by-
products. It is hypothesised that further enhancements in cell and product yields may be 
achieved than those which were observed in the batch encapsulated cultures. Any 
implications such a cultivation scheme may have on the quality (glycosylation and/or 
aggregation) of the rIgG1 will be monitored. 
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Chapter 2:   Materials and Methods 
This chapter reviews the standard instruments and methods that were used routinely 
throughout the work. 
Abbreviations 
AFM     Atomic force microscopy 
APS     ammonium peroxodisulfate 
CHO     Chinese hamster ovary 
DTT     dithiothreitol 
GU     glucose unit 
HCl     hydrochloric acid 
HILIC    hydrophilic interaction liquid chromatography 
IgG1     Immunoglobulin G1 
L-GLN   L-glutamine 
L-GLU   L-glutamate 
NaOH    sodium hydroxide 
SEC     size exclusion chromatography 
TEMED   N,N,N,N′-tetramethyl-ethylenediamine 
 
2.1: Cell line and inoculum development 
As a recombinant glycoprotein production model, a Chinese hamster ovary (CHO) 
DP-12 cell line, producing recombinant immunoglobulin G1 (IgG1) was selected for these 
studies. These cells were transfected to secrete recombinant IgG1, a glycoprotein of 
molecular weight 150 kDa. Cells, from a working cell bank stored at -196 °C, were rapidly 
thawed at 37 °C. The cells were used to inoculate a T-flask (75 ml) containing 10 ml of 
ExCell 325 PF CHO Serum-Free medium (w/o L-glutamine) (Sigma Aldrich #: 24340 C) 
supplemented with 4 mM L-glutamine (L-GLN) (Sigma Aldrich #: G7513) and 10 mg/L 
insulin (Sigma Aldrich #: 91077C) at an initial cell density of 1 * 10
6
 cells/ml. After 
incubation at 37 °C and 5 % CO2 for 6 hours, the 10 ml of culture was transferred to a 125 ml 
Erlenmeyer shake flask. A sufficient quantity of media was added to the 125 ml Erlenmeyer 
shake flask resulting in an initial cell density of 0.3 * 10
6
 cells/ml. The cells were incubated 
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in a non-gassed incubator, at 37 °C, 100 rpm agitation in non-vented shake flasks. Cell 
growth was monitored for 5 days. For each of the 5 days, a sufficient quantity of culture 
media was added to the flask in order to adjust the cell density to 0.3 * 10
6
 cells/ml. On day 
5, the cells were harvested and subculture into 30 ml of ExCell 325 PF CHO Serum-Free 
medium (w/o L-glutamine) supplemented with 4 mM L-glutamine, 10 mg/L insulin and 1 μM 
methotrexate (MTX) (Sigma Aldrich #: M9929) at an initial cell concentration of 0.3 * 10
6
 
cells/ml. Upon reaching a cell density of ~ 2 * 10
6
 cells/ml, the cells were harvested by 
centrifugation and used to inoculate a 500 ml Erlenmeyer shake flask containing 150 ml of 
culture medium. 
 
2.2: Cell cultures 
 
2.2.1: Cultivation of CHO DP-12 cells in varying concentrations of L-GLN, L-GLU and 
Ammonia 
 Small-scale experiments for cells grown in varying concentrations of L-GLN, L-
glutamate (L-GLU) and Ammonia were performed in 1 L Erlenmeyer shake flasks with a 
working volume of 350 ml, incubated at 37 °C, 0 % CO2 and 100 rpm agitation. For such 
experiments exponentially growing cells were centrifuged at 200 g for 5 mins and 
resuspended in the appropriate fresh medium for each test case in triplicate at a seeding 
density of 0.3 * 10
6
 cells/ml. 
 
2.2.1.1: Culture medium 
 Cells were cultured in ExCell CHO 325 PF media supplemented with 10 g/L insulin 
and 1 μM MTX and 1:100 Penicillin/Streptomycin (Sigma Aldrich cat #: P0781). Both 
insulin and MTX were prepared as working stock solutions (Section 2.2.1.2). For L-GLN 
cultures, the concentration of L-GLN in the media was varied in the ranges of 0 mM, 4 mM 
and 12 mM. The media was supplemented with L-GLN from a 200 mM stock solution. For 
L-GLU cultures, media was supplemented with a final concentration of 4 mM L-GLU. A L-
GLU stock solution was prepared by adding 2 g of L-Glutamic acid (Sigma Aldrich #: 
G8415) to 20 ml of 1 M hydrochloric acid (HCl). The pH of the solution was adjusted to 7.2 
by adding 15 ml of 2 M sodium hydroxide (NaOH) resulting in a final concentration of 388 
mM. 33 ml of ultra pure H2O was subsequently added to the L-GLU stock solution, resulting 
in a final concentration of 200 mM. For Ammonia cultures, the concentration of ammonium 
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chloride in the media was varied in the ranges of 5 mM and 15 mM. The media was also 
supplemented with 4 mM L-GLN. A 1 M Ammonium chloride stock solution was prepared 
by adding 1.34 g of Ammonium chloride (Sigma Aldrich #: 9434) to 25 ml of ultra pure H2O. 
The pH of the solution was adjusted to 7.2 using 2 M NaOH. The concentration of the stock 
solution was adjusted to 200 mM and 500 mM using ultra pure water for supplementation of 
the media with a final concentration of 5 mM and 15 mM Ammonia respectively. 
 
2.2.1.2: Preparation of insulin and methotrexate (MTX) stock solution 
 A 500X (5 mg/ml) working stock solution of insulin was routinely prepared by adding 
10 mg Insulin, Recombinant human 5f to 10 ml of a 0.01 M HCl solution. The solution was 
sterile syringe filtered (0.22 μm Fisher Scientific cat #: FDM-340-010U). The stock solution 
was added to culture medium directly before use in order to achieve a concentration of 10 
mg/L insulin in media. 
A 2.2 mM MTX stock solution was prepared by adding 16.5 mg of MTX to 16.5 ml of 1 M 
NaOH. The solution was sterile filtered and added to culture medium directly before use in 
order to achieve a concentration of 1 μM MTX in the media. 
 
2.2.2: Cultivation of CHO DP-12 cells in suspension in bench top minifors reactor under 
batch cultivation conditions 
 For experiments at larger scale, cells were grown in 1.7 L (1.2 L working volume) 
Minifors reactors (Infors, Bottmingen, Switzerland). Cells were cultured in ExCell CHO 325 
PF media supplemented with 4 mM L-GLN, 10 g/L insulin and 1 μM MTX, 0.01 % antifoam 
C (Sigma Aldrich #: 59920C). Cultures were carried out at 37 °C and 100 rpm agitation. The 
minifors reactor was operated under conditions of 95 % DO by means of sparging with 
compressed air (flowrate of 0.06 L/min). The pH was also controlled at 7.2 through automatic 
addition of 2 M  NaOH, via a feed line, or CO2 sparging (through the headspace at a flowrate 
of 0.047 vvm).   
Batch suspension culture experiments were carried out in triplicate in order to identify the 
growth, metabolism and rIgG1 production kinetics and quality of the CHO DP-12 cell line.  
For such experiments exponentially growing cells in 500 ml Erlenmeyer shake flasks were 
centrifuged at 200 g for 5 mins and resuspended in the appropriate fresh medium in order to 
inoculate the reactor at a seeding density of 0.3 * 10
6
 cells/ml. 
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No data was found in literature concerning ExCell CHO 325 PF medium density or kinematic 
viscosity. These values correspond to average values of other culture medium, as utilised for 
similar maximum shear rate in similar stirred tank configured reactors by Fernandes-
Platzgummer et al., (2011). 
 
Table 2.2.2.1: 1.7 L minifors reactor characteristics and culture medium properties 
Parameter Value 
Working volume (VL) 1.2 L 
Vessel diameter (DT) 10.5 cm 
  
Impeller diameter (Di) 6.7 cm 
Impeller thickness (Ti) 0.13 mm 
Impeller width (Wi) 6.9 cm 
  
Culture medium density (ρ) 1.005 g/ml 
Culture medium kinematic viscosity (υ) 0.0092 cm2/s 
 
2.2.2.1: Estimation of maximum shear stress under stirred conditions in 1.7 L minifors 
reactor 
 The maximum shear stress under stirred conditions in the 1.7 L minifors reactor was 
determined based on the work presented by Fernandes-Platzgummer et al., (2011), in which 
the effect of shear stress, brought about by stirred conditions, on a mouse embryonic stem 
cell line was determined. Theoretical values of maximum shear stress under stirred 
conditions, max  (dyn/cm
2
), can be determined through the evaluation of Equation (2.2.2.1.1). 
The equation assumes that the shear stress created by impeller rotation is a result of flow 
through Kolmogorov eddies. Agitation results in the formation of turbulent eddies which 
dissipate energy by disintegrating into Kolmogorov eddies. (Cherry and Kwon, 1990; Yoon 
et al., 2005; Abranches et al., 2006). 
  2/1max )..(.33.5  t     (2.2.2.1.1) 
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where  denotes fluid density and v  denotes the kinematic viscosity. t  is the total energy 
dissipated per unit mass and in sparged conditions is defined by equation (2.2.2.1.2) as 
described by Fernandes-Platzgummer et al., (2014). 
  Sist         (2.2.2.1.2) 
S is the energy dissipation rate from the sparging given by: 
gSS .        (2.2.2.1.3) 
where S  denotes the superfacial gas velocity (cm/s) and g is the gravitational constant (981 
cm/s
2
). S  is determined by the following equation: 
  
2
4
i
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S
D
Q

        (2.2.2.1.4) 
where airQ  is the air flow rate (cm
3
/min) and iD in the impeller diameter. 
iS is the energy dissipation rate from the impeller under sparged conditions given by: 
  


L
S
iS
V
P
       (2.2.2.1.5) 
where LV is the working volume of the reactor and  is the fluid density. SP is the power 
consumption under sparged conditions and may be determined from the following equation: 
  53 iSS DNNpP       (2.2.2.1.6) 
where N  is the agitation rate (s
-1
). SNp  is the dimensionless power number under sparged 
conditions. As described by Fernandes-Platzgummer et al., (2014), NpNpS   for air 
flowrates  typically used in mammalian cell culture. The power number Np can be 
calculated from Nagata correlations (Sen et al., 2002), as described by Fernandes-
Platzgummer et al., (2011). 
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where, 
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where, 
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where iW is the impeller width, tD is the vessel diameter and Re is the Reynolds number. 
  

NDi .Re
2
       (2.2.2.1.12) 
 
2.2.3: Cultivation of CHO DP-12 cells in Alginate-poly-L-lysine-alginate microcapsules in 
bench top minifors reactor and 1 L Erlenmeyer shake flasks under batch and control-fed 
perfusion cultivation conditions 
 
2.2.3.1: Alginate-poly-L-lysine-alginate microcapsule formation 
Microcapsules were prepared under completely sterile conditions using an 
encapsulation device (Encapsulator® Inotech, Dottikon, Switzerland). This instrument may 
be described as a droplet generator which utilises laminar jet break up technology for the 
production of highly monodisperse small droplets (200 μm to 1500 μm). The device is 
comprised of a 2-litre glass reaction vessel with stainless steel top and bottom plates and 
attached agitator. The top plate contains a nozzle attached to a vibrating device. The vibrating 
device is insulated from the surrounding structures by rubber mounts in order to avoid the 
generation of resonance frequencies in the system. A feed line connects the nozzle to the 
66 
 
polymer solution vessel. The flow of alginate from the polymer vessel to the nozzle is 
achieved through the delivery of compressed air to the headspace of the polymer vessel to 
provide a headspace pressure of 0.1-2 bar. By regulating the pressure it is therefore possible 
to control the flow rate of alginate through the nozzle, allowing the extrusion of large 
volumes of polymer (1-2 L/h). 
The main steps of the microcapsule production procedure such as precipitation, gellation, 
membrane coating and washing of the microcapsules are performed in the glass reaction 
vessel. The base plate of the vessel houses a porous steel disc, connected to an outlet enabling 
the withdrawal of the different solutions used in the step-wise production of the 
microcapsules, while retaining the capsules inside the vessel. A second port on the top plate 
is connected to a feed line which enables the connection of vessels containing buffers 
required in microcapsules formation to be attached to the glass vessel. The flow of buffers to 
the glass vessel is also achieved through the delivery of compressed air to the headspace of 
the buffer vessel. The glass vessel, feed lines and polymer and buffer vessels are all fully 
autoclavable, enabling the complete microcapsule production process to be performed under 
sterile conditions. 
For the production of microcapsules, the alginate is supplied from the polymer vessel to the 
nozzle at a set feed rate in order to obtain a jet of liquid. A magnetically operated cup is 
suspended from the top plate and may be positioned directly below the nozzle. The cup 
enables the retrieval of any initial polymer drops during priming of the nozzle. A sinusoidal 
vibration frequency is applied to the 300-400 μm diameter nozzle, which disrupts the flow of 
alginate, achieving jet break-up into droplets. An electrical potential is then applied between 
the nozzle and stainless steel ring placed below (~30 mm) the nozzle outlet. The ring is 
electrically insulated from the nozzle and reactor vessel. Due to the electrical charge applied 
between the steel ring and the nozzle, the alginate drops have a highly negatively charged 
surface. As they pass through the steel ring, they are deflected away from the vertical and so 
impact with the gelling solution over a wider defined area.  The result of the applied electrical 
potential is an improvement in the formation and monodisperse of the regular droplets. The 
formation of the monodispersed droplets can be observed through the glass vessel with the 
aid of a stroboscopic light, the frequency of which is directly related to the one applied to the 
nozzle. Vertical dropping beads would impact the gelling solution in the same area and thus 
impact each other resulting in the formation of nonspherical, coalescent drops (Serp et al., 
2000). 
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Figure 2.2.3.1: Schematic representation of the Inotech Encapsulator® according to 
(Gugerli, 2003). 
 
2.2.3.2: CHO DP-12 cell encapsulation in Alginate-poly-L-lysine-alginate microcapsules 
All encapsulation experiments carried out in the 1.7 L minifors reactor required a total 
volume of 300 ml of alginate containing CHO cells per run. Due to the time taken to extrude 
300 ml of alginate, the process was completed in 2 batches of 150 ml alginate containing 
CHO cells. All encapsulation experiments carried out in 1 L Erlenmeyer shake flasks 
required a total volume of 100 ml of alginate containing CHO cells per flask. All of the 
microcapsules required to seed 1 flask could be prepared as one batch. 
Exponentially growing cells in suspension were centrifuged at 200 g for 5 minutes and 
resuspended in the required volume of pre-sterilized (0.2 μm microfiltration) sodium alginate 
solution (1.5 % w/v, Keltone LV Inotech Switzerland) at a density of 0.5 * 10
6
 cells/ml 
sodium alginate. The required volume of alginate was dependent upon the experiment which 
the microcapsules would be used in. For minifors reactor experiments the required volume of 
alginate was 300 ml to be extruded in 150 ml batches (X2). For 1 L Erlenmeyer shake flask 
experiments the required volume was 100 ml per flask, which could be extruded all at once. 
Calcium Alginate (Ca-alginate) beads were formed by extrusion of the sodium alginate 
solution, containing the CHO cells, through the encapsulator nozzle ( diameter 300 μm) into 
the encapsulator glass vessel containing 1L of a 110 mM aqueous CaCl2 solution (pH 7.0) 
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(Sigma Aldrich #: C5670). The reaction was stopped after 10 minutes by the withdrawal of 
the CaCl2 solution through the porous steel disc of the reaction vessel. The beads were 
washed in copious amounts of a saline buffer (0.9 % NaCl, 10 mM MOPS (Sigma Aldrich #: 
M3183), pH 7.0) in order to remove any un-reacted alginate material. For 1.7 L minifors 
reactor experiments this first batch of beads extruded (150 ml) was transferred to a second 
reaction vessel in the saline solution by means of a feed line connected to a second port at the 
base of the first reaction vessel. The second batch of 150 ml beads were then prepared as 
above in the first reaction vessel and subsequently transferred in saline solution to the second 
reaction vessel. All of the following steps for the preparation of capsules were performed on 
the 300 ml of alginate beads containing CHO cells in the second reaction vessel. For 1 L 
Erlenmeyer shake flask, as the total volume of alginate for the experiment could be extruded 
in one batch, and so all of the subsequent microcapsule preparation steps could be performed 
in the first reaction vessel. There was no need for a second reaction vessel for these 
experiments. Capsules were formed by the addition of 1.2 L per 300 ml beads prepared of a 
0.05 % poly-L-lysine (PLL) (Sigma Aldrich #: P2636) in 110 mM CaCl2 solution. The PLL 
was labelled with a fluorescent dextran to enable visualisation of the membrane (Sigma 
Aldrich #: F7250) The molecular weight of the PLL used was 30,000-75,000 kDa. After 
incubation at room temperature for 30 minutes with gentle mixing, the beads were again 
washed with saline buffer, followed by incubation in 1 L, per 300 ml beads prepared, of 0.03 
% (w/v) sodium alginate for 10 minutes. The solid alginate beads formed were again washed 
with saline buffer. Liquefaction of the solid alginate beads to form capsules was achieved 
through incubation of the capsules in 0.05 M sodium citrate (Sigma Aldrich #: S1804) for 15 
minutes with gentle mixing. The resulting microcapsules were washed once with saline 
buffer and equilibrated once with ExCell CHO 325 PF media. Finally the microcapsules were 
immersed in an equal volume of ExCell CHO 325 PF media, supplemented with 4 mM L-
GLN, 10 mg/L insulin and 1 μM MTX. The microcapsules and media were transferred into 
an inoculation bottle attached to the fully porous port in the base plate of the first or second 
reaction vessel, depending on whether all of the microcapsule preparation was being 
conduction in the first or second reaction vessel. The microcapsules were immediately used 
to inoculate the 1.7 L Minifors reactor or 1 L Erlenmeyer shake flasks. All batch 
encapsulated culture experiments were also carried out in triplicate. The control-fed perfusion 
experiment carried out in the 1.7 L minifors reactor was carried out only once. Control-fed 
perfusion experiments carried out in 1 L Erlenmeyer shake flasks were carried out in 
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triplicate. A capsule volume of 300 ml per 900 ml of culture medium (ratio 1:3) was used for 
the 1.7 L minifors reactor cultures. A ratio of 100 ml of capsules per 300 ml of culture media 
was used for 1 L Erlenmeyer shake flask cultures. 
 
2.2.3.3 Bioreactor and shake flask conditions for encapsulated cultures 
 All 1.7 L minifors reactor conditions were maintained as explained above, under 
Section 2.2.3.1, for all batch and the control-fed perfusion cultures carried out. The batch and 
control-fed perfusion cultures performed in 1 L Erlenmeyer shake flask cultures were 
incubated under conditions of 37 °C, 100 rpm agitation in a non-CO2 incubator. Such cultures 
were performed in non-vented 1 L Erlenmeyer shake flasks. A control-fed perfusion culture 
in 1 L Erlenmeyer shake flasks was also carried out in triplicate in a 5 % CO2 incubator under 
conditions of 37 °C and 100 rpm agitation. 
 
2.2.3.4: Control-fed perfusion strategy 
 All control-fed perfusion cultures acted as batch cultures essentially until day 5 of the 
culture period. Perfusion was accomplished by removing one quarter of the volume of the 
total culture volume in microcapsule free spent media and replacing it with the same volume 
of fresh media. Fresh media was ExCell CHO 325 PF supplemented with 10 g/L insulin and 
1 μM MTX.  In 1.7 L minifors reactor cultures, the agitation was switched off in the 
bioreactor to allow the microcapsules to settle. The spent media was subsequently removed 
via a harvest line connected to a graduated Duran bottle. The harvest line was positioned at a 
level in the minifors reactor so as that it was immersed in media only and did not make 
contact with the settled microcapsule bed formed at the bottom of the reactor. Immediately 
after fresh media was added, the agitation in the reactor was re-started. It was estimated that 
the entire perfusion procedure took no longer than 5 minutes. Perfusion was performed once 
daily for  the control-fed perfusion culture carried out in the 1.7 L minifors reactor culture. 
In 1 L Erlenmeyer shake flask cultures, shake flasks were removed from their relevant 
incubators and aseptically placed in a Biosafety cabinet. After approximately 1 minute, 100 
ml of spent media was removed from the shake flask aseptically using a graduated pipette. 
The media was removed by allowing contact of the pipette with the surface of the media 
present in the flask. Care was taking not to remove capsules which had settled at the bottom 
of the shake flask. The same volume of fresh media was then added to each flask using 
aseptic technique. Fresh media was ExCell CHO 325 PF supplemented with 10 g/L insulin 
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and 1 μM MTX. Flasks were immediately returned to their respective incubators. Perfusion 
was performed once daily for unvented shake flask cultures incubated in the non-CO2 
incubator and twice daily from day 9 onwards for the vented shake flask cultures incubated in 
the CO2 incubator. 
Prior to perfusion, sampling of the cultures was performed, Section 2.3 below. Sampling 
enabled enumeration of cell numbers as well as glucose, glutamine and ammonia 
concentrations to be determined. Based on cellular growth rates and specific metabolite 
consumption and production rates calculated, the concentration of glucose and glutamine in 
the fresh medium was adjusted. The adjustments were made to meet the concentrations that 
would be required by a forecasted predicted cell number which would be present in the 
culture on the following day based on the growth rate displayed by the cells. (See Section 2.9 
for calculations). Additional glucose was added by dissolving glucose anhydrous (Sigma 
Aldrich #: 158968) in 7 ml of cell culture grade water. The solution was sterile filtered (0.22 
μm) prior to addition to the pre-sterile filtered fresh perfusion medium. The volume of 
glucose solution being added to the fresh medium was kept constant each day in order to keep 
the dilution factor of the medium constant. The amount of glucose added to the water was 
adjusted according to the cells requirements. The desired concentration of L-glutamine in the 
fresh media was added from a 200 mM stock solution. Once stationary growth had been 
established the glucose and glutamine concentrations were added to meet the requirements of 
the non-growing cells based on the calculated specific consumption rates during this culture 
period. 
The perfusion rate was only adjusted if the ammonia concentration in the control-fed 
perfusion culture approached > 5 mM (i.e. the maximum concentration usually present in a 
batch culture). 
 
2.3. Samples analysis 
Sampling of the shake flask cultures and Minifors reactor cultures was completed on a 
daily basis for biomass concentration determination, concentration of culture metabolites, 
IgG1 purification and quantitation.  Biomass concentration was determined in a daily basis. 
Culture supernatants (4 ml) were aliquoted after centrifugation and filtration (0.45 μm) and 
stored frozen at -80 °C for later analysis. From day 4 onwards, ~10 ml of culture supernatant 
was stored at -80 °C after centrifugation for purification of IgG1 at a later stage. Sampling of 
encapsulated cultures also involved capsule size and capsules strength determination. 
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2.3.1: Biomass determination in suspension cultures 
 Cell concentration and viability was determined microscopically using the Trypan 
blue extrusion method. Cultures samples were initially diluted 1: 2 with 0.4 % trypan blue 
solution (Sigma Aldrich #: T8154). The dilution factor was increased with increasing 
biomass concentrations. The total and viable cell numbers were counted microscopically 
using a Neubauer haemocytometer. 
 
2.3.2: Biomass determination in encapsulated cultures 
Extracapsular biomass was determined microscopically using the trypan blue 
exclusion method according to 2.3.1. Intracapsular biomass concentration determination 
firstly involved release of the cells from the microcapsules. Microcapsules were separated 
from culture media in offline samples using a cell sorter. The cell sorter device consisted of a 
mesh which was impermeable to particles >100 μm, therefore ideal for separating 
microcapsules from culture media. The separated capsules were washed with 1X PBS to 
remove any extracapsular cells present on the surface of the microcapsules. A known volume 
of the microcapsules, mixed with a known volume of 1X PBS in a 1 ml syringe, was then 
extruded through a 300 μm needle 3 times, in order to dissociate cell clusters if present. 
Biomass concentration was subsequently determined using the trypan blue exclusion method 
outlined in 2.3.1. 
 
2.3.3: Metabolite determination 
 Glucose and lactate concentrations were determined by HPLC analysis using a 
Supelco H column, H2SO4 as solvent and a RI detector for all batch cultures. As the control-
fed perfusion cultures required immediate quantification of glucose present in spent media 
samples, the glucose concentration present in the media was determined using a 
commercially available enzymatic kit (Sigma Aldrich #: GAGO20-1KT). Glucose present in 
samples is oxidised to gluconic acid and hydrogen peroxide. O-dianisidine subsequently 
becomes oxidised in a reaction with the hydrogen peroxide and forms a coloured compound 
(brown). A more stable coloured product (pink) is formed upon addition of sulphuric acid to 
the samples. The intensity of the pink colour measured at 540 nm is proportional to the 
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concentration of glucose present in the sample. Glucose concentrations in samples are 
determined from a standard curve prepared from glucose solution provided in the kit.  
Ammonia and L-GLN concentrations were determined enzymatically using a commercially 
available kit (Megazyme; L-Glutamine/Ammonia (Rapid) K-GLNAM 10/08). L-glutamine 
present in samples is deaminated in the presence of Glutaminase to L-glutamate and 
ammonium ions. In the presence of reduced nicotinamide-adenine dinucleotide phosphate 
(NADPH) and glutamate dehydrogenase (GIDH), the ammonia formed in the initial reaction, 
reacts with 2-oxoglutarate to form L-glutamate and NADP
+
. The amount of NADP
+
 formed 
is stoichiometric with the amount of glutamine and ammonia. NADPH consumption is 
measured by the decrease in absorbance at 340 nm. 
 
2.3.4: Capsule size determination 
 Capsule size determination was carried out using a laboratory microscope (Nikon 
Eclipse TI) with the corresponding software for image analysis (NIS-element AR). Thirty 
capsules were measured individually to calculate the average radius and standard deviation, 
as estimated by comparison with a calibrated scale. Generally size distribution was below 3 
% between microcapsules in a given culture conditions at a given time. 
 
2.3.5: Mechanical strength of microcapsules using a Texture analyser 
 Capsule mechanical resistance was routinely measured throughout each of the 
encapsulated culture runs by means of a Texture analyzer (TA.XT plus, Stable Micro 
Systems, United Kingdom). The instrument consists of a mobile piston driven at a constant 
speed. A layer of capsule beneath the piston may be compressed until deformation of the 
capsules is achieved. The force required by the piston to deform the capsules is representative 
of the capsules mechanical resistance. The mechanical resistance is represented as Force 
(g)/capsule. The average number of capsules in the layer compressed is determined using the 
following equation, assuming a hexagonal disposition of the capsules under the probe: 
 
 
2.3.2 caps
probe
caps
r
S
n         (2.3.5.1) 
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With capsn  being the number of capsules under the piston at deformation  , probeS  is the 
probe surface and capsr  is the radius of the capsules at deformation. The average force on each 
capsule is determined by dividing the total measured strength by the number of capsules. 
 
The determination of the capsule radius at deformation, capsr , is based on the deformation 
model described by Gugerli, (2003). 
 
Figure 2.3.5.1: Schematic compression of a capsule  by Texture Analyser piston (Gugerli, 
2003). 
When a capsule is under compression, the radius may be determined by Pythagoras theorem 
in which, ncompressior , is the hypotenuse of a right angled triangle formed in Figure 2.3.5.1 
above. The opposite is )1(0 burstr   and adjacent is given by y . 
By Pythagoras theorem: 
 
 
2
0
22 ))1(()()( burstncompressio ryr       (2.3.5.2) 
 
 
0l
l
          (2.3.5.3) 
With 0l  being the initial diameter of the microcapsules and l  being the compression distance. 
l  is determined by calculating the difference in distance travelled by the piston between 
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when the piston comes into contact with the capsules and that observed when the capsules are 
at 100 % deformation. 
y  may subsequently be determined by the following equation for the volume of a capsules: 
 













643
4 3223
0
xx
yxyrV

   with )1(2 0 burstrx   (2.3.5.4) 
 
Once the number of capsules has been enumerated, Equation 2.3.6.1, the average force 
imposed on each capsule may be determined by dividing the total measured strength by the 
number of capsules. 
 
2.3.6: Determination of capsule permeability to rIgG1 protein 
 Capsules removed from cultures were washed in PBS (1X). 300 μl of capsules were 
immersed in 600 μl of a dextran standard solution (ranging in molecular weight from 10 kDa-
500 kDa; Sigma Aldrich #: FD10S; FD70S; FD150S; FD250S; FD500S ). Dextran standard 
solutions were prepared at a concentration of 0.05 % w/v in PBS. Immediately after addition 
of dextran standards to the microcapsules, 300 μl of the liquid was withdrawn and filtered 
(0.45 μm) for analysis at 450 nm. The concentration of dextran in the solution could be 
enumerated from a standard curve prepared for each molecular weight dextran analysed.  
This value served as the initial concentration denoted by 0C . The capsules immersed in 
dextran standard solution were incubated at room temperature under agitation for 2 hours. 
Following the incubation period, the supernatant was removed from the capsules and filtered 
(0.45 μm) for analysis at 450 nm. Concentrations were enumerated using the standard curve. 
The value for the concentration of dextran in the solution after incubation was denoted by 
fC . The ratio of 
fC
C0  was determined. Values equal to 1 are indicative of no diffusion of 
dextran into microcapsules as the concentration of dextran in the solution surrounding the 
sample is the same before and after incubation. Values approaching 1.5 are indicative of free 
diffusion, Values between 1.5 and 1 indicate permitted diffusion of the dextran, however with 
difficulty. Confirmation of movement of the dextran from the surrounding liquid, into the 
capsules was made using confocal microscopy analysis. 
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2.3.7: IgG1 Purification and quantification 
 rIgG1 was purified from culture supernatants using commercially available high 
affinity Protein A/G Nab spin column kits (Thermo Scientific PN89948). The CHO 
supernatant was thawed and purified immediately as per manufacturer’s instructions. Briefly, 
the Protein A/G Nab spin columns are equilibrated with Binding Buffer (100 mM phosphate, 
150 mM sodium chloride) (2x400 μl). The pre-equilibrated columns are loaded with 500 μl of 
CHO supernatant and incubated at room temperature for 10 minutes with end-over-end 
mixing. The spin column is placed in a collection tube and centrifuged for 1 minute to 
remove the non bound sample components. The column is subsequently washed with Binding 
Buffer (3x400 μl). The rIgG is eluted from the column into a new collection tube with IgG 
Elution Buffer (3x400 μl). The elution buffer is neutralised with Neutralisation Buffer (1 M 
Tris•HCl) (40 μl) Eluted rIgG1 was quantified immediately using nanodrop A 280 nm. The 
purified protein samples were stored at -80 °C for glycan analysis at a later stage. 
The concentration of protein in purified samples was later verified using SEC analysis using 
an Aquity UPLC BEH200 1.7 μm 4.6x150 mm column. A mobile phase containing 50 mM 
sodium phosphate buffer at pH 8.0 was used to identify the IgG1 peak over a run time of 6 
minutes. The flow rate was 0.4 ml/min and the column was maintained at ambient 
temperature. Protein was detected by UV 280nm.  A standard curve of IgG1 (Sigma Aldrich 
#: 14506) was prepared by making dilutions of the 10 mg/ml IgG1 standard in water resulting 
in a range of concentrations from 0.5 mg/ml to 5 mg/ml. The standard curve was prepared by 
plotting the peak area detected vs. the protein concentration in the standard samples. The 
equation generated from this plot was used to enumerate the concentration of IgG1 in the 
purified culture samples. The average error between the concentrations of IgG1 detected 
using the nanodrop and SEC ranged from 0.05 % – 9 %, with a trend for decreasing error as 
the concentration of purified protein in the sample increased. 
 
2.3.8: IgG1 N-glycan analysis 
The N-glycan profiles of the samples were characterized using hydrophilic interaction 
liquid chromatography (HILIC) with fluorescence detection 
 
2.3.8.1: Glycan release and labelling 
IgG samples (100 μg) were reduced in a polypropylene 96-well flat-bottomed 
microplate by adding 2 μl of 5× sample buffer (0.625 ml of 0.5 M Tris [pH 6.6], 1 ml of 10% 
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SDS, and 3.375 ml of water), 2 μl of water, and 1 μl of 0.5 M dithiothreitol (DTT) and 
subsequently incubated at 65 °C for 15 min. The samples were then alkylated by adding 1 μl 
of 100 mM iodoacetamide and were incubated for 30 min in the dark at room temperature. 
The sample was then set into a gel block by adding 22.5 μl of 30% (w/w) acrylamide/0.8% 
(w/v) bis-acrylamide stock solution (37.5:1.0, Protogel, National Diagnostics, Hessle, Hull, 
UK), 11.25 μl of 1.5 M Tris (pH 8.8), 1 μl of 10% SDS, 1 μl of 10% ammonium 
peroxodisulfate (APS), and finally 1 μl of N,N,N,N′-tetramethyl-ethylenediamine (TEMED), 
mixed, and then left to polymerize. The gel blocks were transferred to a filter plate (Whatman 
protein precipitation plate) and then washed with 1 ml of acetonitrile with vortexing on a 
plate mixer (Sarstedt, Leicester, UK) for 10 min, followed by removal of the liquid (all 
washes and elutions were performed on a vacuum manifold). This washing procedure was 
repeated twice with 1 ml of 20 mM NaHCO3 (pH 7.2) followed by 1 ml of acetonitrile. The 
gel pieces were dried in a vacuum centrifuge. N-glycans were released by adding 50 μl of 0.1 
U/ml PNGaseF (Prozyme, Leandro, CA, USA) in 20 mM NaHCO3 (pH 7.2) to reswell the 
gel pieces for 5 min, 50 μl of 20 mM NaHCO3 (pH 7. 2) was added, and then the plates were 
sealed with adhesive film (SealPlate, Web Scientific, Crewe, UK) and incubated overnight at 
37 °C. The released glycans were collected in a 2-ml square tapered polypropylene 96-well 
plate by washing the gel pieces with 3 × 200 μl of water, 200 μl of acetonitrile, 200 μl of 
water, and finally 200 μl of acetonitrile. The released glycans were dried, 20 μl of 1% formic 
acid was added, and the mixture was incubated at room temperature for 40 min and then re-
concentrated. Samples for HILIC analysis were labeled by adding 5 μl of 2AB labelling 
solution (LudgerTag 2AB labelling kit, Ludger, Abingdon, UK), vortexed for 10 min, 
incubated for 30 min at 65 °C, vortexed again for 10 min, and incubated for a further 90 min.  
Excess 2AB was removed using Phynexus normal phase chromatographic tips. Duplicate 
releases were performed for all samples. 
 
2.3.8.2: HILIC Fluorescence  
HILIC was carried out on a 3 μm TSKgel amide-80 (150 mm x 4.6 mm) column as 
detailed in Royle et al., (2008) with retention times expressed as glucose units (GU). The 
principle of this method involves the interaction of the charged silanol groups on the amide 
column with the hydroxyl groups on the carbohydrates in a gradient decreasing acetonitrile. 
The glycans are eluted based on the hydrophilic surface area exposed to resin. The retention 
time of the glycan peaks can be compared with an external 2-AB labelled dextran standard 
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for structural elucidation by converting the retention time of the peaks into GU. The dextran 
standard is a glucose homopolymer obtained by controlled acid hydrolysis of dextran 
resulting in homopolymers between 1 – 22 glucose residues. The GU value of the glycan 
peak is directly related to the number and linkage of its component monosaccharide units. 
 
2.3.8.3: Assignment of GU values 
HILIC analysis of the 2AB labelled N-glycan pool released from IgG1 samples 
purified from cultures separated into a total of 7 main peaks, each with a corresponding GU 
value as determined by comparison with the dextran standard. The corresponding number and 
linkage of the component monosaccharide units represented by each GU value was elucidated 
by carrying out a series of exoglycosidase digestions on one of the released glycans. Each 
exoglycosidase enzyme has a different specificity resulting in the loss of a distinct 
monosaccharide from the previously released glycans. The following exoglycosidase 
enzymes were used: 
 
HILIC analysis of the exoglycosidase treated glycans results in the loss of specific peaks 
from the chromatogram which represent a glycan structure containing the monosaccharide 
which the enzyme used was specific for. The release of a monosaccharide from the glycan 
confers a new structure to the glycan, resulting in a decrease in the GU value representing the 
structure which the treated glycan has now conformed to. As a result of exoglycosidase 
Digestion Enzyme Specificity 
ABS Releases α(2-3), α(2-6) and α(2-8) lined non-reducing 
terminal sialic acid 
BTG Hydrolyses non-reducing terminal β(1-3) and β(1-4) linked 
galactose 
BKF Releases α(1-2) and α(1-6) linked non-reducing terminal 
fucose. Used for release of core α(1-6) fucose residues. 
JBH Releases non-reducing terminal β(1-2,3,4,6) linked N-
acetlyglucosamine and N-acetylgalactosamine residues 
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treatment of the released glycans and use of GlycoBase, the following peaks were identified 
from the GU values obtained: 
 
Table 2.3.8.3.1: Assignment of corresponding number and linkage of the component 
monosaccharide units represented by each GU value elucidated by carrying out a series of 
exoglycosidase digestions on one of the released glycans. 
Peak Structure UOXF Symbol GU 
 
1 
 
F(6)A1/A2 
 
 
 
 
5.39 +/- 0.05 
 
2 
 
F(6)A2 
  
 
5.85 +/- 0.05 
 
3 
 
M5 
 
 
 
6.18 +/- 0.05 
 
4 
 
F(6)A2[6]G1 
 
 
 
6.64 +/- 0.05 
 
5 
 
F(6)A2[3]G1 
 
 
 
6.77 +/- 0.05 
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6 
 
F(6)A2G2 
  
 
7.54 +/- 0.05 
 
7 
 
F(6)A2G2S1 
  
 
8.28 +/- 0.20 
 
 
 
2.3.8.4: Glycan nomenculture 
All N-glycans have two core GlcNAcs: F at the start of the abbreviation indicates a 
core α(1-6) fucose linked to the inner GlcNAc; Mx number (x) of mannose on core GlcNAcs; 
Ax, number of antenna (glcNAc) on trimannosyl core; A2, biantennary with both GlcNAcs as 
β(1-2) linked; A3 triantennary with a GlcNAc linked β1-2 to both mannose and a third 
GlcNAc linked β(1-4) to the α(1-3) linked mannose; A3’, triantennary with a GlcNAc linked 
β(1-2) to both mannose and the third GlcNAc linked β(1-6) to the α(1-6) linked mannose; A4, 
GlcNAcs linked as A3 with additional GlcNAc β(1-6) linked to a α(1-6) mannose; B, 
bisecting GlcNAc linked β(1-4) to β(1-3) mannose; Gx number (x) of β1-4 linked galactose 
on the antenna; Fx, number (x) of linked fucose on antenna, (4) or (3) after the F indicates 
that the Fuc is α(1-4) or α(1-3) linked to the GlcNAc; Sx, number (x) of sialic acids linked to 
galactose; the number 3 or 6 in parentheses after S indicates whether the sialic acid is in an 
α(2-3) or α(2-6) linkage. 
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2.3.9: IgG1 aggregation analysis 
Approximately 10 μg of purified rIgG1, at a concentration of 1 μg/μl, was prepared 
for aggregation analysis using size exclusion chromatography (SEC). The IgG1 aggregates 
and monomers were separated by SEC using an Aquity UPLC BEH200 1.7 μm 4.6x150 mm 
column. The separation was based on an isocratic gradient using 50mM sodium phosphate 
buffer at pH 8.0 over 6 minutes. The flow rate was 0.4 ml/min and the column was 
maintained at ambient temperature. Protein was detected by UV 280nm. The peaks were 
quantified by calculating the relative percentage areas of multimeric, dimeric and monomeric 
species. The results were subsequently expressed in terms of the relative % abundance of 
monomeric rIgG1 present in the samples. 
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2.4: Calculations 
 The specific growth rate,  , was determined by plotting the logarithm of the viable 
cell density *10
6
 (cells/ml) over the cultivation time period (h) during the exponential phase 
of growth. The specific rIgG1 productivity, 1rIgGq , was based on data obtained at the end of 
the stationary phase of growth and evaluated using the following equation: 
   
t
XX
cc
q
tt
tproteintprotein
rIgG
0
)0()(
1 

    (2.4.1) 
 
With c = quantity rIgG1 present (μg), q = specific production rate (ug/ 106 cells/h), Xt0 = 
initial cell number present (10
6
 cells), Xt = cell number present at end of stationary phase, i.e 
maximum viable cells present (10
6
 cells), t = elapsed time (h). 
 
The specific rates of glucose, glutamine, glutamate, lactate and ammonia consumption and 
production were determined based on data obtained during the exponential growth phase and 
evaluated using the following equation 
  metaboliteq  
t
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0
)0()(


  (2.4.2) 
With c = quantity of metabolite present (moles), q = specific consumption/production rate of 
the metabolite, Xt0 = initial number of cells present (10
6
 cells), Xt = number of cells present 
(10
6
 cells), t = elapsed time (h). 
 
The predicted number of cells which would be present in the bioreactor on the following day 
was determined for control-fed perfusion cultures using the following: 
E.g. On day 5 of a culture period, it can be predicted that the number of cells which would be 
present in the bioreactor on day 6 were determined using the following equation: 
  )ln(.)ln( 0max xtx        (2.4.3) 
With x  being the number of cells present in the reactor on day 6, 0x  the number of cells 
present in the reactor on day 5, max the maximum specific growth rate being displayed by the 
cells, t  the length of time between x and 0x , (days). 
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The specific consumption rate being displayed by the cells for glucose and glutamine is 
enumerated using equation 2.9.2 above. The amount of the nutrient required by the predicted 
number of cells present on day 6 was calculated using the following equation: 
  txqQuantity metabolitemetabolite **     (2.4.4) 
With metaboliteq  represented the calculated specific consumption rate being displayed by the 
cells for a given nutrient, x  being the number of cells predicted to be present on day 6, t  
being the length of time between day 5 and 6 (days). 
 
The % colonisation of microcapsules with cells was calculated based on the total number of 
cells present in the culture expressed as a % of the total theoretical maximum number of cells 
possible in the volume of capsules in the culture. 
The maximum number of cells possible in a capsule may be determined by dividing the 
volume of a capsule by the volume of a cell using the following equation: 
 
 
)(
)(
LVolume
LVolume
cell
capsule
  sKepler ' Conjective    (2.4.5) 
 
With the volumes determined using 3
3
4
r , in which r is the radius of the cell or capsule. 
The number of capsules present in a given volume of capsules may be calculated using the 
following equation: 
 
  sKepler
Volume
Volume
capsule
inatea
'
lg
 Conjective     (2.4.6) 
 
Therefore the total theoretical maximum number of cells possible per capsule may be 
determined my multiplying equation 2.9.5 by 2.9.6 
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Chapter 3: Determination of the effect of Ammonia, L-glutamine and L-glutamine 
substitutes on rIgG1 glycosylation and aggregation 
Abstract 
The inefficient energy metabolism of mammalian cells in culture is still a major 
limiting factor for improvements in large scale high cell density cultures. A dynamic study 
was designed in which cells were cultured in varying concentration of L-GLN (0-12 mM) 
with the aim of determining critical levels of both L-glutamine and ammonia effecting cell 
growth, productivity and product quality for a CHO DP-12 cell line producing rIgG1. L-GLN 
was identified as the growth limiting substrate for this cell line. Exponential growth ceased 
upon the depletion of L-GLN in a culture containing 4 mM L-GLN initially. A 65 % decrease 
in specific growth rate occurred in the absence of L-GLN. No significant differences in 
specific growth rates or cell yields were noted when the initial concentration of L-GLN was 
increased to 12 mM. In such cultures cells entered stationary phase before all of the L-GLN 
was depleted, at which point the ammonia concentration was determined to be ~ 7 mM. The 
incorporation of L-GLU (4 mM) in culture media as a substitute for L-GLN reduced the 
cellular growth rate by 46 %, subsequently decreasing the yield of cells in the culture. There 
were no significant difference in the specific rIgG1 production rate displayed by the cells 
when cultured in the presence of 4-12 mM L-GLN and 4 mM L-GLU. A 50 % higher specific 
production rate was observed in the 4 mM L-GLN cultures in comparison to cultures 
containing 0 mM L-GLN. The complex processing of glycan structures attached to the IgG1 
protein were also greatly reduced in both the absence of L-GLN and its substitution with L-
GLU.   
The effects of high initial NH4Cl concentrations (5 and 15 mM) were also determined. This 
study has identified that an accumulation of high concentrations of ammonia (13 mM) 
throughout a culture period, does not impact negatively on the complex processing of glycans 
as is observed in cultures containing high initial NH4Cl concentrations (15 mM). The main 
outcome of this study is that it has identified that L-GLN is a growth limiting substrate for the 
in-house CHO DP-12 cell line. At an accumulated ammonia concentration of 7 mM 
ammonia, exponential cell growth ceased. 
 
Abbreviations 
ATP      adenosine tri-phosphate 
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BHK      baby hamster kidney 
CHO      Chinese hamster ovary 
CMP-NANA     Cytidine 5’ –monophospho-N-acetyl neuraminic acid 
CPP-s     Critical process parameters 
EPO      erythropoietin 
GFAT      glutamine:fructose-6-phosphate 
GlcNAc     N-acetylglucosamine 
GnT      N-acetlyglucosamine transferase 
GS      Glutamine synthase 
HCG      human chorionic gonadotropin  
HEK      human embryo kidney 
IFN-γ      interferon-γ 
IgG1     immunoglobulin-G1 
Il-2      interlukin-2 
L-GLN     L-glutamine 
L-GLU     L-glutamate 
NCAM     Neural adhesion molecule 
NH4Cl     ammonium chloride  
OST      oligosaccharyl transferase 
TCA      tricarboxylic acid 
t-PA      tissue plasminogen activator 
TNFR      tumour necrosis factor receptor 
 UDP-GNAc     Uradine Di Phosphate-N-acetlyhexosamines  
UDP-GalNAc    Uradine Di Phosphate-N-acetlygalactosamine  
 UDP-GlcNAc    Uradine Di Phosphate-N-acetlyglucosamine 
 
3.1: Introduction 
The continued lack of rapid commercialisation of recombinant therapeutic drugs 
produced in mammalian cell cultures is attributed to the necessity to monitor and control a 
vast range of critical process parameters (CPP-s) which affect cell growth, productivity and 
product quality, namely protein glycosylation and/or aggregation. The CPP-s affecting high 
density Chinese hamster ovary (CHO) cell growth and large scale production of high quality 
recombinant protein drugs have been extensively reviewed in Chapter 1, and include 
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temperature, pH, levels of dissolved gases etc. Variations in the possible outcomes of altering 
culture parameters exist between different cell types (hybridoma, baby hamster kidney 
(BHK), CHO etc). Furthermore, different cell lines of the same cell type have been noted to 
respond differently to a changing culture condition.  
It has been reported that the inefficient energy metabolism of mammalian cells in culture is 
still a major limiting factor for improvements in large scale high cell densities and 
recombinant protein production (Taschwer et al., 2012). Metabolism of mammalian cells is 
complex. Over the past three decades efforts have been made to understand the control and 
regulation of carbon source utilisation such as glucose and l-glutamine (L-GLN). It has been 
reported that cells in culture convert approximately 80 % of glucose to lactate (Zeng et al., 
1998), irrespective of cell line. Such rapid aerobic glycolysis and glutaminolysis require the 
use of high concentrations of glucose and L-GLN in cultures resulting in an accumulation of 
subsequently toxic levels of the biosynthetic waste products lactate and ammonia.   
 L-GLN is an amino acid which may be rapidly used by cells that have high energy demands 
and synthesize large amounts of proteins and nucleic acids in addition to glucose as a carbon 
energy source. The metabolic fates of L-GLN in mammalian cells have been extensively 
documented and reviewed by Vriezen et al., (1997) and Schneider et al., (1996), as noted in 
the Introduction Chapter, Section 1.2.5. The theoretical yield of ammonia resulting from the 
catabolism of 1 mole of L-GLN is 2 moles. However due to the alternative possible pathways 
for both the amido group and amino group from L-GLN the actual yield is ammonia may be 
lower (Vriezen et al., 1997). It must also be considered that the fate of L-GLN nitrogen is 
dependent upon the cell line and concentration of other metabolites in the culture such as 
glucose and other amino acids. Mammalian cell lines are derived from different species and 
organs and so therefore differ in specific enzymatic and metabolic patterns, as reviewed by 
Schneider et al., (1996).  An access of L-GLN in cell culture medium undergoes irreversible 
chemical degradation to form pyrrolidonecarboxylic acid in aqueous solutions, such as cell 
culture media. For every one mole of L-GLN degraded, one mole of ammonia is released 
(Schneider et al., 1996), as described in the Introduction Chapter, Section 1.2.5. Typical 
concentrations of L-GLN in mammalian cell cultures vary in the range of 1-7 mM, depending 
on cell type and line, and typically yield concentrations up to 5 mM ammonia. (Freshney, 
1987; Hayter et al., 1991). However there are reports of ammonia accumulation of up to 10 
mM in a standard batch culture (Ozturk et al., 1992). In addition, initial L-GLN 
concentrations of 8-40 mM have also been reported, which in turn would result in the 
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accumulation of high ammonia concentrations (Flickinger et al., 1992). Efforts have been 
made in order to identify the optimum L-GLN concentration required for maximum cell 
growth and productivity, while maintaining the ammonia concentration accumulated in the 
culture below the critical level at which toxification is induced. Yang and Butler, (2000) 
demonstrated no significant difference in cell growth for CHO cells producing the 
recombinant protein erythropoietin (EPO) in the presence of 2 mM and 4 mM L-GLN. 
However the final yield of cells in 20 mM L-GLN was 50 % lower than that observed in 4 
mM L-GLN. The highest recombinant protein concentration was present in the 2 mM L-GLN 
culture. Similar results were presented by Rajendra et al., (2000), in that the highest 
concentration of rIgG produced in CHO cell cultures occurred in the presence of 2 mM L-
GLN. The effects of L-GLN limitation and an excess of L-GLN were investigated by Vriezen 
et al., (1997).  In fed-batch cultures, it was determined that an L-GLN feed concentration of 
0.5 to 2 mM resulted in a linear increase in biomass concentration for two murine hybridoma 
cell lines. No further increases in biomass yield were achieved when the concentration of L-
GLN was in excess at 4 mM. Low L-GLN feed concentrations have also been noted to 
improve product yields. An L-GLN feed concentration of 0.3 mM enabled a 10-fold increase 
in the yield of interferon-γ (IFN-γ) in a CHO cell line. Although lower L-GLN concentrations 
appear to promote cell growth and productivity, reduced cellular growth rates and 
recombinant protein accumulation have been reported in cultures containing no glutamine 
(Burleigh et al., 2011; Rajendra et al., 2012) and cultures containing extremely limiting L-
GLN concentrations, such as 0.1 mM (Wong et al., 2004). 
As L-GLN has been presented above as one of the main energy and nitrogen sources for 
actively growing cells in culture, one may have previously hypothesised that increased 
concentrations of L-GLN in cultures would in turn promote higher biomass yields and 
subsequently increased recombinant protein production. In the above studies presented, it was 
concluded that the inhibitory effects of high L-GLN concentrations on cell growth and 
productivity, were due to an accumulation of a higher concentration of ammonia in the 
culture, in comparison to the levels obtained for low L-GLN concentrations. The 
accumulation of ammonia limits the growth and productivity enhancement possibilities of 
high L-GLN concentrations. Canning and Fields, (1983); Hansen and Emborg, (1994); Yang 
and Bulter, (2000) have all reported a negative effect of an ammonia concentration as low as 
2 mM on cell growth and recombinant protein production.  
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Varying ammonia concentrations in cultures have also been noted to impact greatly on the 
quality (glycosylation) of the produced recombinant proteins, with many studies having 
reported on decreased sialyation levels caused by the accumulation of ammonia in culture 
media (Anderson and Goochee, 1995; Gawlitzek et al., 2000; Yang and Butler 2002). 
Anderson and Goochee, (1995) reported that ammonia levels as low as 2 mM resulted in 
overall decreased sialyation. At 50 mM ammonium chloride (NH4Cl) there was a decrease in 
the relative percentage of disialyated forms in comparison to monosialyated forms. The 
presence of ammonia in the culture environment has also been reported to give rise to 
increased heterogeneity of glycoproteins resulting from an increase in antennarity of glycan 
structures (Gawlitzek et al., 1998: Grammatikos et al., 1998; Yang and Butler, 2000).  Yang 
and Butler, (2002) investigated CHO cell cultures producing the recombinant protein EPO 
containing a concentration of 30 mM NH4Cl. The accumulation of tetraantennary structures 
was reduced by 57 % in comparison to control cultures in which no ammonia was added. 
Gawlitzek et al., (2000) reported no significant difference in oligosaccharide branching for a 
CHO cell line producing the recombinant protein tumour necrosis factor receptor (TNFR-
IgG). Variations in the effect of ammonia concentrations on production of the recombinant 
protein have also been noted to be cell line specific. Anderson and Goochee, (1995) showed 
that the secretion rate of a CHO cell line producing granulocyte colony-stimulating factor 
was not affected by an ammonia concentration of 0-25 mM NH4Cl. 
Two main mechanisms have been proposed to explain the relationship between ammonium 
toxicity and glycosylation, as reviewed in the Introduction Chapter, Section 1.3.4.2.2. One 
such mechanism explains how ammonium ions act as a weak base, which accumulates in the 
slightly acidic trans-golgi compartment, altering the pH outside of the range for optimal sialy 
transferase activity (Anderson and Goochee, 1995; Gawlitzek et al., 2000). Another 
mechanism describes that elevated ammonium alters the balance of intracellular nucleotide 
sugar pools, resulting in increased levels of UDP-N-acetlyhexosamines (UDP-GNAc) 
including UDP-N-acetlyglucosamine (UDP-GlcNAc) and UDP-N-acetlygalactosamine 
(UDP-GalNAc) in a dose dependent manner (Gawlitzek et al., 1998; Yang and Butler, 
2002).). Lower expression levels for the galactosylation and sialyation enzymes, β1,4-
galctosyltransferase and α2,3-sialytransferase, was observed under increased ammonium 
concentration conditions (Chen and Harcum, 2006). 
In an effort to reduce the accumulation of ammonia in the culture media, a number of 
physical strategies have been employed, reviewed by Schneider et al., 1995 and noted in 
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Section 1.2.5 of Introduction Chapter. An alternative approach involved the substitution of L-
GLN with less ammoniagenic substrates or analogs such as L-GLU, asparagines, and 
dipeptides such as l-alanyl-glutamine (commercially known as Glutamax) and glycyl-l-
glutamine (Altamirano et al., 2004 Altamirano et al., 2000; Hassel et al., 1991). L-GLU in 
comparison to L-GLN has only one amino group and is utilised by cells much more 
efficiently than L-GLN resulting in lower accumulations of ammonia brought about by cell 
metabolism. L-GLU does not suffer from spontaneous decomposition into ammonium ions 
are so is a favourable substitute over glutamine as a carbon energy source (Altamirano et al., 
2000). 
A great deal of effort has been made to understand the impact of L-GLN, ammonia and L-
GLN substitutes on mammalian cell growth, productivity and product quality over the past 
three decades. The results to date, do however suggest that the extent of the impact of the 
above metabolites may be cell line specific (Anderson and Goochee, 1995), with reports 
suggesting that CHO cells may be less sensitive to ammonia than other cell lines (Hassell et 
al., 1991). The impact of altering carbon and ammonia concentration on glycosylation has 
primarily focused on their effect on sialyation of glycoproteins, with only few papers 
reporting on their influence on other glycoforms, such as galactosylation (Hong et al., 2010). 
The authors of this study by Hong et al., (2010) suggested that the use of high ammonia 
concentrations, in the form of NH4Cl, at the beginning of the culture, may impact the 
glycosylation profiles of recombinant proteins more adversely than that which may occur 
when high ammonia concentrations arise throughout the culture period as a result of cell 
metabolism/chemical degradation of L-GLN.  In fitting with the overall first aim of the thesis, 
efforts will be made to identify L-GLN and ammonia as CPP-s affecting high cell densities, 
productivities and product quality with the overall aim of finding optimum medium 
concentrations of the metabolites for most efficient growth and productivity and quality. In 
doing so complete glycol profiles will be obtained using methods described by Royle et al., 
(2008) allowing a thorough analysis of effect of L-GLN, ammonia and L-GLN substitution 
on complete protein quality characterisation. Aggregation of protein will also be investigated. 
The experimental design will involve the inclusion of L-GLN concentrations in the range of 
0, 4 and12 mM, L-GLU concentrations in the range of 0-4 mM and ammonia concentrations 
(NH4Cl) in the range of 5-15 mM. A concentration of 4 mM L-GLN is typical for the 
majority of mammalian cell culture process, according to medium manufacturer guidelines 
(Sigma Aldrich, 2012). In previous studies, mentioned above, it has been noted that higher 
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concentrations of L-GLN such as 40 mM have been previously tested for mammalian cell 
lines (Flickenger et al., 1992). However in this study 12 mM L-GLN was chosen for the 
highest concentration of L-GLN tested as the concentration of ammonia arising from its 
metabolism would be more comparable to those levels which typically arise in batch cultures 
(Ozturk et al., 1992). The 4 mM L-GLU concentration may be directly compared and 
contrasted to the 4 mM L-GLN culture enabling the determination of the possibility of this 
metabolite as a substitute for L-GLN. The rationale behind choosing 5-15 mM NH4Cl is due 
to the fact that these are the concentrations of NH4Cl typically incorporated into cell culture 
medium to test the effect of ammonia (Hong et al., 2010). To ensure that any growth 
characteristics displayed by the cells in the ammonia cultures are due to the impact of 
ammonia and not due to the absence of a carbon source, 4 mM L-GLN will also be included 
in these 5-15 mM NH4Cl cultures. It is hypothesised that the results of such an experiment 
will enable (i) the determination of the effect of the varying concentrations of the above 
metabolites on this specific cell line, CHO DP-12 producing the recombinant protein 
Immunoglobulin G1 (IgG1) (ii) a complete and dynamic study of the effect of the above 
metabolites on the heterogeneity of a range of N-glycan structures, including galactose and 
sialic acid structures and (iii) the determination if previous reports investigating the effect of 
ammonia through the addition of high initial NH4Cl concentration in the cultures, do over-
estimate the impact of ammonia in comparison to high concentrations arising throughout the 
cultivation period. It is envisaged that comparison of results from the 12 mM L-GLN culture 
and 15 mM Ammonia culture will enable such comparisons. 
 
3.2: Results 
 
3.2.1: Effect on CHO cell growth and viability 
 To evaluate the effect of varying concentrations of L-GLN, L-GLU and ammonia on 
the CHO cell growth and viability, CHO cells at an initial concentration of 3 * 10
5
 cells/ml 
were grown in ExCell CHO 325 PF media supplemented with 0-12 mM L-GLN, 0-4 mM L-
GLU and 5 and 15 mM Ammonia. The Ammonia cultures also contained 4 mM L-GLN. The 
final culture volume was 300 ml and cultures were carried out in 1 L Erlenmeyer shake flasks 
in triplicate.  
Figures 3.2.1.1 and 3.2.1.2 and the growth stats presented in Table 3.2.1.1 below, allow the 
growth patterns and viability of the cells in the various cultures to be compared and 
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contrasted. The highest maximum specific growth rate, μmax (h
-1
), was displayed by cells 
cultured in media containing 4 mM L-GLN, 65 % higher than that observed in cultures 
containing no L-GLN. Increasing the concentration of L-GLN in the media to 12 mM 
resulted in a minimal decrease in the maximum specific growth rate displayed by the cells. 
However the maximum viable cell density attained in these cultures was not significantly 
different. The inclusion of 4 mM L-GLN and 12 mM L-GLN in the culture media resulted in 
an increased maximum viable cell density of 51 % and 42 %, respectively, in comparison to 
the 0 mM L-GLN culture. The viability remained high, above 96 %, until day 6 in the 4 mM 
L-GLN culture and until day 5 in the 12 mM L-GLN culture. 
The lowest maximum specific growth rate was displayed by cells cultured in media 
containing 4 mM L-GLU. Neither the growth nor the maximum viable cell density displayed 
by the cells in the 4 mM L-GLU culture were significantly different from the 0 mM culture. 
Both the 4 mM L-GLU culture and the 0 mM culture displayed increased culture longevity in 
comparison to all other cultures. Viability in the 0 mM and 4 mM L-GLU cultures remained 
above 86 % until day 16 and above 96 % until day 11 respectively.  
The inclusion of 5 mM Ammonia and 15 mM Ammonia in the culture media, already 
containing 4 mM L-GLN, resulted in a 38 % and 58 % lower maximum specific growth rate, 
respectively, in comparison to the 4 mM L-GLN culture. However the maximum specific 
growth rate displayed by the cells was higher than that of the 0 mM culture. Overall the 
lowest maximum viable cell density reached was in the 15 mM ammonia culture. The cells 
cultured in the presence of 15 mM Ammonia had a 60 % lower maximum viable cell density 
at the end of the exponential growth period in comparison to cells culture in 4 mM L-GLN. 
The inclusion of 5 and 15 mM ammonia in the culture media did not however appear to affect 
the viability of the cells. The viability of the cells appeared to follow the same trend as that 
observed in the 4 mM and 12 mM L-GLN cultures. 
As noted in Figure 3.2.1.1 there were differences in the time points at which cells entered in 
the exponential phase, stationary phase and death phase between each of the culture 
conditions tested. For the remainder of the results to follow, comparisons will be made 
between concentrations of protein produced, quality of protein produced and metabolic 
consumption and production profiles over the various exponential and stationary growth 
periods. As there are differences in the time points when these specific growth periods 
occurred, Table 3.2.1.2 below presents the periods of time when the lag, exponential and 
stationary phases ended in each culture. 
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Figure 3.2.1.1: Correlation of the viable cell density displayed by cells over time when 
cultured in varying concentrations of L-GLN, L-GLU and ammonia. Cells were inoculated at 
0.3 * 10
6
 cell/ml into a culture volume of 300 ml ExCell CHO 325 PF media containing 0-12 
mM GLN, 0-4 mM GLU and 5-15 mM Amm. Cultures were performed in 1 L Erlenmeyer 
shake flasks. Viable cell density was determined daily until viability reached below ~50 %.  
Values are means +/- STD of triplicate cultures performed for each condition tested. 
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Figure 3.2.1.2: Correlation of the % viability over the cultivation period for cells grown in 
the presence of varying concentrations of GLN, GLU and Amm. Cell viability was 
determined on a daily basis until cultivation was ceased when viability decreased to ~50 %. 
Values are means +/- STD of triplicate cultures performed for each culture condition tested. 
Table 3.2.1.1: Calculated maximum specific growth rates displayed by cells cultured in 
varying concentrations of L-GLN, L-GLU and ammonia over the exponential growth period. 
The growth rate was calculated from a plot of the logarithm of the viable cell density over the 
cultivation time (days) Values are mean of triplicate cultures performed for each of the 
conditions tested +/- STD. 
Culture μmax (h
-1
)
0 mM L-GLN/L-GLU/Amm 0.0107 +/- 0.0005
4 mM L-GLN 0.0312 +/- 0.0006
12 mM L-GLN 0.0282 +/- 0.0005
4 mM L-GLU 0.0096 +/- 0.0002
5 mM Amm + 4 mM L-GLN 0.0195 +/- 0.0015
15 mM Amm + 4 mM L-GLN 0.0130 +/- 0.0002
2.337 +/- 0.085
2.49 +/- 0.240
1.715 +/- 0.120
Max VCD (*10
6
 cells/ml)
2.425 +/- 0.075
4.295 +/- 0.191
4.222 +/- 0.371
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Table 3.2.1.2: Time point (day) at which each corresponding growth phase ended in each of 
the culture conditions tested as determined from an LN plot of viable cells density (*10
6
 
cells/ml) over the cultivation period. 
End of lag phase End of exponential End of stationary 
phase phase 
0 mM L-GLN/L-GLU/Amm 5 13 17
4 mM L-GLN 1 4 7
12 mM L-GLN no lag phase 4 7
4 mM L-GLU 3 11 13
5 mM Amm + 4 mM L-GLN 1 5 7
15 mM Amm + 4 mM L-GLN 1 6 10
Culture
 
 
3.2.2 Effect on cell metabolism 
 The concentration of the major carbon sources, glutamine and glucose, and their 
corresponding by-products, ammonia and lactate, were measured in cultures supplemented 
with GLN, GLU and AMM (Figures 3.2.2.1-3.2.2.4). Samples were removed from cultures 
on a daily basis and centrifuged at 200 g for 5 minutes, followed by filtration of the 
supernatant (0.22 μm PTFE) in order to remove cells and culture debris. Glucose and lactate 
concentrations were determined using HPLC analysis, and glutamine and ammonia analysis 
was carried out using commercially available enzymatic assays kits, as described in Materials 
and Methods section 2.3.3. Determination of the concentration of the various metabolites 
enabled the calculation of the specific substrate uptake rates for each of the experimental 
cultures (Tables 3.2.2.1 and 3.2.2.2). 
Note: no specific production rates were calculated for ammonia for the 0 mM L-GLN/L-
GLU/Amm culture and 4 mM L-GLU as the concentration of ammonia remained at an almost 
constant levels ranging between 1-1.6 mM for the 0 mM L-GLN/L-GLU/Amm culture and 
between 1-1.3 mM for the 4 mM L-GLU culture.  
All cultures were performed in ExCell CHO 325 PF media supplemented with varying 
concentrations of L-GLN, L-GLU and ammonia. The concentration of glucose in the 
commercially available media is expected to be 17.4 mM. In cultures containing 4 mM and 
12 mM L-GLN, all glucose was consumed at the end of the stationary phase of growth. There 
was no difference portrayed in the relative specific consumption rates of glucose between the 
two culture conditions. The specific production of lactate was similar for both culture 
conditions, with similar yields of lactate from glucose reported for both culture conditions. 
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The absence of L-GLN/L-GLU/Ammonia from cultures resulted in the consumption of 
glucose by the end of the exponential growth period. However the specific rate of glucose 
consumption was similar to that displayed by cells cultured in the presence of 4 and 12 mM 
L-GLN. A 2-fold increase in the specific lactate production rate was observed for the 0 mM 
L-GLN/L-GLU/Ammonia culture in comparison to the 4 mM L-GN culture. A yield of 1.39 
mmol/mmol of lactate on glucose was determined over the culture period in the 0 mM L-
GLN/L-GLU/Ammonia culture, in comparison to a yield of 0.95 mmol/mol, which was 
determined for the 4 mM L-GLN culture. The results suggest a less favourable utilisation of 
glucose, via the glycolytic pathway, by the cells resulting in increased lactate production. The 
specific glucose consumption rate displayed by the cells cultured in 4 mM L-GLU was 40 % 
and 33 % lower than that observed in the 0 mM L-GLN/L-GLU/Ammonia and 4 mM L-GLN 
cultures respectively. No significant difference in the specific lactate production rate was 
observed in comparison to the 0 mM L-GLN/L-GLU/Ammonia culture and the overall yield 
of lactate on glucose was similar to that observed in the 0 mM L-GLN/L-GLU/Ammonia 
culture, 1.35 mmol/mmol. Such results again signify inefficient glucose metabolism when 
glutamine is replaced by glutamate. There was no significant difference in the glucose 
consumption rate displayed by cells cultured in 5-15 mM ammonia, also containing 4 mM L-
GLN, in comparison to the 4 mM L-GLN culture. There was however a significant difference 
in the specific lactate production rate observed in the 15 mM ammonia culture in comparison 
to the 5 mM Ammonia culture and the 4 mM L-GLN culture. This did not however result in 
an increased accumulation of lactate due to the lower number of cells present producing the 
lactate. Glucose was not depleted in the 5 mM Ammonia culture until day 10, 3 days after 
cells left stationary growth phase. A concentration of 0.5 mM glucose was present in the 15 
mM Ammonia culture at the end of the culture period, 2 days after the cells had left the 
stationary phase. 
A 65 % higher specific glutamine consumption rate was noted in the 12 mM L-GLN culture, 
in comparison to the 4 mM L-GLN culture. L-GLN was depleted at the end of the 
exponential phase in the 4 mM L-GLN cultures. It was not however depleted at any stage in 
the 12 mM L-GLN cultures. The growth of cells was limited in the 4 mM L-GLN culture by 
L-GLN. As expected increased ammonia production rates were noted in the 12 mM L-GLN 
culture, in comparison to the 4 mM L-GLN culture. As both the rates of L-GLN consumption 
and ammonia production increased proportionally in the 12 mM L-GLN culture in 
comparison to the 4 mM L-GLN culture, it would be expected that the yield of ammonia 
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from L-GLN would be similar for both culture conditions. This was the case with yields of 
ammonia from L-GLN determined as 1.07 and 1.05 mmol/mmol for the 4 mM L-GLN and 
12 mM L-GLN cultures, respectively. Both the absence of L-GLN and its replacement by L-
GLU proved beneficial in reducing the accumulation of ammonia in the cultures. The 
concentration of ammonia remained below 1.6 mM and 1.3 mM during exponential growth 
for both the 0 mM L-GLN/L-GLU/Ammonia and the 4 mM L-GLU cultures. In the ammonia 
cultures (5 & 15 mM), which had an initial L-GLN concentration of 4 mM, L-GLN was not 
consumed at the end of the exponential growth phase. It was consumed before the end of the 
stationary phase in the 5 mM Ammonia culture. Similar specific L-GLN consumption rates 
were displayed in the 5 and 15 mM Ammonia cultures and were approximately 52 % higher 
than those displayed in the 4 mM L-GLN culture. The increased specific L-GLN 
consumption rates did not result in an accumulation of ammonia. The cell specific ammonia 
production rate in the 5 and 15 mM ammonia cultures was lower than that observed in the 4 
mM L-GLN cultures. The lower specific production rate combined with the lower number of 
cells present in the ammonia cultures resulted in an ammonia accumulation of only ~ 2 mM 
higher than the concentration which was present initially in the media. The lower levels of 
ammonia production in these two cultures resulted in expected low yields of ammonia from 
L-GLN, determined to be 0.64 and 0.63 for the 5 mM and 15 mM ammonia cultures, 
respectively. 
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Figure 3.2.2.1: Concentration of glucose present in cultures containing varying 
concentrations of L-GLN, L-GLU and ammonia over the duration of the respective 
cultivation periods. The concentrations of glucose were determined offline by HPLC analysis 
using Supelco H column. Values are mean of triplicate cultures performed in parallel, +/- 
STD, for each of the culture conditions tested. 
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Figure 3.2.2.2: Concentration of lactate present in cultures containing varying concentrations 
of L-GLN, L-GLU and ammonia over the duration of the respective cultivation periods. The 
concentrations of lactate were determined offline by HPLC analysis using Supelco H column. 
Values are mean of triplicate cultures performed in parallel, +/- STD, for each of the culture 
conditions tested. 
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Figure 3.2.2.3: Concentration of glutamine present in cultures containing varying 
concentrations of L-GLN, L-GLU and ammonia over the duration of the respective 
cultivation periods. The concentrations of glutamine were determined offline using a 
commercially available enzymatic assay kit. Values are mean of triplicate cultures performed 
in parallel, +/- STD, for each of the culture conditions tested. 
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Figure 3.2.2.4: Concentration of ammonia present in cultures containing varying 
concentrations of L-GLN, L-GLU and ammonia at the end of the exponential and stationary 
culture periods. The concentrations of ammonia were determined offline using a 
commercially available enzymatic assay kit. Values are mean of triplicate cultures performed 
in parallel for each of the culture conditions tested. 
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Table: 3.2.2.1: Calculated rates of consumption and production of glucose and lactate as 
determined by offline analysis throughout the culture period. Cell specific consumption and 
production rates of the key metabolites were determined during the exponential growth 
phase. Values are mean of triplicate cultures performed in parallel, +/- STD, for each of the 
culture conditions tested. 
  
Glucose 
consumption 
Lactate 
production qglucose qlactate 
  
rate 
(mM/day) 
rate 
(mM/day) 
(mmoles/10
6
 
cell/day) 
(mmoles/10
6
 
cell/day) 
0 mM L-GLN/L-
GLU/Amm 0.99 +/- 0.07 
1.86 +/- 
0.007 
9.27 * 10
-4
 +/- 
2.82 * 10
-5
 
2.32 * 10
-3
 +/- 
5.62 * 10
-5
 
4 mM L-GLN 3.19 +/- 0.003 3.49 +/- 0.17 
8.3 * 10
-4
 +/- 
5.23 * 10
-5
 
1.1 * 10
-3
 +/- 
8.59 * 10
-5
 
12 mM L-GLN 3.28 +/- 0.18 3.65 +/- 0.30 
7.7* 10
-4
 +/- 
9.52 *10
-5
 
1 * 10
-3
 +/- 1.5 * 
10
-4
 
4 mM L-GLU 1.33 +/- 0.12 2.35 +/- 0.25 
5.6 * 10
-4
 +/- 
4.86 * 10
-5
 
2.7 * 10
-3
 +/- 7 * 
10
-4
 
5 mM Amm + 4 
mM L-GLN 2.03 +/- 0.16 2.94 +/- 0.03 
8 * 10
-4
 +/- 7.88 
* 10
-5
 
1.1 * 10
-3
 +/- 2 * 
10
-4
 
15 mM Amm + 4 
mM L-GLN 1.59 +/- 0.02 2.25 +/- 0.13 
1.1 * 10
-3
 +/- 1 * 
10
-4
 
2.4 * 10
-3
 +/- 
4.92 * 10
-6
 
 
Table: 3.2.2.2: Calculated rates of consumption and production of glutamine and ammonia 
as determined by offline analysis throughout the culture period. Cell specific consumption 
and production rates of the key metabolites were determined during the exponential growth 
phase. Values are mean of triplicate cultures performed in parallel, +/- STD, for each of the 
culture conditions tested. 
  
Glutamine 
consumption 
Ammonia 
production qglutamine qammonia 
  rate (mM/day) 
rate 
(mM/day) 
(mmoles/10
6
 
cell/day) 
(mmoles/10
6
 
cell/day) 
4 mM L-GLN 0.89 0.9 2.26 * 10
-4
 3.11 * 10
-4
 
12 mM L-GLN 1.34 1.66 3.84 * 10
-4
 4.81 * 10
-4
 
5 mM Amm + 4 
mM L-GLN 0.86 0.814 4.79 * 10
-4
 3.24 * 10
-4
 
15 mM Amm + 4 
mM L-GLN 0.47 0.567 4.99 * 10
-4
 3.2 * 10
-4
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Table 3.2.2.3: Calculated yield of mmoles of by-product produced per mmoles of 
metabolites consumed over the culture period in cultures containing varying concentrations 
of L-GLN, L-GLU and ammonia. Values are mean of triplicate cultures performed in 
parallel, +/- STD, for each of the culture conditions tested. 
 Ylactate/glucose  
(mmol/mmol) 
Yammonia/glutamine 
(mmol/mmol) 
0 mM L-GLN 
1.39 +/- 0.07 NA 
4 mM L-GLN 
0.95 +/- 0.11 1.07 
12 mM L-GLN 
1.04 +/- 0.06 1.05 
4 mM L-GLU 
1.35 +/-0.03 NA 
5 mM Amm + 4 mM L-GLN 
0.98 +/- 0.09 0.64 
15 mM Amm + 4 mM L-
GLN 
0.92 +/-0.18 0.63 
 
3.2.3 Effect on rIgG1 production 
 To evaluate the effect of varying concentration of GLN, GLU and ammonia in culture 
media on rIgG1 production, samples were removed from the cultures on a daily basis from 
day 4 onwards. As explained in Section 2.3.6 of the materials and methods section, rIgG1 
was purified from media samples removed from the cultures prior to centrifugation at 200 g 
for 5 minutes to remove cells. rIgG1 present in the media was purified using Protein A/G Nab 
spin columns and quantified using the nanodrop at A 280 nm. 
Figure 3.2.3.1 allows comparison of the quantities of rIgG1 produced in all cultures at the end 
of the exponential and stationary growth phases respectively. The highest concentration of 
rIgG1 present at the end of the exponential and stationary growth phases was present in the 4 
mM L-GLU culture. The concentration of rIgG1 present at the end of the stationary phase 
was 50 %, 21 % and 28 % higher than that present in the 0 mM, 4 mM L-GLN and 12 mM L-
GLN cultures respectively. There did not appear to be a significant difference in the 
concentration of rIgG1 produced in the 4 mM L-GLN and 12 mM L-GLN cultures. Both 
contained ~30 % higher concentrations of rIgG1 than the 0 mM culture. The lowest quantities 
of rIgG1 produced were in the 5 mM ammonia and 0 mM culture. The 15 mM ammonia 
culture contained a 20 % higher rIgG1 concentration in comparison to the 5 mM ammonia 
culture at the end of the stationary phase of growth.  
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The above variations in the concentrations rIgG1 produced in the above cultures are due to 
variations in the culture longevities as opposed to differences in the specific rIgG1 rates 
displayed by the cells. Table 3.2.3.1 summaries the rIgG1 production rates and the specific 
production rates, qIgG1, displayed by the cells in the various media. All cultures, with the 
exception of the 0 mM culture, displayed the same specific rIgG1 productivities. It may 
therefore be proposed that the 4 mM L-GLU culture contained the highest concentration of 
rIgG1 due to a cultivation period of 13 days (including exponential and stationary growth 
phases). In regards to efficiency, the 4 mM L-GLN was more beneficial in that the 
concentration of IgG1 was only 18 % lower at the end of the culture period on day 8, in 
comparison to the maximum concentration reached in the 4 mM L-GLU culture on day 13.  
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Figure 3.2.3.1: Concentration of rIgG1 measured at the end of the exponential and stationary 
growth phases in cultures containing varying concentrations of L-GLN, L-GLU and 
ammonia. rIgG1 was first purified using Protein A/G spin columns and quantified in 
duplicate using nanodrop A280 nm with an average value being recorded. Values are the 
mean of triplicate cultures performed in parallel, +/- STD, for each of the culture conditions 
tested. 
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Table 3.2.3.1: Calculated rIgG1 production rates and cell specific production rates for cells 
cultured in varying concentrations of L-GLN, L-GLU and ammonia. rIgG1 was first purified 
using Protein A/G spin columns and quantified using nanodrop A280 nm. Purified rIgG1 was 
quantified in duplicate, with an average value being recorded.  IgG1 production rates were 
calculated from the time point at which protein was harvested until cessation of the culture 
period. Values presented above are the mean of triplicate cultures performed in parallel for 
each of the culture conditions tested. 
Culture
0 mM L-GLN/L-GLU/Amm
4 mM L-GLN
12 mM L-GLN
4 mM L-GLU
5 mM Amm + 4 mM L-GLN
15 mM Amm + 4 mM L-GLN
0.266 +/- 0.014
0.250 +/- 0.02
0.278 +/- 0.014
q IgG1 μg/10
6
 cells/h
0.2694
0.61
0.3997
0.1 +/- 0.025
0.217 +/- 0.029
0.220 +/- 0.005
IgG1 production rate μg/ml/h
0.7291
0.3301
0.5953  
 
3.2.4 Effect on rIgG1 quality 
 To assess the affect of varying concentrations of L-GLN, L-GLU and ammonia on the 
quality of rIgG1 produced, both glycan and aggregation analysis were completed on the 
purified rIgG1 samples harvested cultures at both the end of the exponential and stationary 
growth phases The samples harvested were subjected to N-glycan release and labelled as 
outline in Materials and Methods section 2.3.7.1. HILIC characterisation of the released and 
labelled N-glycans produced a chromatogram consisting of 8 distinctly separated peaks. Each 
of the peaks was assigned a distinctive glucose units (GU) value by comparison to the 
retentions times of the standard A-AB labelled external dextran. Examination of 
exoglycosidase treated samples allowed for the corresponding number and linkage of the 
component monosaccharide units represented by each GU value to be elucidated, as 
described in Materials and Methods section 2.3.7.3. Aggregation analysis of the purified 
samples was carried out using size exclusion chromatography (SEC) 
Figure 3.2.4.1 below illustrates the relative % of the different glycans present on rIgG1 
samples harvested from the cultures at the end of the exponential growth phase. The results 
presented below are similar to that observed at the end of the stationary growth phase (results 
not shown). Irrelevant of the concentration of L-GLN, L-GLU or ammonia, all cultures 
displayed a similar trend in the relative % of glycans present. The earliest form of N-
glycosylation of rIgG1 is denoted by M5, F6A1/A2 and F6A2 as described in Materials and 
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methods section 2.3.7.3. The highest relative percentage of glycans present on the rIgG1 
samples were the early glycoforms, predominantly F6A2. The galactosylated glycoforms are 
denoted by F(6)A2[6]G(4)1 and F(6)A2[3]G(4)1, which contain 1 galactose unit on either of 
the outer GlcNAc arms, and F(6)A2G2 and A2G2 which contain a galactose residue on each 
of the outer GlcNAc arms. Of the galactosylated glycoforms present, the F(6)A2[6]G(4)1 
were the predominant form in all cultures, independent of supplement concentration. The 
glycan which was of lowest relative % in the cultures was the most complex fucosylated and 
sialyated glycan F(6)A2G2S1 
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Figure 3.2.4.1: Relative % of N-glycan forms detected on rIgG1 samples harvested from 
cultures containing varying concentrations of L-GLN, L-GLU and Ammonia at the end of the 
exponential growth phase. N-glycans were released from the rIgG1 samples by means of 
PNGaseF digestion. Samples for HILIC analysis were labeled by adding 5 μl of 2AB 
labelling solution. The retention time of the glycan peaks was compared with an external A-
AB labelled dextran standard for structural elucidation by converting the retention time of the 
peaks into GU. Each IgG1 sample was analysed in duplicate. The results are the average of 
the triplicate cultures carried out for each condition tested. 
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It is evident that there was no significant difference in the trends of glycoforms identified on 
rIgG1 harvested from each of the different cultures. However a more in depth evaluation of 
the relative % of each type of glycoform present does indicate significant differences in the 
levels of glycosylation between cultures.  Figure 3.2.4.2 displays the relative % of the F(6)A2 
glycoform present on purified rIgG1 samples harvested from cultures at the end of the 
exponential phase of growth. For this early glycoform type, the highest relative % occurred in 
the 15 mM ammonia culture. Figure 3.2.4.3 shows the relative % of M5, another early 
glycoform, present on rIgG1 harvested in each of the cultures at the end of the exponential 
phase. Similarly, the highest relative % of this glycoform occurred in the 15 mM ammonia 
culture. The lowest relative % occurred in the cultures containing L-GLN, independent of the 
L-GLN concentration present. The relative % was 65 % lower for the 4 mM L-GLN culture 
and 60 % lower for the 12 mM L-GLN culture in comparison to the 0 mM culture. Although 
the 5 mM and 15 mM Ammonia cultures did contain 4 mM L-GLN, the relative & of M5 
glycans present was significantly higher than the L-GLN cultures. The relative % of M5 
glycans present on rIgG1 samples in 15 mM ammonia cultures was 30 % higher than the 5 
mM ammonia culture. Similar results were obtained from glycan analysis of rIgG1 purified at 
the end of the stationary phase in cultures (results not shown). 
M5 is the earliest glycoform resulting from N-glycosylation of rIgG1. It arises as a result of 
early glycan trimming in the Endoplasmic Reticulum (ER) membrane. The lower levels of 
M5 present on rIgG1 samples harvested from cultures containing 4 mM and 12 mM L-GLN 
indicate that a higher level of complex type glycan processing took place in these cultures. 
The higher relative % of M5 present on rIgG1 purified from the ammonia cultures 
demonstrates the impact of high initial ammonia concentrations on complex glycan 
processing. The relative % of M5 present in 4mM L-GLU cultures was similar to that of the 0 
mM cultures. The substitution of GLN with GLU does not achieve the same level of complex 
glycan processing. 
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Figure 3.2.4.2: Relative % of F(6)A2 glycan forms detected on rIgG1 samples harvested 
from cultures containing varying concentration of L-GLN, L-GLU and ammonia. F(6)A1/A2 
was detected using HILIC following PNGaseF release and 2-AB labelling The results above 
are based on the analysis of samples harvested at the end of the stationary growth period for 
each culture condition tested. Results are directly comparable results to those found for the 
analysis of samples from the end of the exponential growth period. Each IgG1 sample was 
analysed in duplicate. The results are the average of the triplicate cultures carried out for each 
condition tested +/- STD. 
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Figure 3.2.4.3: Relative % of M5 glycan forms detected on rIgG1 samples harvested from 
cultures containing varying concentration of L-GLN, L-GLU and ammonia. M5 was detected 
using HILIC following PNGaseF release and 2-AB labelling The results above are based on 
the analysis of samples harvested at the end of the stationary growth period for each culture 
condition tested. Results are directly comparable results to those found for the analysis of 
samples from the end of the exponential growth period. Each IgG1 sample was analysed in 
duplicate. The results are the average of the triplicate cultures carried out for each condition 
tested +/- STD. 
 
In order to determine if complex glycan processing is dependent the presence of GLN in the 
culture and affected by high initial ammonia concentrations, it is necessary to compare and 
contrast the relative % of complex type glycans present on rIgG1 harvested from each of the 
cultures. Complex processing of glycans may result in an array of glycoforms containing 
varying levels of GlcNAc, galactose and sialic acid residues. 
Figures 3.2.4.4 and 3.2.4.5 illustrate the relative % of glycoforms containing 1 galactose 
residue attached to either of one of the GlcNAc outer arms. There was no significant 
difference in the relative % of these two glycoforms between the cultures, with the exception 
of the 15 mM Ammonia culture. The relative % of F(6)A2[6]G(4)1 and F(6)A2[3]G(4)1 were 
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21 % and 16 % lower in the 15 mM ammonia cultures in comparison to the 0 mM culture. 
Figure 3.2.4.6 shows the relative % of fucosylated glycans containing 2 galactose residues 
attached to the GlcNAc outer arms. For this glycoform a 44 % decrease in the relative % was 
noted in the 15 mM ammonia culture in comparison to the 0 mM culture. Of the A2G2 
glycoform again the lowest relative % of this glycan occurred in the 15 mM ammonia culture. 
However there was no significant difference in comparison to the culture containing 0 mM L-
GLN. These results do indicate that complex glycan processing is affected by high ammonia 
concentrations. However the culturing of cells in varying concentrations of GLN did not 
appear to influence the galactosylation of glycans in comparison to cultures containing no L-
GLN and cultures containing L-GLU.  
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Figure 3.2.4.4: Relative % of F(6)A2[6]G(4)1 glycan forms detected on rIgG1 samples 
harvested from cultures containing varying concentration of L-GLN, L-GLU and ammonia. 
F(6)A2[6]G(4)1 was detected using HILIC following PNGaseF release and 2-AB labelling 
The results above are based on the analysis of samples harvested at the end of the stationary 
growth period for each culture condition tested. Results are directly comparable results to 
those found for the analysis of samples from the end of the exponential growth period. Each 
IgG1 sample was analysed in duplicate. The results are the average of the triplicate cultures 
carried out for each condition tested +/- STD. 
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Figure 3.2.4.5: Relative % of F(6)A2[3]G(4)1 glycan forms detected on rIgG1 samples 
harvested from cultures containing varying concentration of L-GLN, L-GLU and ammonia. 
F(6)A2[3]G(4)1 was detected using HILIC following PNGaseF release and 2-AB labelling 
The results above are based on the analysis of samples harvested at the end of the stationary 
growth period for each culture condition tested. Results are directly comparable results to 
those found for the analysis of samples from the end of the exponential growth period. Each 
IgG1 sample was analysed in duplicate. The results are the average of the triplicate cultures 
carried out for each condition tested +/- STD. 
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Figure 3.2.4.6: Relative % of F(6)A2G2 glycan forms detected on rIgG1 samples harvested 
from cultures containing varying concentration of L-GLN, L-GLU and ammonia. F(6)A2G2 
was detected using HILIC following PNGaseF release and 2-AB labelling The results above 
are based on the analysis of samples harvested at the end of the stationary growth period for 
each culture condition tested. Results are directly comparable results to those found for the 
analysis of samples from the end of the exponential growth period. Each IgG1 sample was 
analysed in duplicate. The results are the average of the triplicate cultures carried out for each 
condition tested +/- STD. 
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Figure 3.2.4.7: Relative % of A2G2 glycan forms detected on rIgG1 samples harvested from 
cultures containing varying concentration of L-GLN, L-GLU and ammonia. A2G2 was 
detected using HILIC following PNGaseF release and 2-AB labelling. The results above are 
based on the analysis of samples harvested at the end of the stationary growth period for each 
culture condition tested. Results are directly comparable results to those found for the 
analysis of samples from the end of the exponential growth period. Each IgG1 sample was 
analysed in duplicate. The results are the average of the triplicate cultures carried out for each 
condition tested +/- STD. 
 
Complex glycan processing may also result in the addition of a sialic acid residue onto one of 
the galactose residues present on F(6)A2G2 resulting in a glycoform termed F(6)A2G2S1. 
Figure: 3.2.4.8 shows the relative percentage of F(6)A2G2S1 present on rIgG1 purified from 
each of the cultures at the end of the exponential phase of growth.. The highest relative % of 
F(6)A2G2S1 sialyated glycoforms was present in the cultures containing 4 mM and 12 mM 
L-GLN. The cultures contained 71 % and 64 % higher relative % of the glycoform 
respectively in comparison to the 0 mM culture. GLN therefore appears to be essential for 
complex glycan processing, in particular in relation to sialylation. The 5 mM ammonia and 
15 mM ammonia cultures had a 44 % and 29 % higher level of F(6)A2G2S1 respectively 
than the 0 mM culture. It may be observed that complex glycan processing was completed 
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due the inclusion of 4 mM L-GLN in these cultures. However the level of sialylation was 48 
% and 59.6 % lower respectively than that of the 4 mM L-GLN cultures indicating an effect 
of higher ammonia concentrations on the sialylation of glycans. The inclusion of 4 mM L-
GLU in culture media did resulted in a 25 % increase in the level of sialylation in comparison 
to the 0 mM culture. However the level of sialylation in the 4 mM L-GLN culture was 62 % 
higher than in that observed in the 4 mM L-GLU culture, indicating the necessity for L-GLN 
for the sialylation of glycans. 
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Figure 3.2.4.8: Relative % of F(6)A2G2S1 glycan forms detected on rIgG1 samples 
harvested from cultures containing varying concentration of L-GLN, L-GLU and ammonia. 
F(6)A2G2S1 was detected using HILIC following PNGaseF release and 2-AB labelling The 
results above are based on the analysis of samples harvested at the end of the stationary 
growth period for each culture condition tested. Results are directly comparable results to 
those found for the analysis of samples from the end of the exponential growth period. Each 
IgG1 sample was analysed in duplicate. The results are the average of the triplicate cultures 
carried out for each condition tested +/- STD. 
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The impact that varying the concentration of L-GLN, L-GLU and Ammonia may have on the 
aggregation of the rIgG1 protein at the upstream level was investigated. SEC analysis was 
carried out on purified rIgG1 samples harvested from the cultures throughout the cultivation 
period. Figure 3.2.4.9 below represents the relative percentage of monomer present in the 
purified samples. As it may be noted, over 96 % of the protein harvested from all cultures 
was in a monomeric form. These results indicate no direct impact of varying the 
concentrations of L-GLN, L-GLU or ammonia on rIgG1 aggregation at the upstream level. 
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Figure 3.2.4.9: Relative % of monomeric form of rIgG1 samples as detected by SEC. IgG1 
samples were harvested from cultures containing varying concentrations of L-GLN, L-GLU 
and ammonia. The above results are based on the analysis of samples harvested at the end of 
the stationary growth period. The results for samples harvested over the culture period in 
each of the cultures are directly comparable (data not shown). IgG1 samples were analysed in 
duplicate. The results are presented as the average of triplicate cultures performed for each of 
the conditions tested +/- STD. 
 
3.3: Discussion: 
Culture conditions were varied with regards to the initial concentration of GLN (0-12 
mM), GLU (0-4 mM) and Ammonia (5-15 mM) present in the cultures. Such studies enabled 
the determination of the effect of increased L-GLN concentrations, L-GLN substitution and 
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high initial ammonia concentrations on cell growth, productivity and product quality. The 
underlying aim of the work was to investigate the critical ammonia level, above which cell 
growth, productivity and product quality may be adversely affected. Utilisation of L-GLN by 
cells in culture results in the accumulation of ammonia as a metabolic byproduct, with a 
maximum yield ratio of 1 mole of glutamine: 2 moles of ammonia.  The incorporation of 
alternative carbon energy sources, such as L-GLU, in place of L-GLN is suspected to give 
rise to decreased ammonia accumulation as it is more chemically stable than L-GLN. Results 
to date investigating critical ammonia concentrations affecting product quality, in regards to 
glycosylation, involve the introduction of high NH4Cl concentrations at the beginning of the 
culture. No comparisons are however made between the results obtained for high initial 
ammonia concentrations and conditions in which comparably high ammonia concentrations 
arise throughout the culture period.  The results of the accumulation of a high concentration 
of ammonia throughout the culture period in the 12 mM L-GLN culture may be compared 
and contrasted to the results obtained from the 15 mM Ammonia culture in order to decipher 
if realistic ammonia accumulation throughout the culture period is a more effective indication 
of critical ammonia levels 
 
3.3.1: Effect of L-GLN boosting 
L-GLN is an amino acid which is utilised by cells that have high energy demands and 
synthesise large amounts of proteins and nucleic acids in favour of glucose as a carbon 
energy source. The energy obtained from L-GLN, in the form of ATP, is rapidly utilised by 
fast growing mammalian cells. Anabolic pathways for glutamine utilisation results in the 
production of building blocks for biomass and product synthesis. (Scheider et al., 1995; 
Vriezen et al., 1997). Therefore ignoring the potential adverse affects associated with 
ammonia accumulation on growth and productivity limitations of mammalian calls in culture, 
the effect of increased L-GLN concentration (0-12 mM) on cellular activities was 
investigated. 
Cells were seeded at 0.3 * 10
6
 cells/ml in a total culture volume of 300 ml ExCell CHO 325 
PF media supplemented with 0 mM, 4mM and 12 mM L-GLN. The highest maximum 
specific growth rate, μmax, 0.0312 (h
-1
), was displayed by cells cultured in media containing 4 
mM L-GLN, 65 % higher than that observed in cultures containing no L-GLN.  Increasing 
the concentration of L-GLN in the media to 12 mM resulted in a minimal decrease in the 
maximum specific growth rate displayed by the cells, however the biomass concentration 
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obtained (4.22 * 10
6
 cells/ml)  was similar to the 4 mM L-GLN (4.3 * 10
6
 cells/ml). Cells 
cultured in the presence of 12 mM L-GLN showed an increased exponential phase of 
approximately 1 day in comparison to the 4 mM L-GLN culture. These results are 
comparable to those obtained by Vriezen et al., (1997) in which the effect of glutamine 
limitation in feed media on growth of two murine hybridoma cell lines was investigated. An 
excess of L-GLN in feed media did not result in an increased cell concentration in either cell 
line investigated. Yang and Butler, (2000) also investigated the effect of varying L-GLN 
concentrations (2-20 mM) on the growth and productivity of an EPO producing CHO cell 
line. Similarly to the results obtained for this study, the maximum specific growth rate was 
obtained in cultures containing 4 mM L-GLN. However an excess of L-GLN at a 
concentration of 20 mM resulted in a reduced specific growth rate and negatively impacted 
on biomass production which was reflected in a 50 % decreased yield in comparison to the 4 
mM L-GLN culture. The above two studies also investigated the effect of very low L-GLN 
concentrations on mammalian cell growth. However in this report cells were cultured in the 
absence of L-GLN. Cells cultured in the absence of L-GLN displayed a significantly reduce 
growth rate, 65 % lower than that observed in the 4 mM L-GLN culture. Cells remained in a 
lag phase for 6 days before they entered exponential phase at the reduced maximum specific 
growth rate. The maximum viable cell density attained in such cultures was 51 % and 42 % 
lower than that achieved in the 4 mM and 12 mM L-GLN cultures respectively. Similarly 
Burleigh et al., (2011), reported lower viable cell densities in the first 3 days of the culture 
period for human chorionic gonadotropin (HCG) producing CHO cells grown in the absence 
of L-GLN in comparison to cells grown in concentrations of 4 and 8 mM L-GLN. However, 
growth was not limited to the same extent as was noted in this study, as the cells displayed a 
higher maximum specific growth rate at later stages of the culture in comparison to the 
cultures containing L-GLN. Rajendra et al., (2012) looked at the effect of L-GLN reduction 
of CHO and human embryo kidney (HEK)-293E cells and reported that the absence of L-
GLN had a negative effect on cell density and cell viability. The results so far do indicate that 
L-GLN is necessary in culture media in order to promote cell growth. Limitation of cell 
growth in the absence of L-GLN is easily explained by the concept that L-GLN is a major 
carbon source which has metabolic fates giving rise to both energy production (catabolism) 
and building blocks for biosynthesis (anabolism). However, the lack of increased growth at 
higher L-GLN concentrations may be explained by investigating the cells metabolism. 
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L-GLN was completely consumed during the exponential phase of growth, at a rate of 0.89 
mM/day, in cultures containing 4 mM L-GLN. The specific consumption rate displayed by 
the cells was 2.3 * 10
-4
 mmoles/cell/day. In 12 mM L-GLN cultures, all of the L-GLN was 
not consumed, even as cells entered death phase. The rate of L-GLN consumption during the 
exponential growth phase was higher than of the 4 mM L-GLN cultures, 1.34 mM/day. The 
cells cultured in the presence of 12 mM L-GLN displayed a specific L-GLN consumption 
rate of 3.8 * 10
-4
 mmoles/cell/day. Overall a trend for increasing L-GLN utilisation in the 
presence of high L-GLN concentrations was observed; similar to the results obtained for an 
EPO producing CHO cell line cultured in the presence of 2, 4 and 20 mM L-GLN (Yang and 
Butler, 2000). It may be concluded that the growth of cells in the 4 mM L-GLN culture 
became limited by the availability of GLN at the end of the exponential phase. L-GLN 
however was not limiting in the 12 mM L-GLN culture at the end of the exponential growth 
phase. It has previously been explained that the generation of ammonia in high L-GLN 
cultures is likely to be the inhibitory factor causing a reduction in growth rate. As the purpose 
of this study was to investigate L-GLN as a growth limiting substrate for this cell line and 
also the effect of accumulating ammonia on cellular activities, it is important to note that the 
concentration of ammonia was ~ 7 mM when the cells present in the 12 mM L-GLN culture 
ceased growing exponentially. Yang and Butler, (2000) observed that in the presence of 10 
mM NH4Cl, cell yield was reduced by 19 %. The specific ammonia production rate was 25 % 
and 21 % higher than glutamine in the 4 mM L-GLN and 12 mM L-GLN cultures. As the 
specific production rates of ammonia changed somewhat proportionally to the specific 
consumption rates of L-GLN in the cultures, no major changes in the pathways of 
glutamolysis occurred between the two different culture conditions, similar to results 
displayed by Yang and Butler, (2000). This is verified by the fact that yield of ammonia from 
glutamine is similar for both culture conditions tested, 1.07 mmol/mmol and 1.05 
mmol/mmol for 4 mM and 12 mM L-GLN cultures respectively. Therefore it may be 
proposed than the higher ammonia concentration present in the 12 mM L-GLN culture, 
resulted in the transfer of cells from exponential growth phase into stationary growth phase. 
Such results may be cell line specific as no significant difference was observed in the 
accumulation of ammonia in cultures containing 4 mM and 8 mM L-GLN for a HCG 
producing CHO cell line (Burleigh et al., 2012). The concentration of ammonia present in the 
0 mM L-GLN cultures remained below 2 mM for the entire exponential growth period. These 
results are comparable with those displayed by Wong et al., (2004). CHO cells cultured in the 
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presence of a feed concentration of 0.3 mM L–GLN displayed a reduced specific production 
of ammonia. However again, these results are cell line specific. For CHO cells producing 
HCG (Burleigh et al., 2012), a significant accumulation of ammonia was evident in the 
presence of 0 mM L-GLN. However, the growth kinetics displayed by such cells was also 
somewhat difference to that which was observed in this current study. 
As stated above L-GLN may be utilised by cells in favour of glucose as a carbon energy 
source, in cases of glucose limitation. In such cultures, glucose was not limited, but remained 
constant, as defined by the media used, at a concentration of ~17.4 mM. For both the 4 mM 
and 12 mM L-GLN culture, a general trend was observed in that all glucose present in the 
cultures was consumed by the end of the stationary growth phase.  No significant difference 
was observed in the specific consumption rates of glucose between the 4 mM L-GLN culture, 
8.3 * 10
-4
 mmoles/cell/day, and 12 mM L-GLN culture, 7.7 * 10
-4
 mmoles/cell/day. These 
results are comparable to those observed for other CHO cell lines in which it was 
demonstrated that glucose consumption was not affected by the initial amount of L-GLN, in a 
range of 0-6 mM, present in cultures (Rajendra et al., 2012). However the results may also be 
cell line specific. For a CHO cell line producing the recombinant protein EPO, a decrease in 
the specific glucose consumption rate was observed for cultures containing increasing 
concentrations of L-GLN (Yang and Butler, 2000). Vriezen et al., (1997) demonstrated that 
such variations do exist between different cell lines. For two murine hybridoma cell lines 
investigated, one displayed a decreased glucose consumption rate with increasing L-GLN 
concentrations, whereas the second cell line displayed no apparent effect. There was no 
significant difference in the specific lactate production rate, or the yield of lactate from 
glucose, 0.95 mmol/mmol and 1.04 mmol/mmol respectively, for 4 mM and 12 mM L-GLN. 
For the 0 mM L-GLN culture, glucose was consumed by the end of the exponential growth 
phase. No significant difference in the specific rate of glucose consumption was observed in 
the 0 mM L-GLN culture, however, the increased duration of the exponential growth period 
resulted in complete consumption of glucose present. The fact that the glucose consumption 
rate remained the same, suggests that the lower specific growth rate of the cells was in fact 
due to the absence of L-GLN as an energy source for biomass production. In the case in 
which L-GLN is absent, glucose becomes the growth limiting substrate. Although in this case 
the cells did demonstrate the ability to grow on glucose in the absence of L-GLN, it is evident 
that L-GLN remains the critical component for optimised growth, denoted by the 65 % higher 
growth rate observed in the 4 mM L-GLN culture. These results again prove to be cell line 
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specific as CHO producing HCG displayed lower glucose consumption rates in the absence 
of GLN in comparison to cultures containing 4 and 8 mM L-GLN (Burleigh et al., 2011). A 
2-fold increase in the specific lactate production rate was observed for the 0 mM L-GLN/L-
GLU/Ammonia culture. The results suggest a less favourable utilisation of glucose, via the 
glycolytic pathway, by the cells resulting in increased lactate production. The highest yield of 
lactate from glucose was observed in the 0 mM L-GLN culture, 1.39 mmol/mmol. 
The results of Protein A purification of rIgG1 from culture media harvested from day 4 
onwards, do indicate significant differences in the relative productivities displayed by cells 
cultured in the presence of L-GLN.  A 50 % higher concentration of rIgG1 was obtained at 
the end of the stationary growth phase in cultures containing 4 mM L-GLN. This is reflected 
by the enhanced specific production rate of 50 % observed in this culture in comparison to 
the 0 mM L-GLN culture. No significant difference in the specific productivity of cells 
cultured in the 4 mM and 12 mM L-GLN was observed. The results observed are similar to 
those documented by Burleigh et al., (2011). The concentration of HCG produced by CHO 
cells in 0 mM L-GLN was statistically lower than that produced in 4 mM L-GLN on day 5 of 
the culture period. However the effect of L-GLN concentration on recombinant protein 
production in mammalian cell lines does vary. For CHO cells producing the recombinant 
protein EPO, the concentration of EPO produced decreased with increasing L-GLN 
concentration from 2-20 mM. Cell specific productivities observed were reported highest in 
the 20 mM L-GLN culture (Yang and Butler, 2000). In CHO cells cultivated in 0-6 mM L-
GLN, the highest rIgG concentration was observed in the 2 mM L-GLN culture. It was 
concluded that the overall improvement in IgG production at reduced GLN concentrations 
was due to the reduced ammonia accumulation observed (Rajendra et al., 2012). However in 
the case of this current study, rIgG1 production was not inhibited by the higher accumulation 
of ammonia in the 12 mM L-GLN culture, but by the absence of L-GLN in the 0 mM L-GLN 
culture. 
The results so far indicate the necessity for L-GLN for optimised growth and recombinant 
protein production. It is also necessary to investigate if such growth and productivity patterns 
have an influence on the quality of the protein being produced. Higher cellular growth rates 
and production rates are routinely associated with lower quality recombinant proteins due to 
the limited time available for complex glycan processing. On the other hand, the lower 
growth and production rates in the absence of L-GLN may not in turn result in higher glycan 
processing due to the necessity of GLN for the synthesis of glycosylation nucleotide sugars 
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and their corresponding donors. Therefore increased L-GLN concentrations may in turn result 
in higher levels of glycan processing due to increased levels in the pools of nucleotide sugars 
and their donors. 
In order to determine the influence of L-GLN and L-GLN concentration on rIgG1 quality, 
glycan analysis was completed on rIgG1 samples harvested from the cultures at the end of the 
exponential and stationary phases of growth. Irrelevant of the concentration of L-GLN 
present, all cultures displayed a heterogeneously similar trend in the range of glycan 
structures released from the rIgG1 samples. The highest relative percentage present was of 
the early, unprocessed glycoform such as M5 and F2A2. The lowest relative % were of the 
sialyated glycans.  
The earliest form of glycosylation arising from the action of the oligosaccharyltransferase 
(OST) enzymes, followed by glucosidase and mannosidase enzymes present in the 
endoplasmic reticulum (ER) is M5. It is a high mannose structure consisting of the 2 N-
acetlyglucosamine (GlcNAc) residues and 5 mannose residues (Man5GlcNAc2) which are 
attached via a glycosylytic bond to the aspargine residue at position Asn297 at the hinge 
region of IgG1. This intermediate glycan structure typically undergoes more complex glycan 
processing in the golgi by a series of in house N-acetlyglucosamine transferases, galactosyl 
transferases and sialy transferases enzymes. The highest relative percentage of this 
intermediate unprocessed glycan structure occurred in the 0 mM L-GLN culture. A 65 % and 
60 % decrease in the relative percentage of M5 present in the 4 mM and 12 mM cultures was 
observed respectively. The lower relative % of M5 in these cultures was in fact due to the 
presence of a higher relative % of fully fucosylated, galactosylated and sialyated F6A2G2S1 
glycans. There was no significant difference observed in the relative % of glycans containing 
one galactose residue at the α2,3 or α2,6 positions or glycans containing two galactose 
residues. Similar results were noted for the glycosylation of HCG produced in CHO cell 
cultures containing 0, 4 and 8 mM L-GLN. At the end of the culture period, a decrease in 
sialyation, fucosylation and antennarity was noted in cultures containing 0 mM (Burleigh et 
al., 2011). Wong et al., (2004) observed that glycan chain extension and sialyation may be 
affected by glutamine limitation. In fed-batch cultures of CHO cells producing the 
recombinant protein IFN-γ, decreased sialyation and increased high mannose structures were 
reported for an L-GLN feed concentration of 0.1 mM in comparison to that of 0.3 mM. A 23 
% decrease in sialyation was observed for 0.1 mM L-GLN fed-batch cultures, in comparison 
to 4 mM L-GLN batch cultures. 
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The mechanism by which L-GLN limitation effects complex glycan processing is explained 
by an associated intracellular decrease in the availability of the nucleotide sugar donor UDP-
GlcNAc, brought about by a lack of synthesis the amino sugar N-acetylglucosamine 1-P 
(Nyberg et al., 1999). Complex processing in the golgi initiates with the cleavage of 
Man5GlcNAc2, to form Man3GlcNAc2 by the action of the enzyme Mannosidase II. A series 
of N-acetlyglucosmaine transferase (GnT) enzymes are responsible for the addition of 
GlcNAc residue from the nucleotide sugar donor UDP-GlcNAc onto the free α1,3 and α1,6 
mannose arms of Man3GlcNAc2, thus forming a biantennary structure. This biantennary 
structure is further processed by a series of galactosyl and sialy transferase enzymes. As seen 
in Figure 3.3.1.1, below, a reaction catalysed by glutamine:fructose-6-P amidotransferase 
(GFAT), sees the transfer of ammonia from glutamine to fructose-6-phosphate, forming 
glucosamine-6-phosphate. This step serves as the limiting step in the determination of the 
formation of the amino sugar. Therefore under conditions of glutamine limitation, a decrease 
in the pool of UDP-GlcNAc may be is observed, typically resulting in a decreased level of 
complex glycans and an increased level of intermediate glycan structures such as M5 
(Nyberg et al., 1999). However in the case of this study, complex glycan processing in the 
form of biantennary structures and galactosylation did occur in the same extent in the 0 mM 
L-GLN culture, as was observed in the 4 and 12 mM L-GLN, indicating that the pool of 
UDP-GlcNAc residues may have been unaffected by the lack of GLN. The increased ratio of 
M5 in the 0 mM L-GLN culture coincides with a decreased ratio of glycan structures 
containing sialic acid residues. L-GLN limitation is known to affect sialylation, again through 
altering the intracellular pool of UDP-GlcNAc nucleotide sugar donors. UDP-GlcNAc is a 
necessary precursor for the synthesis of the sialic acid donor CMP-NANA (Burleigh et al,. 
2011). A process consisting of 5 enzymatic steps resulting in the fusion of a hexose and a 3 
carbon pyruvate structure cumulates in the conversion of UDP-GlcNAc into CMP-NANA 
(Butler, 2006). It was stated above that the intracellular pool of UDP-GlcNAc does not 
appear to have been altered in the 0 mM L-GLN culture as the proportion of biantennary and 
galactosylated structures remained consistent with the 4 and 12 mM, L-GLN cultures. 
However the lack of sialylation observed in the 0 mM L-GLN culture suggests that there was 
a decrease in the pool of UDP-GlcNAc under the glutamine limitation conditions induced. 
This decreased pool did not alter the level of biantennary structures, but did influence the 
availability of CMP-NANA as a sialic acid precursor. It has been suggested that as sialylation 
is the last step in N-glycan processing, it is probably more sensitive to the effects of substrate 
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depletion in comparison to the other steps of glycan processing (Wong et al., 2004). It is also 
important to note that the inclusion of a higher concentration of L-GLN (12 mM) did not 
significantly enhance the degree of complex glycan processing in comparison to the 4 mM L-
GLN culture. 
 
 
Figure 3.3.1.1: Role of glutamine and glucose in nucleotide sugar donor synthesis Nyberg et 
al., (1999) 
 
3.3.2: Substitution of L-GLN with L-GLU 
 A study was designed in order to determine if L-GLN replacement with L-GLU 
would result in any significant difference in the growth, metabolism, productivity and quality 
of the product produced in the CHO DP-12 cell line. There are a number of possible 
outcomes associated with the substitution of L-GLN with L-GLU as an alternative carbon 
source.  As L-GLU has only one amino group in its structure, in comparison to the two 
present in L-GLN, and is transported into the cell at a lower velocity, more efficient cell 
metabolism should result, thus leading to reduced ammonia formation. However as noted 
above in the introduction, the amino groups of L-GLN and L-GLU have both catabolic and 
anabolic fates required for both energy and biomass building block production. Therefore the 
replacement of L-GLN, containing 2 amine groups, with a carbon source containing one 
amine group, may result in reduced energy production, giving rise to decreased cellular 
productivity. Also as noted in Section 3.3.1, the ammonia of L-GLN plays an essential role in 
maintaining the levels of nucleotide sugar donors, UDP-GlcNAc, at sufficient levels to allow 
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for complex glycan processing. In order to evaluate the effects of L-GLN replacement with 
L-GLU, cells were seeded at 0.3 * 10
6
 cells/ml in a culture volume of 300 ml ExCell CHO 
325 PF media supplemented with either 4 mM L-GLN, 4 mM L-GLU or 0 mM L-GLN/L-
GLU. 
The maximum viable cell density attained in the 4 mM L-GLU culture was 46 % lower than 
that in the 4 mM L-GLN culture. Cell cultured in the presence of L-GLU grew at a reduced 
maximum specific growth rate, 0.0096 h
-1
, in compassion to that displayed by cells culture in 
L-GLN, 0.0312 h
-1
. There was no significant difference in the maximum specific growth rate 
or maximum viable cell density achieved between cells culture in 0 mM L-GLN/L-GLU and 
cells cultured in 4 mM L-GLU. These cultures did however show increased culture longevity 
with viability remaining above 86 % until day 16 for the 0 mM L-GLN/L-GLU culture and 
until day 11 for the 4 mM L-GLU culture. Viability was only maintained at such a level until 
day 7 in the 4 mM L-GLN culture. These results are comparable with those obtained by Hong 
et al., (2010) for CHO cells producing rIgG1. A lower growth rate and maximum viable cell 
density and increased culture longevity was noted for cells cultured in 6 mM L-GLU in 
comparison to those cultured in the presence of 6 mM L-GLN. These results are however 
noted to be cell line specific. In other studies, the substitution of L-GLN with L-GLU in a 
glucose based media resulted in a higher final cell concentration (Altamirano et al., 
2000).The cell line used for this study, conducted by Altamirano et al., (2000), displayed 
glutamine synthase (GS) activity in which L-GLN could be formed from L-GLU. The 
replacement of L-GLN with L-GLU has also been associated with enhanced rIgG1 
production (Hong et al., 2010). However these results may be cell line specific, as the 
replacement of L-GLN with L-GLU did not affect the specific production rate displayed by 
the cells. A decrease of 40 % and 21 % in the concentration of rIgG1 present at the end of the 
exponential and stationary phase respectively was present in the 4 mM L-GLN culture in 
comparison to the 4 mM L-GLU culture. This increased rIgG1 concentration present, was 
however due to an extended culture period in the 4 mM L-GLU culture. 
The substitution of L-GLN with L-GLU did not appear to be beneficial in regards to biomass 
production. However one associated positive aspect of the substitution lies in the reduced 
accumulation of ammonia in L-GLU cultures. Throughout the exponential growth period, the 
concentration of ammonia in the 4 mM L-GLU remained below 1.3 mM, whereas a 
concentration of 4.9 mM ammonia was present in the 4mM L-GLN culture at the end of the 
exponential growth period. Such results are comparable to those observed by Hong et al., 
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(2010), in that the accumulation of ammonia was said to be 3-fold lower in glutamate cultures 
than that observed in glutamine cultures. However the beneficial effects of reduced ammonia 
concentration appear to be outweighed by the negative impact replacement of L-GLN with L-
GLU has on cell growth. Glucose metabolism did appear to be affected by the substitution of 
L-GLN with L-GLU. The specific glucose consumption rate displayed by the cells cultured in 
4 mM L-GLU was 40 % and 33 % lower than that observed in the 0 mM L-GLN/L-GLU and 
4 mM L-GLN cultures. This fact highlights the relationship between glycolysis and 
glutaminolysis and their interconnection. The substitution of L-GLN with L-GLU has been 
associated with a decrease in the rate of glutaminolysis. The reduction in this rate results in a 
reduced requirement for pyruvate to be incorporated into the tricarboxylic acid (TCA) cycle, 
and thus the glycolysis rate may be reduced (Altamirano et al., 2000). It is often reported that 
decreased glucose consumption rates is coupled with decreased lactate production rates in 
situations of L-GLN substitution (Hong et al., 2010; Altamirano et al., 2000). Such results 
were not observed as the specific lactate production rate was not significantly different to that 
observed in 0 mM L-GLN/L-GLU cultures, with a similar lactate yield from glucose of 1.35 
mmol/mmol being determined for the 4 mM L-GLU culture. Therefore the combination of 
reduced glucose consumption rates, coupled with increased lactate production rates would 
suggest a similar inefficient metabolism of glucose by cells cultured in the presence of L-
GLU in comparison to 0 mM L-GLN/L-GLU/Amm.  
The substitution of L-GLN with L-GLU also had negative effects in regards to the quality of 
the glycan structure attached. The results obtained are directly comparable to the 0 mM L-
GLN/L-GLU culture in that a higher relative % of M5 were detected while a lower relative % 
of sialyated structures were detected, in comparison to the 4 mM L-GLN culture. Other 
studies report on the positive influence L-GLU has on galactosylation in comparison to 
glutamine (Hong et al., 2010). The formation of galactosylated, biantennary structures was 
not influenced by the substitution of L-GLN with L-GLU.  The reasoning for such a display 
of glycans may also be explained by a decrease in the intracellular concentration of UDP-
GlcNAc, as above. It may be proposed that the incorporation of L-GLU into the culture did 
result in the formation of a sufficient quantity of UDP-GlcNAc to allow for biantennary 
fucosylated glycan processing. However, the supply of UDP-GlcNAc available for CMP-
NANA formation may have been limited in comparison to cultures containing 4 mM L-GLN. 
 
 
124 
 
3.3.3: Influence of high initial ammonia concentrations 
Many studies to date investigating the effects of ammonia accumulation on not only growth 
and productivity of mammalian cells, but also product quality, have focussed on the inclusion 
of high initial concentrations of ammonia in the form of NH4Cl (0-30 mM) (Borys et al., 
1994; Anderson and Goochee, 1995; Gawlitzek et al., 2000; Yang and Butler, 2000; Yang 
and Butler, 2002) Other studies have looked at increasing ammonia concentration throughout 
the culture period by the inclusion of varying concentrations of NH4Cl feed media (Hansen 
and Emborg, 1994; Gawlitzek et al., 1998). 
The concentrations of ammonia added may have been typical of the reported accumulations 
of ammonia in standard mammalian cell cultures (Anderson and Goochee, 1995). However 
many studies failed to investigate the significance of the difference between increased 
ammonia accumulation arising throughout the culture period, as a result of cell metabolism 
and/or chemical degradation or high concentrations of ammonia added exogenously, in the 
form of NH4Cl, at some stage during the culture period. Gawlitzek et al., (2000) attempted to 
investigate this by conducting studies with CHO cells producing TNFR-IgG in which initial 
concentrations of L-GLN were varied between 1-11 mM and ammonium between 0-13 mM. 
However in this study cellular growth was arrested before the cells were subjected to such 
concentrations. Therefore in order to investigate the effect of both high initial ammonia 
concentrations (typical of that which arises during a standard mammalian cell culture) and the 
effect of ammonia which arises due to cell metabolism, cells were cultured in the presence of 
an initial concentration of 5 and 15 mM NH4Cl. The inclusion of 5 mM ammonia at the 
beginning of the culture period is comparable to the culture which contained 4 mM L-GLN. 4 
mM L-GLN gave rise to an accumulation of 5 mM Ammonia. The inclusion of an initial 
concentration of 15 mM ammonia is comparable to the 12 mM L-glutamine culture, as this 
culture gave rise to the high ammonia concentration of 13 mM.  
The growth rate of the cells appeared to be effected by ammonia in a dose-dependent manner. 
Cells cultured in the presence of 15 mM ammonia had a 33 % lower maximum specific 
growth rate, than that displayed by cells cultured in the presence of 5 mM ammonia. The 
maximum viable cell density achieved in the 15 mM ammonia culture was 31 % lower than 
that attained in the 5 mM ammonia culture. These results are similar to those presented by 
Yang and Butler, (2000), in which the biomass yield for an EPO producing CHO cell line 
decreased with increasing initial concentrations of NH4Cl ranging from 0-40 mM.  In this 
study, it was reported that the inhibitory concentration of ammonia for a 50 % (IC-50) 
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decrease in biomass yield was 33 mM. Chen and Harcum, (2006) also reported a reduced 
growth rate in the presence of high initial ammonia concentrations of 10 mM, in comparison 
to a standard culture containing 7 mM L-GLN (concentration of ammonia in standard culture 
did not reach above 4 mM).  In this current study, the maximum viable cell density occurred 
in the 4 mM L-GLN culture. The maximum viable cell density achieved in the 15 mM 
ammonia culture was 59 % lower than that achieved in the 4 mM L-GLN culture, indicating 
that 15 mM ammonia is the approximate IC-50 values for this cell line.  The influence of an 
initial ammonia concentration of 5 mM in comparison to the influence of an accumulation of 
5 mM ammonia (as seen in 4 mM L-GLN culture) resulted in a 30 % decrease in the 
maximum specific growth rate displayed by the cells. The incorporation of a high initial 
ammonia concentrations (15 mM), also resulted in a 54 % decrease in the maximum specific 
growth rate of the cells when compared to the 12 mM L-GLN culture (gave rise to 
accumulation of a total of 13 mM Ammonia on day 6). Therefore, the effect of high initial 
ammonia concentrations on cell growth may be more profound than the actual implications of 
high ammonia accumulations throughout the culture period.  It was stated in the Section 3.3.1 
that cells cultured in the presence of 12 mM L-GLN left the exponential growth phase when 
L-GLN was still available for consumption. The concentration of ammonia present in the 
culture at this point was ~ 7 mM and it was hypothesised that this concentration of ammonia 
may have cause a cease in the exponential growth phase. However, cells cultured in initial 
ammonia concentrations ranging between 5-15 mM did exhibit an exponential growth period 
and thus growth was not inhibited but reduced between these concentrations. Therefore it 
may also be proposed that the cessation of growth in the 12 mM L-GLN culture may be due 
to the depletion of some other media component. Cells cultured in the presence of 5 and 15 
mM ammonia also entered stationary phase before L-GLN was depleted. Therefore it may be 
deduced that in the presence of higher concentrations of ammonia, other media components 
become the growth limiting substrate. 
The specific L-GLN consumption rate displayed by the cells was similar in both the 5 mM 
and 15 mM ammonia culture. The specific L-GLN consumption rate displayed by the cells 
cultured in an initial concentration of 5 mM ammonia was 52 % higher than that displayed in 
cultures containing 4 mM L-GLN. Similarly the specific L-GLN consumption rate displayed 
by the cells cultured in the presence of an initial concentration of 15 mM ammonia was 22 % 
higher than that of the cells cultured in 12 mM L-GLN. Similar results were noted for in 
studies investigating the effects of a range of high ammonia concentrations on cellular 
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activities. Hansen and Emborg, (1994) found that L-GLN was extensively consumed by not 
completely depleted when ammonia concentrations ranged between 0-7.5 mM. In this current 
study the inclusion of high initial concentrations of ammonia resulted in a change in 
metabolism illustrated by an increased specific L-GLN consumption rate coupled with 
reduced ammonia accumulation. Similar results were reported by Hansen and Emborg, 
(1994) for CHO cells producing tissue plasminogen activator (t-PA). Feed media containing 
5 and 7.5 mM ammonia resulted in a final culture ammonia concentration 1 and 0.5 mM 
respectively, even through L-GLN was extensively consumed in these cultures. In this current 
study the yield of ammonia from L-GLN consumed was significantly lower in the 5 mM and 
15 mM ammonia cultures, 0.64 and 0.63 mmol/mmol respectively, in comparison to that 
which was determined for the 4 mM and 12 mM L-GLN cultures, 1.07 and 1.05 mmol/mmol 
respectively. Cells have a mechanism to ensure that less ammonia is generated during growth 
under high ammonium concentrations. This shift in metabolism was explained by a shift from 
the glutamate dehydrogenase pathway to the use of the alanine amidotransferase pathway. 
This shift is initiated by the conversion of L-GLU to 2-oxogluterate. Hansen and Emborg, 
(1994) reported an increase of alanine by 30 % under high ammonia concentrations. 
Therefore the inclusion of high initial ammonia concentrations does suggest an alternative 
effect on cellular metabolism than that which is observed when high ammonia concentrations 
accumulate in culture. However, the results may be cell line dependent. Yang and Butler, 
(2000) illustrated that for CHO producing EPO, high L-GLN consumption rates are coupled 
with high ammonia production rates under high concentrations of ammonia. 
The specific glucose consumption rate displayed by cells cultured in 15 mM Ammonia was 
30 % higher than that of the 5 mM Ammonia culture and also the 4 and 12 mM L-GLN 
cultures. Therefore only very high initial ammonia concentrations effect glucose metabolism. 
These results are different to those reported by Hansen and Emborg, (1994) which report a 
decrease in the specific glucose consumption rate with increasing concentrations of ammonia. 
However for a CHO cell line producing the recombinant protein EPO, the specific glucose 
consumption rate was noted to increase with increasing ammonia concentrations from 0-40 
mM (Yang and Butler, 2000). Cells cultured in the presence of 15 mM ammonia had a higher 
specific lactate production rate than that displayed by cells cultured in the presence of 5 mM 
ammonia. However this did not result in an increased accumulation lactate due to the lower 
cell numbers present in the culture. As both the glucose and lactate specific production rates 
were noted to increase in the 15 mM ammonia culture, no significant difference in the yield 
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of lactate from glucose would be expected, which was determined. The yield of lactate from 
glucose was similar in the 15 mM ammonia culture, determined as 0.92 mmol/mmol, to those 
observed in the 5 mM Ammonia, 0.98 mmol/mmol, and 4 mM and 12 mM L-GLN cultures, 
0.95 and 1.04 mmol/mmol respectively. The increased lactate production rate indicates 
inefficient glucose metabolism displayed by cells cultured in the presence of high initial 
ammonia concentrations. Glucose metabolism is favoured towards glycolytic and opposed to 
oxidative for ATP production (Hansen and Emborg, 1994). Such inefficient glucose 
metabolism is not noted in the presence of 5 mM ammonia or in situations in which high 
ammonia concentrations accumulate in the cultures. 
Typically cells cultured in the presence of increasing initial concentrations of ammonia 
display decreased specific recombinant protein productivities attributed to possible losses of 
productivity or adverse depletion of metabolites necessary for cell production under high 
ammonia concentrations (Hansen and Emborg, 1994). However the effect of high initial 
ammonia concentrations may be cell line specific. For CHO cells producing HGC no 
difference was displayed in the secretion rate at ammonia concentrations ranging from 0-25 
mM (Anderson and Goochee, 1995). For CHO cells producing TNFR-IgG, Gawlitzek et al., 
(2000) also reported no difference in productivity at varying initial ammonia concentrations 
ranging from 0-13 mM. However for CHO cells producing the recombinant protein EPO, 
increased specific productivity was noted at initial ammonia concentrations of 40 mM in a 
study which investigated the effects of initial ammonia concentrations ranging from 0-40 mM 
(Yang and Butler, 2000). It should also be noted that for CHO cells producing rMouse 
placental lactogen-I, specific production rate was noted to decrease with increasing ammonia 
concentrations over the range 0-9 mM. Production was inhibited at 9 mM ammonia (Borys et 
al., 1993). In this current study there was no significant difference in the specific rIgG1 
production rate demonstrated between cells cultured in 5 and 15 mM ammonia. Cells cultured 
in the presence of 15 mM ammonia displayed a 26 % increase in the specific rIgG1 
production rate in comparison to cells cultured in the presence of 12 mM L-GLN. However 
due to the adverse effects of high initial ammonia concentrations on cell growth, no direct 
increase in the quantity of rIgG1 produced at the end of the exponential or stationary phase 
was observed in this culture. 
Variations were noted between the levels of the different glycoforms present on samples 
taken from the cultures containing the two different initial ammonia concentrations. There 
was a 45 % increase in the proportion of the intermediate glycan M5 in samples harvested 
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from the 15 mM ammonia culture in comparison to that observed on samples taken from the 
15 mM ammonia culture. Due to the increased levels of the intermediate unprocessed glycan 
in the 15 mM ammonia culture, an expected decrease in the relative proportions of processed 
galactosylated and sialyated glycans was noted between the 5 and 15 mM ammonia cultures. 
There was a 22 % and 26 % decrease in the proportions of glycans containing one galactose 
residue, F6A2[6]G(4)1 and F6A2[3]G(4)1 respectively, in the 15 mM ammonia culture in 
comparison to the 5 mM ammonia culture. Fully galactosylated glycans were reduced by 29 
% in the higher ammonia concentration culture. The was a and 22 % reduction in the relative 
% of the sialyated glycan F(6)A2G2S1, when the initial concentration of ammonia increased 
from 5 to 15 mM. Borys et al., (1993) demonstrated that inhibition of mouse placental 
lactogen-I glycosylation correlated with the concentration of ammonia species with adverse 
effects being noted as the concentration of ammonia is increased from 0-9 mM. 
 In literature the effects of increasing initial ammonia concentrations have been associated 
with increased proportions of bi-antennary glycan such as F6A2, coupled with decreased 
glycan processing in regards to sialylation.  Anderson and Goochee, (1995) reported for CHO 
producing granulocyte colony-stimulating factor an initial ammonia concentration of 2 mM 
was noted to significantly reduce O-linked glycosylation. A decrease in the disialyated forms 
relative to monosialyated forms was noted at an ammonia concentration of 50 mM. 
Gawlitzek et al.,1998 illustrated that for BHK-21 cells producing human interleukin-2 (Il-2), 
a 45 % increase in high branched complex structures was noted in cultures containing 15 mM 
ammonia in comparison to standard culture conditions in which ammonia accumulation was 
reported between 2 and 4 mM. Zanghi et al., (1998a&b) reported that 10 mM ammonia gave 
rise to a 10 % decrease in the polysialic content of neural adhesion molecule (NCAM) 
expressed in CHO cells. Gawlitzek et al., (2000) noted that the galactose and sialic acid 
content of TNFR-IgG expressed in CHO cells decreased with increasing medium ammonia 
concentrations in the range of 0-13 mM. However in this situation no differences in 
branching were observed.  Yang and Butler, (2000) noted that the relative proportion of EPO 
with 4 sialic acid residues was reduced with increased ammonia concentrations in the range 
of 30 mM. However a decrease in antennary was noted with a 57 % reduction in the 
proportion of tetraantennary structures. There have been limited reports on the effect of 
increasing ammonia concentrations on the galactosylation profile of glycan structures. Hong 
et al., (2010) reported an increase in ungalactosylated structures, coupled with a decrease in 
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structures containing one or two galactose residues as the concentration of ammonia 
increased from 0-15 mM. 
The results to date therefore appear to be consistent in that the galactosylation and sialylation 
of glycoproteins is adversely affected by increasing initial concentrations of ammonia. Such 
results were observed in this current study. However the impact of high ammonia 
concentrations on glycan antennary appears to be cell type or line specific. In studies in 
which more complex glycosylation has been noted for increased initial ammonia 
concentrations it was noted observed that the increased complexity was directly related to an 
increase in the intracellular content of UDP-GNAc which increase the availability for 
GlcNAc and GalNac residues to be attached to the emerging polypeptide chain (Gawlitzek et 
al., 1998). As it was explained in Section 3.3.1, the formation of UDP-GNAc requires the 
donation of ammonia to fructose-6-phosphate for conversion to glucosamine-6-phosphate. 
Therefore increased ammonia levels may in turn increase the formation of nucleotide sugar 
donors. Studies have also been conducted which note an increase in the activity of the 
enzyme glutamine:fructose-6-P amidotransferase in high ammonia concentrations of 15 mM 
(Calyli et al.,1999), which again promotes the formation of UDP-GNAc. It was also reported 
by Gawlitzek et al., (1998) that the corresponding increases in the pool of UDP-GNAc’s was 
noted in four different cell lines (BHK, CHO, Ltk929 and hybridoma) when subjected to high 
initial ammonia concentrations. It was later determined that the increased pool of UDP-
GNAc induced an increased level of activity in GnT (Grammatikos et al., 1998). Other 
studies have also reported such findings of increased intracellular pools of UDP-GNAc in the 
presence of ammonia (Gawlitzek et al., 1998 and Grammatikos et al., 1998). The results 
presented in this current study do not conform to this theory in that similar levels of bi-
antennary structures were noted in cultures containing 5 and 15 mM ammonia. Also there 
was a decrease in the proportion of galactosylated glycans in the 15 mM ammonia culture in 
comparison to the 5 mM ammonia culture.  
The theory behind decreased sialylation in the presence of high ammonia concentrations has 
been extensively studied and a number of mechanisms have been proposed. One such 
mechanism is based on the presence of a higher concentration of UDP-GNAc pools in the 
cytoplasm, which are thought to impair the transport of CMP-NANA into the golgi, thus 
resulting in decreased sialylation (Pel Rijken et al., 1995). In Section 3.3.1 above, it was 
proposed that increased pools of UDP-GNAc promote the formation of CMP-NANA thus 
leading to increased sialyation in the presence of L-GLN in comparison to situations in which 
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L-GLN is absent. However it is also proposed that the transport of CMP-NANA into the 
golgi apparatus may also be inhibited by increased concentrations of UDP-GNAc. A 
feedback mechanism does exist in the pathway that forms CMP-NANA from UDP-GNAc. 
Enzymes involved in this process are regulated by CMP-NANA concentration in the 
cytoplasm. High concentrations of CMP-NANA in the cytoplasm brought about by high 
concentration of UDP-GlcNAc are prevented from being transported into the golgi (Butler, 
2006). However as it is unlikely in this study that higher concentrations of UDP-GNAc did 
exist in the presence of increase ammonia concentrations, it is more probable that the 
decreased sialylation was due to alterations in the golgi pH brought about by the ammonia 
ions (Borys et al., 1994). 
 The results of decreased galactosylation and sialylation noted in this current study can 
perhaps be better explained by evaluating the effect of ammonia on glycosylation at the gene 
level. Lower expression levels for the galactosylation and sialyation enzymes, β1,4-
galctosyltransferase and α2,3-sialytransferase, was observed under increased ammonium 
concentration conditions of 10 mM.  Gene expression of CMP-SiaT was also sensitive to 
ammonium chloride, which would also reduce the level of sialylation. However this was only 
the case observed at early culture times. Previous studies reporting on decrease 
galactosylation suggested a decrease in β1,4-galctosyltransferase activity due to an increase 
in the intracellular pH, brought upon by high ammonia concentrations (Gawlitzek et 
al.,2000). This statement correlates with the decreased gene expression noted by Chen and 
Hercum, (2006). 
The impact of high initial ammonia concentrations on the glycosylation profile of the 
recombinant protein produced was notably different to that observed in cultures in which 
similar levels of ammonia accumulated over time throughout the culture period. A 98 % 
decrease in the proportion of glycan of M5 nature was noted in the 5 mM ammonia culture, in 
comparison to the culture which gave rise to an accumulation of 5 mM ammonia throughout 
the culture period. Similarly the effect of high initial ammonia concentrations in comparison 
to high ammonia accumulations resulted in a 150 % in the proportion of M5 glycans in 
comparison to a culture which gave rise to an ammonia accumulation of 13 mM. 
Corresponding decreases were noted in complex glycan structures when the 5 mM and 15 
mM ammonia cultures were compared to the 4 and 12 mM L-GLN cultures, respectively. For 
example approximately a 50 % decrease in the proportion of sialyated glycans, F6A2G2S1, 
was noted between the 5 mM ammonia and 4 mM L-GLN culture and 15 mM ammonia and 
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12 mM L-GLN culture. The inclusion of high initial ammonia concentrations has enabled the 
understanding of the mechanisms by which high ammonia concentrations (typical of the 
expected concentration accumulated over a culture period) affect cell growth and 
productivity. However this work has established that the results due to some extent over-
estimated the impact of an accumulation of a high concentration of ammonia in a mammalian 
cell culture. In order to verify that alterations in cell growth, metabolism, productivity and 
product quality obtained for the 15 mM ammonia culture were not due to the adverse effects 
of an increased osmolality in the medium brought about through the addition of ammonium 
chloride, a similar study was repeated in which an initial concentration of 15 mM sodium 
chloride and 4 mM L-GLN were added. The results obtained for all cellular activities were 
not significantly different from the 4 mM L-GLN culture. 
 
3.4: Conclusion 
 The main outcome of this work is that it has signified the importance of L-GLN in 
mammalian cell culture media for this particular CHO DP-12 cell line producing rIgG1. 
Optimised growth (growth rate and maximum viable cell density reached), productivity and 
product quality were achieved in cultures containing 4 mM L-GLN in comparison to cultures 
containing 0 mM L-GLN and 4 mM L-GLU. In conforming to the overall aim of the thesis, 
this study has highlighted the ideal concentration of L-GLN to incorporate into ExCell CHO 
325 PF media for growth of the CHO DP-12 cell line. Increasing the L-GLN concentration to 
12 mM did not improve cell or product yields or impact on product quality. The steps 
forward from this work will involve investigating if higher cell densities may be achieved, 
greater than the maximum observed in the 4 mM L-GLN culture in this study. An 
investigation for increased cell yields will be conducted through means of up-scaling of the 
suspension cultures to a 1.7 L minifors reactor platform and also encapsulation of the 
suspension cell line in alginate-poly-L-lysine-alginate microcapsules. Depending on the 
results achieved for higher cell density in the experiments to follow, various feeding 
strategies, such as continuous (perfusion), may be applied in order to further enhance any 
achievements in higher cell densities which are made. It is possible that if cells are cultured to 
higher cell densities than those achieved in this early study, the concentration of the growth 
limiting nutrient, L-GLN, may have to be increased in subsequent studies in order to meet the 
energy demands of the cells. Therefore this initial study in the thesis also investigated the 
effect of higher initial L-GLN concentrations (12 mM) on all cellular activities and 
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recombinant protein quality. The main aim of increasing the L-GLN concentration was not 
only to determine if it had a beneficial effect on cellular activities, but also to determine if the 
higher accumulation of ammonia would impact on cellular activities. There were no striking 
concerns in regards to a negative impact of the higher ammonia concentrations accumulated 
throughout this culture on cellular activities and protein quality. It is however important to 
note that in such cultures exponential growth ceased and cells entered stationary phase when 
the ammonia concentration reached 7 mM. At this time point not all of the glutamine had 
been consumed. This study has therefore demonstrated the importance of maintaining the 
accumulated ammonia concentration below 7 mM. The majority of publications reporting on 
the impact of ammonia on mammalian cell activities, particularly on product quality, have 
investigated this effect by means of incorporating high initial ammonia concentrations in the 
culture. This study has identified that the incorporation of high initial ammonia 
concentrations (5-15 mM) in a culture over-exaggerates the negative impact of high ammonia 
accumulation throughout the culture period on protein quality.  
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Chapter 4. Scale of CHO DP-12 cultures from shake flask to bench-scale minifors 
reactor 
 
Abstract: 
Conventional stirred-tank reactors are suitable for industrial production as they can be 
scaled up conveniently, provide a homogeneous environment for cell growth and 
proliferation and enable product quality to be controlled relatively easily. An investigation of 
the scale-up of CHO DP-12 cultures from 1 L Erlenmeyer shake flask platforms to 1.7 L 
minifors reactors for enhanced cell yields and recombinant protein production was conducted.  
Findings suggested that up-scaling does not improve cell or product yields with reduced 
growth rates and specific productivity rates of 11 % and 28 % , respectively observed in 
comparison to the 1 L Erlenmeyer shake flask studies. The effect of resulting shear stresses 
(4.5 dyn/cm
2
) altered the metabolic profile of the cells cultured in the 1.7 L minifors reactor 
in comparison to 1 L Erlenmeyer shake flask cultures. Unfavourable glycolytic metabolism 
of glucose was noted resulting in a lactate molar yield in the ratio of 1 mole of glucose: 2 
moles of lactate. It was concluded that the reduced galactosylation levels detected on the 
rIgG1 samples from the 1.7 L minifors reactor cultures were a direct effect of reduced 
nucleotide sugar donor synthesis in the form of UDP-GalNAc. The nucleotide sugar 
precursor for UDP-GalNAc, UTP, requires aspartate for synthesis. Reduced entry of pyruvate 
into the TCA cycle due to increased lactate dehydrogenase activity may have resulted in a 
depletion of available aspartate for UTP synthesis. This work has signified both the 
importance of cell adaptation to larger scale environments and also the requirement for cell 
protection from hydrodynamic shear stress 
 
Abbreviations 
APA    alginate-ploy-L-lysine alginate 
CHO     Chinese hamster ovary 
CFD     Computational fluid dynamics 
CO2     carbon dioxide 
DO     dissolved oxygen 
EDR     energy dissipation rate 
GA     Golgi apparatus 
GlcNAc    N-acetylgalactosamine 
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IgG1     Immunoglobulin G1  
NaOH     sodium hydroxide 
O2     oxygen 
SEC     size exclusion chromatography 
TCA     tricarboxylic acid 
UDP-GalNAc   uridine di-phosphate N-acetylgalactosamine 
UDP-GlcNAc   uridine di-phosphate N-acetylglucosamine 
UDP-GNAc    uridine di-phosphate N-acetlyhexosamine 
UTP     uridine tri-phosphate 
 
4.1 Introduction 
 The demand for increased yields in recombinant therapeutic proteins from 
mammalian cell culture systems is constantly rising, requiring cheaper, more efficient, cost 
effective process optimisations than those which currently exist. Antibodies are among the 
most expensive therapeutics being used, due to their associated low potencies thus requiring 
higher doses for therapeutic efficiency. Consequently large scale processes are required to 
produce 10-100 kg/year to provide for such demands. The biotechnological industry has 
responded to this need with advances being made in cultivation systems and their capacities, 
allowing for the upscaling of mammalian cell cultures resulting in increased volumetric 
productivity of 100-fold over the past decade as reviewed by Jain and Kumar, (2008). 
In vitro cell culture techniques require a suitable cell cultivation system design allowing for 
adequate mass transfer of both nutrients and by-products and gases (oxygen (O2) and carbon 
dioxide (CO2) and low shear stresses to the cells (Glacken et al., 1983).The use of small scale 
cell culture vessels such as Erlenmeyer shake flasks and stacked plates is associated with 
low-volume speciality applications such as vaccine production and gene therapies (Chu and 
Robinson, 2001). Working volumes are typically in the range of 10-500 ml (Zhang et al., 
2010). Agitation rates applied to the shake flasks allow for the mixing of oxygen and 
nutrients within the culture medium and reduce the boundary layer at the construct surface 
(Jain and Kumar, 2008). Mammalian cells have relatively low demands for O2 and 
consequently require lower specific power input, this being typically between 1-10 Wm
-3
. 
(Zhang et al., 2010). Typical cell densities achieved in shake flasks are in the range of 2.5-4 * 
10
6
 cells/ml (Muller et al., 2004). The industrial scale production of therapeutic recombinant 
proteins utilising mammalian cell culture primarily involves the use of continuous stirred tank 
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bioreactors, which are associated with ease of scale-up and convenient means of control (Chu 
and Robinson, 2001). The popular stirred-tank bioreactor system consists of a vessel, pipes, 
valves, pumps, and a motor. Small stirred-tank bioreactor vessels are usually made of heat 
resistant silicate borate glass and tend to be used in research laboratories. Larger stainless 
steel vessels tend to be used for industrial applications, as reviewed by (Jain and Kumar, 
2008). Stir-tank reactors are associated with many advantages making them suitable for 
industrial production. They can handle both anchorage-dependent and non-anchorage-
dependent cell lines, can be scaled up conveniently, provide a homogeneous environment for 
cell growth and proliferation and enable product quality to be controlled relatively easily 
(Wang et al., 2005). 
A range of operational parameters are required for consideration when scaling from low 
volume cell culture vessels, such as shake flasks, to larger scale platforms, such as stirred-
tank reactors. Such parameters include temperature, pH, CO2 pressure, dissolved oxygen 
(DO), and osmolality. The effects of alterations in such conditions on cellular activities, 
including quality of the produced recombinant protein, have all been extensively reviewed in 
Chapter 1.  As the below experimental design focuses on the scale up of the cultures from 1 L 
Erlenmeyer shake flask to 1.7 L stirred-tank minifors reactor, the effects of shear stress 
caused to cells as a result of agitation and aeration systems employed in typical stirred-tank 
reactors will be a point of consideration for any alterations in the activities of the cells noted 
between cultivation in the two different vessels. Shear stress associated with agitation is as a 
result of turbulence within the liquid, whereas shear stress caused by aeration is due to gas-
liquid interfacial effects, as reviewed by Zhang et al., (2010). 
Shear stressed caused by extremely intense flows of liquid in the culture environment can be 
lethal resulting in the onset of cell death. At the physiological level, shear stresses are 
associated with the leakage of membrane ions, thus affecting the cytosolic pH of the cells 
(Ziegelstein et al., 1992). It has been estimated that a mean energy dissipation rate (EDR) of 
10
5
-10
6
 W/kg is sufficient to disrupt animal cells (Zhang et al., 1993). The resistance level of 
Chinese Hamster Ovary (CHO) cells, in particular, to EDRs has been estimated at 10
4
-10
5
 
W/kg (Ma et al., 2002). When in culture, it is estimated that cells are typically exposed to an 
average EDR of 0.01-0.15 W/kg (Nienow, 2006). It may therefore be concluded that the 
onset of cell death due to shear stress associated with flows of liquid is not an issue for 
consideration in mammalian cell culture systems. However there is cause for concern due to 
the vast amount of reports focusing on the non-lethal effects of culture associated shear 
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stresses on the physiological functions of cells. Such shear stresses have been associated with 
altered cell function, growth rate and viability, enhanced metabolism, inducement of 
transcriptional activators and alterations in the surface content of cellular receptors, as 
summarised by (Zhang, 2004). It is important to point out that alterations in recombinant 
protein production in CHO cells at 1 W/kg have been demonstrated. In such situations there 
was no alteration in cell morphology observed (Keane, 2003). 
The avoidance of shear stress damage to cells through the application of minimal intensity of 
agitation in stirred-tank bioreactors for mammalian cell culture may in itself pose a risk in the 
optimisation of cellular activities. Low rates of agitation have been associated with 
inadequate levels of mixing and homogenisation of the culture environment, as reviewed by 
Zhang, (2004). The typical EDR value in a large scale 800 L aerated vessel is 0.035 W/kg 
2.8-fold lower than that recommended for adequate mixing (Nienow et al., 1996). The low 
agitation rates in combination with low gas flowrates can affect DO gradients, pH control, 
dispersion of nutrients and waste products etc, as reviewed by Zhang et al., (2010). DO 
gradients may be observed in the bulk of the fluid and stagnant layer surrounding the bubbles. 
Inadequate gas dispersion has been associated with a build up of pCO2 in the culture media 
causing the accumulation of levels which are inhibitory to cells. The use of alkaline solutions 
to control pH is brought about through addition of 2 M NaOH from the top of the stirred tank 
bioreactor. Sparged conditions result in pH excursions from the mean. 
Shear stress damage to cells associated with gas-liquid interfaces may be caused at the 
regions of bubble generation, bubble coalescence and break-up in the bulk fluid, bubble 
rising area and bubble disengagement area, as reviewed by Zhang et al., (2010). Bubble 
associated cell damage is still not clear. Efforts have been made to quantify mammalian cell 
damage due to rising bubbles using Computational fluid dynamic (CFD) simulations. It was 
determined that at Reynolds numbers at which mammalian cells cultures typically operate, 
the high shear zone was confined to the wake of each bubble, with the EDR estimated to be 
around 4-8 W/kg for a bubble diameter greater than 1 mm.. Such EDR is expected to cause 
no cell damage (Koynov et al., 2007). 
An experiment was designed which enabled an investigation of the scale-up from a 1 L 
Erlenmeyer shake flask platform to a 1.7 L minifors reactor. In keeping with the overall aim 
of the thesis, it was hypothesised that scale-up may be utilised as a means of achieving higher 
cell densities and enhanced recombinant protein production than that which was observed in 
the previous chapter for the recombinant CHO cell line DP-12, producing Immunoglobulin 
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G1 (IgG1). In the previous Chapter optimised growth, productivity and product quality were 
observed when cells were cultured in a concentration of 4 mM L-glutamine. This specific 
media composition was therefore applied to the scale up experiments in seeking to achieve 
further growth and productivity enhancements. Any alterations in cell growth, metabolism, 
productivity and product quality as a result of scale-up considerations would be identified. 
 
4.2 Results 
 To evaluate the effect of scale up on the growth, metabolism and rIgG1 production 
and quality on the CHO DP-12 cell line, cells were cultured in both 1.7 L minifors reactors 
and 1 L Erlenmeyer shake flasks. The seeding density of the cells was approximately 0.3 * 
10
6
 cells/ml in a total culture volume of 300 ml in the Erlenmeyer shake flasks and 1.2 L in 
the minifors reactor. Cells were cultured in Excel CHO 325 PF media supplemented with 4 
mM L-GLN, as determined to be the optimum L-GLN concentration for growth, production 
and rIgG1 quality in Chapter 3. Cultures conditions were maintained at 37 °C and 100 rpm 
agitation in both culture vessels. The minifors reactor was operated under conditions of 95 % 
DO by means of sparging with compressed air (flowrate of 0.06 L/min). The pH was also 
controlled at 7.2 through automatic addition of 2 M  NaOH, via a feed line, or CO2 sparging 
(through the headspace at a flowrate of 0.047 vvm). All cultures were completed in triplicate. 
 
4.2.1 Effect on CHO cell growth and viability 
 To determine the effect of scale-up on the growth and viability of the CHO DP-12 cell 
line, samples were taken on a daily basis from cultures seeded at 0.3 * 10
6
 cells/ml in both 1 
L Erlenmeyer shake flasks and 1.7 L minifors reactors. Cell numbers were quantified using a 
haemocytometer and trypan blue exclusion method. The results of such cell counts are 
presented in terms of viable cell densities achieved, Figure 4.2.1.1, and viability over the 
culture period, Figure 4.2.1.2, are illustrated below. The maximum specific growth rate 
displayed by the cells during the exponential growth period and maximum viable cell density 
achieved are presented in Table 4.2.1.1 
A similar growth pattern was displayed by the cells when cultured in 1 L Erlenmeyer shakes 
and in 1.7 L minifors reactors. Both modes of cultivation resulted in a lag period of 1 day 
before the entry of cells into exponential growth. Exponential growth was noted to last from 
days 1-4 for both cultures. A difference was noted however in the decline in viable cell 
density.  Even though exponential growth at the maximum specific growth rate had ceased on 
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day 4 in 1 L Erlenmeyer shake flask cultures, cells did not enter a stationary phase until day 
5. A significant fall off in viable cell numbers present did not occur until day 7. Logarithm 
plots of viable cell density over the culture period would suggest that cells were in stationary 
phase until day 7 (results not shown), the time at which the first decrease in viability 96 % to 
81 % may be noted.  Alternatively, viable cell number decreased rapidly 1 day after 
exponential growth had ceased for 1.7 L minifors reactor cultures. There were no further 
increases in viable cell number after cells had ceased growing at the maximum specific 
growth rate. Cells cultured in 1 L Erlenmeyer shake flasks displayed a maximum specific 
growth rate approximately 12 % higher than that displayed by cells cultured in 1.7 L minifors 
reactors. The combined result of an increased maximum specific growth rate and increase in 
viable cell number after exponential growth resulted in an increased biomass yield of 38 % 
when cells were cultured in 1 L Erlenmeyer shake flasks in comparison to 1.7 L minifors 
reactors. 
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Figure 4.2.1.1: Growth of CHO-DP12 cells cultured in 1L Erlenmeyer shake flasks and 1.7 L 
minifors reactor. Cells were cultured as 37 C, 100 rpm agitation. Shake flask cultures were 
performed in un-vented shake flasks. Minifors reactor cultures were sparged with compressed 
air at a flowrate of 0.06 L/min. Agitation was achieved using a 3-blade pitched stainless steel 
impeller (45 ° angle). The pH was also controlled at 7.2 through automatic addition of 2 M  
NaOH, via a feed line, or CO2 sparging (through the headspace at a flowrate of 0.047 vvm). 
Cell numbers were enumerated on a daily basis using trypan blue exclusion method and a 
Neubauer haemocytometer. Duplicate cell counts were performed. Both cultures conditions 
had a seeding viable cell density of 0.3 * 10
6
 cells/ml. Values presented above are the average 
of triplicate cultures carried out in parallel +/- STD for both culture conditions tested. 
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Figure 4.2.1.2: % viability of CHO cells cultures in 1L Erlenmeyer shake flasks and 1.7 L 
minifors reactor. % viability was determined by the enumeration of total and live cell 
numbers present in the culture using trypan blue exclusion method and Neubauer 
haemocytometer. % viability is expressed as a percentage of live cells over dead cells present. 
Cell counts were performed in duplicate and average % viability determined on a daily basis. 
Values presented above are the average of triplicate cultures carried out in parallel +/- STD, 
for both culture conditions tested. 
 
Table 4.2.1.1: Calculated maximum specific growth rates displayed by cells cultured in 1 L 
Erlenmeyer shake flasks and 1.7 L minifors reactor over the exponential growth period. The 
growth rate was calculated from a plot of the logarithm of the viable cell density over the 
cultivation time (days). Values presented above are the average of triplicate cultures carried 
out in parallel +/- STD, for both culture conditions tested. 
Culture μmax (day
-1
)
1 L Erlenmeyer shake flask 0.725 +/- 0.013
1.7 L minifors reaction 0.645 +/- 0.037
Max VCD (*10
6
 cells/ml)
4.295 +/- 0.191
3.12 +/- 0.27  
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4.2.2: Effect on cell metabolism 
 The concentration of the major carbon sources, glutamine and glucose, and their 
corresponding by-products, ammonia and lactate, were measured in cultures 1 L Erlenmeyer 
shake flask cultures and 1.7 L minifors reactor cultures (Figures 4.2.2.1 and 4.2.2.2). Samples 
were removed from cultures on a daily basis and centrifuged at 200 g for 5 minutes, followed 
by filtration of the supernatant (0.22 μm PTFE) in order to remove cells and culture debris. 
Glucose and lactate concentrations were determined using HPLC analysis, and glutamine and 
ammonia analysis was carried out using commercially available enzymatic assays kits, as 
described in Materials and Methods section 2.3.3. Determination of the concentration of the 
various metabolites enabled the calculation of the specific substrate uptake rates for each of 
the experimental cultures (Table 4.2.2.1). 
An evaluation of the consumption profiles of glutamine for both 1 L Erlenmeyer shake flask 
cultures and 1.7 L minifors reactor cultures would suggest that the different modes of 
cultivation impacted on the utilisation of this carbon energy source by the cells.  When cells 
were cultured in 1 L Erlenmeyer shake flasks, glutamine was exhausted by the end of the 
exponential growth phase, suggesting a cessation of maximum specific growth due to the 
depletion of this energy source. Alternatively glutamine was not depleted in 1.7 L minifors 
reactor cultures until cells went into decline phase, suggesting that this carbon source was not 
growth limiting. Although alterations were displayed on the requirement of glutamine for the 
maintenance of exponential growth of the cells, they did not however display significant 
differences in the rate of glutamine consumption. Ammonia accumulation was as expected 
for both cultures. As there were no significant differences in the specific rate of glutamine 
consumption displayed by the cells, it is also acceptable that the specific rate of ammonia 
production was also similar for the cells. A yield ammonia from glutamine of 1.07 
mmol/mmol was determined for the shake flask cultures. The yield of ammonia from 
glutamine was not significantly different for the minifors reactor cultures, determined as 1.23 
+/- 0.15 mmol/mmol. 
All cultures were performed in ExCell CHO 325 PF media. The concentration of glucose in 
the commercially available media is expected to be 17.4 mM. The two modes of cultivation 
investigated also resulted in significantly different utilisation profiles of glucose by the cells. 
In 1 L Erlenmeyer shake flask cultures, glucose was exhausted on day 7, the point at which 
the first significant decline in cell number and % viability was noted. In 1.7 L minifors 
reactor cultures, glucose was completely consumed on day 4 of the culture period, signalling 
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the end of exponential growth.  It would therefore appear that scale up of cultures from 1 L 
Erlenmeyer shake flask cultures to 1.7 L minifors reactor cultures did effect the growth 
limiting substrate required by the cells for exponential growth. A 2-fold increase in the 
specific glucose consumption rate was observed in 1.7 minifors reactor cultures in 
comparison to 1 L Erlenmeyer shake flask cultures during exponential growth. There was 
over a 2.2-fold increase in the concentration of lactate accumulated at the end of exponential 
growth by cells present in the 1.7 L minifors reactor in comparison to those cultured in the 1 
L Erlenmeyer shake flasks. Similarly a 2.6-fold increase in specific lactate production rate 
was noted for the same culture conditions. A yield of lactate from glucose of 1.81 
mmol/mmol was determined for the minifors reactor cultures. A significantly lower yield of 
0.95 mmol/mmol was determined for the shake flask cultures. The results signify that 
although glucose did appear to be the growth limiting substrate in 1.7 L minifors reactor 
cultures, the inefficient glycolytic utilisation of glucose was evident under such conditions, 
resulting in high lactate concentrations. The cessation of maximum specific growth displayed 
by cells cultured in the 1.7 L minifors reactor may have been the result of a combination of 
glucose depletion and a build up of high lactate concentrations in the culture. 
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Figure 4.2.2.1: Concentration of glutamine and ammonia present in both 1 L Erlenmeyer 
shake flask cultures (SF) and 1.7 L minifors reactor cultures (MR) over the duration of the 
respective cultivation periods. The concentrations of glutamine and ammonia were 
determined offline using a commercial available enzymatic assay kit. Values presented above 
are the average of triplicate cultures carried out in parallel +/- STD, for each of the two 
conditions tested. 
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Figure 4.2.2.2: Concentration of glucose and lactate present in both 1 L Erlenmeyer shake 
flask cultures (SF) and 1.7 L minifors reactor cultures (MR) over the duration of the 
respective cultivation periods. The concentrations of glucose and lactate were determined 
offline by HPLC analysis using Supelco H column. Values presented above are the average 
of triplicate cultures carried out in parallel +/- STD, for each of the two conditions tested. 
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Table: 4.2.2.1: Calculated rates of consumption and production of key metabolites as 
determined by offline analysis throughout the culture period. Cell specific consumption and 
production rates of the key metabolites were determined during the exponential growth 
phase. Yields of by-product on metabolite were calculated over the cultivation period. The 
results presented below are the average of that calculated for triplicate cultures carried out in 
parallel for each of the culture conditions tested. 
 1 L Erlenmeyer shake flask 1.7 L minifors reactor 
Glucose consumption rate 
(mM/day) 
3.20 +/- 0.033 5.37 +/- 0.39 
Glutamine consumption 
rate (mM/day) 
0.89 0.81 +/- 0.057 
Lactate production 
rate (mM/day) 
3.49 +/- 0.17 10.54 +/- 0.40 
Ammonia production 
rate (mM/day) 
0.902 0.78 +/- 0.04 
qglucose 
(mmoles/10
6
 cell/day) 
8.35 *10
-4
 +/- 5 * 10
-5
 1.69 * 10
-3
 +/- 1.00 * 10
-4
 
qglutamine 
(mmoles/10
6
 cell/day) 
2.26 * 10
-4
 3.00 * 10
-4
 +/- 3.31 * 10
-5
 
qlactate 
(mmoles/10
6
 cell/day) 
1.15 * 10
-3
 +/- 8.59 * 10
-5
 3.07 * 10
-3
 +/- 3.3 * 10
-4
 
qammonia 
(mmoles/10
6
 cells/day) 
3.11 * 10
-4
 3.46 * 10
-4
 +/- 2.74 * 10
-5
 
Ylactate/glucose 
(mmol/mmol) 
0.95 +/- 0.11 1.81 +/- 0.09 
Yammonia/glutamine 
(mmol/mmol) 
1.07 1.23 +/- 0.15 
 
4.2.3: Effect on rIgG1 production 
 To evaluate the effect of the two modes of cultivation on rIgG1 production, media 
samples were removed from the suspension cultures on a daily basis from day 4 onwards and 
on day 5 onwards from the encapsulated cultures. As explained in Section 2.3.6 of the 
Materials and Methods section, rIgG1 was purified from media samples removed from the 
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cultures after centrifugation at 200 g for 5 minutes to remove cells. rIgG1 present in the 
media was purified using Protein A Nab spin columns and quantified using the nanodrop at A 
280 nm. 
Evaluation of the concentration of rIgG1 produced by cells cultured in the two different 
modes, as presented in Figures 4.2.3.1 and 4.2.3.2 below, suggested that enhanced 
recombinant protein production was observed when cells were cultured in 1 L Erlenmeyer 
shake flasks in comparison to 1.7 L minifors reactors. Investigation of the specific production 
rate displayed by the cells cultured in the 1 L Erlenmeyer shake flask, presented in table 
4.2.3.1, suggests that this is not due to the increased number of cells present producing the 
protein. Both enhanced volumetric productivity and enhanced specific productivity (1.4-fold) 
of the rIgG1 was observed for the cultivation of cells in the 1 L Erlenmeyer shake flasks. 
Such observations cumulated in a 2.2-fold higher concentration of rIG1 present at the end of 
the stationary phase for the 1 L Erlenmeyer shake flask cultures in comparison to that 
observed in 1.7 L minifors reactor cultures. 
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Figure 4.2.3.1: Concentration of rIgG1 purified from cell free media samples harvested from 
both 1 L Erlenmeyer shake flask cultures and 1.7 L minifors reactor cultures from day 4 
onwards. rIgG1 present in the media was purified using commercially available protein A/G 
Nab spin columns and quantified using the nanodrop A280 nm in duplicate which the average 
value recorded. Values presented above are the average of triplicate cultures carried out in 
parallel at both scales +/- STD. 
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Figure 4.2.3.2: Concentration of rIgG1 purified from cell free media samples harvested from 
1 L Erlenmeyer shake flask cultures and 1.7 L minifors reactor cultures at the end of the 
stationary growth period. rIgG1 was purified using Protein A/G spin columns and quantified 
using nanodrop A280 nm. Samples were quantified in duplicate with the average value 
recorded. Values presented above are the average of triplicate cultures carried out in parallel 
+/- STD. 
 
Table 4.2.3.1: Calculated rIgG1 production rates and cell specific production rates for cells 
cultured in 1L Erlenmeyer shake flask and 1.7 L minifors reactors. The specific production 
rate was calculated over the exponential growth phase for all cultures. The results presented 
below are the average of triplicate cultures, +/- STD, carried out in parallel for the two culture 
conditions tested. 
Culture
1 L erlenmeyer shake flask
1.7 L minifors reactor
q IgG1 μg/106 cells/day
16.787
10.522
5.16 +/- 0.29
3.74 +/- 0.23
IgG1 production rate μg/ml/day
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4.2.4: Effect on rIgG1 quality 
 To assess the affect of scale-up from 1 L Erlenmeyer shake flasks to 1.7 L minifors 
reactors on the quality of rIgG1 produced, both glycan and aggregation analysis were 
completed on the purified rIgG1 samples harvested from both the shake flask and minifors 
reactor cultures at both the end of the exponential and stationary growth phases Samples 
harvested from the shake flask and reactor cultures were subjected to N-glycan release and 
labelled as outline in Materials and Methods section 2.3.7.1. HILIC characterisation of the 
released and labelled N-glycans produced a chromatogram consisting of 8 distinctly 
separated peaks. Each of the peaks was assigned a distinctive glucose units (GU) value by 
comparison to the retentions times of the standard A-AB labelled external dextran. 
Examination of exoglycosidase treated samples allowed for the corresponding number and 
linkage of the component monosaccharide units represented by each GU value to be 
elucidated, as described in Materials and Methods section 2.3.7.3 Aggregation analysis of the 
purified samples was carried out using size exclusion chromatography (SEC) 
Figure 4.2.4.1 below illustrates the relative % of the different glycans present on rIgG1 
samples harvested from the cultures at the end of the stationary growth phase. It is important 
to note that the relative % of glycans present on IgG1 samples harvested at the end of the 
exponential and stationary growth phases did not vary significantly for each of the culture 
conditions investigated. Irrelevant of the mode of cultivation, all cultures displayed a similar 
trend in the relative % of glycans present. The earliest form of N-glycosylation of rIgG1 is 
denoted by M5, F6A1/A2 and F6A2. The highest relative percentage of glycans present on 
the rIgG1 samples were the early glycoforms, predominantly F6A2. The galactosylated 
glycoforms are denoted by F(6)A2[6]G(4)1 and F(6)A2[3]G(4)1, which contain 1 galactose 
unit on either of the outer GlcNAc arms, and F(6)A2G2, which contains a galactose residue 
on each of the outer GlcNAc arms. A2G2 contains galactose residues on each outer arm but if 
not fucosylated. Of the galactosylated glycoforms present, the F(6)A2[6]G(4)1 were the 
predominant form in all cultures, independent of the mode of cultivation employed. 
Similar to the analysis completed in Chapter 3; Section 3.2.4, a more in depth evaluation of 
the relative % of each type of glycoform present was completed and did indicate significant 
differences in the levels of glycosylation between cultures. Figure 4.2.4.2, below, illustrates 
the relative % of F(6)A1/A2 glycan structures released from rIgG1 samples harvested from 
shake flask and reactor cultures. An average of 10 % increase in the relative % of this glycan 
was present on rIgG1 samples harvested from minifors reactor cultures in comparison to 
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shake flask cultures. This fucosylated N-glycan, containing either one or two GlcNAc 
residues is one of the earliest form of glycosylation arising from initial processing in the 
Golgi apparatus (GA). The proportion of this glycoform may suggest a lack of further 
processing of glycans on proteins produced by cells cultured in 1.7 L minifors reactor in 
comparison to that which is observed when cells are cultured in 1 L Erlenmeyer shake flasks. 
This statement is confirmed by the presence of a lower relative % of glycan structures 
containing one or two galactose residues present on proteins harvested from the reactor 
cultures in comparison to the shake flask cultures, as noted in Figures 4.2.4.3 and 4.2.4.4. A 
18 % lower relative % of, F6A2[6]G(4)1, and a 31 % lower relative % of F6A2G2 was noted 
for glycans released from rIgG1 harvested from 1.7  minifors reactor samples in comparison 
to 1 L Erlenmeyer shake flask samples. The level of sialyation did not appear to be 
significantly affected by the scale up of the cultures. It may therefore be proposed that the 
scale-up of cultures from 1 L Erlenmeyer shake flask cultures to 1.7 L minifors reactor 
cultures effects the complex processing of glycan structures present on recombinant proteins 
at the galactosylation level. Aggregation analysis confirmed that over 99 % of the rIgG1 
harvested from 1 L Erlenmeyer shake flask cultures and 1 L minifors reactor cultures was in 
monomeric form.  These results suggest that neither the culture conditions investigated nor 
the resulting glycoform profile of the recombinant protein affected the aggregation state of 
the protein. 
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Figure 4.2.4.1: Relative % of N-glycan forms detected on rIgG1 samples harvested from 1 L 
Erlenmeyer shake flask and 1 L minifors reactor studies at the end of the stationary growth 
phase. N-glycans were released from the rIgG1 samples by means of PNGaseF digestion. 
Samples for HILIC analysis were labelled by adding 5 μl of 2AB labelling solution. The 
retention time of the glycan peaks was compared with an external A-AB labelled dextran 
standard for structural elucidation by converting the retention time of the peaks into GU. 
Each IgG1 sample was analysed in duplicate. The results are the average of the triplicate 
cultures carried out for each condition tested. 
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Figure 4.2.4.2: Relative % of F(6)A1/A2 glycan forms detected on rIgG1 samples harvested 
from 1 L Erlenmeyer shake flask and 1 L minifors reactor studies at the end of the stationary 
growth phase, as detected using HILIC following PNGaseF release and 2-AB labelling. 
Results are directly comparable results to those found for the analysis of samples from the 
end of the exponential growth period. Each IgG1 sample was analysed in duplicate. The 
results are the average of the triplicate cultures carried out for the two culture conditions 
tested +/- STD 
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Figure 4.2.4.3: Relative % of F(6)A2[6]G(4)1 glycan forms detected on rIgG1 samples 
harvested from 1 L Erlenmeyer shake flask and 1 L minifors reactor studies at the end of the 
stationary growth phase, as detected using HILIC following PNGaseF release and 2-AB 
labelling. Results are directly comparable results to those found for the analysis of samples 
from the end of the exponential growth period. Each IgG1 sample was analysed in duplicate. 
The results are the average of the triplicate cultures carried out for the two culture conditions 
tested +/- STD. 
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Figure 4.2.4.4: Relative % of F(6)A2G2 glycan forms detected on rIgG1 samples harvested 
from 1 L Erlenmeyer shake flask and 1 L minifors reactor studies at the end of the stationary 
growth phase, as detected using HILIC following PNGaseF release and 2-AB labelling. 
Results are directly comparable results to those found for the analysis of samples from the 
end of the exponential growth period. Each IgG1 sample was analysed in duplicate. The 
results are the average of the triplicate cultures carried out for the two culture conditions 
tested +/- STD. 
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Figure 4.2.4.5: Relative % of monomeric form of rIgG1 samples as detected by SEC. IgG1 
samples were harvested from cultures performed in 1 L Erlenmeyer shake flask and 1.7 L 
minifors reactor platforms. The above results are based on the analysis of samples harvested 
at the end of the stationary growth period. The results for samples harvested over the culture 
period in each of the cultures are directly comparable (data not shown). IgG1 samples were 
analysed in duplicate. The results are presented as the average of triplicate cultures performed 
for the two culture conditions tested +/- STD. 
 
4.2.5: Estimation of maximum shear stress under stirred conditions 
 It is possible to quantitatively determine the maximum shear stress experienced by the 
CHO DP-12 cells cultivated in the 1.7 L minifors reactor platform employing both 
mechanical aeration and agitation. Air was sparged into the reactor at a flowrate of 0.06 
L/min. A 3 blade pitched stainless steel impeller (45 ° angle) was employed for agitation of 
the reactor. 
The resulting EDR, denoted as t  , resulting from aeration and agitation was calculated by 
the sum of the calculated energy dissipation rate from sparging S  and the energy dissipation 
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rate from the impeller under sparged conditions iS . Such calculations were made utilising 
the parameters listed in Table 2.2.2.1 and Equations 2.2.2.1.2 – 2.2.2.1.12 in Materials and 
Methods sections 2.2.2 and 2.2.2.1, respectively. 
Once the overall EDR from aeration and agitation was calculated, it was possible to estimate 
the overall maximum shear stress, max , on the cells using Equation 2.2.2.1.1 from Materials 
and Methods section 2.2.2.1. Table 4.2.5 below gives the calculated S , iS  and overall EDR 
( t ), all in W/kg. The max is also presented in the table below dyn/cm
2
. 
 
Table 4.2.5: Maximum shear stress exerted on the cells under conditions of mechanical 
agitation and aeration in 1.7 L minifors reactor. Overview of the energy dissipation rates from 
sparging S , impeller agitation under conditions of sparging iS , overall EDR ( Sist   ) 
and maximum shear stress on cells max . 
S  (W/kg) iS  (W/kg) t  (W/kg) max (dyn/cm
2
) 
0.0024 0.0058 0.0082 4.5 
 
4.3 Discussion 
 An experiment was designed which enabled an investigation of the scale-up from a 1 
L Erlenmeyer shake flask platform to a 1.7 L minifors reactor. In keeping with the overall 
aim of the thesis, it was hypothesised that scale-up may be utilised as a means of achieving 
higher cell densities and enhanced recombinant protein production than that which was 
observed in the previous chapter for the recombinant CHO cell line DP-12, producing IgG1. 
Typical cell densities achieved in shake flasks are in the range of 2.5-4 * 10
6
 cells/ml (Muller 
et al., 2004). The industrial scale production of therapeutic recombinant proteins utilising 
mammalian cell culture primarily involves the use of continuous stirred tank bioreactors, 
which are associated with ease of scale-up and convenient means of control (Chu and 
Robinson, 2001)  In the previous chapter optimised growth, productivity and product quality 
were observed when cells were cultured in a concentration of 4 mM L-glutamine. This 
specific media composition was therefore applied to the scale up experiments in seeking to 
achieve further growth and productivity enhancements.  
The overall results of the effect of scale-up from a 1 L Erlenmeyer shake flask to 1.7 L 
minifors reactor was a reduction in cell growth, denoted by an 11 % reduction in the 
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maximum specific growth rate and  a 27 % reduction in the viable cell density achieved. The 
reduction in cell yield was as a result of the combined effect of the reduced maximum 
specific growth rate and also the fact that cells cultured in the 1 L Erlenmeyer shake flask 
continued to grow for one extra day after maximum growth had ceased. Cells cultured in 1.7 
L minifors reactor only maintained the maximum cell yield achieved for that condition for 
approximately one day after maximum growth had ceased. Lee et al., (2005) also reported a 
27 % decrease in the maximum cell density achieved between shake flask and STR cultures 
under batch cultivation conditions. Reductions in the final yield of recombinant protein 
produced were also noted in this current study for cells cultured in the 1.7 L minifors reactor, 
in comparison to those cultured in the 1 L Erlenmeyer shake flask. The reduced yield was as 
a result of the lower cell numbers producing the protein, and also a noted 28 % reduction in 
the specific production rate displayed by the cells. In a similar study Lee et al., (2005) 
reported on a 35 % reduction in the maximum specific production rate when cells were 
cultured in 1 L (working volume) STR in comparison to shake flask cultures for a 
recombinant CHO cell line. The scale-up of the cultures did also impact on the quality of the 
recombinant protein produced, in terms of the level of galactosylation achieved. rIgG1 
harvested from 1.7 L minifors reactors had an 31 % reduction in the relative percentage of 
fully galactosylated N-glycan structures, F6A2G2,  and an 18 % reduction in the relative % 
of N-glycan structures containing 1 galactose residue, F6A2[6]G(4)1, in comparison to the 
rIgG1 harvested from 1 L shake flask cultures.  
Culture conditions which affect cell growth and productivity, such a temperature and pH 
were maintained as consistent as possible between the two culture conditions. Significant 
differences in operational parameters between the two cultivation platforms exist in the 
agitation of the minifors reactor and it’s gassing, as explained in Materials and Methods 
section 2.2.2. The minifors reactor was operated under conditions of 95 % dissolved oxygen 
(DO) by means of sparging with compressed air (flowrate of 0.06 L/min). The pH was also 
controlled at 7.2 through automatic addition of 2 M NaOH, via a feed line, or CO2 sparging 
(through the headspace at a flowrate of 0.047 vvm). Three things to consider in scaling up of 
vessels which effect cellular activities: (1) shear stress associated with turbulence in the 
liquid brought about by agitation (2) the presence of DO gradients , inadequate pH control 
and nutrient dispersion brought about by inadequate mixing, again associated with agitation 
(3) shear stresses associated with the gas to liquid interface. Shear stress associated with 
agitations and aeration can have both lethal, resulting in cell death, and non-lethal, altering 
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growth, metabolism and productivity profiles of the cells, effects. It may be suggested that 
the reduced growth and productivity demonstrated by the cells in the minifors reactor was as 
a result of shearing stresses brought about by the conditions. It has been estimated that a 
mean EDR of 10
5
-10
6
 W/kg is sufficient to disrupt animal cells (Zhang et al., 1993). The 
resistance level of CHO cells, in particular, to EDRs has been estimated at 10
4
-10
5
 W/kg (Ma 
et al., 2002). Variations in the susceptibility of mammalian cells to mechanical agitation have 
been varied. Chisti, (1993) scaled up hybridoma cells from 20 L to 300 L and found that the 
cells were fairly resistant to high impeller speeds. Reynolds numbers, submerged aeration, 
grinding action of the mechanical seals and support bearings of the magnetic agitators did not 
cause much damage to the cells up to 300 L. In relation to the shear stress associated with 
gassing, a maximum EDR of 10
3
-10
4
 W/kg was calculated due to bubble rupture of small 
bubble diameter (less than 2 mm) (Boulton-Stone and Blake, 1993; Garcia-Briones and 
Chalmers, 1994). Kioukia et al., (1992) found that the most important region for cell damage 
was the bubble disengagement region and the more frequently cells passed through that 
region, the greater the cell damage was. pH perturbations brought about by a combination of 
sparging and NaOH addition at the top of the reactor result in hybridoma cell death when pH 
is below its mean value (Osman et al., 2002). Low shear stress levels, EDR values of 1 W/kg, 
have also been noted to affect the productivity of recombinant CHO cells. In protein-free 
media, without the presence of protectants, productivity ceased from CHO cells when a shear 
stress of 1 W/kg was generated in a flow chamber. In this current study the EDR from the 
combination of sparging and impeller agitation was calculated at approximately 0.0082 
W/kg, which is considerably lower than the EDR which has been noted to impact on cell 
growth and productivity in the above mentioned studies. Increasing shear stresses, with EDR 
in the range of 0.05-8 W/kg reduced productivity from 100 % to 49 % respectively for the 
same cell line (Keane et al., 2003). The overall maximum calculated shear stress on the cells, 
max , was however calculated as 4.5 dyn/cm
2
. A study performed by Fernandes-Platzgummer 
et al., (2011) investigated the effect of increases in maximum shear stress values, from 1.2-
3.0 dyn/cm
2
, on the growth of mammalian cells. The mouse embryonic stem (mES) cells in 
the study demonstrated inefficient cell expansion when cultured in the presence of a shear 
stress level of 3.0 dyn/cm
2
 in comparison to cells cultivated in the presence of 1.2 and 2.0 
dyn/cm
2
, with reduced viability also being noted on day 2 in the 3.0 dyn/cm
2
 cultures. 
Shear stresses created by scale up have been noted to affect the metabolism of cells. Under 
most culture conditions, cells predominantly take up glucose as a carbon source, which is 
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catabolised via different pathways with a large proportion converted to lactate (Chen et al., 
2012). The tolerance levels towards lactate seem to be cell line specific and vary widely 
(Hassell et al., 1991). The effect of shear stress is somewhat varied in the response of cells by 
means of altered glucose consumption and lactate production, Keane et al.,(2002) reported 
that a shear stress in the range of 1-8 W/kg resulted in a concurrent increase in glucose uptake 
rate from 115% to 142% in compared to control cultures with no shear. Lactate productivity 
was decreased from 92 to 50 % over the same range. These results do not comply with those 
presented by Shiragami and Unno, (1994), who found metabolite production increased with 
exposure to moderate shear stress with dissipation energy of the flowing medium. The effects 
of non-lethal levels of shear stress on the metabolism of various cell types were established 
by examining the induction of the transcriptional activator c-fos (Ranjan et al., 1996). CHO 
cell response to 25 W/kg shear stress was within minutes.  The mechanism of action on 
intracellular responses has been associated with involvement of intracellular Ca
++
 in a 
membrane event linked to the activation of the phospholipase C pathway (Levesque et al., 
1989, Wiesner et al., 1997). However it has also been associated with the activation of a 
specific GTP-binding (G protein), activated by shear stress within 1 sec of onset in human 
cells (Gudi et al., 1996). The impact of scale-up from 1 L Erlenmeyer shake flask to 1.7 L 
minifors reactor is portrayed by an altered glucose consumption and lactate production 
profile. The specific consumption and production profiles of glutamine and ammonia were 
similar for both culture conditions investigated. Glucose appeared to be the growth limiting 
substrate for cells cultured in the 1.7 L minifors reactor. A 2-fold increase in the glucose 
consumption rate was observed over the exponential growth phase in comparison to that 
observed when cells were cultured in the 1 L Erlenmeyer shake flasks. A 2.6-fold increase in 
the specific lactate production rate was also observed for the cells cultured in the minifors 
reactor. Cells cultured in 1.7 L minifors reactors underwent higher rates of glycolysis 
resulting in yields of lactate from glucose, determined as 1.81 mmol/mmol. Cells cultured in 
1 L Erlenmeyer shake flasks displayed significantly reduced yields of lactate, remaining at 
0.95 mmol/mmol. It may therefore also be proposed that the effects of scale-up in cell and 
protein yields may also be a direct result of the alterations in the metabolic profiles of the 
cells between the two culture platforms. High lactate concentrations, induced by the addition 
of 60 mM sodium lactate have been noted to inhibit growth in CHO cells by 25 % (Lao and 
Toth, 1997). At the end of the cultivation period in hybridoma cultures, the concentration of 
lactate was noted to be 63 mM which was thought to be associated with the onset of cell 
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death (Zhang et al., 2004). The maximum lactate accumulation at the end of the exponential 
phase in the minifors reactor cultures was 36 mM. Such a level is not suggested to be 
inhibitory of cell growth, but may in turn have caused cell stress which did not occur in the 
shake flask studies, resulting in reduced cell growth and productivity. 
The altered metabolic glucose patterns may also serve as a possible reasoning for the reduced 
levels of galactosylation noted on the final product. As explained in Chapter 1, galactose 
residues are transferred from the pool of nucleotide sugar donors uridine di-phosphate N-
acetylgalactosamine (UDP-GalNAc) present in the Golgi apparatus (GA), onto the N-
acetylgalactosamine (GlcNAc) residue of an emerging glycan chain of a newly synthesised 
protein. This process is very much dependent upon both the action of galactosyl transferase 
enzymes and also the pool of free nucleotide sugar donors in the GA. A limitation in the 
concentration of glucose has been noted to reduce the pool of nucleotide sugar donors formed 
by means of reducing the intracellular concentration of nucleoside triphosphates, uridine tri-
phosphate (UTP) (Nyberg et al., 1999). In the 1.7 L minifors reactor studies, the 
concentration of glucose was not limiting in comparison to that present in the 1 L Erlenmeyer 
shake flask studies. However the fact that the majority of glucose present was converted to 
lactate suggests that a reduction in the amount of pyruvate entering the tricarboxylic acid 
(TCA) cycle was likely to occur. A key precursor for UTP synthesis is aspartate The 
importance of the TCA cycle in providing aspartate for UTP synthesis has been demonstrated 
by DeFrancesco et al., (1976), in which Chinese hamster lung fibroblasts could not readily 
take up exogenously supplied aspartate and demand for intracellular aspartate replied on it’s 
production from oxaloacetate, an intermediate of the TCA cycle. As pyruvate directly feeds 
into the TCA cycle, a reduction in pyruvate due to increase lactate production may result in a 
reduction in available aspartate for UTP synthesis. A reduction in UTP synthesis would 
subsequently reduce the intracellular pool of uridine di-phosphate N-acetlyhexosamines 
(UDP-GNAc) such as UDP-GalNAc. There was no apparent reduction in the concentration of 
uridine di-phosphate N-acetylglucosamine (UDP-GlcNAc) residues due to similar relative % 
of GlcNAc containing glycans, such as F6A2, present on rIgG harvested from both culture 
conditions studied. It may therefore also be suggested that perhaps only the further processing 
steps, such as galactosylation, may have been affected by a reduced pool of UTP. 
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4.4 Conclusion: 
 An investigation of the scale-up of CHO DP-12 cultures from 1 L Erlenmeyer shake 
flask platforms to 1.7 L minifors reactors for enhanced cell yields and recombinant protein 
production was conducted. In this study scale-up was not shown to enhance cell or product 
yields with reduced growth rates and specific productivity rates of 11 % and 28 % , 
respectively observed in comparison to the 1 L Erlenmeyer shake flask studies. The 
maximum shear stress exerted on the cells in the 1.7 L minifors reactor was calculated as 4.5 
dyn/cm
2
, due to a combination of sparging and impeller agitation. The altered growth and 
productivity profiles of the cells in the minifors reactor in comparison to the shake flask 
platform were due to the non-lethal effects of such a shear stress on the cells. The effect of 
resulting shear stresses altered the metabolic profile of the cells cultured in the 1.7 L minifors 
reactor, with enhanced glucose consumption and lactate production observed in comparison 
to 1 L Erlenmeyer shake flask cultures. Unfavourable glycolytic metabolism of glucose was 
noted resulting in a lactate molar yield in the ratio of 1.81 mmol/mmol. It was concluded that 
the reduced galactosylation levels detected on the rIgG1 samples from the 1.7 L minifors 
reactor cultures were a direct effect of reduced nucleotide sugar donor synthesis in the form 
of UDP-GalNAc. The nucleotide sugar precursor for UDP-GalNAc, UTP, requires aspartate 
for synthesis. Reduced entry of pyruvate into the TCA cycle due to increased lactate 
dehydrogenase activity may have resulted in a depletion of available aspartate for UTP 
synthesis. 
A step forward from this study could include an investigation of the optimisation of 
bioreactor parameters in the 1.7 L minifors reactor platform, in order to determine if the 
adverse growth, productivity and product quality noted to occur, in comparison to shake flask 
cultures, could be improved. Optimisation of bioreactor parameters are typically the measures 
taken at an industrial level. This current study has focused on the effect of increased shear 
stress brought about by mechanical aeration and agitation in 1.7 L minifors reactor platforms 
in comparison to shake flask cultures. Although the maximum shear stress calculated in the 
reactor, 4.5 dyn/cm
2
, was at a level which was previously determined to disrupt the growth 
expansion of a stem cell line under stirred conditions (Fernandes-Platzgummer et al., 2011), 
the EDR were not at the levels which have previously been reported to disrupt CHO cell 
growth, in both a lethal or non-lethal manner, as noted in the discussion section. In order to 
optimise cellular activities in the reactor and overcome the adverse growth, productivity and 
metabolism noted it would be necessary to investigate all parameters which were different 
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between the 1 L Erlenmeyer shake flask and 1.7 L minifors reactor platform, which include: 
1) shear stress (agitation and aeration), which has already been investigated in this Chapter. 
2) The oxygen transfer rate (OTR). The importance of the OTR in the supply of oxygen to 
cells in culture has been described in Chapter 1, Section 1.2.4. It is influenced by several 
parameters including the air flowrate, bubble size, agitation rate and liquid properties (Morão 
et al., 1999). Variations in the volumetric oxygen mass transfer coefficient, (kLa), have been 
noted for airflow rates ranging from 100-300 cm
3
/min (Fernandes-Platzgummer et al., 2014). 
The air flowrate used in this current study was 60 cm
3
/min. 3) The sparging of the reactor 
with CO2 (shake flask cultures were previously conducted in a non-gased incubator in capped 
shake flasks) and 4) the impact of osmolality changes in the reactor brought about by NaOH 
addition for pH control. The combined effects of CO2 sparging and osmolality increases 
brought about by NaOH addition on cellular activities have been reviewed in the Introduction 
Chapter, Section 1.2.3. Inhibition of cell growth with increasing levels of dissolved CO2 was 
noted in studies reported by deZengotita et al., (1998). A decrease in the growth rate of the 
cells by 86% in comparison to the growth rate observed for cells cultured in medium at an 
osmolality of 342 mOsm/kg. An important consideration is the adaptation of cells. When 
cells are transferred from one growth environment to another a period of adaptation is 
required. Another step further would therefore include efforts to adapt the cells to the reactor 
environment by conducting several passages of the cells in the minifors reactor. 
The growth of cells in suspension will, however, become limited at a certain level. Various 
authors have reported on improved cell growth and enhanced recombinant protein yields 
through the manipulation of key culture parameters (including temperature, feeding strategy 
etc). This has however proven limited in successfully achieving increased cell and product 
yields with low specific productivities and maximum cells densities reported (1-10 pg/cell/h 
and 1-5 * 10
6
 cells/ml) as reviewed by Selimoglu, and Elibol, (2010). Therefore a more 
desirable approach is the investigation of the encapsulation of the cells in alginate-poly-L-
lysine-alginate (APA). It is evident from this study that the cells are under stress in the 
bioreactor environment, therefore, alternatively efforts could be made to protect the cells 
from this environment as oppose to altering the conditions of the environment. The 
microcapsules would not only serve to protect the cells from their surrounding environment 
by entrapping them in a liquid core gel surrounded by a membrane of alginate cross-lined 
with poly-L-lysine, but it also provides a 3-D structure for the growth of mammalian cells, 
which have a natural tendency to aggregate. The cultivation of cells in close proximity to one 
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another enhances cell to cell communication for optimised cell growth and productivity. 
Immobilisation/entrapment/encapsulation of cells has been utilised as an effective tool for 
achieving higher cell densities than those which occur in optimal suspension conditions 
(Breguet et al., 2007; Peirone, 1998). However the outward effect on such a cultivation 
technique of recombinant protein quality is yet to be characterised.  
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Chapter 5: Encapsulation of CHO-DP12 cells in Alginate-Poly-l-lysine-Alginate 
microcapsules: Implications on rIgG1 quality  
 
Abstract 
 A primary objective for the production of monoclonal antibodies on the industrial 
scale is sustained productivity at high cell densities. Various authors have reported on 
improved cell growth and enhanced recombinant protein yields through the manipulation of 
key culture parameters (including temperature, feeding strategy etc). Cell immobilisation has 
been suggested as a cultivation method which protects cells from bioreactor associated shear 
forces for sustained viability and enhanced productivity. The concentration of autocrine 
factors are considered to be locally higher inside the immobilisation matrix, as opposed to 
being diluted in the surrounding media when cells are present in suspension.  
A study was designed which involved the encapsulation of a CHO DP-12 cell line, producing 
the recombinant protein IgG1 in Alginate-poly-L-lysine-alginate (APA) microcapsules. The 
aim of the experiment was to investigate increased cell and product yields than those 
achieved in previous suspension cultures. Encapsulated culture yields (cells/mlreactor) were 
3.7-fold higher than those achieved when cells are cultured in suspension. Due to the 
increased number of cells producing the recombinant protein, an increase in the volumetric 
productivity (4.8-fold) and final yield of rIgG1 was achieved in encapsulated cultures.  The 
quality of the rIgG1 was also monitored and noted be 99 % monomeric. The glycosylation 
profile of the rIgG1 were similar for both suspension and encapsulated cultures at the end of 
the stationary growth period. A greater increase in high mannose glycan structures was 
present over the stationary growth period in encapsulated cultures in comparison to 
suspension. It was attributed to the batch nature of the culture in which the concentration of 
glutamine was depleted by the end of the exponential phase, thus limiting the availability of 
glutamine derived nucleotide sugar precursors over the extended stationary phase which 
occurred in the encapsulated cultures in comparison to the suspension cultures. 
  
Abbreviations 
AFM     atomic force microscopy 
APA     alginate-poly-L-lysine-alginate 
CHO     Chinese hamster ovary 
BHK     Baby hamster kidney 
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ER     Endoplasmic reticulum 
FDA     Food and drinks authority 
GA     golgi apparatus 
GalNAc    N-acetlygalactosamine 
GFAT    glutamine:fructose-6-phosphate 
GlcNAc    N-acetlyglucosamine  
GU     glucose units 
HEK     human embryo kidney 
HEM-MMA     hydroxyethyl methacrylate-co-methyl methacrylate 
IL-6     Interluekin-6 
IgG     Immunoglobulin G 
IL-6     Interluekin-6 
IFN-α     Interferon-α   
mAb     monoclonal antibody 
MDCK    madin darby canine kidney  
PLL     Poly-L-lysine 
SEC     size exclusion chromatography 
TGFβ1    Transforming growth factor β 1  
UDP-GNAc   uridine di-phosphate N-acetylhexosamine 
UTP    uridine tri-phosphate 
VEGF165b    Vascular endothelial growth factor165b  
 
5.1 Introduction: 
A primary objective for the production of monoclonal antibodies on the industrial 
scale is sustained productivity at high cell densities. Efforts have been made to improve 
maximum cell densities and increase recombinant protein yields through manipulation of 
environmental culture conditions. Biphasic approaches employing temperature shift 
optimisation allow for high cell densities to be achieved while inducing optimised specific 
productivities in the cells (Fox et al., 2004). Optimisation of media components and feed 
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strategies has alleviated the inhibition of cell growth and productivity associated with the 
accumulation of toxic by-products (Xie and Wang, 2006). Manipulation of culture conditions 
have however proven limited in successfully achieving increased cell and product yields with 
low specific productivities and maximum cells densities reported (1-10 pg/cell/h and 1-5 * 
10
6
 cells/ml) (Selimoglu, and Elibol, 2010). High cell densities are impeded by mechanical 
and shear forces resulting from agitation and aeration schemes in large scale industrial 
bioreactors. Cell immobilisation has been suggested as a cultivation method which protects 
cells for sustained viability and enhanced productivity (Seifert and Philips, 1999). 
A stated in the Introduction Chapter, Section 1.2.7, microencapsulation was first used in the 
treatment of diabetes, in which pancreatic islet cells were first immobilised in alginate and 
delivered in vivo without the occurrence of a rejection reaction (Lin and Sun, 1980). Since 
then mammalian cell immobilisation has been used for various applications including the 
encapsulation of recombinant cells containing genes encoding therapeutic proteins, with 
enhanced cell densities and/or increased culture longevity being achieved, greater than those 
which occur for cells cultured freely in suspension (Sinacore et al., 1989; Lee and Palsson 
1990; Ma et al., 2006; Breguet et al., 2007; Selimoglu et al., 2012). The advantages of 
encapsulation for mammalian cell cultivation leading to higher cell densities than those 
achieved in suspension have been described in the Introduction Chapter in Section 1.2.7, all 
of which relate to the provision of a protective environment for the fragile mammalian cells 
from shear forces associated with the bioreactor environment (Papoutsakis, 1991).  
Initial studies performed by Lim and Moss (1981) suggested that a 10-fold increase in 
monoclonal antibody (mAb) yield could be achieved in immobilised hybridoma cultures in 
comparison to suspension cultures due to an increase in cell densities achieved, as reviewed 
by Selimoglu and Elibol, (2010). In relation to enhanced productivity associated with 
encapsulated cultivation of mammalian cells, the microcapsule environment is associated 
with enabling increased higher local concentrations of autocrine productivity promoting 
factors, such as Il-6 (Farrell et al., 1994). The microcapsule provides space limitation which 
limits cell proliferation. Once the higher cell densities have been achieved and the space 
within the microcapsules has been occupied, lower growth rates enable enhanced specific 
recombinant protein production (Yamaguchi et al., 1997). Enhanced productivity in 
immobilised culture platforms has been reported by various investigating authors to date 
(Sinacore et al., 1989; Lee and Palsson 1990; Lee et al., 1993; Peirone, 1998; Seifert and 
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Philips 1999; Rokstad et al., 2003 Breguet et al., 2007; Zhang et al., 2007; Selimoglu et al., 
2012).    
As reported in Chapter 4, the maximum viable cell density achieved for the Chinese hamster 
ovary (CHO) DP-12 cell line used, when cultured in a 1.7 L minifors reactor was 3.12 * 10
6
 
cells/ml. The maximum concentration of recombinant immunoglobulin G (IgG1) produced in 
the culture was approximately 60 μg/ml. Previous shake flasks studies reported in Chapter 3 
investigated the optimisation of cell growth and productivity through the manipulation of 
medium components, focusing on glutamine and ammonia concentrations. However the 
scaling up of these experiments, with optimised L-glutamine concentrations, did not enhance 
the cell or product yields achieved. Therefore in an effort to seek enhanced cell densities and 
product yields, encapsulation in alginate-poly-L-lysine-alginate (APA) microcapsules as a 
mode of cultivation was investigated for the CHO DP-12 cell line producing the recombinant 
protein IgG1. APA microcapsules are reportedly the most widely studied microcapsules 
applied to mammalian cell cultures for enhanced recombinant protein production (Zhang et 
al., 2007), due to a number of advantages associated with alginate, as outlined in the 
Introduction Chapter, Section 1.2.7. CHO cells were immobilised in a sodium alginate 
solution. Extrusion of the solution though a 300 μm diameter nozzle and the application of 
vibration nozzle technology allowed the formation of alginate gelled beads containing the 
cells, upon incubation in (0.1M) Ca2+. Ca2+ is the most suitable ion in relation to 
biocompatibility of mammalian cells to the ion and also affinity for the sodium alginate. The 
beads were coated with PLL (Mw 30,000-75,000), followed by a second layer of alginate 
(0.03 % w/v) and liquefied with 0.05 M sodium citrate. The results of such liquefaction are 
that cells float freely around the interior of the capsule. (Gugerli, 2003). The APA 
microcapsules were used to inoculate the same 1.7 L minifors reactor in an approximate ratio 
of 300 ml of capsules and 900 ml of excel CHO 325 PF media. Batch cultures were 
performed in triplicate and the average seeding density was 0.32 * 10
6
 cells/mlreactor, as 
deduced by initial cell counts performed immediately post inoculation. 
 The overall aim of the study was to investigate the implications of encapsulation as a mode 
of cultivation on the growth, metabolism and productivity of the mammalian cell line in 
culture in comparison to the profiles observed for the same cell line when cultured freely in 
suspension. Of the many studies, noted above, demonstrating the growth, recombinant 
protein production and stability of microcapsules in vitro (Breguet et al., 2007; Peirone, 1998; 
Rokstad et al., 2003), the effects, if any, such a mode of cultivation may have on the quality 
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of recombinant proteins produced (glycosylation and/or aggregation) have somewhat been 
overlooked. Enhanced high cell numbers and recombinant protein yields are only to be 
desired providing there is no trade-off in the quality of the protein produced. It may be 
hypothesised that due to the decreased growth rates associated with immobilised mammalian 
cells, the time in which recombinant proteins remain exposed to glycosylation enzymes may 
be increased. Enhanced volumetric productivity of the rIgG1 may promote aggregation 
through self association at high concentrations in the resulting culture media. However, the 
intrinsic structure of the APA microcapsule may provide a barrier to the release of the 150 
kDA IgG molecules, promoting aggregation of the molecule inside the capsule. The reported 
molecular weight cut-off point of APA microcapsules is <100kDa. However in the presence 
of living cells, APA microcapsules have reportedly demonstrated full permeability to protein 
products with molecular weights ranging from 21-300kDa (Awrey et al., 1996). The diffusion 
of a solute through a membrane is not just dependent on the molecular weight cut-off of the 
membrane but also on the ionic charge, size, shape and radius of gyration of the solute (Tyn 
and Guesk, 1990).  
 
5.2.Results: 
To evaluate the effect of encapsulation as a mode of cultivation for mammalian cells, 
CHO DP-12 cells, which grow in suspension, producing the recombinant protein IgG1 were 
encapsulated in APA microcapsules. Approximately 300 ml of alginate containing 0.5 * 10
6
 
cells/ml of alginate was extruded through a 300 μm nozzle into a bath containing 110 mM 
CaCl2 solution to form beads. The beads were then incubated for 30 minutes in poly-l-lysine. 
The core of the beads was liquefied through incubation in 0.05 M sodium citrate solution. 
The liquid core capsules were then used to inoculate a minifors reactor in a total culture 
volume of 1.2 L comprised of 900 ml of ExCell CHO 325 PF media, supplemented with 4 
mM L-glutamine, and 300 ml of capsules. 
Suspension cultures were also carried out in parallel. A total media volume of 1.2 L ExCell 
CHO 325 PF media, supplemented with 4 mM L-GLN was inoculated with CHO DP-12 cells 
producing the recombinant protein IgG1 at a cell density of 0.3 * 10
6
 cells/ml.  Samples were 
taken on a daily basis for the determination of cell growth, metabolite concentration, IgG 
concentration, glycosylation and aggregation. Samples of microcapsules were also examined 
microscopically for size determinations. Microcapsule strength was determined every second 
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day using atomic force microscopy (AFM). Both encapsulated and suspension cultures were 
carried out in triplicate. 
 
5.2.1. Characterisation of microcapsules 
 
5.2.1.1. Capsule size 
 The determination of microcapsule size throughout the culture period is an important 
parameter as changes in the size affect the diffusion of metabolites and other cellular products 
in and out of the capsules. Large capsules (> 1 mm) may suffer diffusion limitations resulting 
in reduced cell growth and necrosis within the core. However it was reported that with greater 
bead sizes higher cell concentrations could be reached. Inoculum density is directly 
proportional to bead size in almost all encapsulation systems (Selimoglu and Elibol, 2010). 
The APA microcapsules were formed by the extrusion of a sodium alginate solution through 
a 300 μm nozzle. Due to liquefaction of the alginate core, swelling of such microcapsules in 
the range of 150-200 % of the original volume has been reported (Breguet et al., 2007). 
Based on previous studies, the final diameter of the microcapsules would be expected to be in 
the range of 700-900 μm. Capsule size determination was carried out using a laboratory 
microscope (Nikon Eclipse TI) with the corresponding software for image analysis (NIS-
element AR). Thirty capsules were measured individually to calculate the average radius and 
standard deviation, as estimated by comparison with a calibrated scale. Generally size 
distribution was below 3 % between microcapsules in a given culture conditions at a given 
time. 
 Figure 5.2.1.1.1 below demonstrates the capsule radius size as determined from samples 
taken throughout the culture period in the triplicate cultures performed. The capsules size was 
determined microscopically. The average initial capsule radius for the 3 cultures performed 
was ~ 460 μm. The capsule size remained within a consistent range throughout the cultivation 
period. However it is important to note, that size was only determined for intact capsules. The 
appearance of broken capsules towards the end of the culture period, from day 7-9 was 
omitted. Capsule breakup by the end of the culture period, day 9, was determined to be 18 % 
of the total volume of capsules present. 
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Figure 5.2.1.1.1: Capsule radius size (μm) over the duration of the cultivation period for each 
of the three encapsulated cultures completed. The size of approximately 30 capsules was 
measured at each time point. Values are the mean of 30 microcapsules analysed on a daily 
basis +/- STD. 
 
5.2.1.2 Capsule strength 
 Capsule resistance is one of the critical factors when capsules are intended for 
bioreactor cultures. The bursting of capsules would result in the release of cells, cell 
components and genetic material. Furthermore, resistance is a key variable of microcapsules, 
being directly responsible for controlling the permeability (Gugerli, 2003). The mechanical 
strength of the bead is dependent upon the molecular size of the alginate used. Inflexibility in 
solution increases in the order of MG<MM<GG content of the alginate (Selimoglu and 
Elibol, 2010). Samples of capsules from the cultures were evaluated every second day using a 
Texture Analyser.  
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Evaluation of Figure 5.2.1.2.1 below indicates a decrease in the force (g)/capsules over 
cultivation time, representative of a decrease in the mechanical resistance of the APA 
microcapsules throughout the culture period. The decrease in capsule strength mainly 
occurred during days 0-3 (inclusive) in which the force (g)/capsule decreased from 0.49 +/- 
0.09 g/capsule to 0.07 +/- 0.01 g/capsule. The decrease in microcapsule strength during this 
time period may be attributed to the introduction of shear forces to do the capsules in the 
reactor and also an equilibration with the medium. As no reactor conditions changed in this 
batch culture over time, no further decrease in capsule strength was noted later in the culture 
period. However the integrity of these weakened capsules became an issue from day 7 
onwards when there was an estimated 18 % loss of capsules due to breakage in the culture. 
This may be due the fact that these weakened capsules then contained the maximum viable 
cell number observed in the culture (day 6). The method used to determine the force 
(g)/capsule analysed a layer of capsules at a time. This method is effective for efficient 
measurement of large numbers of capsules. However the results are affected by large size 
distributions. It was however noted in Figure 5.2.1.1.1 that the size distributed between 
capsules is typically low, 3-5 %. 
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Figure 5.2.1.2.1: Mechanical resistance (force (g)/capsule) over cultivation period for 300 
μm radius APA microcapsules containing CHO DP-12 cells cultivated in a 1.7 L minifors 
reactor. A total of 3 layers of microcapsules were analysed on a daily basis. Values presented 
are average of such triplicate analysis +/- STD for one of the encapsulated cultures carried 
out in the study. 
 
5.2.1.3: Permeability of microcapsules 
 The permeability of the microcapsules to dextrans ranging in molecular weights, up to 
500 kDa and including the molecular weight of the IgG1 protein which the cells produce (150 
kDa), was determined for the 300 μm radius APA microcapsules. 300 μl of capsule 
suspension was incubated in 600 μl of a 0.05 % fluorescent dextran solution of a particular 
molecular weight. The capsules were incubated under agitation for 2 hours and analysed 
using confocal microscopy. 
Figure 5.2.1.3.1 below illustrates the permeability of the microcapsules used in these cultures 
to the fluorescent dextrans of molecular weight 150 and 500 kDa. The method was not 
optimised at this point for quantitative determination of the molecular weight cut-off of the 
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microcapsules. However such image analysis which was performed on days does indicate 
that the microcapsules were permeable to components of molecular weights > 150 kDa. The 
IgG1 protein produced by the cells is 150 kDa. 
 
         
      150 kDA    500 kDA 
Figure 5.2.1.3.1: Confocal microscopy analysis (100 X) of 300 μm APA microcapsules 
incubated in fluorescent dextran (150-500 kDa) at a volume ration of 1:3 microcapsules: 
dextran solution 
 
5.2.2.: Effect of encapsulation on CHO cell growth 
 
5.2.2.1 Growth of encapsulated cells 
 Microscopic analysis on a daily basis of the microcapsules enabled direct 
visualisation of the colonisation of the microcapsules with cells. 300 ml of alginate was 
inoculated with a cell density of 0.5 * 10
6
 cells/ml alginate. Prior to such an inoculation the 
required cell number was calculated and the appropriate volume of a suspension culture was 
centrifuged at 200 g for 5 minutes. The resulting pellet was resuspended in the alginate using 
gently aspiration. Appropriate mixing, by means of aspiration was essential at this point in 
order to ensure sufficient distribution of the cells in the alginate microcapsules. Figure 
5.2.2.1.1 below illustrates the colonisation of the cells in the microcapsules over the 
cultivation period (days 0, 2, 4 and 6). Examination of day 0 illustrations indicates that the 
inoculum was evenly distributed throughout the capsules formed. Very few empty capsules 
were evident. However, irrelevant of the even distribution of cells throughout the capsules on 
day 0, the cells appear to grow in extremely close proximity inside the capsules, forming one 
distinct cluster of cells in each capsule. Animal cells have a natural tendency to aggregate; 
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therefore an immobilisation process will offer optimal growth conditions. Figure 5.2.2.1.2 
below illustrates the morphology of the cells in the clusters on day 6 of the cultivation period. 
The cells do not appear to be aggregated, but conform to their single cell morphology 
common of their growth in suspension.  
       
 
        
Figure 5.2.2.1.1: Microscopic analysis (40 X) (unstained) of microcapsule colonisation by 
cells over the cultivation days 0, 2, 4 and 6. Cells were originally seeded at 0.5 * 10
6
 cells/ml 
alginate and which was extruded through a 300 μm nozzle as part of the liquid core 
microcapsule formation. The resulting microcapsules were used to seed a reactor with a ratio 
of 300 ml capsules and 900 ml media. 
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Figure 5.2.2.1.2: Microscopic analysis (400 x and 600 x) (unstained) of the cluster of cells 
present inside microcapsules on day 6 of the culture period. Microcapsules were originally 
seed at 0.5 * 10
6
 cells/ml alginate. Although cells are evenly distributed throughout the 
capsules on day 0, growth patterns displayed by the cells demonstrate the formation of 
clusters of singly growing cells inside the capsules. 
 
5.2.2.2 Growth of cells in capsules -v- suspension 
 Microcapsules formed through the extrusion of 300 ml of alginate inoculated with 0.5 
* 10
6
 cells/mlalginate through the 300 μm nozzle were used to inoculate a minifors reactor 
containing 900 ml of media. Due to variations in the encapsulation procedure the average 
seeding viable cell density of the three encapsulated cultures performed was 0.32 * 10
6
 
cells/mlreactor +/- 0.165 * 106 cells/ml. The average seeding density of the three suspension 
cultures inoculated in 1.2 L of media in the minifors reactor was 0.30 * 10
6
 cells/mlreactor. All 
bioreactor conditions remained the same between the two modes of cultivation. To evaluate 
the effect of cell encapsulation on the growth of cells, samples were removed from the reactor 
on a daily basis. Cell counts were performed using the trypan blue exclusion method and 
haemocytometer. Prior to performing cell counts, microcapsules were ruptured by extrusion 
through a 300 μm needle and diluted in PBS. 
Figures 5.2.2.2.1 and 5.2.2.2.2 and the growth stats presented in Table 5.2.2.2.1 below, allow 
the growth patterns and viability of the cells in the various cultures to be compared and 
contrasted. The maximum specific growth rate displayed by the cells in suspension and 
encapsulated in 300 μm radius capsules was similar. Both culture conditions resulted in a lag 
period of 1 day before exponential growth was achieved. Encapsulated cultures spent 
approximately 2 extra days in exponential phase resulting in a maximal viable cell density 3.7 
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fold higher than that achieved when the cells were cultured in suspension. A short stationary 
phase of 1 day existed in the growth profiles displayed by cells cultured in suspension. A 
stationary phase of 2 days was observed for cells cultured in the liquid capsules. This is 
supported by the sharp fall off in viability one day after the maximum viable cell density has 
been achieved, day 5 for suspension cultures and day 7 for encapsulated cultures. The initial 
viability of the encapsulated cells was slightly lower than that displayed in the suspension 
cultures. However during exponential growth it was maintained above 85 %. 
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Figure 5.2.2.2.1: Growth of CHO cell cultures in suspension and encapsulated 300 μm radius 
liquid core APA microcapsules. The cell concentration is given with respect to the volume of 
the reactor and not with respect to the capsule’s volume. Encapsulated and suspension 
cultures were seeded at an average viable cell density of 0.3 * 10
6
 cells/mlreactor. Cell numbers 
were enumerated on a daily basis using trypan blue exclusion method and a Neubauer 
haemocytometer. Encapsulated cells were liberated prior to counting via extrusion of a 
capsule/PBS suspension through a 300 μm needle 3 times. Duplicate cell counts were 
performed. Values presented above are the average of triplicate cultures carried out in parallel 
+/- STD, for both culture conditions tested. 
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Figure 5.2.2.2.2: % Viability of CHO cells cultured in suspension and encapsulated in 300 
μm liquid capsules. % viability was determined by the enumeration of total and live cell 
numbers present in the culture using trypan blue exclusion method and Neubauer 
haemocytometer. % viability is expressed as a percentage of live cells over dead cells present. 
Cell counts were performed in duplicate and average % viability determined on a daily basis. 
Values presented above are the average of triplicate cultures carried out in parallel +/- STD. 
 
Table 5.2.2.2.1: Calculated maximum specific growth rates displayed by cells cultured in 
suspension and encapsulated in 300 μm liquid capsules over the exponential growth period. 
The growth rate was calculated from a plot of the logarithm of the viable cell density over the 
cultivation time (days). The maximum viable cell density is presented with respect to per ml 
reactor working volume. The results presented below are the average determined for triplicate 
cultures performed for each of the two conditions tested. 
Culture μmax (day
-1
)
Encapsulated cells 0.759 +/- 0.12
Suspension cells 0.645 +/- 0.0377
Max VCD (*10
6
 cells/ml)
3.12 +/- 0.273
11.02 +/- 1.35
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5.2.3: Effect of encapsulation on rIgG1 production 
 To evaluate the effect of the two modes of cultivation on rIgG1 production, media 
samples were removed from the suspension cultures on a daily basis from day 4 onwards and 
on day 5 onwards from the encapsulated cultures. As explained in Section 2.3.6., of the 
Materials and Methods Section, rIgG1 was purified from media samples removed from the 
cultures after centrifugation at 200 g for 5 minutes to remove cells. Capsules were separated 
from the media before the centrifugation step for the encapsulated culture samples. rIgG1 
present in the media was purified using Protein A Nab spin columns and quantified using the 
nanodrop at A 280 nm. 
Figure 5.2.3.1 below allows comparison of the concentration of rIgG1 produced by cells 
cultivated in both suspension and encapsulated in 300 μm liquid capsules. The values 
presented are the mean of triplicate cultures +/- standard deviation. The concentration of 
IgG1 produced by the encapsulated cells was not outside the standard deviation of the 
concentration produced by the cells cultured in suspension. This is due to the fact that the 
specific production rate displayed by the encapsulated cells was similar to that displayed by 
the cells cultured in suspension. Overall an increase production rate was noted for the 
encapsulated culture, as noted in Table 5.2.3.1. This was however due to the increased 
number of cells present at each time point and also the ended cultivation period. As noted in 
Figure 5.2.3.2, an increased concentration of rIgG1 was harvested from the encapsulated 
cultures at the end of the exponential and stationary growth phases than that which was 
harvested from the suspension cultures for the same culture stages. A greater increase in the 
concentration of rIgG1 was measured at the end of the stationary phase in comparison to the 
end of the exponential growth phase in the encapsulated cultures. This observation is due to 
the increased cell number producing the protein. At the end of stationary phase the 
concentration of rIgG1 in encapsulated cultures was an average of ~3.1- fold higher than that 
observed in suspension cultures. This 3.1- fold increase is in line with the 3.7- fold increase 
noted in viable cell number and therefore verifying that there was no changes in the specific 
production rate. 
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Figure 5.2.3.1: Concentration of rIgG1 purified from cell free media samples harvested from 
encapsulated cultures on day 5 onwards and suspension cultures on day 4 onwards. rIgG1 
present in the media was purified using commercially available protein A/G Nab spin 
columns and quantified using the nanodrop A280 nm in duplicate which the average value 
recorded. Values presented above are the average of triplicate cultures, +/- STD, carried out 
in parallel for both culture platforms. 
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Figure 5.2.3.2: Concentration of rIgG1 purified from cell free media samples harvested from 
the encapsulated and suspension cultures at the end of the exponential and stationary growth 
period. rIgG1 was purified using Protein A/G spin columns and quantified using nanodrop 
A280 nm. Samples were quantified in duplicate with the average value recorded. Values 
presented above are the average of triplicate cultures carried out in parallel +/- STD. 
 
Table 5.2.3.1: Calculated rIgG1 production rates and cell specific production rates for cells 
cultured in suspension and encapsulated in 300 μm radius liquid capsules. The specific 
production rate was calculated over the exponential growth phase for all cultures. The results 
presented below are the average of triplicate cultures, +/- STD, carried out in parallel for the 
two culture conditions tested 
Culture
Suspension cells
Encapsulated cells
IgG1 production rate μg/ml/day q IgG1 μg/10
6
 cells/day
10.52 +/- 2.80 3.74 +/- 0.23
50.74 +/- 5.38 2.39 +/- 1.02  
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5.2.4 Effect of encapsulation on cell metabolism 
 Both encapsulated and suspension cultures were performed in ExCell CHO 325 PF 
media supplemented with 4 mM l-glutamine. The concentration of glucose in the 
commercially available media is expected to be 17.4 mM. The concentration of the major 
carbon sources, glutamine and glucose, and their corresponding by-products, ammonia and 
lactate, were measured from media samples taken from all cultures on a daily basis (Figure 
5.2.4.1 and 5.2.4.2). Samples were removed from cultures on a daily basis and centrifuged at 
200 g for 5 minutes, followed by filtration of the supernatant (0.22 μm PTFE) in order to 
remove cells and culture debris. Glucose and lactate concentrations were determined using 
HPLC analysis, and glutamine and ammonia analysis was carried out using commercially 
available enzymatic assays kits, as described in Materials and Methods Section 2.3.3. 
Determination of the concentration of the various metabolites enabled the calculations of the 
specific substrate uptake rate for each of the experimental cultures (Table 5.2.4.1). 
An evaluation of the consumption profiles of glucose for both suspension and encapsulated 
cultures suggests that the different modes of cultivation impacted on the utilisation of this 
carbon energy source by the cells. In suspension cultures, all of the glucose was consumed at 
the end of the exponential growth phase. However, for cells cultured in 300 μm radius liquid 
capsules, glucose was not depleted until the end of the stationary growth period. Both the rate 
of glucose consumption and the cell specific glucose consumption rate were 60 % and 80 % 
higher, respectively, in the suspension cultures in comparison to the encapsulated cultures. As 
a result of increased glucose consumption a 3-fold higher concentration of lactate was 
accumulated in the suspension cultures in comparison to the encapsulated cultures. A 50 % 
higher yield of lactate on glucose occurred over the culture period in the suspension cultures 
in comparison to the encapsulated cultures. 
The second major carbon source in mammalian cell culture, glutamine, was depleted at the 
end of the exponential phase in encapsulated cultures. It was not completely depleted until 
the end of the stationary phase in the suspension cultures. However there was a 73 % 
decrease in the cell specific consumption rate of glutamine in encapsulated cultures in 
comparison to suspension cultures, suggesting that glutamine was utilised more efficiently by 
cells cultures in liquid capsules, as oppose to in suspension. The decreased cell specific 
glutamine consumption rate noted in encapsulated cultures is coupled with a decreased cell 
specific ammonia production rate in the encapsulated cultures in comparison to the 
suspension cultures. As both the cell specific consumption and production rates decreased 
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proportionally in the encapsulated cultures in comparison to the suspension cultures, there 
was no significant difference in the yield of ammonia on glutamine between the two culture 
conditions. The yields were calculated for each of the three cultures carried out in parallel for 
the two conditions tested in this study. The results presented in Table 5.2.4.1 are the average 
of the triplicate cultures performed for each condition tested. As noted there was a high 
standard deviation for the yield of ammonia on glutamine for the three cultures performed for 
each condition tested. 
The results may suggest an alternative growth limiting substrate between the two modes of 
cultivation (glucose for suspension cultures, meanwhile glutamine for encapsulated cultures). 
However it must also be considered that the high concentration of lactate may have also been 
responsible for the rapid decline in viable cell density noted in the suspension cultures. 
It must be noted that there is a difference in the initial concentration of the two carbon energy 
sources between the suspension and encapsulated cultures. This is due to a dilution of the 
encapsulated cultures due to the ratio of capsules to media. 
 
183 
 
0
5
10
15
20
25
0 2 4 6 8 10 12
Time, days
G
lu
co
se
 c
o
n
ce
n
tr
a
ti
o
n
 (
m
M
)
-5
0
5
10
15
20
25
30
35
40
45
L
a
ct
a
te
 c
o
n
ce
n
tr
a
ti
o
n
 (
m
M
)
EC glucose SC glucose EC lactate SC lactate
 
Figure 5.2.4.1: Concentration of glucose and lactate present in both suspension cultures (SC) 
and encapsulated cultures (EC) over the duration of the respective cultivation periods. The 
concentrations of glucose and lactate were determined offline by HPLC analysis using 
Supelco H column. Values presented above are the average of triplicate cultures carried out 
in parallel, +/- STD, for each of the two conditions tested. 
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Figure 5.2.4.2: Concentration of glutamine and ammonia present in both suspension cultures 
(SC) and encapsulated cultures (EC) over the duration of the respective cultivation periods. 
The concentrations of glutamine and ammonia were determined offline using a commercial 
available enzymatic assay kit. Values presented above are the average of triplicate cultures 
carried out in parallel, +/- STD, for each of the two conditions tested. 
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Table: 5.2.4.1: Calculated rates of consumption and production of key metabolites as 
determined by offline analysis throughout the culture period. Cell specific consumption and 
production rates of the key metabolites were determined during the exponential growth 
phase. Yields of by-product on metabolite were calculated over the cultivation period. The 
results presented below are the average of that calculated for triplicate cultures carried out in 
parallel for each of the culture conditions tested. 
 Encapsulated cells Suspension cells 
Glucose consumption rate 
(mM/day) 
2.09 +/- 0.12 5.37 +/- 0.39 
Glutamine consumption 
rate (mM/day) 
0.59 +/- 0.19 0.81 +/- 0.057 
Lactate production 
rate (mM/day) 
2.55 +/- 0.71 10.54 +/- 0.40 
Ammonia production 
rate (mM/day) 
0.459 +/- 0.18 0.78 +/- 0.04 
qglucose 
(mmoles/10
6
 cell/day) 
3.11 *10
-4
 +/- 1.12 * 10
-4
 1.69 * 10
-3
 +/- 1.00 * 10
-4
 
qglutamine 
(mmoles/10
6
 cell/day) 
8.42 * 10
-5
 +/- 6.21 * 10
-6
 3.00 * 10
-4
 +/- 3.31 * 10
-5
 
qlactate 
(mmoles/10
6
 cell/day) 
5.32 * 10
-4
 +/- 1.88 * 10
-4
 3.07 * 10
-3
 +/- 3.3 * 10
-4
 
qammonia 
(mmoles/10
6
 cells/day) 
1.31 * 10
-4
 +/- 1.16 * 10
-5
 3.46 * 10
-4
 +/- 2.74 * 10
-5
 
Ylactate/glucose 
(mmol/mmol) 
1.22 +/- 0.18 1.81 +/- 0.09 
Yammonia/glutamine 
(mmol/mmol) 
1.88 +/- 0.23 1.23 +/- 0.15 
 
5.2.5: Effect of encapsulation of on product quality 
 To assess the affect of encapsulation as a mode of cultivation for suspension cells on 
the quality of rIgG1 produced, both glycan and aggregation analysis were completed on the 
purified rIgG1 samples harvested from both the encapsulated and suspension cultures at both 
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the end of the exponential and stationary growth phases To study the influence of 
encapsulation as a mode of cultivation on the glycosylation of rIgG1, samples harvested from 
the suspension and encapsulated cultures were subjected to N-glycan release and labelled as 
outline in Materials and Methods Section 2.3.7.1. HILIC characterisation of the released and 
labelled N-glycans produced a chromatogram consisting of 8 distinctly separated peaks. Each 
of the peaks was assigned a distinctive glucose units (GU) value by comparison to the 
retentions times of the standard A-AB labelled external dextran. Examination of 
exoglycosidase treated samples allowed for the corresponding number and linkage of the 
component monosaccharide units represented by each GU value to be elucidated, as 
described in Materials and Methods section 2.3.7.3. Aggregation analysis of the purified 
samples was carried out using size exclusion chromatography (SEC) 
Figure 5.2.5.1 below illustrates the relative % of the different glycans present on rIgG1 
samples harvested from the cultures at the end of the stationary growth phase. 
The earliest form of glycosylation, and an intermediate in the formation of more complex 
glycans is M5. There was a 25 % decrease in the relative present of M5 glycan structures 
present on rIgG1 samples harvested from encapsulated cultures, in comparison to those 
harvested from suspension cultures at the end of the exponential growth period. By the end of 
the stationary growth phase, the relative % of M5 on IgG1 protein harvested from both 
cultures had increased from the amount present on the protein at the end of the exponential 
growth phase. The increase in M5 over the stationary phase for suspension cultures was not 
significant. There was however a ~2.8- fold increase in M5 present on the protein harvested 
from encapsulated cultures at the end of the stationary phase, compared to that harvested at 
the end of the exponential phase. The increase in M5 in encapsulated cultures was much more 
dramatic than that observed in suspension cultures. Therefore although encapsulation did 
initially seem to be beneficial in resulting in reduced levels of M5 at the end of the 
exponential phase, there was in actual fact no significant difference in the glycoform profile 
of the protein harvested from both culture conditions by the end of the stationary growth 
period. These studies do suggest that should the stationary phase of the encapsulated cultures 
be lengthened, a lower quality product could result due to the increasing levels of non-
complex M5 noted to occur for encapsulated cultures over this time frame. As there were no 
significant decreases in the relative % of the more complex glycoforms, the increase in the 
levels of M5 over the cultivation period cannot be attributed to the action of proteases 
released from the cells. In such cases increased occurrence of M5 is associated with a 
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depletion of nutrient over time which act as nucleotide sugar precursors, as is explained in 
detail in Discussion section 5.3. 
Figure 5.2.5.2 illustrates the % of rIgG1 purified from cultures in a monomeric form. Over 95 
% of the rIgG1 harvested from culture media was in a monomeric form. Similarly IgG1 
harvested from suspension cultures demonstrated to be 99 % in a monomeric form. 
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Figure 5.2.5.1: Relative % of N-glycan forms detected on rIgG1 samples harvested from 1 L 
encapsulated and suspension cultures at the end of the stationary growth phase. N-glycans 
were released from the rIgG1 samples by means of PNGaseF digestion. Samples for HILIC 
analysis were labeled by adding 5 μl of 2AB labelling solution. The retention time of the 
glycan peaks was compared with an external A-AB labelled dextran standard for structural 
elucidation by converting the retention time of the peaks into GU. Each IgG1 sample was 
analysed in duplicate. The results are the average of the triplicate cultures carried out for each 
condition tested, +/- STD. 
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Figure 5.2.5.2: Relative % monomeric from of rIgG1 samples as detected by SEC. IgG1 
samples were harvested from encapsulated and suspension cultures performed. IgG1 samples 
were analysed in duplicate. The results are presented as the average of triplicate cultures 
performed for the two culture conditions tested, +/- STD. 
 
5.3: Discussion 
 The beneficial effects of cell immobilisation in 3-D microcapsules have been 
extensively reviewed since the first encapsulation of pancreatic islet cells for the treatment of 
diabetes (Selimoglu, and Elibol, 2010). The application of encapsulation to recombinant cell 
lines producing therapeutic proteins both in vivo (Liu et al., 1993; Change et al., 1993; 
Hughes et al., 1994.) and in vitro, as reviewed by Selimoglu, and Elibol, (2010) has been 
extensively documented with increased cell yields and concentrations of recombinant 
proteins produced coming to the fore. Results have been however been varied with cell line 
and cell type. Lee et al., (1994) tested a number of hybridoma cell lines and noted that 
increased specific mAb productivities demonstrated when cells are immobilised is cell line 
specific.   There has also been a lack of research conducted regarding the implications of 
encapsulation as a mode of cultivation on recombinant protein quality. A study was therefore 
conducted which investigated the effects of CHO DP-12 cultivation in APA microcapsules on 
cell growth, metabolism rIgG1 production and also the quality (glycosylation and/or 
aggregation state) of the produced rIgG1. APA microcapsules containing the CHO cells were 
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used to inoculate a 1.7 L minifors reactor at an average initial cell density of 0.32 * 10
6
 
cells/mlreactor with a ration of 300 ml capsules and 900 ml of media. Free suspension cultures 
of the CHO DP-12 cells were carried out in parallel with the same initial seeding density of 
0.30 * 10
6
 cells/mlreactor.  
The growth profiles of cells encapsulated in 300 μm radius microcapsules were characterised 
by both microscopic analysis of the microcapsules on a daily basis and also the performance 
of cell counts using a haemocytometer and trypan blue exclusion method, proceeding 
rupturing of the capsules. Cells were initially seeded in a homogeneous manner, evenly 
distributed throughout the microcapsule core. Growth of the cells resulted in the formation of 
cell clusters within the capsule core. The vast majority of research conducted on the growth 
of mammalian cells in microcapsules in vitro reported consistently similar results (Peirone et 
al., 1998; Afkhami et al., 2012; Bohari et al., 2011; Ma et al., 2006; Afkhami et al., 2010). It 
is common that cells, which are already adherent cell lines, would form cell-to-cell 
associations for viability when placed in a microenvironment. Lahooti and Sefton, (2000) 
reported the formation of single aggregates from free floating adherent human embryo kidney 
(HEK) cells in the core of poly(hydroxyethyl methacrylate-co-methyl methacrylate (HEM-
MMA) capsules, just one day post-encapsulation. The aggregation of suspension adapted cell 
lines, such as CHO, has also been reported extensively in encapsulated cultures. Zhang et al., 
(2007) reported on the formation of small spherical aggregates of CHO cells during first 4 
days post-encapsulation in APA microcapsules, which rapidly enlarged throughout the 
cultivation period. The morphology of cells inside microcapsules does appear to be 
dependent upon the seeding density used. Wen-tao et al., (2005) reported that for cells seeded 
at 5 * 10
5
 cells/mlcapsules, cells formed very few light aggregates. However at a seeding 
density of 5 * 10
6
 cells/mlcapsules, cells grew to form multiple very large aggregates. It was 
concluded that as cells altered from single cell morphology initially to an aggregated state 
inside the capsules, the microcapsule environment allows for self-organization of the cells. 
Seeding density has also been reported as critical in determining the speed at which spheroids 
of encapsulated cells arise for other cell types (Bohari et al., 2011). The CHO DP-12 cells in 
this study did appear to display an aggregated morphology. However closer observation of 
the colonies (400 and 600 X magnification), suggested that the cells grew in close proximity 
to each other, maintaining their single cell status, as opposed to adhering together. Animal 
cells do tend to aggregate. However, the aggregation of cells within microcapsules has been 
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associated with the formation of necrosis cores due to poor diffusion of nutrients and oxygen 
to the central cells of the aggregate.  
Based on the results of daily cell counts, the growth profiles of cells encapsulated in APA 
microcapsules, and that of cells cultured freely in suspension, portrayed a similar pattern. A 
lag period of 1 day was observed prior to exponential growth. Encapsulated cells spent 2 
extra days in exponential growth resulting in a maximal viable cell yield of 3.7 fold higher 
than that which was achieved by the freely suspended cells. The increased yield brought 
about through encapsulation is somewhat more dramatic than those achieved by Breguet et 
al., (2007). They reported a maximum viable cells density of 2.2 * 10
6
 cells/mlreactor for 
encapsulated cultures in comparison with 1.41 * 10
6
 cells/mlreactor for suspension cultures for 
a CHO cell line. The magnitude of increased cell yield brought about by encapsulation is cell 
type and line dependent. Awrey et al., (1996) reported that for a series of genetically 
modified mammalian cells encapsulated in APA microcapsules, the increase in cell number 
over time varied in the range of 10- to 153- fold, dependent on the cell type.  Breguet et al., 
(2007) did however report on a decreased maximum specific growth rate for the encapsulated 
cells in comparison to that observed in suspension cultures. There was no significant 
difference in the maximum specific growth rate displayed by encapsulated and suspension 
cells in this current study. Similar cellular growth rates for suspension and encapsulated 
cultures have also been reported for hybridoma cells producing mAbs. Sinacore et al., (1989) 
noted an increased cell yield in immobilised cultures due to an exponential phase double the 
length of that observed in suspension cultures. Increased growth periods and maintenance of 
viability has been associated with the protection microcapsules offer cells from shear forces 
(Lee and Palsson, 1990). In this current study the stationary phase for both cultures was short, 
1 day for suspension cells and 2 days for encapsulated cells. Different cell types display 
different growth profiles. Hybridoma cells encapsulated in APA microcapsules displayed a 4 
day stationary phase which was comparably longer than that displayed when the cells were 
cultured in suspension (Ma et al., 2006). It may be concluded therefore that cells show an 
improved growth process in microcapsules. The APA microcapsules in this culture were 
strong enough to support the increasing cell numbers until the end of the stationary phase. 
However there was a calculated 18 % loss in microcapsules due to breakage between days 7-
9. Although, APA liquid core microcapsules have been widely reported for their support of a 
range of mammalian cell growth, as noted above, they are however widely associated with 
instability issues, which could prove detrimental should the culture period wish to be 
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extended by the introduction of various feeding strategies. Brequet at al., (2007) reported that 
the liquefaction of solid or gelled core microcapsules results in a decrease in the mechanical 
resistance properties of the microcapsules. Liquid core microcapsules have being documented 
as better for the support of cell growth rather than solid core (Zhang et al., 2007), however, a 
range of factors, including the fact that their core is liquefied by sodium citrate, influence 
their stability. Alginate viscosity (Koch et al., 2003), concentration and number of PLL layers 
(Leick et al., 2011), and microcapsule size (Zhang et al., 2007; Brequet et al., 2007) have 
been some of the parameters put forward which determine microcapsule stability and 
integrity in cultures. There have been variations in the reported integrity time when used as 
matrices for mammalian cell culture. Koch et al., (2003) reported that 0.03 % microcapsules 
remained intact for 8-12 weeks when fully colonised with BHK cells. For APA liquid core 
with CHO cells and two diff types of PLL membranes, Ma et al., (2012) reported that 
capsules remained intact for > 25 days.   
The microcapsules used in this experiment decreased dramatically in mechanical resistance 
from days 0 (0.49 +/- 0.09 (g/capsule)) to day 3 (0.07 +/ 0.01 (g/capsule). A similar trend was 
noted for 500 μm and 800 μm diameter liquid core APA microcapsules by Brequet et al., 
(2007) for a perfusion culture conducted in a 1.5 L bioreactor. Their results suggested that 
shearing in the bioreactor was a parameter that influenced microcapsule stability. However it 
is also important to note that they reported decreased stability brought about by the perfusion 
experiment conducted. The constant displacement of equilibrium between medium and 
microcapsules was destructive. The instability was however not a major issue in this study as 
the cell number had reached a maximum and viability had began to decrease, due to the batch 
nature of the experiment, before major capsule breakup was observed. 
Microscopic analysis of the capsules also indicated a lack of complete colonisation of the 
microcapsules. The degree of colonisation was determined to be around ~5 % on day 6 when 
the maximum cell number reached   The degree of colonisation of cells in microcapsules has 
been demonstrated to be somewhat varied in literature depending on cell type, line and 
microcapsule used. The encapsulation of a murine fibroblast cell line in small (350 μm 
diameter) APA microcapsules resulted in complete colonisation of the capsule after 4 weeks 
in culture (Bohari et al., 2011). Hybridoma cells encapsulated in both solid and liquid core 
APA microcapsules completely colonised the capsules within 11 days in culture (Ma et al., 
2006). However for a CHO cell line producing endostatin in APA microcapsules, only 50 % 
colonisation was reported (Zhang et al., 2007). Similarly another CHO cell line was only 
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capable of colonising 20 % of the capsules volume when cultured in liquefied APA capsules 
(Brequet et al., 2007). Brequet et al., (2007) reported that capsule size is an important 
parameter in regards to the promotion of high cell densities inside the capsule matrix. Large 
capsules (> 1 mM) are often associated with diffusion limitations of critical nutrients 
resulting in reduced cell growth and necrosis within the capsule core (Glacken et al., 1983; 
Robitaille et al., 1999). The effect of capsule size on colonisation of the capsules was 
investigated by Brequet et al., (2007). It was found that in the range of capsule sizes 
investigated (500-800 μm), colonisation was not significantly affected by size. It was 
presumed that low values of colonisation were in fact due to an inability of cells to grow 
freely in the capsule inner core. An incubation of 30 minutes in PLL may be sufficient time 
for the PLL to penetrate the capsule membrane resulting in polymerisation of the capsule 
core. Depending on the degree of polymerisation, the growth of cells inside the capsules may 
have been limited by free available space. Also polymerisation of the capsule core is 
associated with shrinkage in the size of the capsules due to crosslinking of the alginate 
(Peirone et al., (1998). The size of the capsules in this current study were, however, in the 
outer limits of the expected size range for the encapsulation process (700-900 μm) (Brequet 
et al., 2007). It is therefore possible that this is not a plausible explanation for the lack of 
complete colonisation observed. Brequet et al., (2007) also investigated the possibility of 
inhibition of cell growth by alginate. The presence of alginate in the core of microcapsules is 
thought to inhibit cell growth through electrostatic interactions between the cells and the 
highly anionic polyelectrolyte. However studies in which cells cultured in the presence of 
alginate in suspension portrayed an increased doubling time, thus suggestion cell growth and 
capsule colonisation is not inhibited by alginate. Alginate itself is reported non-cytotoxic 
(Robitaille et al., 1999). It may therefore be proposed that the only inhibition alginate may 
induce on cell growth is as a physical hindrance occupying space within the capsule.  
It may also important to consider diffusion limitations as a factor restricting complete 
colonisation of the capsules. However the fact that both carbon sources, glutamine and 
glucose, were exhausted by the end of the exponential and stationary growth phases, 
respectively, indicate that further cell growth and colonisation may have been restricted by 
the depletion of nutrients, glutamine (in particular). 
In relation to metabolism encapsulated cells displayed different metabolic profiles in 
comparison to suspension cultures. As noted above, the growth limiting substrate for the 
encapsulated cultures was determined to be glutamine, verified by its complete exhaustion at 
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the end of the exponential growth period. Cells were maintained in the stationary growth 
phase through the utilisation of glucose. 
An evaluation of the consumption profiles of glucose for both suspension and encapsulated 
cultures suggests that the different modes of cultivation impacted on the utilisation of this 
carbon energy source by the cells. Both the rate of glucose consumption and the cell specific 
glucose consumption rate were 60 % and 80 % higher, respectively, in the suspension 
cultures in comparison to the encapsulated cultures. As a result of increased glucose 
consumption a 3-fold higher concentration of lactate was accumulated in the suspension 
cultures. A 50 % higher yield of lactate on glucose occurred over the culture period in the 
suspension cultures in comparison to the encapsulated cultures. The lower yield of lactate 
observed in encapsulated cultures has been observed in other CHO cell lines cultivated in 
APA microcapsules as oppose to in suspension (Brequet et al., 2007). Lower lactate yields 
indicate more efficient oxidative utilisation of glucose by the cells in microcapsules. Similar 
results were also noted for other immobilised cell types, including hybridoma cell lines (Ma 
et al., 2006). The immobilisation of cells facilitated signal transduction and mass transfer in 
the organised community 9wen-tao et al., (2005). 
The second major carbon source in mammalian cell culture, glutamine, was depleted at the 
end of the exponential phase in encapsulated cultures. It was not completely depleted until 
the end of the stationary phase in the suspension cultures. However there was a 73 % 
decrease in the cell specific consumption rate of glutamine in encapsulated cultures in 
comparison to suspension cultures, suggesting that glutamine was utilised more efficiently by 
cells cultures in liquid capsules. The decreased cell specific glutamine consumption rate 
noted in encapsulated cultures is coupled with a decreased cell specific ammonia production 
rate in the encapsulated cultures. The utilisation of amino acids by encapsulated cells has 
been noted to be different to that of suspension cells. CHO cells cultured in APA 
microcapsules have been noted to consume a variety of amino acids, including glutamine at a 
faster rate than suspension cells. It is proposed that encapsulated cells may grow under a 
special oxidation stress microenvironment and so cells may undergo great biochemistry 
changes during the process of microencapsulation and adaptation to 3-D culture conditions 
(Lv., et al., 2008). 
The results may suggest an alternative growth limiting substrate between the two modes of 
cultivation (glucose for suspension cultures, meanwhile glutamine for encapsulated cultures). 
194 
 
However it must also be considered that the high concentration of lactate may have also been 
responsible for the rapid decline in viable cell density noted in the suspension cultures. 
In regards to protein production by encapsulated cells, no increase in the specific rIgG1 
production rate was noted between cells cultured in APA microcapsules and cells grown 
freely in suspension. The affects of encapsulation on the specific protein production rate 
displayed by the cells appears to be dependent upon the cell type and line. It has been 
reported that the immobilisation of hybridoma cells in alginate gel beads does not interfere 
with the expression of mAbs. Increased protein yields were achieved due to higher cell 
number producing the protein (Sinacore et al., 1989). However, 2-3 fold increases in the 
specific recombinant protein production rates have been noted for a CHO cell line when 
encapsulated in APA capsules in comparison to growth in suspension (Brequet et al., 2007). 
Increased mAb production was also noted for hybridoma cells immobilised in alginate beads 
in comparison to when the cells were cultured in suspension (Lee and Palsson, 1990). 
However, the co-encapsulation of two HEK cell lines producing Vascular endothelial growth 
factor165b (VEGF165b) and interferon (IFN-α) resulted in a similar production profile to that 
observed by non-encapsulated cells (Afkhami et al., 2012). The same was observed for the 
encapsulation of HEK producing VEGF165b on its own (Afkhami et al., 2010). Enhanced 
volumetric (30-60 fold) and specific productivities (4-8 times) were on the other hand 
achieved when BHK cells where immobilised in collagen gel fibres (Yamaguchi et al., 1997).  
Enhancement of the specific production rate through the immobilisation of cells is thought to 
be due to a number of potential factors. Various commercially available alginates suffer 
impurities within their structure leading to immobilisation stress. It is proposed that this stress 
increases the specific productivities displayed by the cells within the bead (Selimoglu and 
Elibol, 2010). It has been observed in immobilised hybridoma cultures producing mAb, a loss 
in viable cell density may occur in the first week post-immobilisation due to the stress of the 
procedure on the cells. However in this time period mAb production continued to increase, 
thought to be induced by immobilisation stress (Selimoglu et al., 2012). Low growth rates 
displayed by certain cell lines in immobilised culture conditions has also been associated with 
increased specific production rates (Yamaguchi et al., 1997). Related to a reduction in growth 
rate is the concept of reduced genetic drift and production instabilities associated with fast 
growing cells (Lee and Palsson, 1990). There is also reason to believe that increased specific 
mAb production is achieved due to localisation of the cells in the immobilised matrix, thus 
exposing them to higher concentrations of autocrine factors. Hybridoma cells produce 
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autocrine growth factors which either promote, (IL-6), or inhibit, transforming growth factor 
β 1 (TGFβ1), mAb production (Lee et al., 1993). As specific growth rates or specific rIgG1 
production rates displayed by cells cultured in APA microcapsules were not significantly 
different to those displayed by cells cultured in suspension, it may be presumed that the 
encapsulated cells were not influenced by immobilisation stress or the influence of autocrine 
factors concentrated in the local area. 
Productivity was however improved in that an increased volumetric productivity was 
achieved due to high cell numbers producing the protein. Therefore microencapsulation did 
prove beneficial for enhanced cell yield and productivity, in comparison to suspension 
cultures. It should also be noted that the protein was produced into the extracapsular media. 
The rIgG1 protein has a molecular weight of 150 kDa. The molecular weight cut-off point of 
the microcapsules is in theory determined by the PLL used, in this case 30,000-75,000 Da. 
Various studies have reported on the secretion of proteins from immobilisation matrices 
whose molecular weights are higher than the cut-off point presumed of the matrix. Alginate 
beads of concentration 0.8 % w/v, containing entrapped hybridoma cells permitted the free 
diffusion of IgG1 (Sinacore et al., 1989). APA capsules containing madin darby canine 
kidney (MDCK) cells permitted the diffusion of proteins within a range of 22-300 kDa 
(Peirone et al., 1998). Similarly, APA microcapsules with a presumed molecular weight cut-
off point of <100 kDA, permitted the secretion of protein products with molecular weights in 
the range of 21-300 kDa (Awrey et al., 1996). As mentioned in the introduction, Section 5.1, 
the authors suggested that the permeability of the proteins through the membrane of the APA 
capsule was determined by not just the size of the protein but also it’s ionic charge, shape and 
radius of gyration. The same authors also proposed that the encapsulation process itself does 
also influence the porosity of the microcapsule, regardless of the molecular weight cut-off 
point of the PLL used. When alginate capsules are fist extruded with the cells as a 
suspension, some cells may become lodged in the periphery of the gelled spheres. The 
presence of cells on the periphery interrupts the subsequent laminating steps with PLL, thus 
creating pores in the membrane. This concept was verified by a separate study conducted by 
the authors in which cells were not mixed with membrane forming solutions. The absence of 
cells on the periphery maintained the molecular weight of the capsules at the presumed level 
of >100 kDa.  
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Confocal analysis of the APA capsules containing cells on day 1 of this current study verifies 
that cells were present on the periphery of the capsule membrane, as noted in Figure 5.3.1 
below. 
                            
Figure 5.3.1: Confocal analysis of the surface APA microcapsules containing cells sampled 
on day 1 from culture. Live cells (stained green) appear on the periphery of the capsule, 
protruding the membrane. 
At the beginning of the study, it was hypothesised that the use of encapsulation as a mode of 
cultivation may also have implications on the quality of the recombinant protein produced. 
The quality of the recombinant protein is defined in terms of it’s glycosylation and 
aggregation state. As noted in the results section, over 95 % of the rIgG1 harvested from 
culture media was in a monomeric form. Similarly IgG1 harvested from suspension cultures 
demonstrated to be 99 % in a monomeric form. The results suggest that aggregation of the 
protein did not occur due to encapsulation. As the protein was secreted, concentration 
induced aggregation would not have occurred brought about by the presence of high protein 
concentrations localised within the capsules. 
It was also hypothesised that the cultivation of cells in APA microcapsules would affect the 
growth and productivity of the cells differently to that observed when the cells are cultured in 
suspension. Increased yields in maximum viable cell density reached and maximum 
concentration of recombinant protein produced were observed when cells when cells were 
encapsulated. However the specific rates of growth and productivity were not individually 
affected. The specific growth rate and production rate of the cells are known to affect the 
glycosylation of produced recombinant proteins from both a macro- and micro-heterogeneity 
point of view. This concept has been extensively reviewed in literature (Butler, 2006, Hossler 
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et al., 2009). Both rates determine the rate of translation of the recombinant proteins, and 
subsequently the time in which the protein spends in the processing vehicles, such as the 
endoplasmic reticulum (ER) and golgi apparatus (GA). In the ER, the enzyme 
oligosaccharide transferase is involved in the attachment of glycans to emerging polypeptide 
backbones of newly synthesised proteins. Alterations in the activity of the enzyme, often 
brought about by the length of time the protein spends in the ER gives rise to 
microheterogeneity. Newly synthesised proteins are transported to the GA where a series of 
transferase enzymes are involved in the process of attaching residues such as galactose and 
sialic acids to the glycan structure.  Specific rates of growth and productivity are known to 
affect glycan processing as extensively reviewed by Butler, (2006). Analysis of the 
heterogeneity of glycan structures harvested from rIgG1 from both encapsulated and 
suspension cultures indicate that no significant difference in the glycosylation profile of the 
protein induced by either culture condition. Protein harvested from encapsulated cultures had 
a slightly reduced (25 %) relative percentage of M5 structures attached at the end of the 
exponential growth period, indicating more complex glycan processing. However ~2.8-fold 
increases in the relative % of this glycan did occur over the stationary growth period in the 
encapsulated cultures. The overall result was that there was no significant difference in the 
glycoform profile of protein harvested from suspension and encapsulated cultures at the end 
of the stationary growth period. Such results may be expected based on the similar specific 
growth and production rates displayed by the cells when cultured under both conditions. 
Increased levels of M5 are associated with reduced levels of complex glycan processing. 
Complex glycan processing relies on the availability of uridine di-phosphate N-
acetylhexosamine (UDP-GNAc) for the transfer of N-acetlyglucosamine (GlcNAc) and N-
acetlygalactosamine (GalNAc) residues to the non-complex glycan structure in the Golgi 
apparatus. A decrease in UDP-GNAc is associated with limiting levels of glucose and/or 
glutamine. An evaluation of the incorporation of glucose and glutamine into the 
glutamine:fructose-6-phosphate (GFAT) network, as described by Nyberg et al., (1999) 
describes such an effect of glucose and glutamine limitation. Due to the batch nature of both 
cultures in this experiment, both glucose and glutamine did become limiting. The metabolism 
of glucose and glutamine in the encapsulated and suspension cultures was noted to be 
different in that glutamine was depleted at the end of the exponential phase in encapsulated 
cultures and glucose by the end of the stationary phase. The opposite was noted for 
suspension. The increase in M5 noted at the end of encapsulated culture in comparison to that 
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observed at the end of the stationary phase may be attributed to the decrease available for 
glutamine in the GFAT network  over the stationary growth phase resulting in overall lower 
Glucosamine 6-Phosphate for UDP-GNAc synthesis. The synthesis involves the conversion 
of Glucosamine 6-Phosphate to N-acetlyglucosamine 1-P. The N-acetlyglucosamine 1-P is 
converted to UDP-GNAc using uridine triphosphate (UTP). Glucose is necessary for UTP 
synthesis. UTP synthesis relies on the entry of pyruvate (from glucose) into the TCA cycle 
resulting in aspartate production, which is necessary for UTP synthesis as illustrated by 
DeFrancesco et al., (1976).  As glucose was not limiting in the encapsulated culture until the 
end of stationary phase, then there would have been more UTP. However there would have 
already been a depletion of N-acetlyglucosamine 1-P due to the glutamine depletion. This is a 
suitable explanation for the increase in the relative % of M5 throughout the stationary phase 
in the encapsulated culture. The relative % of M5 is quite low in comparison to all other 
glycans in general. On a positive note, the increase in M5 over the encapsulated culture did 
not significantly reduce the relative % of the more complex glycans which are usually present 
at high levels. 
 In the suspension culture, glucose was limiting over the stationary phase. It must be noted 
that this stationary phase was however relatively short and that the glucose limitation may not 
have affected the intracellular UTP for the short amount of time to result in an increase in M5 
that was noted for encapsulated cultures which had a longer stationary phase to experience 
the glutamine shortage resulting in an impact on product quality. These results have shown 
how the length of time that the shortage of a metabolite occurs affects the quality of the 
protein. 
 
5.4: Conclusion 
 The encapsulation of a specific CHO DP-12 cell line producing rIgG1 in liquefied 
APA microcapsules, 300 μm in radius did not enhance the specific growth rate or rIgG1 
production rate in comparison to that which is observed when cells are cultured in 
suspension. The results are therefore consistent with those that propose that the effect of 
immobilisation as a technique for enhanced cellular growth and production may be cell line 
specific. The growth pattern displayed by the cells was however to some extent affected in 
that the length of time encapsulated cells spent in exponential and stationary growth phases 
was increased in comparison to suspension cultures. Encapsulation did therefore provide a 
mechanism for the achievement of higher cell yields (cells/mlreactor) in comparison to those 
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achieved when cells are cultured in suspension. Due to the increased number of cells 
producing the recombinant protein, an increase in the volumetric productivity and final yield 
of rIgG1 was achieved in encapsulated cultures. There was no significant difference in the 
quality of the recombinant protein produced at the end of the stationary growth period when 
cells were cultured in APA microcapsules in comparison to when cells were cultured in 
suspension. Such results signify that increased cell and product yields may be achieved 
through encapsulation without a trade-off in the quality of the recombinant protein produced. 
The principle that alterations in the growth or productivity of immobilised cells may alter 
product quality is something which other researchers have failed to address. This study did 
however interestingly show that the relative % of the non-complex high mannose M5 glycan 
does increase more dramatically throughout the stationary growth period in encapsulated 
cultures in comparison to suspension cultures. This could therefore become a potential issue 
should culture conditions be manipulated which result in an increased stationary phase. This 
study has identified the necessity for maintenance of key metabolites glucose and glutamine, 
which act a nucleotide sugar precursors for glycosylation, during all culture periods. 
A lack of complete colonisation of the capsules (~5 %) was observed for the CHO DP-12 cell 
line cultured in the liquefied APA microcapsules. This was attributed to the depletion of the 
carbon energy sources L-glutamine and glucose, as oppose to inhibition of cell growth due to 
capsule size, presence of alginate or diffusion limitations. The operation of the encapsulated 
cultures in a perfusion mode of operation would serve to alleviate the growth limitation due 
to substrate depletion. Perfusion would also prove beneficial in the removal of metabolic 
waste products. Although the production of such waste products did not prove inhibitory for 
encapsulated cultures, the enhanced culture longevity envisaged to be brought about through 
perfusion would result in increased by-product accumulation if media was not removed. The 
microencapsulation system provides an excellent and economical means of cell retention, 
facilitating ease of operation for perfusion cultures. 
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Chapter 6: Application of a control-fed perfusion strategy for enhance colonisation of 
Alginate-poly-L-lysine-alginate with CHO DP-12 cells; Implications on rIgG1 quality 
 
Abstract 
In order to enhance the colonisation of APA microcapsules with a recombinant CHO DP-12 
cell line, further than that observed in previous batch cultures (5 %), a control fed-perfusion 
strategy was designed. The strategy successfully enabled the concentration of the nutrients 
glucose and glutamine to be maintained within the range required by the growing cells, while 
the removal of spent medium prevented the accumulation of high concentrations of metabolic 
waste products, lactate and ammonia. The culminating result was an increase in the degree of 
capsule colonisation, which was determined to be in the range of 27 % of the total 
microcapsule volume. Maximum cell numbers per mlculturevessel were noted to increase ~ 10 
fold in comparison to batch suspension cultures. Volumetric productivities were increased 2.6 
–fold in comparison to other batch encapsulated cultures. During extended growth periods 
observed in control-fed perfusion cultures in comparison to batch cultures, protein quality 
improved, denoted by an increase in the relative % of complex glycans present on rIgG1 
harvested. There was 73 % and 36 % increases in the relative % of double galactosylated 
glycans, F(6)A2G2 and A2G2 respectively, for the control-fed perfusion culture in 
comparison to the batch culture. A limitation in the success of the study was however noted 
by a decrease in the level of complex glycans over the course of the stationary phase in the 
control-fed perfusion cultures. This was attributed to the higher total cell numbers present in 
this culture. The cell viability was not dramatically low (~63 %) at any point during the 
stationary growth phase. However the use microcapsules as effective cell retention systems 
prohibited the removal of dead cells from the culture environment, highlighting a limitation 
in the use of microcapsules in perfusion systems. Dead cells release glycosidase enzymes 
which cleave complex glycan structures reducing the overall quality of recombinant protein 
produced. The study has however also highlighted the advantages of encapsulation as a mode 
of cultivation in combination with a perfusion strategy to enhance cell and product titres and 
protein quality up to a specific time point. 
 
Abbreviations: 
APA    Alginate-poly-L-lysine-alginate 
CHO    Chinese hamster ovary 
CMP-NANA    Cytidine-5′-monophospho-Nacetylneuraminic acid 
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CO2    Carbon dioxide 
EPO    erythropoietin 
ER    Endoplasmic reticulum 
GA    Golgi apparatus 
GalNAc    N-acetlygalactosamine 
GFAT     glutamine;fructose-6-P amidotransferase 
GlcNAc   N-acetylglucosamine 
GU    Glucose unit 
HILIC    hydrophilic interaction liquid chromatography 
HPLC    high performance liquid chromatography 
IFN-γ    Interferon-gamma 
IgG1    Immunoglobulin-1 
Non-CO2   non-Carbon dioxide 
OUR    Oxygen uptake rate 
PAT    Process analytical technology 
SEC    Size exclusion chromatography 
UDP-GNAc    Uridine Di Phosphate-N-acetlyhexosamines  
UDP-GalNAc   Uridine Di Phosphate-N-acetlygalactosamine  
UDP-GlcNAc   Uridine Di Phosphate-N-acetlyglucosamine 
UTP    Uridine Tri Phosphate 
 
 
6.1: Introduction 
 A primary objective for the production of monoclonal antibodies on an industrial 
scale is sustained productivity at high cell densities. Various approaches have been 
investigated involving the alteration of environmental culture conditions for enhanced growth 
and productivity of suspension cells in culture (Fox et al., 2004; deZengoitia et al., 1998). 
Aside from the manipulation of culture conditions, cell immobilisation has been noted as an 
effective strategy for the enhancement of maximum viable cell densities and increased 
specific and/or volumetric productivities for a range of cell lines (Sinacore et al., 1989; Lee 
and Palsson 1990; Awrey et al., 1996; Brequet et al., 2007). For the particular CHO DP-12 
cell line producing recombinant IgG1, encapsulation of the cells in APA microcapsules and 
cultivation under batch conditions resulted in 3.7- fold increases in the maximum viable cell 
number attainable and volumetric production, in comparison to cells cultivated in suspension, 
as documented in Chapter 5 of the thesis. However due to the batch nature of this experiment, 
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maximum cell density was achieved at ~ 5 % degree of colonisation of the microcapsules. An 
obvious step forward from this study would be to identify a suitable feeding strategy, which 
would alleviate the nutrient limitations leading to a cessation of the microcapsule 
colonisation. The four major cultivations methods for mammalian cell culture are: batch, fed-
batch, continuous and perfusion (Xie and Wang, 2006), and have been described in the 
Introduction Chapter, Section 1.2.6. Presented below is an overview of the main advantages 
and disadvantages to each of the methods in order to devise a suitable feeding strategy to 
apply to the encapsulated cell cultures. 
Batch cultivation of mammalian cells is considered one of the simplest modes of cultivation 
and is particularly effective when protein expression is growth associated (Gugerli, 2003) and 
as reviewed in the Introduction Chapter, Section 1.2.6. However, one trait of mammalian 
cells in culture which is not satisfied by a batch mode of cultivation is their highly 
deregulated metabolism. Under batch cultivation conditions this characteristically results in 
the rapid exhaustion nutrients, accumulation of toxic metabolic by-products (namely lactate 
and ammonia), resulting in the consequent initiation of programmed cell death or apoptosis 
very shortly after the attainment of maximum cell number. The level of glycosylation has 
been adversely affected by glucose starvation, the point at which glucose becomes limiting 
(Chapman and Calhoun 1988; Hayter et al., 1992). Both glucose and glutamine depletion 
have an impact on the microheterogeneity of the attached glycans (Nyberg et al., 1999; Wong 
et al., 2004). Waste product accumulation, associated with batch cultivation also affects the 
microheterogeneity of attached glycans. The effect increased ammonia concentrations in 
cultures have on the degree of sialyation has been particularly well documented. (Butler, 
2006; Hossler et al., 2009; Jenkins et al., 1996). The sharp fall off in viability associated with 
batch cultivation has been associated with adverse release of glycosidase enzymes into the 
culture environment, resulting in yields of protein with characteristically compromised 
integrity and quality (Yang and Butler, 2000; Gramer and Goochee, 1993). Solutions to the 
aforementioned problems have focused on the development of nutrient feeding schemes in an 
effort to minimise nutrient fluctuations and reduce waste accumulations, namely fed-batch 
and continuous (perfusion) mode of cultivation (Chon and Zarbis-Papastoitsis, 2011; 
Bonham-Carter and Shevitz, 2011; Gugerli, 2003; Gambhir et al., 2003). 
The fed-batch strategy seeks to avoid early complete depletion of key media components, 
common to batch cultivation, by feeding highly concentrated nutrient feeds to the culture at 
set points. Two methods for the optimisation of the concentration of nutrients in the feed 
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medium have been proposed and reviewed in the Introduction Chapter, Section 1.2.6. The 
major advantages and disadvantages of this feeding strategy have also been outlined in 
Introduction Chapter, Section 1.2.6 Although fed-batch processes have been associated with 
higher final volumetric product concentrations, in comparison to continuous or perfusion 
modes (Hu et al., 2011), this principle may have detrimental effects on the product quality. 
Increased culture longevity gives cause for concern regarding the length of time the protein 
remains in the culture environment and may be subjected to concentration dependent 
aggregation. Also, if harvest time is not optimised and cell viability becomes compromised, 
the risk of the protein being exposed to proteases and glycosidase enzymes is greatly 
increased. The result may lead to high yields of poor quality product (Gramer and Goochee, 
1993). In a fed-batch process toxic waste products are expected to accumulate to higher 
concentration than observed in a batch culture due to the addition of metabolites beyond the 
concentration present in the initial medium. Various studies have been conducted in which 
the presence of high concentrations of metabolic by-products have been noted to be 
detrimental to glycosylation of recombinant proteins (Hossler et al., 2009;Yang and Butler, 
2000 Jenkins et al., 1996). 
The problems associated with fed-batch modes of cultivation may be alleviated with the 
progression to a continuous or perfusion feeding strategy. The main advantages of 
continuous/perfusion modes of cultivation are that it can avoid nutrient limitation, while 
reducing the concentration of growth inhibitory metabolites (Yang et al., 2000 and 
Konstantinov et al., 1996). Product quality and purity may be enhanced, not only due to the 
reduced byproduct concentration, but also as an effect of the continuous withdrawal of 
protein containing spent media form the culture environment, thus reducing the overall 
residence time of the protein in the culture environment in which it may be exposed to 
proteases and glycosidase enzymes (Rastilho et al., 2002; Ryll et al., 2000). The method of 
operating a continuous culture and the relevant equations governing the achievement of 
steady state of cells in such environments have been explained in depth in the Introduction 
Chapter, Section 1.2.6. The main shortcoming of a continuous mode of cultivation is the 
relatively low cell concentrations attainable at steady-state due to the necessary bleed rate 
(Vits and Hu, 1992). A continuous process can only compete economically with batch 
cultures if a higher cell density and high protein concentrations can be reached. Cell 
concentration and volumetric productivity can be effectively increased by cell recycle or 
partial or complete cell retention Coupling a cell retention device to a continuous bioreactor, 
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in what is frequently called a perfusion bioreactor, can lead to a 5-10 fold increase in cell 
concentration (Vits and Hu 1992).  
A diverse set of devices have been developed over the years which enable the retention of 
cells in bioreactors, while minimising damage to the cells. Some of such devices work better 
than other and have been extensively reviewed by Gugerli, (2003), Chon and Zarbis-
Papastoitsis, (2011), Bonham-Carter and Shevitx, (2011) and Voisard et al., (2003). For cells 
cultivated in suspension, separation is usually based on either filtration, gravity settling or 
centrifugation (Bonham-Carter and Shevitx, 2011). The performance of cell separating 
devices relies on a set of five physical or chemical characteristics of cells as particles 
including: 1) size, 2) density, 3: electrical charges, 4) dielectric constant 5), surface properties 
(Voisard et al., 2003). A range of filtration devices are available commercially for the 
retention of cells in bioreactors based on their size. These include: cross-flow filters, hollow 
fiber filters, controlled shear filtration, vortex flow filters and spin filters. All have been 
extensively reviewed (Voisard et al., 2003). Benefits associated with such filtration devices 
include the selective removal and concentration of a particular product (Langes, 2011). 
Although filtration devices, such as spin filters in particular, were one of the first devices 
used in perfusion, they have been largely phased out due to the limited scale up potential and 
reliability. Bioreactor volumes scale up by the cube of the radius. An internal attached filter 
would therefore require scaling up by the square of it’s radius, resulting in a large portion of 
space inside the vessel being taken up by the filter (Bonham-Carter and Shevitx, 2011). 
Although external filters may overcome the issue with regards to occupation of internal 
reactor space, they are considered costly and provide no mechanism for the return or recycle 
of cells from the spent medium back into the reactor in order to maintain a high cell density 
(Hu and Aunins 1997). As well as a lack of scale up potential, the problem of membrane 
clogging or fouling has been widely reported (Blasey and Jager, 1991; Buntemeyer et al., 
1994). 
The retention of cells inside a bioreactor during a perfusion culture may also be achieved 
based on the density of the cells. Devices enabling the sedimentation of cells include gravity 
settlers, centrifuges, hydroclones and centrifugal bioreactors. Gravitational settlers, often 
present in external loops, are one of the simplest cell retention devices suitable for cells that 
are shear sensitive. Such devices are more effective for viable cells than dead cells, enabling 
the delivery of a viable cell free harvest stream (Voisard et al., 2003). However the main 
drawback of the method is the significant amount of time cells spend in the suboptimal 
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external loop within the settler (Bonham-Carter and Shevitx, 2011). Enhanced sedimentation 
may be brought about by centrifugation.  However the implementation of such devices may 
compromise the main beneficial properties of sedimentation as a retention device due to the 
introduction of shear brought about by the moving mechanical parts (Ryll et al., 2000). 
Immobilisation or entrapment of cells within a matrix, such as alginate-poly-L-lysine (APA) 
microcapsules is a more favorable proposed as a mechanism for the retention of cells in 
perfusion bioreactor. We have seen in Chapter 5 how encapsulation has been beneficial in 
offering an efficient protection system for the growth of cells within a 3-D matrix. However a 
second beneficial property of encapsulation is in the provision of an effective mechanism for 
retaining cells within a bioreactor without the requirement of a separation device (Brequet et 
al., 2007). Cells may be retained inside the bioreactor while being protected from 
hydrodynamic shear created by agitation (Seifert and Philips, 1997). It is proposed that the 
benefit of the ease of cell retention in the bioreactor, coupled with the protective action of the 
microcapsules against shear forces would enable perfusion to provide recombinant proteins 
with fewer variations in glycosylation, thus more consistent in biological activity (Langer, 
2011). Cell retention by immobilisation using both macroporous microcarriers and 
encapsulation has been previously investigated (Goldman et al., 1998; Wang et al., 2002; 
Brequet et al., 2007; Seifert and Philips, 1997). 
It has been explained in the Introduction Chapter, Section 1.2.6 that if cells are completely 
retained, no steady state should be reached and the cell concentration should go towards 
infinity. In practice, however, Gugerli, (2003) described how cells grow until one or several 
nutrients become limiting. When cells are typically cultivated in situations of complete 
retention the characteristic behaviours of cells may be summarised as 4 distinct phases: (1) a 
first exponential growth phase due to excess nutrients (2) a second linear growth phase 
limited by the feed rate, (3) a decrease in growth due to insufficient nutrient feeding (4) slow 
cell death due to apoptosis (Gugerli, 2003). 
In the past two decades, efforts have been made to optimise the criteria governing a perfusion 
process, which include 1) the time point at which perfusion is initiated, 2) the magnitude of 
the perfusion rate, 3) the extent to which the cells are retained (Vits and Hu, 1992; Dowd et 
al., 2001; Wang et al., 2002; Konstantinov, 1996; Golmes, 1998; Meuwly, 2004), as noted in 
the Introduction Chapter, Section 1.2.6 However even with the optimisation of such criteria, 
there are 2 costly disadvantages associated with altering the perfusion rate. Increasing the 
perfusion rate results in the consumption of large volumes of medium, which increases the 
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overall cost and labour requirements of the process. The resulting harvest stream emerging 
from the culture contains very dilute concentrations of the recombinant protein (Gugerli 
2003). Although this is advantageous in comparison to fed-batch cultivation modes, in which 
high levels of the protein remain in the reactor for extended periods of time, the result of the 
perfusion operation usually requires increased complex purification processes. The product 
concentration in the emerging harvest stream is often lower than that which is present in a 
typical fed-batch culture (Ozturk, 1996). This can often translate into higher failure rates than 
a typical fed-batch process (Chon and Zarbis-Papastoitsis). 
A different mode of cultivation, namely controlled-fed perfusion, seeks to address these 
issues and encompasses the advantages of both perfusion and fed-batch. To alleviate the 
product dilution in perfusion cultures, noted above, perfusing cultures at lower rates using a 
medium fortified with specific nutrients (such as glucose or glutamine) has been 
demonstrated to be successful (Ozturk 1994; Runstadler et al., 1992). Banik and Heath, 
(1996) also suggested that a more appropriate perfusion mechanism would involve one that 
would increase the level of specific nutrients in the feed medium as opposed to increasing the 
rate at which the medium is perfused. However an underlying issue in this mechanism was 
noted by the high concentration of by-products which accumulated in the culture. Yang et al., 
(2000) sought to minimise this byproduct accumulation, while adhering to the controlled-fed 
perfusion mode of cultivation. Their strategy involved making a forward rate adjustment to 
the perfusion stream, in accordance with the predicted cell number and their nutrient demands 
for the next day. The perfusion stream was fortified with glucose at a concentration beyond 
that which was usually present in the medium formulation. The result was a 9.5- fold and 1.8- 
fold increase in viable cell number in comparison to that achieved for batch and perfusion 
cultures respectively. The yield of recombinant protein in such controlled-fed perfusion 
cultures was in the range of 10- fold and 2.5- fold higher than batch and perfusion cultures 
respectively. Variations of this method have been recently published in which Teng et al., 
(2011) conducted a controlled fed-perfusion culture in which the perfusion stream was 
accompanied by a separate feed stream containing key nutrients in concentrations required by 
the cells, as determined by the consumption rates displayed by the cells. Cell growth 
exceeded 3.8- fold higher than that observed in batch cultures and over a 2- fold increase in 
the concentration of recombinant protein product. 
In this current study a variation of the controlled fed-perfusion strategy was designed in order 
to assess if further cell growth resulting in increased colonisation, beyond that observed in the 
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batch encapsulated cultures in Chapter 5, could be achieved. The strategy involved 
maintaining the perfusion rate to a set limit of 1 or 2 medium changes per day, in which the 
volume of media removed was a quarter of the total culture volume and the same volume of 
media replaced. The number of medium changes per day was defined by both the 
accumulation of by-product and also the mechanical and labour resources available. Daily 
sampling and spent media analysis would enable determination of cell number, and glucose, 
glutamine and ammonia concentrations which would be used to determine the growth rate 
and cell specific consumption and production rates. The concentration of the relevant 
metabolites to add to the feed media was adjusted in accordance with a projected cell density 
for the next day, to meet the predicted nutrient demands. The model was initially proposed 
based on the data accumulated from the batch encapsulated cultures carried out in Chapter 5. 
The main aim of the study was to determine if enhanced capsule colonisation could be 
achieved, beyond that achieved in batch cultures (5 %) in Chapter 5, by eliminating nutrient 
limitations which were identified in the batch cultures and associated with growth cessation. 
The underlying aims of the study were to identify whether the applied control-fed perfusion 
strategy would in turn not only affect colonisation but also all cellular growth, metabolic and 
production activities for the, Chinese hamster Ovary (CHO), CHO DP-12 cell line producing 
rIgG1. An overall aim of the study was to determine if any altered cellular activities induced 
by the control-fed perfusion strategy would in turn impact of the quality (glycosylation and/or 
aggregation state) of the recombinant Immunoglobulin 1 (rIgG1) protein produced. 
 
6.2. Results: 
 To evaluate the potential for a perfusion strategy to enhance the colonisation of APA 
microcapsules, beyond that observed in Chapter 5 (5% colonisation), a number of studies 
were conducted. In section (6.2.1) initial efforts involved the application of a controlled-fed 
perfusion strategy to the CHO DP-12 cell line encapsulated in APA microcapsules and used 
to inoculate a 1.7 L minifors reactor at a ratio of 300 ml capsules: 900 ml media. The 
controlled-fed perfusion strategy involved offline determination of cell number and 
metabolite concentrations, namely glucose, glutamine and ammonia on a daily basis. The 
results of the evaluated parameters were then used to determine the growth rate and specific 
consumption and production rate displayed by the cells for the named metabolites. 
Subsequently a forward adjustment was made in the concentration of the metabolites in the 
perfusion medium in accordance with the projected cell density for the next day, to meet the 
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predicted nutrient demand. In this particular study the perfusion rate was not adjusted due to 
the untimely cessation of the culture as a result of capsule instabilities. Perfusing of the 
reactor involved the removal of 300 ml of spent media and the addition of 300 ml of fresh 
media (containing glucose and glutamine concentrations required by the actively growing 
cells).  Simply adjusting the concentration of the named nutrients in the perfusion medium 
was sufficient to meet the cellular demands. (6.2.2) In order to overcome the instability issues 
of the microcapsules in the 1.7 L minifors reactor, an investigation was conducted in which 
CHO DP-12 cells encapsulated in APA microcapsules were cultured in the less shearing 1 L 
Erlenmeyer shake flask environment. Before the transition could be made to such a platform 
using the perfusion strategy, it was first necessary to identify if of all cellular activities were 
comparable to that observed when cells were cultured in APA microcapsules in the 1.7 L 
minifors reactor platform under batch culture conditions. The perfusion strategy was designed 
based on the analysis of the behaviour of cells cultured in APA microcapsules under batch 
cultivation conditions in Chapter 5. The results in Chapter 4 did indicate that cellular 
activities were altered when cells were cultured in 1 L Erlenmeyer shake flask and 1.7 L 
minifors reactor when in suspension. The cultivation of the cells in APA microcapsules under 
batch cultivation conditions in the 1L Erlenmeyer shake flask platform was completed to 
ensure that any alterations noted in cellular activities after application of the perfusion 
strategy to cells cultured in the 1 L Erlenmeyer shake flask platform, were due to the applied 
perfusions strategy and not due to the change to a 1 L Erlenmeyer shake flask platform. In 
section (6.3.3), after all cellular activities of the CHO DP-12 cells encapsulated in APA 
microcapsules had been characterised when cultured under batch cultivation conditions in the 
1 L Erlenmeyer shake flask platform, it was necessary to apply the controlled-fed perfusion 
strategy to this platform. To date, cells cultured in 1 L Erlenmeyer shake flasks have been 
done so in unvented shake flasks in a non-Carbon dioxide (non-CO2) incubator. Due to the 
possibility of mass transfer issues in such an environment, the perfusion strategy was applied 
to cells cultured in both the unvented shake flasks in a non-CO2 incubator and also cells 
cultured in vented shake flasks in a 5 % Carbon dioxide (CO2) incubator. The ratio of 
capsules to media in all 1 L Erlenmeyer shake flask cultures was comparable to that used in 
the 1.7 L minifors reactor cultures (100 ml capsules: 300 ml of media). Perfusing of the 
cultures in unvented shake flasks was inline with that completed in the 1.7 L minifors reactor 
culture, with the perfusion volume adjusted to 100 ml. It was necessary to complete this 
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procedure twice daily from day 9 onwards in the vented shake flasks due to an increase in 
ammonia accumulation.   
 
6.2.1: Batch encapsulated –v- Perfusion encapsulated in 1.7 L minifors reactor 
 In order to investigate the potential for optimised colonisation of APA microcapsules 
with a CHO DP-12 cell line, a controlled-fed perfusion strategy was designed and applied to 
cells cultured in a 1.7 L minifors reactor platform. The perfusion strategy was designed based 
on the results of cells cultured in APA microcapsules under a batch mode of cultivation in the 
1.7 L minifors reactor. In such batch cultures it was noted that a cessation in the growth of 
cells coincided with a depletion of the nutrients (glutamine and glucose). The perfusion 
culture was operated as a batch culture until day 5, at which point offline cell growth and 
metabolite analysis suggested that the concentration of the key metabolites glucose and 
glutamine was insufficient to meet the requirements of the exponentially growing cells. A 
forward adjustment was made to the concentration of the named metabolites in 300 ml of 
fresh culture media in order to meet the demands projected cell density for the next day. The 
300 ml of fresh media was added to the bioreactor following the removal of 300 ml of rIgG1 
containing spent media. The procedure was applied to the culture until cessation on day 9, 
due to a break down in the capsule structure. 
 
6.2.1.1 Characterisation of microcapsules 
 
6.2.1.1.1 Capsule size: 
 The APA microcapsules were formed by the extrusion of a sodium alginate solution 
through a 300 μm nozzle. Due to liquefaction of the alginate core, swelling of such 
microcapsules in the range of 150-200 % of the original volume has been reported (Breguet 
et al., 2007). Based on previous studies, the final diameter of the microcapsules would be 
expected to be in the range of 700-900 μm. 
Thirty capsules were measured individually in order to calculate the average diameter and the 
standard deviation. Generally the size distribution was in the range of 3-5 %. 
Figure 6.3.1.1.1 below illustrates the capsules radius size over the cultivation period for both 
the batch (Chapter 5) and perfusion cultures. The results presented below for the batch 
cultures are the average of triplicate cultures. Capsule size throughout the perfusion culture is 
consistent with that observed during the batch cultures. Again, it is important to note, that 
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size was only determined for intact capsules. The evolution of broken capsules towards the 
end of the culture period was omitted. It is estimated that the number of capsules present in 
the reactor during the perfusion study decreased by a total of 58 % from days 7-9. However 
the loss of capsules due to breakage between days 7-9 in the batch cultures was estimated at 
~18 %. A combination of media change during perfusion and also the increased number of 
cells/ml capsule serve as plausible explanations for the increased capsule instability observed 
in the perfusion culture. 
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Figure 6.2.1.1.1.1: Average capsule radius size (μm) +/- STD over the duration of the 
cultivation period for each of the three batch encapsulated cultures completed and the single 
control-fed perfusion culture completed. The size of approximately 30 capsules was 
measured at each time point and an average determined.  
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6.2.1.1.2 Capsule strength 
 The mechanical strength of the microcapsules in the batch and control-fed perfusion 
cultures was routinely evaluated in terms of Force (g)/capsule which the capsule could 
withstand using the Texture analyser. 
Evaluation of Figure 6.2.1.1.2.1 below allows for comparisons to be made between the 
mechanical resistance of microcapsules present in batch and perfusion cultures performed in 
the 1.7 L minifors reactor culture. Chapter 5 previously stated that for batch cultures, a 
dramatic decrease in capsules strength may be noted over days 0-3 in the cultures. This may 
be attributed to the introduction of the capsules to the shearing environment of the bioreactor 
and also equilibration of the capsules with media. As the control-fed perfusion culture 
essentially acted as a batch culture from days 0-5, it would be expected that there would be 
no significant difference in the mechanical resistance of the microcapsules under both 
conditions during this time period. This may be observed in Figure 6.2.1.1.2.1 below. Once 
the perfusion strategy is applied, the mechanical resistance of the microcapsules may be 
potentially unfavourably affected by the necessity of further equilibrations with the fresh 
media. No further significant decreases in microcapsule resistance where noted from day 5 
onwards in comparison to the batch. The loss of microcapsules from day 7 onwards due to 
breakage in the control-fed perfusion culture may be attributed to the incapability of already 
weakened microcapsules to withstand the  combination of higher cell number (cells/mlcapsule), 
the equilibrium required with the fresh medium and the shear forces of the bioreactor 
environment. Instead of seeing further decreases in the mechanical resistance, vast capsule 
breakage is noted. At such low mechanical resistances, capsule breakage was also reported in 
the batch cultures, however not to the same degree as that observed in the control-fed 
perfusion cultures. 
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Figure 6.2.1.1.2.1: Mechanical resistance (force (g)/capsule) over cultivation period for 300 
μm APA microcapsules containing CHO DP-12 cells cultivated in a 1.7 L minifors reactor 
under batch and control-fed perfusion conditions. A total of 3 layers of microcapsules were 
analysed on a daily basis for each of the cultures carried out. Values presented are average of 
such triplicate analysis +/- STD for one of the batch cultures performed and the one control-
fed perfusion culture performed. 
 
6.2.1.2.: Growth of encapsulated cells under batch and perfusion modes of cultivation 
 In order to investigate if a designed controlled-fed perfusion strategy has the potential 
to enhance the colonisation of a CHO DP-12 cell line cultured in APA microcapsules, in 
comparison to that which is observed under batch cultivation conditions, it was necessary to 
investigate the growth of cells inside the capsules and cell densities reached in terms of both 
cells/mlcapsules and cells/mlreactor. 
 
6.2.1.2.1 Growth of cells inside microcapsules 
 CHO DP-12 cells were used to inoculate 300 ml of alginate at a seeding density of 0.5 
* 10
6
 cells/mlalginate. Such microcapsules were used to inoculate a reactor at a ratio of 300 ml 
capsules: 900 ml of media. The reactor operated in batch and/or controlled-fed perfusion 
mode for a period of 9 days, with perfusion initiating on day 5 of the culture period. The 
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growth pattern displayed by cells cultured in batch conditions was extensively evaluated in 
Chapter 5 and may be reviewed in Figure 6.2.1.2.1.1 below in which the colonisation of the 
microcapsules with cells on days 6 (one day after cessation of exponential growth) and 8 (end 
of stationary phase of growth) are portrayed. The degree of colonisation of the capsules with 
cells was determined to be 5 % on day 6 of the batch culture. The beneficial effect of a 
controlled-fed perfusion strategy, designed to eliminate a limitation in two key nutrients 
(glucose and glutamine) may also be noted by evaluation of Figure 6.2.1.2.1.1. Colonisation 
of the microcapsules in the controlled-fed perfusion culture may be observed and it may be 
qualitatively determined that the designed perfusions strategy did enable enhanced 
colonisation of the microcapsules. The degree of colonisation of the microcapsules on day 8 
of the perfusion culture was calculated as 9.3 %. Therefore there was an 86 % increase in the 
degree of colonisation brought about by the perfusion strategy applied. 
Figure 6.2.1.2.1.2 below allows comparison between the growth of cells in APA 
microcapsules in the 1.7 L minifors reactor under batch and controlled-fed perfusion 
strategies in terms of the viable cell density per mlcapsules over the cultivation period. Cell 
counts were performed using the trypan blue exclusion method and haemocytometer. Prior to 
performing cell counts, microcapsules were ruptured by extrusion through a 300 μm needle 
and diluted in PBS. Under a batch mode of cultivation, evaluated in Chapter 5, colonisation 
of the capsules continued until day 6. The data portrayed for the batch cultures is based on the 
average of triplicate cultures +/- the standard deviation. Cessation of exponential growth at 
the maximum displayed growth rate did cease on day 5, followed by a short stationary phase 
and subsequent onset of cell death. Cells continued to colonise the capsules until day 8 of the 
controlled-perfusion culture resulting in the attainment of a maximum viable cell number 
(cells/mlcapsules) 36 % higher than that observed in the batch cultures, as noted in Table 
6.2.1.2.1.1.   
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Batch day 6     Perfusion day 6 
  
Batch day 8     Perfusion day 8 
Figure 6.2.1.2.1.1: Microscopic analysis (40 X) (unstained) of microcapsule colonisation by 
cells on cultivation days 6 and 8 in both batch and perfusion cultures. Cells were originally 
seeded at 0.5 * 10
6
 cells/ml alginate and which was extruded through a 300 μm nozzle as part 
of the liquid core microcapsule formation. The resulting microcapsules were used to seed a 
reactor with a ratio of 300 ml capsules and 900 ml media. 
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Figure 6.2.1.2.1.2: Growth of CHO cells cultured in 300 μm liquid core APA microcapsules 
under batch and perfusion modes of cultivation. The cell concentration is given with respect 
to the capsule’s volume. Cultures were seeded at an average viable cell density of 0.3 * 106 
cells/mlreactor. Cell numbers were enumerated on a daily basis using trypan blue exclusion 
method and a Neubauer haemocytometer. Encapsulated cells were liberated prior to counting 
via extrusion of a capsule/PBS suspension through a 300 μm needle 3 times. Duplicate cell 
counts were performed. Values presented above are the average of triplicate cultures carried 
out in parallel +/- STD, for the batch encapsulated cultures performed. Values for the 
perfusion culture represent those obtained for the single culture carried out.  
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Table 6.2.1.2.1.1: Calculated maximum viable cell densities with respect to per ml capsule 
for cells cultured under batch and perfusion modes of cultivation in a 1.7 L minifors reactor 
culture. Max VCD for the batch cultures is the average of triplicate cultures carried out in 
parallel, +/- STD. Value for the perfusion culture is that which was achieved for the single 
culture performed 
Culture
Encapsulated cells (batch)
Encapsulated cells (perfusion)
Max VCD (*10
6
 cells/mlcapsules)
33.2 +/- 3.95
45.3  
 
6.2.1.2.2.Viable cell numbers per mlreactor 
 Microcapsules for both batch and perfusion cultures were formed through the 
extrusion of 300 ml of alginate inoculated with 0.5 * 10
6
 cells/mlalginate through the 300 μm 
nozzle. These capsules were then used to inoculate a minifors reactor containing 900 ml of 
media. The addition and removal of media in the perfusion culture began on day 5, when the 
concentration of the two key metabolites glucose and glutamine were below the concentration 
required by the exponentially growing cells that would be present in the reactor on the 
following day. Due to variations in the encapsulation procedure the average seeding viable 
cell density of the three batch encapsulated cultures and one perfusion culture performed was 
0.32 * 10
6
 cells/mlreactor +/- 0.165 * 10
6
 cells/ml. As the controlled-fed perfusion culture acted 
as a batch culture up until day 5, there should be no significant difference in the behaviour of 
the culture from days 0-5 in comparison with the 3 batch cultures conducted in Chapter 5. 
Figures 6.2.1.2.2.1, 6.2.1.2.2.1 and Table 6.2.1.2.2.1 allow for comparison to be made 
between the batch and perfusion cultures in regards to cell growth (cells/mlreactor), cell 
viability, %, and growth rate and maximum viable cell densities achieved. Both cultures 
displayed an initial lag period of one day before entering exponential phase at the maximum 
growth rate from days 1-5. There was no significant difference in the growth rate of the cells 
in the batch and perfusion cultures from days 1-5 as expected. After cessation of exponential 
growth the viable cell density increased for one more day before the batch cultures entered a 
stationary phase for approximately 2 days. Following the stationary phase, a rapid fall off in 
cell viability on day 9 may be noted. In the controlled-fed perfusion culture, the initial 
perfusion of the culture on day 5, did not result in an increased viable cell density permlcapsules 
or permlreactor than that which was observed in the batch cultures on day 6. However the 
perfusion strategy did come into play in that the cells/mlcapsules did continue to increase on 
days 7-8 in the perfusion culture, when the batch cultures were evidently in a stationary 
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phase. However evaluation of the cells/mlreactor for the perfusion culture would suggest that 
the cells were actually in stationary phase during days 7-8. This is however due to the fact 
that the number of capsules present in the perfusion reactor was decreasing daily from days 7 
until the end of the culture on day 9. It is estimated that there were approximately 29 % less 
capsules present in the perfusion culture when viable cell density/ml capsules was at a 
maximum on day 8. Therefore although it was predicted that there was a 36 % increase in the 
maximum viable cell density (cells/mlcapsules), the failure of the capsules as a retention system 
(29 % loss of capsules) resulted in a reduced maximum viable cell density (cells/mlreactor). Up 
to one third of the extracapsular cells resulting from broken capsules were removed from the 
reactor in the out flowing perfusion harvest stream. The extracapsular cell density of day 8 in 
the controlled-fed perfusion culture was 1.35 * 10
6
 cells/ml in comparison to 0.21 * 10
6
 
cells/ml in the batch culture. (During perfusion and removal of harvest stream, conditions 
were not homogeneous as agitation was turned off so it was difficult to determine true extra-
capsular cell numbers. However the two figures calculated so indicate the failure of retention 
in perfusion). 
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Figure 6.2.1.2.2.1: Growth of encapsulated CHO cells cultured in 300 μm liquid core APA 
microcapsules in a 1.7 L minifors reactor under batch and perfusion modes of cultivation. 
The cell concentration is given with respect to the volume of the reactor. Cell numbers were 
enumerated on a daily basis using trypan blue exclusion method and a Neubauer 
haemocytometer. Encapsulated cells were liberated prior to counting via extrusion of a 
capsule/PBS suspension through a 300 μm needle 3 times. Duplicate cell counts were 
performed. Values for the batch cultures are the average of triplicate cultures performed in 
parallel, +/- STD. Values for the perfusion culture are those which were obtained for the 
single culture carried out. 
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Figure 6.2.1.2.2.2: % Viability of CHO cells encapsulated in 300 μm liquid capsules and 
cultured under batch and perfusion modes of cultivation. % viability was determined by the 
enumeration of total and live cell numbers present in the culture using trypan blue exclusion 
method and Neubauer haemocytometer. Cell counts were performed in duplicate and average 
% viability determined on a daily basis. Values presented above are the average of triplicate 
cultures carried out in parallel +/- STD for the batch encapsulated cultures. Values for the 
perfusion culture are those obtained for the single culture performed. 
 
Table 6.2.1.2.2.1: Calculated maximum specific growth rates displayed by cells encapsulated 
in 300 μm liquid capsules over the exponential growth period under batch and perfusion 
cultivation conditions. The growth rate was calculated from a plot of the logarithm of the 
viable cell density over the cultivation time (days). The maximum viable cell density is 
presented with respect to per ml reactor. The values presented below are the average of 
triplicate batch cultures performed in parallel, +/- STD. The values for the perfusion culture 
are those obtained for the single perfusion culture carried out. 
μmax (day
-1
)
0.759 +/- 0.12
0.636
Culture Max VCD (*10
6
 cells/mlreactor)
Encapsulated cells (batch) 11.02 +/- 1.35
Encapsulated cells (perfusion) 9.6  
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6.2.1.3: Effect of perfusion mode on CHO cell productivity 
 To evaluate the effect of the perfusion mode of cultivation on rIgG1 production, 
media samples were removed from both the batch and perfusion cultures on a daily basis 
from day 5 onwards. As explained in Section 2.3.6., of the Materials and Methods Section, 
rIgG1 was purified from media samples removed from the cultures after centrifugation at 200 
g for 5 minutes to remove any extracapsular cells. Capsules were separated from the media 
before centrifugation. rIgG1 present in the media was purified using Protein A Nab spin 
columns and quantified using the nanodrop at A 280 nm. 
Figure 6.2.1.3.1 below allows comparison of the cumulative total amount of rIgG1 produced 
by cells cultivated under both batch and perfusion modes of cultivation in 300 μm liquid 
capsules. The values presented for the batch cultures are the mean of triplicate cultures +/- 
standard deviation. The amount of IgG1 produced by the encapsulated cells cultured in the 
perfusion reactor was not outside the standard deviation of the amount of IgG1 produced by 
the cells cultured in the batch reactor. Due to the fact that the cells/mlreactor was similar for 
both the batch and perfusion cultures, it would be expected that there would be no increase in 
the total IgG1 produced in the perfusion culture, providing that the specific productivity of 
the cells was not influenced. In order to ensure that the studies were comparable, the cell 
specific productivity was determined for both cultures before the perfusion strategy was 
applied. There was no difference in the specific production rate between the two modes of 
cultivation, as noted in Table 6.2.1.3.1. The fact that the volumetric productivity was the 
same over the entire culture period and there were essentially the same number of cells 
present in the cultures, this indicates that at later stages when cells/mlcapsule were higher in 
perfusion, there were no changes in specific productivity. 
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Figure 6.2.1.3.1: Total amount of IgG1 (μg) measured in cell free media samples harvested 
from encapsulated cultures on day 5 onwards. rIgG1 present in the media was purified using 
commercially available protein A/G Nab spin columns and quantified using the nanodrop 
A280 nm in duplicate which the average value recorded.. Values for cells cultured under 
batch conditions are the average of triplicate cultures performed in parallel, +/- STD. Values 
presented for perfusion conditions are those obtained for the single culture performed. 
 
Table 6.2.1.3.1: Calculated rIgG1 production rates and cell specific production rates for cells 
encapsulated in 300 μm radius liquid capsules and cultured under batch and perfusion modes 
of cultivation. The specific production rate was calculated over the exponential growth phase 
for all cultures. The results presented below for the batch cultures are the average of triplicate 
cultures performed in parallel, +/- STD. The values for the perfusion culture are those 
obtained for the single culture performed under such conditions. 
Culture
Encapsulated cells (batch)
Encapsulated cells (perfusion)
42274 +/- 398 2.39 +/- 1.02
IgG1 production rate μg/day q IgG1 μg/10
6
 cells/day
39637 2.28  
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6.2.1.4: Effect of perfusion mode on CHO cell metabolism 
 Both the batch and controlled-fed perfusion cultures were performed in ExCell CHO 
325 PF media supplemented with an initial 4 mM L-glutamine concentration. The 
concentration of glucose in the commercially available media is expected to be 17.4 mM. The 
concentrations of the metabolites in the media were not altered during the batch cultures. In 
the case of the controlled-fed perfusion culture, after inoculation with 300 ml of capsules, the 
1.7 L (1.2 L working volume) minifors reactor was operated for 5 days in batch mode. 
Perfusion was started on the 5
th
 day. Offline glucose and glutamine assay results indicated 
that on day 5 the concentration of glucose and glutamine were below the level necessary to 
maintain the growth of the exponentially growing cells for the predicted number of cells 
expected to be present on the following day. Glucose and glutamine were monitored 
throughout the run as indicators of the concentration of the two metabolites to be included in 
the perfusion feed medium. The perfusion rate essentially remained constant. Lactate 
concentrations were later determined using high performance liquid chromatography (HPLC) 
as described in Materials and Methods Section 2.3.3. 
The concentration of the major carbon sources, glutamine and glucose, and their 
corresponding by-products, ammonia and lactate, were measured on a daily basis (Figure 
6.2.1.4.1 and 6.2.1.4.2). Determination of the concentration of the various metabolites 
enabled the calculations of the specific substrate uptake rate for each of the experimental 
cultures (Table 6.2.1.4.1). 
Metabolic analysis of cells cultured under batch conditions was extensively evaluated in 
Chapter 5. By the end of the exponential growth phase all of the glutamine had been depleted. 
Glucose was depleted by the end of the stationary phase in batch cultures. As the perfusion 
mode of operation only began from on day 5 in the controlled-fed perfusion cultures, this 
culture acted essentially as a batch culture until this stage. It would therefore be assumed that 
all cell specific metabolite production and consumption rates would be the same during the 
cultivation period of days 1-5. Given that the cell number per mlreactor was not significantly 
different between the batch and perfusion cultures from day 1-5, it would also be expected 
that the volumetric consumption and production rates would not be significantly different. 
Analysis of the cell specific and volumetric production and consumption rates, calculated 
during the exponential growth period, and presented in Table 6.2.1.4.1 below verify this 
assumption. There was no significant difference in the specific consumption rate displayed by 
the cells in the controlled-fed perfusion culture beyond day 5, where the value was 
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determined to be 3.98 * 10
-4
 mmoles/10
6
 cells/day. The glucose concentration in the reactor 
was increased to 25 mM after perfusion on day 6 as it was assumed that the cells would 
continue to colonise the capsules. When it was noted that the cells/mlreactor was not going to 
increase daily after day 6, due to capsule breakup and washout of cells from reactor, the 
concentration of glucose added to the perfusion media was adjusted accordingly. The specific 
lactate production rate was slightly higher after day 5, however it still fell within the standard 
deviation of the batch cultures at 6.26 * 10
-4
 mmoles/10
6
 cells/day. Due to the slightly higher 
specific lactate production rate displayed by the cells, the concentration of lactate present at 
the end of the controlled-fed perfusion culture was 25 % higher than that observed in the 
batch culture. The overall yield of lactate on glucose in the controlled perfusion culture was 
similarly 27 % higher than that observed in the batch culture.  
This may be attributed to the fact that the perfusion strategy design was based on the 
assumption that cells would continue growing exponentially. Therefore the concentration of 
glucose to be added to the culture each day was determined based on the assumption that the 
cells would continuously grow at the rate they were doing so in that time period. This 
however was not the case due to the instability of the capsules and a cell wash out during 
perfusion. The cells were essentially overfed resulting in high lactate yields. 
Similarly for the metabolite glutamine and it’s corresponding by-product ammonia, there was 
no significant difference in both the cell specific and volumetric consumption and production 
rates between the batch cultures and the control-fed perfusion cultures from days 1-5. The 
specific glutamine and ammonia consumption and production rates remained similar to that 
observed during days 1-5 for the duration of the culture period at values of 7.29 * 10
-5
 and 
7.67 * 10
-5
 mmoles/ 10
6
 cells/day, respectively. The molar yield ratio of ammonia on 
glutamine was slightly lower than that observed for the batch culture over the entire culture 
period, but perhaps not significantly. 
It must be noted that there is a difference in the initial concentration of L-glutamine between 
the batch and control-fed perfusion encapsulated cultures. Greater errors occur in the initial 
L-glutamine concentration in the media used for encapsulated cultures due to two main 
factors. Unlike glucose, L-glutamine is added to the media by the user prior to culturing, 
which introduces some batch-batch variations in the concentration between cultures due to 
human errors in volumes added. The media is also diluted by the microcapsules. Due to a 
combination of variations in the volume of microcapsules made per batch and the amount of 
washing buffer remaining in the vessel with the prepared microcapsules prior to addition of 
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the media, variations in initial concentration of nutrients can occur between cultures. The 
culture media becomes diluted by both the microcapsules and any of the washing buffer 
remaining. 
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Figure 6.2.1.4.1: Concentration of glucose and lactate present in both batch and perfusion 
cultures over the duration of the respective cultivation periods. The concentrations of glucose 
were determined using an enzymatic assay kit and lactate concentrations were determined 
offline by HPLC analysis using Supelco H column. Batch values are the average of triplicate 
cultures carried out in parallel, +/- STD. The values for the perfusion culture are those which 
were obtained for the single culture performed. 
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Figure 6.2.1.4.2 Concentration of glutamine and ammonia present in both batch and 
perfusion cultures over the duration of the respective cultivation period. The concentrations 
of glutamine and ammonia were determined offline using a commercial available enzymatic 
assay kit. Batch values are the average of triplicate cultures carried out in parallel, +/- STD. 
The values for the perfusion culture are those which were obtained for the single culture 
performed. 
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Table 6.2.1.4.1: Calculated rates of consumption and production of key metabolites (glucose 
and lactate) as determined by offline analysis throughout the culture period. Cell specific 
consumption and production rates of the key metabolites were determined during the 
exponential growth phase (days 1-5). Yields were calculated over the entire cultivation 
period. Batch values are the average of those calculated for triplicate cultures carried out in 
parallel, +/- STD. The values for the perfusion culture are those which were calculated for the 
single culture performed. 
q glucose
(mmoles/10
6
 cells/day)
rate (mM/day)
Lactate production
Encapsulated batch Encapsulated perfusion
Glucose consumption
rate (mM/day) 2.026
3.90 * 10
-4
3.15
5.93 * 10
-4
q lactate
(mmoles/10
6
 cells/day)
2.09 +/- 0.12
3.11 * 10
-4
 +/- 1.12 * 10
-4
2.55 +/- 0.71
5.32 * 10
-4
 +/- 1.88 * 10
-4
1.55
Ylactate/glucose
(mmole/mmole) 1.22 +/- 0.18  
 
Table 6.2.1.4.2: Calculated rates of consumption and production of key metabolites 
(glutamine and ammonia) as determined by offline analysis throughout the culture period. 
Cell specific consumption and production rates of the key metabolites were determined 
during the exponential growth phase (days 1-5). Yields were calculated over the entire 
cultivation period. Batch values are the average of those calculated for triplicate cultures 
carried out in parallel, +/- STD. The values for the perfusion culture are those which were 
calculated for the single culture performed. 
1.531.88 +/- 0.23
0.62
7.89 * 10
-5
0.387
8.36 * 10
-5
(mmole/mmole)
0.59 +/- 0.19
8.42 * 10
-5
 +/- 6.21 * 10
-6
0.459 +/- 0.180
1.31 * 10
-4
 +/- 1.16 * 10
-5
rate (mM/day)
q ammonia
(mmoles/10
6
 cells/day)
Yammonia/glutamine
rate (mM/day)
q glutamine
(mmoles/10
6
 cells/day)
Ammonia production
Encapsulated batch Encapsulated perfusion
Glutamine consumption
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6.2.1.5: Effect of perfusion mode on product quality 
 To assess the effect of a perfusion strategy as a mode of cultivation on the quality of 
rIgG1 produced, both glycan and aggregation analysis were completed on the purified rIgG1 
samples harvested from both the batch and controlled-fed perfusion encapsulated cultures at 
both the end of the exponential and stationary growth phases Samples harvested from the 
cultures were subjected to N-glycan release and labelled as outline in Materials and Methods 
Section 2.3.7.1. Hydrophilic interaction liquid chromatography (HILIC) characterisation of 
the released and labelled N-glycans produced a chromatogram consisting of 8 distinctly 
separated peaks. Each of the peaks was assigned a distinctive glucose units (GU) value by 
comparison to the retentions times of the standard A-AB labelled external dextran. 
Examination of exoglycosidase treated samples allowed for the corresponding number and 
linkage of the component monosaccharide units represented by each GU value to be 
elucidated, as described in Materials and Methods section 2.3.7.3. Aggregation analysis of 
the purified samples was carried out using size exclusion chromatography (SEC) 
Figure 6.2.1.5.1 illustrates the relative % of glycans present on rIgG1 harvested from the 
batch and perfusion encapsulated cultures on day 5 of the culture period (i.e. before the 
perfusion strategy was applied). No significant difference may be noted in the relative % of 
each type of glycan present on the rIgG1 harvested on day 5 of the batch and perfusion 
encapsulated cultures.  As the perfusion culture essentially acted as a batch culture until day 
5, it would be expected that there would be no significant differences in the relative % of 
each glycan present on the protein at this stage. Irrelevant of the mode of cultivation, all 
cultures displayed a similar trend in the relative % of glycans present. The earliest form of N-
glycosylation of rIgG1 is denoted by M5, F6A1/A2 and F6A2. The highest relative 
percentage of glycans present on the rIgG1 samples were the early glycoforms, 
predominantly F6A2. The galactosylated glycoforms are denoted by F(6)A2[6]G(4)1 and 
F(6)A2[3]G(4)1, which contain 1 galactose unit on either of the outer GlcNAc arms, and 
F(6)A2G2, which contains a galactose residue on each of the outer GlcNAc arms. Of the 
galactosylated glycoforms present, the F(6)A2[6]G(4)1 were the predominant form in all 
cultures, independent of the mode of cultivation employed. 
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Figure 6.2.1.5.1: : Relative % of N-glycan forms detected on rIgG1 samples harvested from 
batch and perfusion encapsulated cultures on day 5 of the culture period (before perfusion 
was initiated) N-glycans were released from the rIgG1 samples by means of PNGaseF 
digestion. Samples for HILIC analysis were labeled by adding 5 μl of 2AB labelling solution. 
The retention time of the glycan peaks was compared with an external A-AB labelled dextran 
standard for structural elucidation by converting the retention time of the peaks into GU. 
Each IgG1 sample was analysed in duplicate. The results are the average of the triplicate 
cultures carried out in parallel for the batch cultures, +/- STD. Values for the perfusion 
culture are those which were obtained for the single culture carried out. 
 
In Chapter 5 there was a noted lower relative % of M5 present on the rIgG1 protein harvested 
from encapsulated cultures in comparison to suspension cultures, at the end of the 
exponential growth period. There was however an increase in the relative % of M5 present on 
IgG1 throughout the culture period for the encapsulated culture. The increase in the relative 
% of M5 present on IgG1 in encapsulated cultures was larger than that which was observed 
for suspension culture and so by the end of the stationary growth phase the relative % M5 
present on IgG1 was higher than that observed in stationary culture. 
In this current study, M5 did also increase over the cultivation period of the controlled-fed 
perfusion culture. However the increases in the relative % of M5 in the perfusion culture 
were less dramatic than those noted in the batch cultures, Table 6.2.1.5.1. 
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Table 6.2.1.5.1: Relative % of M5 present on rIgG1 harvested from batch and control-fed 
perfusion cultures on days 5-7 as detected using HILIC following PNGaseF release and 2-AB 
labelling. Each IgG1 sample was analysed in duplicate. 
Time Relative % M5 Batch Relative % M5 Perfusion 
Day 5 0.94 0.91 
Day 6 1.24 0.97 
Day 7 2.71 1.2 
 
A 2.8- fold increase in the relative % of M5 glycans was noted over the duration of the 
stationary phase in the batch cultures. However only a 32 % increase in the relative % of M5 
was noted in the perfusion cultures 
By the end of the stationary phase (day 8 controlled-fed perfusion), there was 38 % less M5 
present on protein harvested from perfusion cultures, in comparison to batch cultures. 
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Figure 6.2.1.5.2: Relative % of M5 present on rIgG1 harvested from batch encapsulated 
cultures and controlled perfusion cultures at the end of the stationary growth phases (day 7 
batch and day 8 controlled-fed perfusion) as detected using HILIC following PNGaseF 
release and 2-AB labelling. Each IgG1 sample was analysed in duplicate. The values 
presented for the batch are an average of triplicate cultures performed in parallel, +/- STD. 
The values for the perfusion culture are those which were obtained for the single culture 
performed. 
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Another important observation that can be made is that there was an increase in the level of 
fucosylated, sialyated glycans between the exponential and stationary phases in the 
controlled-fed perfusion culture. Due to the fact that the perfusion culture was not performed 
in triplicate, it is difficult to confirm if the finding is significant. 
 
Table 6.2.1.5.2: Relative % of F(6)A2G2S1 present on rIgG1 harvested from batch and 
control-fed perfusion cultures at the end of the exponential and stationary growth phases as 
detected using HILIC following PNGaseF release and 2-AB labelling. Each IgG1 sample was 
analysed in duplicate. The values presented for the batch are an average of triplicate cultures 
performed in parallel, +/- STD. The values for the perfusion culture are those which were 
obtained for the single culture performed. 
Time Relative % F6A2G2S1 batch Relative % F6A2G2S1  perfusion 
End exponential phase 0.24 +/- 0.04 0.18 
End stationary phase 0.3 +/- 0.03 0.34 
 
Looking at the information provided in Table 6.3.1.5.2, it may be observed that there was an 
80 % increase in the relative % of F(6)A2G2S1 present on IgG1 harvested at the end of the 
stationary phase in comparison to the end of the exponential phase for the control-fed 
perfusion culture. However it may also be noted that the relative % of the glycan present in 
the controlled-fed perfusion is simply at the lower range of levels found in the batch culture 
for the same time period. Also, the relative % of the glycan present in the controlled-fed 
perfusion culture is simply at the higher range of the levels found in the batch cultures. 
Over 95 % of the rIgG1 harvested from culture media was in a monomeric form for both 
culture conditions tested, Figure 6.2.1.6.3 
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Figure 6.2.1.5.3: Relative % monomeric form of rIgG1 samples as detected by SEC. IgG1 
samples were harvested from cultures batch and perfusion cultures performed. IgG1 samples 
were analysed in duplicate. The results are presented as the average of triplicate cultures 
performed for the batch encapsulated cultures, +/- STD. Values for the perfusion cultures are 
those which were obtained for the single culture performed. 
 
6.2.2: Batch encapsulated –v- Perfusion encapsulated in 1 L Erlenmeyer shake flasks 
 Based on the results obtained from section 6.2.1, it may be concluded that further 
colonisation of the capsules was achieved by operating a controlled-fed perfusion cultivation 
strategy. The attainment of a higher cell density/mlreactor was however limited due to the 
breakup of capsules in the harsh bioreactor environment. A decision was therefore made to 
repeat the controlled-fed perfusion experiment, however at a smaller scale, in the less harsh 1 
L Erlenmeyer shake flask environment.  
The results of Chapter 4 suggested that, when in suspension, the CHO cells behave 
differently when cultured in shake flasks and 1.7 L minifors reactors platforms. Such 
differences by noted by: reduced growth rate of 11 %, reduced specific productivity of 28 %, 
increased lactate production from glucose and reduced glycosylation in notably the levels of 
galactosylation for suspension cells cultivated in 1.7 L minifors reactor platform in 
comparison to a 1 L Erlenmeyer shake flask platform. 
Therefore, before the perfusion culture may be completed in the shake flask, it is necessary to 
observe if there are similar differences in cellular activity noted between the cultivation of 
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encapsulated cells in shake flask and minifors reactor platforms. For this reason batch 
encapsulated shake flask cultures were performed for comparison to the batch encapsulated 
cultures previously carried out in the 1.7 L minifors reactor . Controlled-fed perfusion 
cultivated encapsulated cells in 1 L Erlenmeyer shake flasks are not directly comparable to 
batch cultivated encapsulated cells in the 1.7 L minifors reactor as changes in cellular activity 
may be brought about by the change in culture vessel as oppose to the change in cultivation 
mode. This experiment will ensure that any alterations that may be noted in encapsulated 
cellular activities under a controlled-fed perfusion mode of cultivation in shake flasks 
(section 6.3.3) are in fact due to the controlled-fed perfusion mode of cultivation and not the 
scale down 
 
6.2.2.1: Capsule characterisation 
 
6.2.2.1.1: Capsule size 
 In both the 1.7 L minifors reactor cultures and 1 L Erlenmeyer shake flask cultures, 
capsules were prepared by the extrusion of alginate through the 300 μm nozzle used in all 
experiments to date. Capsule size was determined on a daily basis. Thirty capsules were 
measured individually in order to calculate the average diameter and the standard deviation. 
Generally the size distribution was in the range of 3-5 %. 
Figure 6.2.2.1.1 below illustrates the capsules radius size over the cultivation period for both 
the batch cultures. The results presented below are the average of triplicate cultures. Capsule 
size throughout the 1 L Erlenmeyer shake flask culture is consistent with that observed during 
the batch cultures. A greater size standard deviation is noted between the triplicate cultures 
performed in the 1.7 L minifors reactor culture. This may be attributed to the larger volume 
of capsules required per run (300 ml) in comparison to that required for shake flask cultures 
(100 ml). 
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Figure 6.2.2.1.1.1: Average capsule radius size (μm) +/- STD over the duration of the 
cultivation period for each of the three encapsulated cultures completed in both 1.7 L 
minifors reactor and 1 L Erlenmeyer shake flask platforms. The size of approximately 30 
capsules was measured at each time point and an average determined. 
 
6.2.2.1.2: Capsule strength 
 The mechanical strength of the microcapsules in the batch cultures conducted in both 
1.7 L minifors reactor and 1 L Erlenmeyer shake flask platforms was routinely evaluated in 
terms of Force (g)/capsule which the capsule could withstand using the Texture analyser. 
Figure 6.2.2.1.2.1 below illustrates the mechanical resistance of the microcapsules in both 1.7 
L minifors reactor and 1 L Erlenmeyer shake flask platforms over the cultivation period. For 
both culture platforms there is a dramatic decrease in the mechanical resistance of the 
capsules from days 0-3, after which the resistance is noted to fall slower before somewhat 
levelling off. On day 3 the mechanical resistance of microcapsules in the 1.7 L minifors 
reactor was determined to be ~0.07 +/- 0.01 g/capsule, as noted in Chapter 5. However it is 
not until day 5 in the 1 L Erlenmeyer shake flask models that the capsule reach such a low 
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resistance. It is interesting to note that the profile of mechanical resistance in both culture 
platforms are typically the same. The aim of this work was to identify if the shake flask 
model could be beneficial in reducing the potential for capsule break up which was noted to 
occur later in perfusion cultures performed above in 1.7 L minifors reactor cultures. 
Evaluation of the results below would suggest that the shake flask environment offers no 
increased benefits for maintaining capsule resistance at a higher level for the entire culture 
period than that observed in the 1.7 L minifors reactor cultures. The decrease in mechanical 
resistance is however reduced. It may be hypothesised that the shake flask environment may 
allow these capsule with low mechanical resistance (~0.07-0.08 g/capsule) to remain intact 
due to the exposure to less harsh shearing forces than would be observed in the minifors 
reactor. Due to the batch nature of the cultures, the cultures were terminated due to a lack of 
cell viability. Therefore whether the capsules resist breakage in shake flasks for extended 
period of time in comparison to reactor cultures under control-fed perfusion strategies in 
shake flasks will have to be determined.  
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Figure 6.2.2.1.2.1: Mechanical resistance (force (g)/capsule) over cultivation period for 300 
μm APA microcapsules containing CHO DP-12 cells cultivated in a 1.7 L minifors reactor 
and 1 L Erlenmeyer shake flask platforms under batch cultivation conditions. A total of 3 
layers of microcapsules were analysed on a daily basis. Values presented are average of 
triplicate analysis +/- STD for one of the encapsulated cultures carried out in the study. 
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6.2.2.2: Comparability of encapsulated cell growth under batch conditions in 1 L 
Erlenmeyer shake flasks and 1.7 L minifors reactors. 
 In order to test the comparability of encapsulated CHO DP-12 cells grown in 1 L 
Erlenmeyer shake flasks, with that previously obtained for encapsulated cells cultured in 1.7 
L minifors reactors, 100 ml of CHO DP-12 containing APA microcapsules were used to 
inoculate 300 ml of culture medium in 1 L Erlenmeyer shake flasks. Both 1.7 L reactor 
cultures and 1 L Erlenmeyer shake flask cultures were conducted in triplicate. The capsule to 
media ration of volume was kept constant between the two culture platforms. For the 
minifors reactor culture the bioreactor was operated under conditions of 37 °C and 100 rpm 
agitation and 95 % DO by means of sparging with compressed air (flowrate of 0.01 vvm). 
The pH was also controlled at 7.2 through automatic addition of 2 M  NaOH, via a feed line, 
or CO2 sparging (through the headspace at a flowrate of 0.047 vvm).  Shake flasks were 
incubated in 37 °C incubator in unvented shake flasks and 100 rpm agitation. All conditions 
were consistent with those utilised in Chapter 4 in which a comparison study was conducted 
between the growth of suspension cells in 1 L Erlenmeyer shake flask and 1.7 L minifors 
reactor platforms The average seeding density was 0.9 * 10
6
  (cells/mlcapsules).  
Figure 6.2.2.2.1 below demonstrates the growth of the encapsulated CHO DP-12 cells inside 
the microcapsules in both the shake flask and reactor platforms. The values are expressed at 
cells/mlcapsules. It is evident from the data portrayed that there was no significant difference in 
the growth pattern or maximum cell number reached in the capsules between the two culture 
platforms investigated. The main steps forward from this study are to progress towards 
applying the controlled-fed perfusion strategy to the 1 L Erlenmeyer shake flask encapsulated 
cultures in a similar means to that which was completed for the 1.7 L minifors reactor 
cultures in section 6.2.1. Therefore it is important to identify at this early stage if the 1 L 
Erlenmeyer shake flask platform has the potential to allow the capsules to act as a suitable 
retention system for the application of controlled-fed perfusion strategy. Figure 6.2.2.2.2 
below demonstrates the growth of CHO DP-12 cells cultured in both 300 μm APA 
microcapsules and freely in suspension in both 1 L Erlenmeyer shake flask and 1.7 L 
minifors reactor platforms. The average viable cell densities in this case are expressed as 
cells/mlvessel. The data for the suspension cultures is taken from Chapter 4 in order to enable 
visualisation of the progress made to date in achieving high cell density cultures. Addressing 
the possibility of capsule retention in 1 L Erlenmeyer shake flask cultures, it is understood 
that there is no significant difference in the growth pattern displayed by encapsulated cells 
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when cultured in 1L Erlenmeyer shake flask and 1.7 L minifors reactor platforms in 
cells/mlvessel. The retention capabilities of the capsules were not compromised by the 
transition to 1 L Erlenmeyer shake flask platforms for the encapsulated cultures. This 
observation is also strengthened by the similar extracapsular cell concentration observed in 
the 1 L Erlenmeyer shake flask study and the 1.7 L minifors reactor study were the same 
(0.21 * 10
6
 cells/ml) 
It is important to note that when batch encapsulated cultures were initially conducted in 1.7 L 
minifors reactor cultures, no cause for concern arose as to the suitability of the APA 
microcapsules as retention devices suitable for an extended cultivation period during a 
controlled-fed perfusion culture. Caution must therefore be taken to the fact that when the 
controlled-fed perfusion strategy may be applied, capsule breakup, similar to that noted in 
section 6.2.1 may still occur. In regards to the progression of the thesis towards high cell 
density culture systems, the return to a shake flask model with the encapsulated cells has not 
resulted in any advancements in cellular growth rate or maximum viable cell densities than 
those achieved through the encapsulation of the cells and cultivation in 1.7 L minifors reactor 
platforms, as discussed in Chapter 5. The increases in maximum viable cell densities 
achieved for batch encapsulated cultures in comparison to batch suspension cultures, in the 
1.7 L minifors reactor platform have been maintained in the encapsulated 1 L Erlenmeyer 
shake flask cultures, Table 6.2.2.2.1. 
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Figure 6.2.2.2.1 Growth of CHO cells cultured in 300 μm liquid core APA microcapsules 
under batch cultivation conditions in 1 L Erlenmeyer shake flask and 1.7 L minifors reactor 
platforms. Cell numbers were enumerated on a daily basis using trypan blue exclusion 
method and a Neubauer haemocytometer. Encapsulated cells were liberated prior to counting 
via extrusion of a capsule/PBS suspension through a 300 μm needle 3 times. Duplicate cell 
counts were performed. The cell concentration is given with respect to the capsule volume. 
Values for both platforms are the average (+/- STD) of triplicate cultures. 
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Figure 6.2.2.2.2: Growth of CHO DP-12 cells both encapsulated in 300 μm APA 
microcapsules and freely in suspension under batch modes of cultivation in 1L Erlenmeyer 
shake flask and 1.7 L minifors reactor platforms. Cell numbers were enumerated on a daily 
basis using trypan blue exclusion method and a Neubauer haemocytometer. Encapsulated 
cells were liberated prior to counting via extrusion of a capsule/PBS suspension through a 
300 μm needle 3 times. Duplicate cell counts were performed. The cell concentration is given 
with respect to the vessel working volume which the cultures were performed in. Values for 
both platforms are the average (+/- STD) of triplicate cultures. 
 
 
239 
 
0
20
40
60
80
100
120
0 2 4 6 8 10
Time, days
V
ia
b
il
it
y
, 
%
Suspension cells (shake flask) Suspension cells (reactor)
Encapsulated cells (reactor) Encapsulated cells (shake flask)
 
Figure 6.2.2.2.3: % Viability of CHO cells cultured in suspension and encapsulated in 300 
μm liquid capsules in 1 L Erlenmeyer shake flask and 1.7 L minifors reactor cultures.  % 
viability was determined by the enumeration of total and live cell numbers present in the 
culture using trypan blue exclusion method and Neubauer haemocytometer. % viability is 
expressed as a percentage of live cells over dead cells present. Cell counts were performed in 
duplicate and average % viability determined on a daily basis. Values are average (+/- STD) 
of triplicate cultures performed in parallel at both culture platforms. 
 
Table 6.2.2.2.1: Calculated maximum specific growth rates displayed by cells cultured in 
suspension and encapsulated in 300 μm liquid capsules in 1L Erlenmeyer shake flask and 1.7 
L minifors reactor platforms over the exponential growth period. The growth rate was 
calculated from a plot of the logarithm of the viable cell density over the cultivation time 
(days). The maximum viable cell density is presented with respect to per mlvessel. Values are 
average (+/- STD) of triplicate cultures performed in parallel at both culture platforms. 
3.12 +/- 0.27
11 +/- 1.35
9.21 +/- 1.15
Suspension cells (reactor)
Encapsulated cells (reactor)
Encapsulated cells (shake flask)
0.725 +/- 0.013
0.645 +/- 0.037
0.759 +/- 0.13
0.789 +/- 0.06
Culture μmax (day
-1
) Max VCD (*10
6
 cells/mlvessel) 
4.30 +/- 0.19Suspension cells (shake flask)
 
240 
 
6.2.2.3: Comparability of encapsulated cell metabolism under batch conditions in 1 L 
Erlenmeyer shake flasks and 1.7 L minifors reactors. 
 Both the 1 L Erlenmeyer shake flask and 1.7 L minifors reactor encapsulated cultures 
were performed in ExCell CHO 325 PF media supplemented with an initial 4 mM L-
glutamine concentration. The concentration of glucose in the commercially available media is 
expected to be 17.4 mM.  The concentration of the major carbon sources, glutamine and 
glucose, and their corresponding by-products, ammonia and lactate, were measured from 
media samples taken from all cultures on a daily basis. Samples were removed from cultures 
on a daily basis and centrifuged at 200 g for 5 minutes, followed by filtration of the 
supernatant (0.22 μm PTFE) in order to remove cells and culture debris. As stated above 
glutamine and ammonia analysis was carried out using commercially available enzymatic 
assays kits. Glucose and lactate concentrations were later determined using HPLC as 
described in Materials and Methods Section 2.3.3. Determination of the concentration of the 
various metabolites enabled the calculations of the specific substrate uptake and production 
rate for each of the experimental cultures (Table 6.2.2.3.1-6.2.2.3.3). 
The results from suspension cultures in 1.7 L minifors reactor and 1 L Erlenmeyer shake 
flasks (Chapter 4) are also presented in the tables in order to demonstrated how the 
movement back to the 1L Erlenmeyer shake flask platform has in no way compromised the 
progress to date regarding the achievement of high density cultures brought about by 
encapsulation. 
By the end of the exponential growth phase all of the glutamine had been depleted in both the 
encapsulated 1 L Erlenmeyer shake flask and 1.7 L minifors reactor cultures. Glucose was 
depleted by the end of the stationary phase in such cultures.  There was no significant 
difference in the glucose consumption rate (mM/day) displayed by the encapsulated cells 
when cultured in 1 L Erlenmeyer shake flask and 1.7 L minifors reactor platforms. Both were 
lower than that observed for the suspension cultures conducted in the 1.7 L minifors reactor 
as discussed in Chapter 5. The batch encapsulated 1L Erlenmeyer shake flask culture also 
displayed a lower glucose consumption rate (mM/day) than the batch suspension 1L 
Erlenmeyer shake flask culture noted to be 3.20 +/- 0.003 in Chapter 4. This again verifies 
the conclusion from Chapter 5 in which it was deduced that encapsulation alters the 
metabolism of cells in comparison to conditions in which they are cultured in suspension, 
thus allowing encapsulated cells to have lower glucose consumption rates (mM/h). The 
specific glucose consumption rates (mmoles/10
6
 cells/day) were not significantly different for 
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the two encapsulated cultures. The specific consumption rates were therefore again lower 
than the suspension reactor and suspension shake flask cultures. 
The lactate production rate (mM/day) and the specific lactate production rate (mmoles/10
6
 
cells/day) were not significantly different between the batch encapsulated 1L Erlenmeyer 
shake flask and batch encapsulated 1.7 L minifors reactor cultures. An unfavourably high 
lactate production rate was noted for the suspension cultures in the 1.7 L minifors reactor 
culture in comparison to all other cultures. This is verified by the increases specific 
production rate for this culture. In agreement with the results presented in Chapter 5, the 
lactate production rate was also lower for the batch encapsulated 1 L Erlenmeyer shake flask 
cultures, in comparison to the batch suspension 1 L Erlenmeyer shake flask cultures.  
Both the glutamine consumption rate (mM/day) and cell specific consumption rate 
(mmoles/10
6
 cells/day) were not significantly different when encapsulated cells were cultured 
in both 1 L Erlenmeyer shake flask and 1.7 L minifors reactor platforms. As noted in Chapter 
5, there was a 73 % decrease in the specific glutamine consumption for the encapsulated cells 
cultured in the 1.7 L minifors reactor, in comparison to the suspension cells cultured in the 
same environment. These results are verified in this study by comparison of the specific 
glutamine consumption rate displayed by the encapsulated cells cultured in the 1 L 
Erlenmeyer shake flask platform to the suspension cells cultured under the same conditions. 
A notably 65 % decrease in the specific consumption rate was noted for the encapsulated 
cells, verifying the fact that encapsulation of cells favours lower specific glutamine 
consumption. 
No significant difference was noted in the ammonia production rate (mM/day) for 
encapsulated cells cultured in the 1 L Erlenmeyer shake and 1.7 L minifors reactor platform. 
The cell specific rate (mmoles/10
6
 cells/day) was determined to be slightly lower in the 1 L 
Erlenmeyer shake flask culture in comparison to the 1.7 L minifors reactor culture. However 
there are significantly large standard deviations for each of the calculated figures. It should 
also be noted that both figures are significantly lower than those calculated for the suspension 
cultures in both culture platforms. 
As all specific rates of glucose and lactate consumption and production were similar to that 
displayed by encapsulated cells cultured in both 1 L Erlenmeyer shake flask cultures and 1.7 
L minifors reactor cultures, as expected there was no significant difference in the yield of 
lactate from glucose in these cultures. The yield of ammonia on glutamine was 35 % lower 
for encapsulated cells cultured in shake flasks in comparison to that observed for 
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encapsulated cells cultured in 1.7 L minifors reactor. This may be attributed to the lower 
specific ammonia production rate displayed by the cells cultured in 1 L Erlenmeyer shake 
flasks. The mean maximum concentration of ammonia present in the encapsulated cultures 
performed in 1 L Erlenmeyer shake flasks was 3.68 +/- 0.09 mM. The corresponding mean 
maximum concentration of ammonia present in the encapsulated cultures performed in the 
1.7 L minifors reactor cultures was 31 % higher at 4.83 +/- 0.60 mM. 
 
Table 6.2.2.3.1: Calculated volumetric and specific consumption and production rates of 
glucose and lactate in batch suspension and encapsulated cultures conducted on 1 L 
Erlenmeyer shake flask and 1.7 L minifors reactor platforms. Values are average (+/- STD) of 
those calculated for triplicate cultures performed in parallel at both culture platforms. 
Culture 
Glucose 
consumption 
Lactate 
production qglucose  qlactate 
  
rate 
(mM)/day) 
rate 
(mM/day) 
(mmoles/10
6
 
cells/ml) 
(mmoles/10
6
 
cells/ml) 
Suspension cells 
(shake flask) 3.20 +/- 0.03 
3.49  
+/- 0.17 
8.3 * 10
-4
  
+/- 5.23 * 10
-5
 
1.15 * 10
-3
  
+/- 8.59 * 10
-5
 
Suspension cells 
(reactor) 5.38 +/- 0.39 
10.55  
+/- 0.40 
1.69 * 10
-3
  
+/- 1 * 10
-4
 
3.1 * 10
-3
  
+/- 3.33 * 10
-4
 
Encapsulated 
cells (reactor) 2.09 +/- 0.11 
2.55  
+/- 0.71 
3.11 * 10
-4
  
+/- 1.12 * 10
-4
 
5.33 * 10
-4
  
+/- 1.9 * 10
-4
 
Encapsulated 
cells (shake flask) 1.89 +/- 0.06 
1.99  
+/- 0.18 
2.69 * 10
-4
  
+/- 7.87 * 10
-5
 
3.42 * 10
-4
  
+/- 8.24 * 10
-5
 
 
Table 6.2.2.3.2: Calculated volumetric and specific consumption and production rates of 
glutamine and ammonia in batch suspension and encapsulated cultures conducted on 1 L 
Erlenmeyer shake flask and 1.7 L minifors reactor platforms. Values are average (+/- STD) of 
those calculated for triplicate cultures performed in parallel at both culture platforms. 
Culture 
Glutamine 
consumption 
Ammonia 
production qglutamine qammonia 
  
rate 
(mM/day) 
rate 
(mM/day) 
(mmoles/10
6
 
cells/ml) 
(mmoles/10
6
 
cells/ml) 
Suspension cells 
(shake flask) 0.89 0.902 2.23 * 10
-4
 3.11 * 10
-4
 
Suspension cells 
(reactor) 0.81 +/- 0.06 
0.78  
+/- 0.04 
3 * 10
-4
  
+/- 3.31 * 10
-5
 
3.46 * 10
-4
  
+/- 2.74 * 10
-5
 
Encapsulated 
cells (reactor) 0.59 +/- 0.19 
0.46  
+/- 0.18 
8.42 * 10
-5
  
+/- 6.21 * 10
-6
 
1.31 * 10
-4
  
+/- 1.16 * 10
-5
 
Encapsulated 
cells (shake flask) 0.53 +/- 0.06 
0.46  
+/- 0.01 
7.81 * 10
-5
  
+/- 2.97 * 10
-5
 
5.98 * 10
-5
  
+/- 1.98 * 10
-5
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Table 6.2.2.3.3: Calculated yields of byproduct/metabolite (mmoles/mmoles) over the 
cultivation period for both encapsulated and suspension cultures conducted using 1 L 
Erlenmeyer shake flask and 1.7 L minifors reactor platforms. Values are average (+/- STD) of 
those calculated for triplicate cultures performed in parallel at both culture platforms. 
Culture Ylactate/glucose Yammonia/glutamine 
  (mmoles/mmoles) (mmoles/mmoles) 
Suspension cells (shake flask) 0.95 +/- 0.11 1.07 
Suspension cells (reactor) 1.81 +/- 0.09 1.23 +/- 0.15 
Encapsulated cells (reactor) 1.22 +/- 0.18 1.88 +/- 0.23 
Encapsulated cells (shake flask) 1.01 +/- 0.05 1.22 +/- 0.11 
 
 
6.2.2.4: Comparability of encapsulated cell productivity under batch conditions in 1 L 
Erlenmeyer shake flasks and 1.7 L minifors reactors. 
 To evaluate the effect of the two modes of cultivation on rIgG1 production in 
encapsulated cells, media samples were removed from both the 1 L Erlenmeyer shake flask 
culture and the 1.7 L minifors reactor cultures on a daily basis from day 5 onwards. As 
explained in Section 2.3.6., of the Materials and Methods Section, rIgG1 was purified from 
media samples removed from the cultures after centrifugation at 200 g for 5 minutes to 
remove cells. Capsules were separated from the media before the centrifugation step for the 
encapsulated culture samples. rIgG1 present in the media was purified using Protein A Nab 
spin columns and quantified using the nanodrop at A 280 nm. 
Figure 6.2.2.4.1 below represents the concentration of IgG1 present in each of the suspension 
and encapsulated cultures conducted in both 1 L Erlenmeyer shake flask and 1.7 L minifors 
reactor platforms at the end of the stationary phase of growth. The aim of the work is to 
identify if there are significant differences in the productivities of the encapsulated cells when 
cultured in 1 L Erlenmeyer shake flask and 1.7 L minifors reactor platforms. No significant 
differences were observed in the cell specific productivity (μg/106 cells/day) or concentration 
of IgG1 at the end of the stationary phase in both the cultivation environments. In Chapter 5 it 
was concluded that the encapsulation of cells did not influence the specific productivity of the 
cells when compared to that displayed by suspension cells cultivated under the same 
conditions in the 1.7 L minifors reactor culture. Increases in the volumetric productivity in 
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this case were noted for the encapsulated cells due to an increase in the number of cells 
producing the recombinant protein. However a comparison of the productivity results for the 
encapsulated and suspension cells cultured in the 1 L Erlenmeyer shake flask platform do 
somewhat contradict this conclusion. The concentration of IgG present at the end of the 
stationary phase for the encapsulated cells is similar to that obtained when the cells were 
cultured in suspension in the same 1 L Erlenmeyer shake flask model. There were however a 
2.5- fold increase in the number of cells producing the protein in the encapsulated cultures. 
The specific productivity of the suspension cells in the 1 L Erlenmeyer shake flask platform 
is ~ 2- fold higher than that observed for encapsulated cells cultured in the same platform, 
Table 6.2.2.4.1 
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Figure 6.2.2.4.1: Concentration of rIgG1 measured in cell free media samples harvested from 
encapsulated and suspension cultures conducted in 1 L Erlenmeyer shake flask and 1.7 L 
minifors reactor cultures. rIgG1 present in the media was purified using commercially 
available protein A/G Nab spin columns and quantified using the nanodrop A280 nm in 
duplicate which the average value recorded. Values are the average (+/- STD) of triplicate 
cultures performed in parallel for each of the conditions tested. 
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Table 6.2.2.4.1: Calculated rIgG1 production rates and cell specific production rates for cells 
cultured in suspension and encapsulated in 300 μm radius liquid capsules in both 1 L 
Erlenmeyer shake flask and 1.7 L minifors reactor platforms. The specific production rate 
was calculated over the exponential growth phase for all cultures. Values are the average (+/- 
STD) of triplicate cultures performed in parallel for each of the conditions tested. 
2.39 +/- 1.02
2.75 +/- 0.67
q IgG1 (μg/10
6
 cells/dayCulture
Suspension cells (shake flask)
Suspension cells (reactor)
16.787
10.522
5.16 +/- 0.29
3.74 +/- 0.23
IgG1 production rate (μg/ml/day)
Encapsulated cells (reactor)
Encapsulated cells (shake flask)
50.78 +/- 5.38
 39.54 +/- 10.82  
 
6.2.2.5: Comparability of encapsulated cell product quality under batch conditions in 1 L 
Erlenmeyer shake flasks and 1.7 L minifors reactors. 
 To assess the comparability of the quality of IgG1 purified from encapsulated cultures 
performed in 1 L Erlenmeyer shake flask and 1.7 L minifors reactor platforms, both glycan 
and aggregation analysis were completed on the purified rIgG1 samples harvested from 
cultures at both the end of the exponential and stationary growth phases Samples harvested 
from the cultures were subjected to N-glycan release and labelled as outline in Materials and 
Methods Section 2.3.7.1. HILIC characterisation of the released and labelled N-glycans 
produced a chromatogram consisting of 8 distinctly separated peaks. Each of the peaks was 
assigned a distinctive GU value by comparison to the retentions times of the standard A-AB 
labelled external dextran. Examination of exoglycosidase treated samples allowed for the 
corresponding number and linkage of the component monosaccharide units represented by 
each GU value to be elucidated, as described in Materials and Methods section 2.3.7.3. 
Aggregation analysis of the purified samples was carried out using SEC. 
The overall aim of conducting glycan analysis on IgG1 samples from batch encapsulated 1 L 
Erlenmeyer shake flask cultures is to identify if there are any significant differences in the 
quality of the protein between that and the protein harvested from 1.7 L minifors 
encapsulated cultures. 
However before such a comparison may be made, it is firstly necessary to investigate if any 
changes in the particular glycoform profile for the recombinant protein occurs over the 
duration of the culture period for the encapsulated 1 L Erlenmeyer shake flask culture. In 
summary, previous suspension cultures in both shake flasks and minifors reactors resulted in 
a glycoform profile which was consistent throughout the culture period (Chapter 4). For 
encapsulated cultures conducted in a 1.7 L minifors reactor platform, the relative % of the 
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glycan M5 was noted to significantly increase over the stationary growth period. For the 
batch encapsulated shake flask cultures the relative % of M5 did also increase over the course 
of the stationary growth phase, along with changes in 4 other glycans typically found on IgG1 
including; the early unprocessed glycan F6A2, the fucosylated and galactosylated glycans 
F(6)A2[6]G(4)1 and F(6)A2G2 and the galactosylated glycan A2G2S1. The changes in the 
relative % of each of these glycans are displayed in Figures 6.2.2.5.1-6.2.3.5.5. M5 was noted 
to increase by 51 % over the course of the stationary phase for the encapsulated shake flask 
cultures. There was a 12 % decrease in the relative % of unprocessed F(6)A2 and a 42 % and 
22 % increase respectively in the relative % of the fucosylated and galactosylated 
F(6)A2[6]G(4)1 and F(6)A2G2 glycans. The fully galactosylated but not fucosylated glycan 
A2G2S1 increased by 22 % from the end of the exponential growth phase until the end of the 
stationary phase. 
All of the changes noted, with the exception of M5 are positive changes as they denote an 
increase in the degree of complexity of the glycan processing throughout the culture period. 
As the complexity of the protein is increasing, the alterations in the relative % of the glycans 
is not due to the action of glycosidase enzymes which may be released from cells should the 
viability decline during the stationary growth period.  
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Figure 6.2.2.5.1: Relative % of F6A2 present on rIgG1 harvested from batch encapsulated 
cultures in 1 L Erlenmeyer shake flasks at the end of the exponential and stationary growth 
phases as detected using HILIC following PNGaseF release and 2-AB labelling. The results 
are the average of the triplicate cultures carried out in parallel +/- STD. 
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Figure 6.2.2.5.2: Relative % of M5 present on rIgG1 harvested from batch encapsulated 
cultures in 1 L Erlenmeyer shake flasks at the end of the exponential and stationary growth 
phases as detected using HILIC following PNGaseF release and 2-AB labelling. The results 
are the average of the triplicate cultures carried out in parallel +/- STD. 
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Figure 6.2.2.5.3: Relative % of F(6)A2[6]G(4)1 present on rIgG1 harvested from batch 
encapsulated cultures in 1 L Erlenmeyer shake flasks at the end of the exponential and 
stationary growth phases as detected using HILIC following PNGaseF release and 2-AB 
labelling. The results are the average of the triplicate cultures carried out in parallel +/- STD. 
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Figure 6.2.2.5.4: Relative % of F(6)A2G2 present on rIgG1 harvested from batch 
encapsulated cultures in 1 L Erlenmeyer shake flasks at the end of the exponential and 
stationary growth phases as detected using HILIC following PNGaseF release and 2-AB 
labelling. The results are the average of the triplicate cultures carried out in parallel +/- STD. 
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Figure 6.2.2.5.5: Relative % of A2G2 present on rIgG1 harvested from batch encapsulated 
cultures in 1 L Erlenmeyer shake flasks at the end of the exponential and stationary growth 
phases as detected using HILIC following PNGaseF release and 2-AB labelling. The results 
are the average of the triplicate cultures carried out in parallel +/- STD. 
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The main aim of this particular study is to note if there are any differences in the quality of 
the protein harvested from encapsulated cultures in 1L Erlenmeyer shake flask and 1.7 L 
minifors reactor culture platforms. Irrelevant of the mode of cultivation, all cultures displayed 
a similar trend in the relative % of glycans present. The earliest form of N-glycosylation of 
rIgG1 is denoted by M5, F6A1/A2 and F6A2. The highest relative percentage of glycans 
present on the rIgG1 samples were the early glycoforms, predominantly F6A2. The 
galactosylated glycoforms are denoted by F(6)A2[6]G(4)1 and F(6)A2[3]G(4)1, which 
contain 1 galactose unit on either of the outer GlcNAc arms, and F(6)A2G2, which contains a 
galactose residue on each of the outer GlcNAc arms. Of the galactosylated glycoforms 
present, the F(6)A2[6]G(4)1 were the predominant form in all cultures, independent of the 
mode of cultivation employed, Figure 6.2.2.5.6 
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Figure 6.2.2.5.6: Relative % of N-glycan forms detected on rIgG1 samples harvested from 
batch suspension and encapsulated cultures performed in both 1 L Erlenmeyer shake flask 
and 1.7 L minifors reactor models.  N-glycans were released from the rIgG1 samples by 
means of PNGaseF digestion. Samples for HILIC analysis were labeled by adding 5 μl of 
2AB labelling solution. The retention time of the glycan peaks was compared with an 
external A-AB labelled dextran standard for structural elucidation by converting the retention 
time of the peaks into GU. Each IgG1 sample was analysed in duplicate. The results are the 
average of the triplicate cultures carried out for each condition tested, +/- STD. 
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The main changes however noted in the relative % of individual glycans present on IgG1 
harvested from encapsulated 1 L Erlenmeyer shake flask and 1.7 L minifors reactor cultures 
were in M5 and F(6)A2G2S1. In both cultures the relative % of M5 was similar at the end of 
the exponential phase, the value for which increased by the end of the stationary phase. 
However the increase in M5 in the 1.7 L minifors reactor culture was much more dramatic 
than that which was noted for the 1 L Erlenmeyer shake flask culture, with an overall 39 % 
lower relative % of the glycan present in samples taken from the shake flask culture. The 
relative % of the fully fucosylated and fully sialyated glycan was 53% higher and the end of 
the exponential phase and  63% higher at the end of the stationary phase in batch 
encapsulated shake flask cultures in comparison to batch encapsulated reactor cultures, 
Figure 6.3.2.5.7. This is an interesting development as sialyation had not previously been 
noted to be different between batch encapsulated 1.7 minifors reactor cultures and batch 
suspension 1.7 L minifors reactor 1 L Erlenmeyer shake flask cultures. 
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Figure 6.2.2.5.7: Relative % of M5 and F(6)A2G2S1 present on rIgG1 harvested from batch 
encapsulated cultures in 1 L Erlenmeyer shake flask and 1.7 L minifors reactor cultures at the 
end of the stationary growth phase as detected using HILIC following PNGaseF release and 
2-AB labelling. Each IgG1 sample was analysed in duplicate. The results are the average of 
the triplicate cultures carried out for the two culture conditions tested +/- STD. 
Although this section is aimed at outlining differences in protein quality between samples 
harvested from in batch encapsulated 1.7 L minifors reactor and 1 L Erlenmeyer shake flask 
cultures, attention may also be paid to the fact that the cultivation of encapsulated cells in the 
1 L Erlenmeyer shake flask resulted in a 2-fold increase in F(6)A2G2S1 in comparison to that 
which was observed for suspension cultures under the same conditions.  
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Figure 6.2.2.5.8: Relative % of F(6)A2G2S1 present on rIgG1 harvested from batch 
encapsulated and suspension cultures in 1 L Erlenmeyer shake flask at the end of the 
stationary growth phase as detected using HILIC following PNGaseF release and 2-AB 
labelling. Each IgG1 sample was analysed in duplicate. The results are the average of the 
triplicate cultures carried out for the two culture conditions tested +/- STD. 
Over 95 % of the protein harvested for both conditions tested was of monomeric form. 
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Figure 6.2.2.5.9: Relative % monomeric form of rIgG1 samples as detected by SEC. IgG1 
samples were harvested from encapsulated cultures performed in 1 L Erlenmeyer shake flask 
and 1.7 L minifors reactor platforms. IgG1 samples were analysed in duplicate. The results 
are presented as the average of triplicate cultures performed for the two culture conditions 
tested +/- STD. 
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6.2.3: Cultivation of encapsulated cells in shake flasks under batch (non-CO2 
incubator), perfusion (non-CO2 incubator) and perfusion (CO2 incubator) cultivation 
conditions 
 In an effort to investigate the possibility for enhanced colonisation (>5 %) in 
comparison to that which was observed when cells were cultured under batch conditions in 
both 1.7 L minifors reactor platforms and 1 L Erlenmeyer shake flask platforms, a controlled 
perfusion strategy has been applied to encapsulated cells culture in 1 L Erlenmeyer shake 
flasks. The study has been conducted in both the standard unvented flasks in a non-CO2 
incubator and in vented flasks in a 5 % CO2 incubator in order to overcome any mass transfer 
issues in the levels of dissolved gases. The basis for using the 1 L Erlenmeyer shake flask 
platform is as a direct result of the findings obtained in Section 6.3.1 in which the stability of 
the microcapsules and their suitability as a retention device in a perfusion culture became 
extremely compromised in the 1.7 L minifors reactor, noted by a 58 % decrease in the total 
number of capsules present in the reactor between days 7-9. Under batch cultivation 
conditions, the 1 L Erlenmeyer shake flask culture did extend to a cultivation time of 9 days, 
after which cell viability was limited by the batch nature of the applied cultivation mode. It is 
predicted that due to the less harsh environment that the 1 L Erlenmeyer shake flask provides, 
in comparison to the 1.7 L minifors reactor, an extended study on the influence of the 
controlled-fed perfusion strategy on capsule colonisation may be achieved. The aim was to 
further enhance the colonisation of the capsules beyond that which has been achieved in 
Section 6.3.1 (~9 %). Any alterations in cellular activities brought about by the controlled-fed 
perfusion strategy or enhanced colonisation were also investigated. 
Flasks were seeded with 100 ml of APA microcapsules containing cells at a density of 0.5 * 
10
6
 cells/mlalginate in 300 ml of ExCell CHO 325 PF media. In keeping inline with the study in 
section 6.2.1, the cultures were initiated with the application of a constant perfusion rate. 100 
ml of spent medium was removed and replaced with 100 ml of fresh medium on a daily basis 
for the entire cultivation period for flasks in the non-CO2 incubator. For flasks cultured in the 
5 % CO2 incubator, two of such medium changes were made per day in order to reduce the 
concentration of ammonia in the cultures. Based on offline analysis of cell numbers and 
metabolite concentrations (glucose and glutamine), forward rate adjustments were made in 
the concentration of the nutrients based on predicted cell numbers for next day and their 
nutrient requirement. All cultures were conducted in triplicate. 
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6.2.3.1: Capsules characterisation 
 
6.2.3.1.1: Capsules size 
 In the 1 L Erlenmeyer shake flask cultures, capsules were prepared by the extrusion of 
alginate through the 300 μm nozzle used in all experiments to date. Capsule size was 
determined on a daily basis. Thirty capsules were measured individually in order to calculate 
the average diameter and the standard deviation. Generally the size distribution was in the 
range of 3-5 %. 
Figure 6.2.3.1.1.1 below illustrates the capsules radius size over the cultivation period for the 
batch cultures, control-fed perfusion (non-CO2) and control-fed perfusion (CO2). The results 
presented below are the average of triplicate cultures. Capsule size throughout the 1 L 
Erlenmeyer shake flask cultures have a relatively low standard deviation between each other 
indicating no alterations in capsule size as a result of the culture conditions applied. 
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Figure 6.2.3.1.1.1: Average capsule radius size (μm) +/- STD over the duration of the 
cultivation period for triplicate encapsulated cultures performed under batch, perfusion 
capped (non-CO2 incubator) and perfusion (CO2 incubator). The size of approximately 30 
capsules was measured at each time point and an average determined. 
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6.2.3.1.2: Capsule strength 
 The mechanical strength of the microcapsules in the batch and control-fed perfusion 
cultures was routinely evaluated in terms of Force (g)/capsule which the capsule could 
withstand using the Texture analyser. 
Evaluation of Figure 6.2.3.1.2.1 below indicates a decrease in the force (g)/capsules over 
cultivation time, representative of a decrease in the mechanical resistance of the APA 
microcapsules throughout the culture period. The main decreases in mechanical resistance in 
all culture conditions were noted to occur from days 0 to 3, as has been previously noted in 
the other encapsulation experiments. Similarly to the batch microcapsules, the control-fed 
perfusion microcapsules did not reach the low level of mechanical resistance, around 0.07 
g/capsules, until after day 3 (day 6 for CO2 and day 7 for non-CO2). After this time point, the 
mechanical resistance levels off. Nevertheless, the capsule in this study were still of a similar 
mechanical resistance to the minifors reactor batch and control-fed perfusion controls when 
high levels of capsule break-up were reported in Section 6.2.1.1.2. Due to the optimal shear 
environment associated with a shake flask culture, the fact that the capsules were weakened 
did not result in the same losses in capsule integrity that were noted in reactor control-fed 
perfusion cultures. Even with the introduction of perfusion on day 5, which brings about a 
medium equilibrium challenge to the already weakened capsules, no major capsule breakage 
was noted to occur. The method used to determine the force (g)/capsule analysed a layer of 
capsules at a time.  
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Figure 6.2.3.1.2.1: Mechanical resistance (force (g)/capsule) over cultivation period for 300 
μm APA microcapsules containing CHO DP-12 cells cultivated under batch and control-fed 
perfusion conditions in 1 L Erlenmeyer shake flasks. A total of 3 layers of microcapsules 
were analysed on a daily basis for each of the cultures carried out. Values presented are 
average of triplicate analysis, +/- STD, for one of the encapsulated cultures carried out in 
each of the studies. 
 
6.2.3.1.3: Capsule permeability 
The permeability of the microcapsules to dextrans ranging in molecular weights from 
10-500 kDa was determined for the 300 μm radius APA microcapsules. 300 μl of capsule 
suspension was incubated in 600 μl of a 0.05 % fluorescent dextran solution of a particular 
molecular weight. The capsules were incubated under agitation for 2 hours and analysed 
using confocal microscopy. Comparison of the initial concentration of dextran ( 0C ) in the 
capsule/dextran suspension and the final concentration of dextran ( fC ) enabled 
determination of the permeability of microcapsules to varying molecular weights. The 
concentrations were determined by spectroscopy at 450 nm. As noted in Materials and 
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Methods section 2.3.7: fCC /0  values equal to 1 indicate a lack of diffusion of the dextran 
into the microcapsule. fCC /0  values of 1.5 are indicative of free diffusion. Values in the 
range of 1-1.5 indicate that diffusion of the dextran did occur, however a difficulty in 
equilibrium was noted. 
Figure 6.2.3.1.3.1, 6.2.3.1.3.2, 6.2.3.1.3.3 below represent the fCC /0   data obtained during 
the batch, perfusion non-CO2 and perfusion CO2 culture periods respectively. The data in 
each case did not determine the exact molecular weight cut-off point of the microcapsules. 
The aim of the analysis was to verify the permeability of the capsules to the rIgG1 protein 
(150 kDa) produced by the cells. In all cases the 150 kDa dextran approached a fCC /0  value 
of 1.5, indicating free diffusion of species in this size range through the capsule membrane. 
As the mechanical resistance of the capsules were decreasing over time, it would be expected 
that the permeability of the microcapsules to dextrans would increase with increasing 
molecular weight over time. This was noted under all 3 culture conditions for the 250 kDa 
dextran. The 500 kDa dextran did not reach a point of ease of diffusion (i.e. a 
fCC /0 approaching 1.5) at any stage in any of the culture conditions. 
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Figure 6.2.3.1.3.1: Permeability of 300 μm APA microcapsules to dextrans of varying 
molecular weight during a batch culture in 1 L Erlenmeyer shake flasks in a non-CO2 
incubator. Permeability is determined by the ratio of the initial concentration of dextran in a 
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microcapsule suspension to the concentration observed after a 2 hour incubation period with 
agitation. A ratio of 1.5 indicates free diffusion. A ratio of 1 is indicative of no permeability 
to the dextran by the capsules. The concentrations of dextran were determined 
spectroscopically at 450 nm. 
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Figure 6.2.3.1.3.2: Permeability of 300 μm APA microcapsules to dextrans of varying 
molecular weight during a control-fed perfusion culture in 1 L Erlenmeyer shake flasks in a 
non-CO2 incubator. Permeability is determined by the ratio of the initial concentration of 
dextran in a microcapsule suspension to the concentration observed after a 2 hour incubation 
period with agitation. A ratio of 1.5 indicates free diffusion. A ratio of 1 is indicative of no 
permeability to the dextran by the capsules. The concentrations of dextran were determined 
spectroscopically at 450 nm 
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Figure 6.2.3.1.3.3: Permeability of 300 μm APA microcapsules to dextrans of varying 
molecular weight during a control-fed perfusion culture in 1 L Erlenmeyer shake flasks in a 5 
% CO2 incubator. Permeability is determined by the ratio of the initial concentration of 
dextran in a microcapsule suspension to the concentration observed after a 2 hour incubation 
period with agitation. A ratio of 1.5 indicates free diffusion. A ratio of 1 is indicative of no 
permeability to the dextran by the capsules. The concentrations of dextran were determined 
spectroscopically at 450 nm 
 
 
 
 
 
259 
 
6.2.3.2: Growth of encapsulated cells in 1L Erlenmeyer shake flasks under conditions of 
batch (non-CO2 incubator), perfusion (non-CO2 incubator) and perfusion (CO2 incubator) 
mode of cultivation. 
 A controlled-fed perfusion strategy was applied to a CHO DP-12 cell line 
encapsulated in APA microcapsules and cultured in 1 L Erlenmeyer shake flasks in both 
unvented (non-CO2 incubator) and vented (5 % CO2 incubator) shake flasks. Cells were 
seeded at average seeding densities 0.36 * 10
6
 cells/mlreactor and incubated at 37 °C and 100 
rpm agitation. Figures 6.2.3.2.1 below allows direct visualisation and comparison of the 
growth of cells inside the capsules for the controlled-fed perfusion cultures in comparison to 
the batch culture previously carried out in 1 L Erlenmeyer shake flasks in Section 6.2.2. The 
maximum viable cell density cessed to increase beyond day 6 in batch cultures resulting in a 
total of 5 % capsule colonisation. Cell numbers continued to increase until day 8 in the 
controlled-fed perfusion culture carried out under non-CO2 conditions. Capsule colonisation 
in the non-CO2 incubated flasks was determined to be ~11 %. Further colonisation of the 
microcapsules occurred in cultures incubated in the 5 % CO2 incubator, with the degree of 
colonisation being 27 % when maximum cell density was reached on day 9. These results are 
verified by the data presented in Figure 6.2.3.2.2 which illustrates the concentration of cells 
in each culture (cells/mlcapsules) over the cultivation period. The max viable cell density 
(cells/mlcapsules) obtained in the perfusion CO2 culture was  ~5- fold higher than that achieved 
in the batch culture and 2.5- fold higher than that achieved in the controlled-fed perfusion 
(non-CO2) culture. 
Figure 6.2.3.2.3 below illustrates the LN plot of the viable cell density (cells/mlreactor) over the 
cultivation period, for the batch and controlled-fed perfusion cultures (non-CO2 and CO2). 
Both controlled-fed perfusion cultures acted as batch cultures until day 5 essentially. The 
growth rates of the 3 cultures from days 1-5, presented in Table 6.2.3.2.1 are not significantly 
different from each other, as expected. Although there was no significant difference in the 
growth rate of the cells in the cultures from days 1-5, it is important to note that there was a 
lower viable cell number (cells/mlreactor), Figure 6.2.3.2.4, present in the controlled-fed 
perfusion culture carried out in the 5 % CO2 incubator. This is the culture in which had the 
lowest mean cell specific growth rate from days 1-5. The significance of this lower viable cell 
number may be important in discussing possible differences in volumetric productivities 
during days 1-5 in the cultures. As noted in Figure 6.2.3.2.3, the batch culture cessed 
exponential growth on day 5 with one more increase in viable cell number occurring on day 6 
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before the cells entered a stationary phase until day 8. For the controlled-fed perfusion (non-
CO2) culture, cell number continued to increase from days 5-8. However, the calculated 
growth rate (0.346 day
-1
) during this time was significantly lower (~ 50 %) than that observed 
during the exponential growth period (0.688 day
-1
). This culture entered a stationary phase 
until day 11 (as determined by LN plots) before a subsequent fall off in cell viability was 
observed, Figure 6.2.3.2.5.  As noted in Table 6.3.3.2.1, the continued cell growth beyond 
day 5 resulted in an increased viable cell density (cells/mlreactor) ~ 2 fold higher than that 
obtained in the batch culture. The controlled-fed perfusion culture conducted in the CO2 
incubator, maintained the maximum exponential growth rate from days 5-9 when perfusion 
was initiated on days 5. After day 9, no further increases in maximum cell number were 
achieved and the cells entered a stationary phase until a fall off in cell viability was noted on 
day 13, Figure 6.2.3.2.5. As expected, the data presented in Table 6.2.3.2.1 illustrates an ~ 5 
and ~2.5 fold increases in maximum cell number achieved in comparison to the batch and 
controlled-fed perfusion (non-CO2) cultures, respectively. 
Comparison of Figure 6.2.3.2.2 and Figure 6.2.3.2.4 gives an indication of the suitability of 
the microcapsules in these conditions as retention devices for perfusion systems. Increases in 
cells per mlcapsule detailed in Figure 6.2.3.2.2 have directly been translated into increases in 
cells per mlvessel in Figure 6.2.3.2.4 
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Figure 6.2.3.2.1: Microscopic analysis (unstained) of microcapsule colonisation by cells 
cultured under batch and controlled-fed perfusion modes of cultivation in both non-CO2 and 
CO2 incubators. Cells were originally seeded at 0.5 * 10
6
 cells/ml alginate and which was 
extruded through a 300 μm nozzle as part of the liquid core microcapsule formation. The 
resulting microcapsules were used to seed 1 L Erlenmeyer shake flask cultures with a ratio of 
100 ml capsules and 300 ml media. 
 
 
262 
 
0.00E+00
2.00E+07
4.00E+07
6.00E+07
8.00E+07
1.00E+08
1.20E+08
1.40E+08
1.60E+08
1.80E+08
2.00E+08
0 5 10 15
Time, days
V
ia
b
le
 c
el
l 
d
en
si
ty
 (
ce
ll
s/
m
l c
a
p
su
le
s
)
Batch Perfusion (non CO2) Perfusion (CO2)
 
Figure 6.2.3.2.2: Growth of CHO cells cultures in 300 μm liquid core APA microcapsules 
under batch and controlled-fed perfusion (non-CO2 and CO2 incubators) cultivation 
conditions in 1 L Erlenmeyer shake flask. Cell numbers were enumerated on a daily basis 
using trypan blue exclusion method and a Neubauer haemocytometer. Encapsulated cells 
were liberated prior to counting via extrusion of a capsule/PBS suspension through a 300 μm 
needle 3 times. Duplicate cell counts were performed. The cell concentration is given with 
respect to the capsule’s volume. Values are the average (+/- STD) of triplicate cultures 
performed in parallel for each condition tested. 
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Figure 6.2.3.2.3: LN plot of viable cell densities (cells/mlvessesl) over the cultivation period 
for cells encapsulated in 300 μm APA microcapsules and cultured under batch and 
controlled-fed perfusion (non-CO2 and CO2 incubator) modes of cultivation in 1 L 
Erlenmeyer shake flasks. Cell numbers were enumerated on a daily basis using trypan blue 
exclusion method and a Neubauer haemocytometer. Encapsulated cells were liberated prior to 
counting via extrusion of a capsule/PBS suspension through a 300 μm needle 3 times. 
Duplicate cell counts were performed and the average recorded. 
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Figure 6.2.3.2.4: Growth of CHO cells cultures in 300 μm liquid core APA microcapsules 
under batch and controlled-fed perfusion (non-CO2 and CO2 incubators) cultivation 
conditions in 1 L Erlenmeyer shake flask. The cell concentration is given with respect to the 
working volume in the shake flask. Cell numbers were enumerated on a daily basis using 
trypan blue exclusion method and a Neubauer haemocytometer. Encapsulated cells were 
liberated prior to counting via extrusion of a capsule/PBS suspension through a 300 μm 
needle 3 times. Duplicate cell counts were performed and the average recorded. Values are 
the average (+/- STD) of triplicate cultures performed in parallel for each condition tested. 
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Figure 6.2.3.2.5: % Viability of CHO cells encapsulated in 300 μm liquid capsules and 
cultured in 1 L Erlenmeyer shake flask under batch and controlled-fed perfusion (non-CO2 
and CO2 incubator) modes of cultivation. % viability was determined by the enumeration of 
total and live cell numbers present in the culture using trypan blue exclusion method and 
Neubauer haemocytometer. % viability is expressed as a percentage of live cells over dead 
cells present. Cell counts were performed in duplicate and average % viability determined on 
a daily basis. Values are average (+/- STD) of triplicate cultures performed in parallel for the 
culture conditions tested. 
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Table 6.2.3.2.1: Calculated maximum specific growth rates displayed by cells encapsulated 
in 300 μm liquid capsules and cultures in 1L Erlenmeyer shake flasks under batch and 
controlled-fed perfusion (non-CO2 and CO2 incubator) cultivation conditions. The growth 
rate was calculated from a plot of the logarithm of the viable cell density over the cultivation 
time (days). The maximum viable cell density is presented with respect to per mlvessel. Values 
are average (+/- STD) of those determined for triplicate cultures performed in parallel for the 
culture conditions tested. 
9.21 +/- 1.15
18.5 +/- 1.33
44.9 +/- 2.54
days 1-5
μmax (day
-1
) Max VCD
(10
6
 cells/mlvessel)day 5-stationary phase
NA
0.346 +/- 0.44
0.622 +/- 0.053
μmax (day
-1
)
0.789 +/- 0.060
0.688 +/- 0.086
0.557 +/- 0.071
Culture
Batch
Perfusion (non-CO2)
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6.2.3.3: Metabolic analysis of encapsulated cells cultured in 1L Erlenmeyer shake flasks 
under conditions of batch (non-CO2 incubator), controlled-fed perfusion (non-CO2 
incubator and CO2 incubator) modes of cultivation. 
 All shake flask cultures were seeded in 300 ml of ExCell CHO 325 PF media 
supplemented with 4 mM L-glutamine. The concentration of glucose in the commercially 
available media is expected to be 17.4 mM.  The concentration of the major carbon sources, 
glutamine and glucose, and the by-product, ammonia were measured from media samples 
taken from all cultures on a daily basis using commercially available enzymatic assay kits. 
The controlled-fed perfusion cultures essentially acted as batch cultures until day 5, the point 
at which it was estimated that the concentration of glucose and glutamine were insufficient to 
meet the needs of the predicted cell numbers present on the following day. Such predictions 
were made based on the cellular growth and cell specific consumption rates. Perfusion was 
initiated on day 5 by the removal of 100 ml of spent media from the culture flasks and 
replacement with 100 ml of fresh media of a daily basis. The concentration of the metabolites 
glucose and glutamine in the fresh media were adjusted on a daily basis to meet the 
requirements of the actively growing cells. The perfusion rate remained constant for the 
duration of the controlled-fed perfusion culture in the non-CO2 incubator. The rate was 
adjusted to 2 media changes per day for the controlled-fed perfusion culture in the 5 % CO2 
incubator after day 9. This was due to the fact that the concentration of ammonia in the 
culture was reaching levels which are normally higher than that noted in batch cultures < 5 
mM. Also, studies conducted in Chapter 3 of the thesis did indicate alterations in the 
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glycosylation profile in regards to the level of sialyation when initial ammonia concentrations 
in the culture were in the range of 5-15 mM. 
Due to the fact that the control-fed perfusion cultures acted as batch cultures until day 5, there 
should be no significant differences in the metabolic profiles displayed by cells cultured in 
the batch and controlled-fed perfusion (non-CO2 incubator) cultures during this time point. 
Any alterations noted in metabolic activity for cells cultured in the controlled-fed perfusion 
cultures in the 5 % CO2 incubator during this time point would be due to the influence of the 
5 % CO2 atmosphere. Table 6.2.3.3.1 and Table 6.2.3.3.3 indicate the volumetric and cell 
specific consumption and production rates displayed by the cells for glucose, glutamine, 
lactate and ammonia. Lactate concentrations throughout the culture period were determined 
using HPLC after culture termination from offline samples stored at -80 °C. There was no 
significant difference in the volumetric or cell specific consumption or production rates of the 
metabolites glucose, glutamine and lactate during days 1-5 of the culture periods for all 
culture conditions tested. There was a significantly lower volumetric ammonia production 
rate during this time period in the controlled-fed perfusion culture conducted in the 5 % CO2 
incubator. This is however as a direct result of the lower cell number present in this culture 
on day 5, which was noted above in Section 6.3.3.2. The cell specific ammonia production 
rate was not affected by the cultivation of the cells in the 5 % CO2 incubator. This data is 
verified by the plots of glucose, lactate, glutamine and ammonia in which the trends for 
consumption and production from days 1-5 are noted to be similar, (Figure 6.2.3.3.1-
6.2.3.3.4) 
In the batch culture all of the glucose and glutamine were depleted by days 9 and 6 
respectively. Lactate and ammonia production resulted in the accumulation of a maximum 
concentration of ~17.6 and ~3.7 mM respectively. The yield of lactate on glucose and 
ammonia on glutamine are therefore as expected, 1.01 +/- 0.05 and 1.22 +/- 0.11 respectively, 
Table 6.2.3.3.4.  In the control-fed perfusion non-CO2 culture, the glucose concentration in 
the culture was increased from ~ 6 mM to ~ 20 mM on day 5, due to the prediction that the 
cells would continue to grow at the same exponential growth rate from days 1-5. However 
due to a fall off in the growth rate over the period of increasing cell number (days 5-8), an 
over estimation was made in the concentration of glucose required by the cells over this time 
period. There was also a 32 % decrease in the specific glucose consumption rate displayed by 
the cells over this time period in comparison to that observed during the exponential growth 
period (days 1-5), Table 6.2.3.3.3. For this reason, no additional glucose, bar the 
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concentration contained in the commercial media, was added to the cultures over the 
extended growth period. For the metabolite glutamine, there was no significant difference in 
the specific consumption rate displayed by the cells over the extended growth period during 
days 5-8 in comparison to that observed during days 1-5, Tables 6.2.3.3.2 & 6.2.3.3.3. The 
concentration of glutamine during the time period of days 5-8 varied in the range of ~1-3 mM 
during this time period. It may therefore be stated that the controlled-fed perfusion culture did 
perform well in that the concentration of metabolites were maintained in excess quantities to 
meet the requirements of the predicted cell numbers for the following days. Neither glucose 
nor glutamine were limiting at the end of the stationary growth period.  
The specific lactate production rate was similar to the specific glucose consumption rate over 
the exponential growth period (days 1-5) in the control-fed perfusion non-CO2 culture. 
Although the specific glucose consumption rate declined over the extended growth period in 
comparison to the exponential growth period, the specific lactate production rate remained 
unchanged, suggesting a movement to less efficient glucose metabolism in this culture. The 
maximum lactate concentration reached in this culture was ~ 22 mM. The overall yield of 
lactate on glucose over the entire culture period was 1.25 +/- 0.07 mmoles/mmoles, which is 
24 % higher than that observed in the batch cultures, due to the shift to less efficient glucose 
metabolism, Table 6.2.3.3.4. There was a 40 % reduction in the specific ammonia production 
rate over the extended growth period (days 5-8) in comparison to that which was observed in 
the exponential growth period, Table 6.2.3.3.3 This decreased ammonia production rate 
indicated more favourable glutamine metabolism over the extended growth period. The 
maximum ammonia concentration at any point in this culture was ~2.5 mM. The yield of 
ammonia on glutamine over the entire culture period was 0.88 +/- 0.15 mmoles/mmoles, 
which is 28 % lower than that observed in the batch culture, which can be attributed to the 
more efficient glutamine metabolism observed over the extended growth period, Table 
6.2.3.3.4 
For the case of the control-fed perfusion culture conducted in the 5 % CO2 incubator, the 
application of the control-fed perfusion strategy to the culture from day 5 onwards, resulted 
in an increased exponential growth until day 9, as noted in Section 6.2.3.2 above. The 
concentration of glucose added to this culture in the perfusion media on day 5 was 
determined based on the cell specific glucose consumption rate over the exponential period. 
The cell number present on the following day was as predicted due to persistence of the 
exponential growth rate beyond day 5. However there was a decrease in the cell specific 
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consumption rate for glucose during this time period, by approximately 50 %, which resulted 
in an over estimation of the concentration of glucose in the perfusion media, Table 6.2.3.3.1 
& 6.2.3.3.3. As noted from the plot of glucose over the culture period, Figure 6.2.3.3.1, 
approximately only 50 % of the glucose added was consumed between days 5 and 6. This 
corresponds with the 50 % decrease in the cell specific glucose consumption rate over the 
extended growth period (days 5-9). The control-fed perfusion strategy did work well for this 
culture as the forward day predictions for cell number and glucose concentration resulted in a 
maintained glucose concentration range of between 7-12 mM. For the metabolite glutamine, 
the cell specific consumption rate also decreased, in this case by 60 %, over the extended 
growth period (days 5-9) in comparison to that calculated for the exponential phase (days 1-
5), Table 6.2.3.3.2 & 6.2.3.3.3. No changes were observed in the specific glutamine 
consumption rate for the same culture conditions, however under a non-CO2 environment. 
The control-fed perfusion strategy did also work well for this control in regards to 
maintaining a glutamine concentration in the range of 1-7 mM throughout the culture period. 
In may be noted that for the control-fed perfusion culture performed in the 5 % CO2 
incubator, a greater decrease in the glucose consumption rate was observed over the extended 
growth period, in comparison to that observed over the same period for the control-fed 
perfusion non-CO2 incubated culture.  
A 60 % reduction in the specific lactate production rate was observed over the extended 
growth period (days 5-9) in comparison to that observed in the exponential growth period for 
the control-fed perfusion culture incubated in the 5 % CO2 incubator, Table 6.2.3.3.1 & 
6.2.3.3.3 There was a similar decrease in both the glucose and the lactate cell specific 
consumption and production rates (+/- 5 %), the cells cultured in these conditions. The cells 
did therefore not experience the same shift to inefficient glucose metabolism over the 
extended growth period as was observed for the control-fed perfusion cultures conducted in 
the non-CO2 incubator. The maximum lactate concentration obtained in this culture was 
~19.15 mM. The yield of lactate on glucose over the entire culture period (0.93 +/- 0.06 
mmoles/mmoles) was 26 % lower than that observed in the non-CO2 incubated control-fed 
perfusion culture. A 3.6- fold decrease in the specific ammonia production rate was observed 
over the extended growth period in comparison to that observed during the exponential 
growth period for cells cultures in the control-fed perfusion cultures in the 5 % CO2 
incubator, Table 6.2.3.3.2 & 6.2.3.3.3. This reduction was significantly higher than the 
reduction observed in glutamine between the exponential growth period and the extended 
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growth period, indicating an increased glutamine metabolic efficiency. The shift to efficient 
glutamine metabolism was even more profound in this culture, in comparison to the same 
culture conducted in the non-CO2 incubator due to the lower yield observed (-30 %) in the 
control-fed perfusion culture in the 5 % CO2 incubator in comparison to that observed for the 
culture in the non-CO2 incubator. Although a lower yield of ammonia and a lower specific 
production rate of ammonia was observed in the 5 % CO2 culture, in comparison to the non-
CO2 culture, due to the increased number of cells present, the concentration of ammonia 
present in the culture on day 9 did approach ~5 mM, actual value (4.4 mM), the perfusion 
rate was subsequently increased to two medium changes per day which maintained maximum 
ammonia concentration observed in this culture at ~ 5 mM. 
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Figure 6.2.3.3.1: Concentration of glucose present in encapsulated batch and controlled-fed 
perfusion cultures (non-CO2 and CO2), performed in 1 L Erlenmeyer shake flasks, over the 
duration of the respective cultivation period. The concentrations were determined offline 
using a commercial available enzymatic assay kit. Values are average (+/- STD) of triplicate 
cultures performed in parallel for the culture conditions tested. 
 
 
271 
 
0
5
10
15
20
25
0 5 10 15
Time, days
L
a
ct
a
te
 c
o
n
ce
n
tr
a
ti
o
n
 (
m
M
)
Batch Perfusion (non-CO2) Perfusion (CO2)
 
Figure 6.2.3.3.2: Concentration of lactate present in batch and controlled-fed perfusion (non-
CO2 and CO2) cultures, performed in 1 L Erlenmeyer shake flasks, over the duration of the 
respective cultivation period. The concentrations were determined offline HPLC analysis 
using Supelco H column. Values are average (+/- STD) of triplicate cultures performed in 
parallel for the culture conditions tested. 
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Figure 6.2.3.3.3: Concentration of glutamine present in batch and controlled-fed perfusion 
cultures (non-CO2 and CO2), performed in 1 L Erlenmeyer shake flasks, over the duration of 
the respective cultivation period. The concentrations were determined offline using a 
commercial available enzymatic assay kit. Values are average (+/- STD) of triplicate cultures 
performed in parallel for the culture conditions tested. 
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Figure 6.2.3.3.3: Concentration of ammonia present in batch and controlled-fed perfusion 
cultures (non-CO2 and CO2), performed in 1 L Erlenmeyer shake flasks, over the duration of 
the respective cultivation period. The concentrations were determined offline using a 
commercial available enzymatic assay kit. Values are average (+/- STD) of triplicate cultures 
performed in parallel for the culture conditions tested. 
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Table 6.2.3.3.1: All glucose and lactate volumetric (mmoles/day) and specific (mmoles/10
6
 
cells/day) consumption and production kinetics calculated over the exponential phase (days 
1-5), before control-fed perfusion strategy was applied to the non-CO2 and CO2 cultures. 
Values are average (+/- STD) of those calculated for triplicate cultures performed in parallel 
for the culture conditions tested. 
  
Glucose 
consumption 
Lactate 
production qglucose  qlactate 
  rate (mM/day) 
rate 
(mM/day) 
(mmoles/10
6
 
cells/day) 
(mmoles/10
6
 
cells/day) 
Culture day 1-5 day 1-5 day 1-5 day 1-5 
Batch 1.89 +/- 0.06 1.99 +/- 0.18 
2.69 * 10
-4
  
+/- 7.87 * 10
-5
 
3.42 * 10
-4
  
+/- 8.24 * 10
-5
 
Perfusion (non-
CO2) 1.83 +/- 0.04 1.87 +/- 0.04 
2.14 * 10
-4
  
+/- 1.83 * 10
-5
 
2.05 * 10
-4
  
+/- 3.37 * 10
-5
 
Perfusion 
(CO2) 1.89 +/- 0.07 1.9 +/- 0.04 
2.1 * 10
-4
  
+/- 1.57 * 10
-5
 
2.16 * 10
-4
  
+/- 3.79 * 10
-6
 
 
 
Table 6.2.3.3.2: All glutamine and ammonia volumetric (mmoles/day) and specific 
(mmoles/10
6
 cells/day) consumption and production kinetics calculated over the exponential 
phase (days 1-5), before control-fed perfusion strategy was applied to the non-CO2 and CO2 
cultures. Values are average (+/- STD) of those calculated for triplicate cultures performed in 
parallel for the culture conditions tested. 
    
Glutamine 
consumption 
Ammonia 
production qglutamine qammonia 
    rate (mM/day) rate (mM/day) 
(mmoles/10
6
 
cells/day) 
(mmoles/10
6
 
cells/day) 
Culture day 1-5 day 1-5 day 1-5 day 1-5 
Batch 0.53 +/- 0.05 0.46 +/- 0.01 
7.81 * 10
-5
  
+/- 2.95 * 10
-5
 
5.98 * 10
-5
  
+/- 1.98 * 10
-5
 
Perfusion 
(Non-CO2) 0.44 +/- 0.02 0.44 +/- 0.02 
5.72 * 10
-5
  
+/- 6.02 * 10
-6
 
4.28 * 10
-5
  
+/- 6.08 * 10
-6
 
Perfusion 
(CO2) 0.54 +/- 0.01 0.28 +/- 0.02 
1.02 * 10
-4
  
+/- 3.09 * 10
-5
 
6.59 * 10
-5
  
+/- 1.06 * 10
-5
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Table 6.2.3.3.3: All specific glucose, lactate, glutamine and ammonia specific consumption 
and production rates (mmoles/10
6
 cells/ml) over the extended growth period for control-fed 
perfusion non-CO2 (days 5-8) and control-fed perfusion CO2 (days 5-9). Values are average 
(+/- STD) of those calculated for triplicate cultures performed in parallel for the culture 
conditions tested. 
  qglucose qlactate qglutamine qammonia 
Culture 
(mmoles/10
6
 
cells/day) 
(mmoles/10
6
 
cells/day) 
(mmoles/10
6
 
cells/day) 
(mmoles/10
6
 
cells/day) 
Perfusion 
(non-CO2) 
1.45 * 10
-4
 +/- 
2.27 * 10
-5
 
2.01 * 10
-4
 +/- 
4.77 * 10
-5
 
3.93 * 10
-5
 +/- 
1.18 * 10
-5
 
2.57 * 10
-5
 +/- 
4.16 * 10
-6
 
Perfusion 
(CO2) 
1.00 * 10
-4
 +/- 
9.19 * 10
-6
 
8.46 * 10
-5
 +/- 
1.59 * 10
-5
 
4.08 * 10
-5
 +/- 
3.95 * 10
-6
 
1.85 * 10
-5
 +/- 
2.18 * 10
-6
 
 
Table 6.2.3.3.4: All yields of by-product/metabolite for batch and control-fed perfusion (non-
CO2 and CO2)  cultures performed in 1 L Erlenmeyer shake flasks over the cultivation period. 
Values are average (+/- STD) of those calculated for triplicate cultures performed in parallel 
for the culture conditions tested. 
    Ylactate/glucose Yammonia/glutamine 
Culture (mmol/mmol) (mmol/mmol) 
Batch 1.01 +/- 0.05 1.22 +/- 0.11 
Perfusion (non-CO2) 1.25 +/- 0.07 0.88 +/- 0.15 
Perfusion (CO2) 0.93 +/- 0.06 0.61 +/- 0.06 
 
 
6.2.3.4: Productivity analysis of encapsulated cells cultured in 1L Erlenmeyer shake flasks 
under conditions of batch (non-CO2 incubator), controlled-fed perfusion (non-CO2 
incubator and CO2 incubator) modes of cultivation. 
 To evaluate the effect of the controlled-fed perfusion mode of cultivation on rIgG1 
production, media samples were removed from both the batch and controlled-fed perfusion 
cultures on alternating days (5, 7, 9, 11, 13, 14). As explained in Section 2.3.6., of the 
Materials and Methods Section, rIgG1 was purified from media samples removed from the 
cultures after centrifugation at 200 g for 5 minutes to remove any extracapsular cells. 
Capsules were separated from the media before centrifugation. rIgG1 present in the media 
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was purified using Protein A Nab spin columns and quantified using the nanodrop at A 280 
nm. 
Figure 6.2.3.4.1 below allows comparison between the concentrations of rIgG1 present in the 
cultures over the course of the cultivation period. The operation of the controlled-fed 
perfusion mode of cultivation maintained the concentration of rIgG1 below the maximum 
concentration typically present in the batch culture. The determination of the concentration of 
recombinant protein in cultures throughout the culture period is important in instances where 
proteins may be sensitive to concentration dependent aggregation. As the rIgG1 protein 
produced by the CHO DP-12 cell line has not been noted to aggregate in the concentrations 
achieved to date, it is not expected that concentration induced aggregation of the protein 
would have occurred in the controlled-fed perfusion cultures, as will be verified in Section 
6.2.3.5. 
Figure 6.2.3.4.2 and the data presented in Table 6.2.3.4.1 allow for comparisons to be made 
between the cumulative total amount of IgG1 produced by cells grown in the 3 different 
culture modes and also the specific and volumetric productivities observed. There was no 
significant difference in the specific production rate displayed by the cells during the 
exponential growth phase when cultured under batch and control-fed perfusion modes of 
cultivation. The lowest mean value over this time period was in the controlled-fed perfusion 
culture conducted in the 5 % CO2 incubator, however it was not significantly lower than that 
observed in the batch cultures. As expected, there was therefore no significant difference in 
the amount of IgG1 present in each culture on day 5. The application of the controlled-fed 
perfusion strategy to the non-CO2 and CO2 cultures on day 5 did result in further growth of 
cells until days 8 and 9 respectively. During this time period the specific productivity of the 
cells remained the same (non-CO2 incubator culture) or decreased (CO2 incubator culture) in 
comparison to that observed from days 1-5. It could be assumed that due to the higher 
number of cells present in both of the controlled-fed perfusion cultures, that the cumulative 
amount of IgG1 present in these cultures would be higher than the batch culture to the same 
degree as the increased cell numbers. Over the stationary growth period the specific 
productivity displayed by the cells in the control-fed perfusion (non-CO2) and (CO2) reduced 
by 36 % and 29 %, respectively. The cumulative amount of IgG1 produced in these cultures 
at the end of the stationary phase in the (non-CO2) culture (day 11) and the (CO2) culture 
(day 13) was 41 % and 2.65- fold higher, respectively, than that observed at the end of the 
stationary phase in the batch cultures (day 8). This is disappointing given the fact that there 
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was a 2- fold higher cell number in the non-CO2 culture and a 5- fold higher cell number in 
the CO2 during the stationary phase in comparison to the maximum cell number achieved in 
the batch cultures. 
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Figure 6.2.3.4.1: Concentration of rIgG1 present in encapsulated batch and controlled-fed 
perfusion (non-CO2 and CO2 incubator) cultures, performed in 1 L Erlenmeyer shake flasks, 
as quantified over the course of the culture period. rIgG1 present in the media was purified 
using commercially available protein A/G Nab spin columns and quantified using the 
nanodrop A280 nm. Samples were quantified in duplicate with the average value recorded. 
Values presented above are the average of triplicate cultures carried out in parallel, +/- STD, 
for each of the conditions tested. 
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Figure 6.2.3.4.2: Total amount of IgG1 (μg) purified from cell free media samples harvested 
from batch and control-fed perfusion encapsulated cultures on alternating days. rIgG1 present 
in the media was purified using commercially available protein A/G Nab spin columns and 
quantified using the nanodrop A280 nm. Samples were quantified in duplicate with the 
average value recorded. Values presented above are the average of triplicate cultures carried 
out in parallel, +/- STD, for each of the conditions tested. 
 
Table 6.2.3.4.1: Calculated rIgG1 production rates and cell specific production rates for cells 
encapsulated in 300 μm radius liquid capsules and cultured under batch and controlled-fed 
perfusion modes of cultivation in 1 L Erlenmeyer shake flasks. The volumetric production 
rate was calculated over the entire culture period. . Values presented are the average of those 
calculated for triplicate cultures carried out in parallel, +/- STD, for each of the conditions 
tested. 
2.82 +/- 0.32
1.74
1.46
q  IgG 1
2.05 +/- 0.14
2.75
1.57
5-end growth phase
q IgG1
(μg/10
6
 cells/day)
8709
8988.5
(μg/10
6
 cells/day)
IgG1 production 
rate (μg/day)
days 1-5
2.58 +/- 0.33
2.73 +/- 0.21
Batch
Perfusion (non-CO2)
Perfusion (CO2) 15752
over stationary phase
(μg/10
6
 cells/day)
q  IgG1Culture
NA
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6.2.3.5: Product quality analysis of encapsulated cells cultured in 1L Erlenmeyer shake 
flasks under conditions of batch (non-CO2 incubator), controlled-fed perfusion (non-CO2 
incubator and CO2 incubator) modes of cultivation. 
 In order to assess if the application of a controlled-fed perfusion strategy would have 
an influence on the quality of rIgG1 harvested from encapsulated CHO DP-12 cultures, 
purified IgG1 samples harvested from batch and control-fed perfusion cultures were 
subjected to both glycan and aggregation analysis. Samples harvested from the cultures were 
subjected to N-glycan release and labelled as outline in Materials and Methods Section 
2.3.7.1. HILIC characterisation of the released and labelled N-glycans produced a 
chromatogram consisting of 8 distinctly separated peaks. Each of the peaks was assigned a 
distinctive GU value by comparison to the retentions times of the standard A-AB labelled 
external dextran. Examination of exoglycosidase treated samples allowed for the 
corresponding number and linkage of the component monosaccharide units represented by 
each GU value to be elucidated, as described in Materials and Methods section 2.3.7.3. 
Aggregation analysis of the purified samples was carried out using SEC. 
As the controlled-fed perfusion cultures essentially acted as batch cultures until day 5 of the 
culture period, it would be expected that there would be no significant difference in the 
glycoprofile obtained from IgG1 samples harvested at this point in batch and control-
perfusion (non-CO2 incubator) cultures. Any alterations in the glycoprofile present on protein 
harvested from control-fed perfusion (CO2 incubator) cultures in comparison to the other two 
culture conditions evaluated would be due to the change in environmental condition. Analysis 
of Figure 6.2.3.5.1 below would suggest that there was no significant difference in the 
glycoprofile present on recombinant IgG1 samples harvested from the 3 different cultures on 
day 5. 
The earliest form of N-glycosylation of rIgG1 is denoted by M5, F6A1/A2 and F6A2. The 
highest relative percentage of glycans present on the rIgG1 samples were the early 
glycoforms, predominantly F6A2. The galactosylated glycoforms are denoted by 
F(6)A2[6]G(4)1 and F(6)A2[3]G(4)1, which contain 1 galactose unit on either of the outer 
GlcNAc arms, and F(6)A2G2, which contains a galactose residue on each of the outer 
GlcNAc arms. Of the galactosylated glycoforms present, the F(6)A2[6]G(4)1 were the 
predominant form in all cultures, independent of the mode of cultivation employed 
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Figure 6.2.3.5.1: Relative % of N-glycan forms detected on rIgG1 samples harvested from 
encapsulated cultures on day 5. Cultures were conducted in 1 L Erlenmeyer shake flasks 
under batch and control-fed perfusion (non-CO2 and CO2) modes of cultivation.  N-glycans 
were released from the rIgG1 samples by means of PNGaseF digestion. Samples for HILIC 
analysis were labeled by adding 5 μl of 2AB labelling solution. The retention time of the 
glycan peaks was compared with an external A-AB labelled dextran standard for structural 
elucidation by converting the retention time of the peaks into GU. Each IgG1 sample was 
analysed in duplicate with the average recorded. The results are the average of the triplicate 
cultures (+/- STD) carried out for each condition tested. 
 
Due to the complexity of the cultivation modes applied, it is necessary to first identify if there 
were changes brought about in the quality of the protein due to the application of the control-
fed perfusion strategy to conditions in which encapsulated cells were cultured in a non-CO2 
environment in capped shake flasks. For this purposes Section 6.2.3.5.1 compares and 
contrasts the relative glycoform profile present on IgG1 samples harvested from batch and 
control-fed perfusion (non-CO2 incubator) cultures. Section 6.2.3.5.2 subsequently moves 
forward to identify if the control-fed perfusion strategy had influences on product quality 
when applied to encapsulated cells cultured in a 5 % CO2 environment. This section therefore 
investigates alterations in the quality of IgG1 harvested from controlled-fed perfusion non-
CO2 and CO2 cultures at various time points. 
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Before analysing alterations in the glycosylation profile between the 3 culture conditions 
tested, it is first necessary to state that no alterations in the aggregation profile were 
indentified for protein harvested from the 3 cultures states. Figure 6.2.3.5.1, below, illustrates 
the relative % of monomeric IgG1 harvested from the cultures over time. 
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Figure 6.2.3.5.2: Relative % monomeric form of rIgG1 samples as detected by SEC. IgG1 
samples were harvested from encapsulated cultures performed in 1 L Erlenmeyer shake flask 
under batch and control-fed perfusion (non-CO2 and CO2) conditions. IgG1 samples were 
analysed in duplicate. The results are presented as the average of triplicate cultures performed 
for the culture conditions tested +/- STD. 
 
6.2.3.5.1: Batch encapsulated culture -v- Controlled-fed perfusion (non-CO2 incubator) 
encapsulated culture 
 Both batch and control-fed perfusion cultures were carried out in a non-CO2 incubator 
maintained at 37 °C. An agitation rate of 100 rpm was applied. Before any alterations in the 
glycosylation profile between IgG1 harvested from both culture conditions are investigated, it 
is firstly necessary to investigate if there were alterations in the glycan profile over the 
respective cultivation periods. This was already completed for the batch encapsulated cultures 
in Section 6.2.2.5 above. To summarise, over the course of the stationary growth period there 
was a decrease in non-complex glycan F(6)A2 to the degree of 12 %. The relative % of 
complex glycans F(6)A2[6]G(4)1, F(6)A2G2 and A2G2 were noted to increase by 42 %, 22 
% and 22 % respectively. The relative % of the unprocessed glycan, M5, which is routinely 
noted to increase over a culture period, increased by 51 %. 
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Table 6.2.3.5.1.1 below gives an overview of the % increases (+) or decreases (-) noted in the 
relative % of specific glycan detected on IgG1 samples, over specified time period in the 
culture. For glycans which did increase or decrease in relative % throughout the culture 
period, the majority of these changes occurred in the extended growth period, from days 5-8. 
Over this extended growth period there was an increase in the relative % of both complex and 
non-complex glycans. It is important to note that the changes over time did not bring about an 
overall change in the specific trend of the glycans on the IgG1 protein, as noted in Figure 
6.2.3.5.1 above. 
 
Table 6.2.3.5.1.1: Overview of the % differences noted in the relative % of glycans detected 
on rIgG1 harvested from controlled-fed perfusion cultures (non-CO2 incubator) at specified 
time point in the culture period. N-glycans were released from the rIgG1 samples by means 
of PNGaseF digestion. Samples for HILIC analysis were labeled by adding 5 μl of 2AB 
labelling solution. The retention time of the glycan peaks was compared with an external A-
AB labelled dextran standard for structural elucidation by converting the retention time of the 
peaks into GU. Each IgG1 sample was analysed in duplicate with the average relative % of 
each glycan structure recorded. The results are the average of those obtained for the 3 
encapsulated cultures performed under the control-fed perfusion strategy in the non-CO2 
incubator. 
Glycan % difference 
between day 5-8 
% difference 
between day 8-11 
% difference 
between day 5-11 
F(6)A1/A2 + 68 % Not significant +77 % 
F(6)A2 -21 % Not significant -23 % 
M5 + 2.7 fold + 15 % + 3.1 fold 
F(6)A2[6]G(4)1 + 14 % Not significant + 16 % 
F(6)A2[3]G(4)1 Not significant Not significant Not significant 
F(6)A2G2 + 73 % + 11 % + 90 % 
A2G2 + 36 % Not significant + 39 % 
F6A2G2S1 Not significant Not significant Not significant 
 
We have already noted in Section 6.2.3.5., above, that the relative % of glycans present on 
IgG1 harvested from the batch and control-fed perfusion cultures on day 5 were not 
significantly different. As there were changes in the relative % of individual glycans over the 
course of the culture periods for both conditions tested, it is therefore necessary to compare 
and contrast the glycoprofiles present on the IgG1 protein harvested from both cultures 
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towards the end of the stationary growth period, (Batch day 7 and Control-fed perfusion day 
11), Figure 6.2.3.5.1.1. Recall that the only differences in the culture conditions if the 
controlled-fed perfusion strategy applied and the fact that such cultures reached a higher 
maximum cell density and degree of capsule colonisation. 
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Figure 6.2.3.5.1.1: Relative % of N-glycan forms detected on rIgG1 samples harvested from 
encapsulated cultures conducted in 1 L Erlenmeyer shake flask cultures under batch and 
control-fed perfusion modes of cultivation (non-CO2 incubator). Samples were harvested at 
the end of the stationary growth period.  N-glycans were released from the rIgG1 samples by 
means of PNGaseF digestion. Samples for HILIC analysis were labeled by adding 5 μl of 
2AB labelling solution. The retention time of the glycan peaks was compared with an 
external A-AB labelled dextran standard for structural elucidation by converting the retention 
time of the peaks into GU. Each IgG1 sample was analysed in duplicate with the average 
recorded. The results are the average of the triplicate cultures (+/- STD) carried out for each 
condition tested. 
 
There were significant differences noted in the relative % of both non-complex and complex 
glycans between rIgG1 harvested at the end of the stationary growth phase for encapsulated 
cells cultured under batch and control-fed perfusion modes of cultivation. Of the non-
complex glycans, F6A1/A2 did not change significantly over the batch culture. In control-fed 
perfusion (non-CO2) culture we did see an increase of 68 % over the culture period. As both 
started out with similar values for F6A1/A2 at the end of the exponential phase, by the end of 
the stationary phase, the relative % of F6A1/A2 in perfusion (non-CO2) was 57 % higher than 
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that observed in the batch. The relative % of the non-complex glycan F6A2 was 13 % higher 
in the batch culture, in comparison that observed at the end of the stationary phase in the 
control-fed perfusion culture. Based on previous studies M5 was expected to increase over 
the course of the culture period in both cultures. This was one of only 2 glycans which further 
increased in relative % over the course of the stationary phase in the control-fed perfusion 
(non-CO2) culture. Over all the relative % of this glycan was over 2-fold higher than that 
observed in the batch culture. Of the complex glycans a slightly greater increase in the 
fucosylated, single arm galactosylated glycan (F(6)A2[6]G(4)1) was observed in the control-
fed perfusion culture after the exponential growth period, in comparison to that which was 
observed in the batch culture. There was, however no significant difference in the relative % 
of the other fucosylated, single arm galactosylated glycan (F(6)A2[3]G(4)1) at the end of the 
stationary phase in both cultures. For the complex fully fucosylated and galactosylated 
glycan, F(6)A2G2, there was a greater increase in the relative % of this glycan occurred over 
the cultivation period in the control-fed perfusion (non-CO2) in comparison to the batch 
culture. This resulted in a 30 % higher relative % of this glycan in the control-fed perfusion 
(non-CO2) culture at the end of the stationary phase, in comparison to the batch culture. The 
increase in the relative % of the galactosylated but non-fucosylated glycan (A2G2) was 
greater in the control-fed perfusion (non-CO2) over the culture period in comparison to the 
batch cultures. However this did not result in a significantly greater relative % in this glycan 
between the two cultures at the end of the stationary phase due to the standard deviation 
between the triplicate samples analysed. The most complex glycan which may be present on 
IgG1 harvested from the CHO cell cultures is F(6)A2G2S1. The relative % of this glycan was 
constant throughout the culture period in the batch and control-fed perfusion (non-CO2) 
cultures. 
It can be concluded that the controlled-fed perfusion culture did behave in a similar manner 
to the batch culture, in that the same glycans were noted to both increase and decrease in both 
cultures over time. The application of the controlled-fed perfusion strategy to the 
encapsulated cells may be considered beneficial as it did result in an overall lower relative % 
of non-complex F(6)A2 and a higher relative % of complex F(6)A2[6]G(4)1 and F(6)A2G2. 
However it must be noted that a greater increase in the relative % of M5 over the culture 
period was observed in the control-fed perfusion cultures in comparison to the batch cultures. 
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6.2.3.5.2: Controlled-fed perfusion (non-CO2 incubator) -v- Controlled-fed perfusion 
(CO2 incubator) encapsulated cultures 
 The main differences in parameters between the controlled-fed perfusion (non-CO2 
incubator) and the controlled-fed perfusion (CO2 incubator) encapsulated cultures was the 
presence of a 5 % CO2 atmosphere. Both cultures were incubated at 37 °C and 100 rpm 
agitation. The main difference observed in the behaviour of cells in the two cultures which 
could influence the quality of the protein produced are in the growth rate and cell specific 
IgG1 production rate. The control-fed perfusion culture incubated in the 5 % CO2 incubator 
performed better in comparison to the other culture due to a ~50 % increased growth rate 
during the extended growth period (after day 5). However during the extended growth period, 
there was a 43 % decrease in the cell specific growth rate in the CO2 incubated culture in 
comparison to the other culture. Before the glycoform profiles of the IgG1 harvested from 
both cultures may be compared and contrasted, it is necessary to determine also if the 
cultivation of the cells in the 5 % CO2 incubator had an effect on the glycoform profile over 
time, Table 6.2.3.5.2.1. 
 
Table 6.2.3.5.2.1: Overview of the % differences noted in the relative % of glycans detected 
on rIgG1 harvested from controlled-fed perfusion cultures (CO2 incubator) at specified time 
point in the culture period. N-glycans were released from the rIgG1 samples by PNGaseF 
digestion. Samples for HILIC analysis were labeled with 5 μl of 2AB labelling solution. The 
retention time of the glycan peaks was compared with an external A-AB labelled dextran 
standard for structural elucidation by converting the retention time of the peaks into GU. 
Each IgG1 sample was analysed in duplicate with the average relative % of each glycan 
structure recorded. The results are the average of those obtained for the 3 encapsulated 
cultures performed under the control-fed perfusion strategy in the CO2 incubator. 
Glycan % difference 
between day 5-9 
% difference 
between day 9-13 
% difference 
between day 5-13 
F(6)A1/A2 + 63 % + 2.09 fold + 3.42 fold 
F(6)A2 - 21 % + 46 % + 16 % 
M5 + 2.6 fold Not significant + 2.8 fold 
F(6)A2[6]G(4)1 + 13 % - 49 % - 43 % 
F(6)A2[3]G(4)1 Not significant - 48 % - 47 % 
F(6)A2G2 + 59 % -3.2 fold - 2 fold 
A2G2 + 46 % - 2.3 fold - 38 % 
F6A2G2S1 + 31 % - 68 % - 58 % 
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The changes which are noted in the relative % of each type of glycan over the extended 
growth period in the controlled-fed perfusion (CO2) culture (days 5-9) are almost identical to 
those noted over the extended growth period in the controlled-fed perfusion (non-CO2) 
culture (days 5-8) (Table 6.3.3.5.1) with the exception of F(6)A2G2 which increased by 73 % 
in the non-CO2 culture and only by 59 % in the CO2 culture. Another difference may be noted 
is in the relative % of the fucosylated and sialyated F6A2G2S1, which was not noted to 
change at all in the non-CO2 but actually increased by 31 % during the extended growth 
period in the CO2 culture. 
The results presented in Table 6.2.3.5.2.1 above and Figure 6.2.3.5.2.1 below would suggest 
that the application of the control-fed perfusion culture in a 5 % CO2 environment did not 
influence the quality of the protein significantly differently at the end of the extended growth 
period (day 9) to that which was observed at the end of the extended growth period (day 8) in 
the non-CO2 culture. In section 6.3.3.5.1 above, it was noted that the application of the 
controlled-fed perfusion strategy to the non-CO2 incubated flasks was beneficial in that the 
relative % of more complex glycans was higher than that observed at the end of a batch 
culture under the same conditions. The same benefits are noted for the control-fed perfusion 
culture in the CO2 incubator, with the additional benefit of a higher increase in the relative % 
of the fully fucosylated and sialyated F6A2G2S1 glycan. This glycan did also increase 
throughout the extended growth period in the non-CO2 culture, however due to standard 
deviations between the triplicate cultures, the result could not be shown to be significant. 
There was no significant difference in the relative % of this F6A2G2S1 glycan between the 
two cultures at the end of the extended growth period. 
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Figure 6.2.3.5.2.1: Relative % of N-glycan forms detected on rIgG1 samples harvested from 
encapsulated cultures conducted in 1 L Erlenmeyer shake flask cultures under control-fed 
perfusion modes of cultivation in both a non-CO2 and 5 % CO2 environment. Samples were 
harvested at the end of the extended growth periods, day 8 for non-CO2 incubated cultures 
and day 9 for CO2 incubated cultures.  N-glycans were released from the rIgG1 samples by 
means of PNGaseF digestion. Samples for HILIC analysis were labelled by adding 5 μl of 
2AB labelling solution. The retention time of the glycan peaks was compared with an 
external A-AB labelled dextran standard for structural elucidation by converting the retention 
time of the peaks into GU. Each IgG1 sample was analysed in duplicate with the average 
recorded. The results are the average of the triplicate cultures (+/- STD) carried out for each 
condition tested. 
 
It was noted in Section 6.2.3.5.1 above that the majority of the changes in the relative % of 
glycans observed in the non-CO2 incubated control-fed perfusion culture occurred by the end 
of the extended growth period on day 8. In contrast to this, significantly large changes were 
noted to occur in the relative % of each glycan, with the exception of M5, over the stationary 
growth period in the CO2 incubated control-fed perfusion culture. Figure 6.2.3.5.2.2 below, 
allows for the glycoform profile present on IgG1 harvested from both control-fed perfusion 
cultures at the end of their respective stationary phases to be compared and contrasted. 
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Figure 6.2.3.5.2.2: Relative % of N-glycan forms detected on rIgG1 samples harvested from 
encapsulated cultures conducted in 1 L Erlenmeyer shake flask cultures under control-fed 
perfusion modes of cultivation in both a non-CO2 and 5 % CO2 environment. Samples were 
harvested at the end of the stationary growth periods, day 11 for non-CO2 incubated cultures 
and day 13 for CO2 incubated cultures.  N-glycans were released from the rIgG1 samples by 
means of PNGaseF digestion. Samples for HILIC analysis were labelled by adding 5 μl of 
2AB labelling solution. The retention time of the glycan peaks was compared with an 
external A-AB labelled dextran standard for structural elucidation by converting the retention 
time of the peaks into GU. Each IgG1 sample was analysed in duplicate with the average 
recorded. The results are the average of the triplicate cultures (+/- STD) carried out for each 
condition tested. 
 
For the non-complex glycans F(6)A1/A2 and F6A2 there was a 2.1 fold and 45 % increases 
respectively in the relative % of these glycans present on IgG1 in the CO2 incubated cultures, 
in comparison to the non-CO2 incubated cultures at the end of the stationary growth period. 
For the other non-complex glycan M5, there was no significant difference in the relative % of 
this glycan between the two culture conditions investigated. A dramatic decrease in the 
relative % of the complex fucosylated and single arm galactosylated glycans, F(6)A2[6]G(4)1 
and F(6)A2[3]G(4)1 ,was noted at the end of the stationary growth period in the CO2 
incubated cultures to the degree of 49 and 48 % respectively. The glycans were therefore also 
49 and 48 % lower in relative % in the CO2 incubated culture in comparison to the non-CO2 
incubated culture also. A 3.2- fold lower relative % of the complex fucosylated and double 
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galactosylated glycan F6A2G2 was observed at the end of the stationary growth period in the 
CO2 incubated culture, which resulted in 72 % lower relative % of this glycan at the end of 
the stationary phase in the CO2 incubated culture in comparison to the non-CO2 incubated 
culture. For the non-fucosylated, double galactosylated glycan A2G2, there was a 2.3- fold 
lower relative % of this glycan at the end of the stationary phase in comparison to the end of 
the extended growth period in the CO2 culture, resulting in a 55 % lower relative % of this 
glycan at the end of the stationary phase in comparison to that observed in non-CO2 cultures. 
For the sialyated glycan F(6)A2G2S1, there was a 68 % lower relative % of this glycan 
present at the end of the stationary phase in comparison to the end of the extended growth 
period for the CO2 incubated culture. In compassion to the non-CO2 incubated culture, the 
relative % of the glycan was 60 % lower  at the end of the stationary growth periods. The 
large increases in non-complex coupled with the large decreases in complex for the CO2 
incubated control-fed perfusion culture suggest that this mode of cultivation had detrimental 
effects on protein quality. They may indicate the importance of harvest time, as the losses 
become more profound over the stationary phase (day 9, 11, 13 comparison) (results not 
shown). 
 
6.3: Discussion: 
 Encapsulation of mammalian cells as a cultivation technique yielding high cell 
densities and high volumetric productivities has been extensively reported, as reviewed by 
Selimoglu, and Elibol, (2010). However the possibilities of implications on protein quality 
(glycosylation and/or aggregation) as a direct effect of cell cultivation in such microcapsule 
environments have been somewhat over looked. Any alterations in cellular growth rates 
(Butler, 2006), cell specific productivities ( Hooker et al., 1999) or cell metabolism (Nyberg 
et al., 1999) as a direct result of the growth of cells in a microcapsules environment, as 
oppose to freely in suspension has the potential to influence the relative glycoform of the 
recombinant protein being produced. As higher volumetric productivities have been noted 
when mammalian cells are cultured in microcapsules, in comparison to that of a suspension 
culture mode (Brequet et al., 2007; Zhang et al., 2007; Wen-tao et al., 2005; Sinacore et al., 
1989), there is also the possibility for concentration dependent aggregation. Previous work in 
this thesis (Chapter 5) has reported on 3.7- fold increases in maximum cell number and 
increased volumetric productivity which occurred when a CHO DP-12 cell line is cultured in 
APA microcapsules under batch cultivation conditions, in comparison to that which may be 
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noted when the cells are cultured in suspension. There was no great implication on the quality 
of the protein as a direct result of cell encapsulation. The relative % of each type of glycan 
was similar for protein harvested from both suspension and encapsulated cultures. There was 
however an increase, 2.7- fold, in the relative percentage of the non-complex, high mannose 
M5 glycan. No changes in M5 were noted over time in the suspension cultures. This could be 
indicative of a loss in complex glycan processing. However this slight increase was not 
coincided with a decrease in any of the complex glycans. It could therefore be concluded that 
the quality of the protein was not overly affected by the movement to an encapsulated mode 
of cultivation. 
The degree of colonisation of the capsules with cells noted in Chapter 5, was calculated at ~ 5 
% due to the batch nature of the culture. A feeding strategy was therefore proposed that 
would alleviate the nutrient limitations which occur in batch cultures and thus potentially 
increase the degree of colonisation of the microcapsules. Perfusion as a mode of cultivation 
yielding increased viable cell numbers and volumetric recombinant protein production in 
comparison to those usually attained in a batch culture has been extensively reported for cells 
cultivated in suspension (Hu et al., 2011; Ryll et al., 2000; Meuwly et al., 2006; Link et al., 
2004; Leelavatcharamas et al., 1999). Suspension cells are retained inside the bioreactor 
usually by means of filtration or sedimentation, as reviewed by Voisard et al., (2003). 
Perfusion modes of cultivation have however also been applied to cells 
immobilised/entrapped on or in some form of 3-D structure such as microcarriers and 
immobilised within microcapsules which protects them from the external environment and 
prevents the cells from being washed out of the cultivation vessel during the removal of 
media. Increased cell yields and volumetric productivities have also been reported for such 
applications in comparison to batch or fed-batch cultivation techniques (Kong et al., 1998; 
Lee et al., 2005; Wang et al., 2002; Goldman et al., 1998; Seifert and Philips, 1997). 
Although the overall aim of this current study was to investigate if the % colonisation of the 
capsules could be increased, the effect of the feeding strategy on all cellular activities 
(growth, productivity, metabolism and product quality) would be determined. A control-fed 
perfusion strategy was designed in which the perfusion rate would remain constant, unless a 
high accumulation of by-products (lactate or ammonia) were noted at a later stage in the 
culture. The concentration of the nutrients glucose and glutamine would be forward adjusted 
in the feed media to meet the nutrient demands of the cell numbers predicted to be present in 
the culture on the following day. Such predictions were made based on cell growth and 
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specific consumption rate data accumulated. Other control-fed perfusion cultures have been 
designed similarly in which the concentration of particular nutrients in the media are altered 
to meet the requirements of a forward predicted cell number for the following day (Jain and 
Kumar, 2008), however the perfusion rate may also have been adjusted. Yang et al., (2000), 
reported on 8- and 1.8- fold increase in maximum viable cell numbers achieved for an Sp2/0-
Ag 14 cell line when cultured under a control-fed perfusion strategy in comparison to that 
observed utilising batch and perfusion modes of cultivation respectively. Teng et al., (2011) 
reported a 3.3- fold increase in maximum viable cell number under a control-fed perfusion 
strategy in comparison to that achieved in batch cultures. Such cultures were carried out 
when cells were in suspension. The potential for a similar-control fed perfusion strategy to 
lead to increased cell yields and volumetric productivities was determined for encapsulated 
cell cultures. 
Initial studies were conducted in the same 1.7 L minifors reactor platform that was utilised 
for the batch encapsulated studies in Chapter 5. The control-fed perfusion strategy was 
applied to the culture on day 5, when glucose and glutamine concentrations were insufficient 
to support the growth of the predicted number of cells which would be present on day 6. The 
study was successful in that the cells/mlcapsules did continue to increase on a daily basis until 
day 9. The degree of colonisation at maximum cell number (cells/mlcapsule) on day 8 was 
noted to be 9.3 %. This was therefore an 86 % increase in capsule colonisation in comparison 
to batch cultures. This increased cell number per mlcapsules did not however translate into an 
overall higher yield in cells/mlreactor in comparison to the batch cultures. An instability in the 
capsules was noted in the control-fed perfusion culture, perhaps due to an increase cell 
numbers present, or the changing of media on a daily basis, which resulted in a loss of 
capsules and subsequent cell wash out as the capsules provided the only mechanism for cell 
retention in the perfusion system. Brequet et al., (2007) reported that the perfusion nature of a 
culture further reduces the stability of the already relatively fragile liquid core microcapsules. 
They reported that in a bioreactor, a combination of shearing forces and a constant 
displacement of equilibrium between the fresh perfusion medium and the microcapsules, may 
be destructive for liquid core APA microcapsules. 
The potential of this initial study for high cell density culture was limited by the capsule 
instability. It did however give an indication of cellular behaviour when cell colonisation 
inside the microcapsules is increased. There were no changes in the specific productivity of 
the cells due to increased colonisation or the application of a feeding strategy eliminating 
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nutrient limitations. The volumetric productivity was similar to that of the batch culture 
throughout the entire culture period and as there was no significant difference in 
cells/mlcapsules in the cultures, the specific productivity was not influenced. The main 
difference between the batch and control-fed perfusion cultures was a lack of depletion of 
glucose and glutamine concentrations throughout the culture period and also the removal of 
spent media thus reducing by-product accumulation. After day 5, the lactate production rate 
was noted to be slightly higher than that observed in the batch cultures, resulting in an 
increased yield of lactate on glucose by 27 % in comparison to the batch cultures. This was 
attributed to the fact that the cells were essentially over-fed with glucose as a direct result of 
the over-prediction of expected cell numbers which would be present the next day. This 
statement is verified by the fact that it has been reported that at low glucose concentrations, 
glucose is used primarily to produce anabolic precursors such as nucleotides, while at higher 
concentrations most of the glucose enters glycolysis and results in pyruvate formation, much 
of which forms lactate (Banik and Heath, 1995). The maximum lactate concentrations 
associated with batch cultures is essentially ~ 17 mM. However the concentration of lactate 
present in the control-fed perfusion culture approached ~ 40 mM by the end of the culture 
period. This concentration of lactate is not considered growth limiting for CHO (Lao and 
Toth, 1997) or other mammalian cell lines such as hybridoma cells (Zhang et al., 2004).  
The specific glutamine and ammonia consumption and production rates remained similar 
throughout the duration of the control-fed perfusion culture. The maximum concentration of 
ammonia present in the perfusion culture was similar to that of the batch cultures, 4.3 and 4.8 
mM respectively. In regards to product quality, the control-fed perfusion culture did give 
indications that the large increases in M5, ~2.8 -fold, which are observed to occur in batch 
cultures over time could be reduced. It was explained for the batch culture in Chapter 5, that 
the increase in M5 over the stationary growth period was as a direct result of a glutamine 
limitation over this time period. An evaluation of the glutamine;fructose-6-P 
amidotransferase (GFAT) network for Uradine Di Phosphate-N-acetlyhexosamines (UPD-
GNAc) synthesis (Nyberg et al., 1999) demonstrates how a limitation in glutamine results in 
decreased Glucosamine-6-phosphate and subsequently lower levels of N-Acetlyglucosamine 
1-P. This N-Acetlyglucosamine 1-P utilises uridine triphosphate (UTP), which is sensitive to 
glucose limitations, for the formation of the nucleotide sugar precursors UDP-GNAc’s. It 
may be recalled that in the batch culture a limitation in glutamine at the end of the 
exponential growth phase occurred. Glucose did not become limiting until later in the 
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stationary phase (day 7). Therefore a limitation in UDP-GNAc may have occurred in batch 
cultures due to a limitation in N-Acetylglucosamine 1-P. A depletion of UDP-GNAc prevents 
the processing of M5 into more complex glycans containing N-acetlyglucosamine (GlcNAc) 
and N-acetylgalactosamine (GalNAc) residues. The relative % of M5 is quite low in 
comparison to all other glycans in general. On a positive note, the increase in M5 over the 
batch culture period did not significantly reduce the relative % of the more complex glycans 
which are usually present at high levels. 
A 32 % increase in M5 occurred over the culture period in the control-fed perfusion culture, 
significantly lower than the 2.7-fold increase noted to have occurred in the batch cultures. 
This is due to the fact that glutamine was not depleted at any stage in the control cultures. 
The control-fed perfusion culture did also give an indication that the relative % of the 
complex fucosylated and sialyated glycan could be increased over time, due to the 
maintenance of key metabolites. There was an 80 % increase in F(6)A2G2S1 over the culture 
period in the control-fed perfusion culture. No increases in this glycan were noted over the 
batch encapsulated culture period. It must however be noted that the perfusion culture was 
only carried out once. It is therefore difficult to interpret if the increase in F(6)A2G2S1 is of 
any significance. A possible explanation for an increase in sialyation would be the presence 
of glutamine throughout the entire culture period in the control-fed perfusion culture. We 
have seen above from an evaluation of the GFAT network that glutamine is necessary for 
maintaining an intracellular concentration of UDP-GNAc’s such as, uridine-N-
acetlyglucosamine (UDPGlcNAc) and uridine-N-acetlygalactosamine (UDP-GalNAc). UDP-
GlcNAc has a role to play in sialyation as it is required for the formation of ManNac which is 
a precursor for the sialic acid transporter donor Cytidine-5′-monophospho-N-
acetylneuraminic acid (CMP-NANA) (Burleigh et al., 2011, Butler 2006) The prevalence of 
glutamine in the control-fed perfusion culture may therefore be responsible for an increase in 
sialyation over time. It must be noted however, that M5 did increase throughout the culture. 
This may be due to the fact that although UDP-GNAc were not limiting, they may have been 
utilised to some extent in the formation of ManNAc leading to increases in sialyation. 
However it is also important to be aware of the fact that it has been noted that UDP-GNAc 
are favourably used in the formation of biantennary glycans structures and that sialyation is 
considered as the last step in glycan processing and possibly more sensitive to a reduction in 
UDP-GNAc’s than the formation of biantennary structures could be (Wong et al., 2004). It 
must be noted that the increases in M5 were not of an extreme nature in the control-fed 
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perfusion culture and in this sense sialyation did increase due to the availability of UDP-
GlcNAc brought about by the lack of glutamine depletion. 
Disregarding the limitations in the microcapsules as effective retention devices for a 
perfusion system, it may be concluded that the control-fed perfusion strategy has been 
successful in allowing for enhanced capsule colonisation coupled with possible enhancements 
in product quality over time.  
 
Following the investigation of a control-fed perfusion strategy on microcapsule colonisation, 
there were two possible steps forward identified: (I) investigation of the production of 
microcapsules with increased stability properties or (II) maintain the utilisation of the APA 
microcapsules with transfer of the control-fed perfusion culture to the less harsh 1 L 
Erlenmeyer shake flask platform. Liquid core APA microcapsules are renowned for relatively 
poor stability properties. This is attributed to the removal of calcium ions from the core as a 
direct result of the final washing step with sodium citrate (typically 0.05 M). Elimination of 
this step results in what are known as semi-liquid core microcapsules. Although they provide 
space limitations for capsule colonisation, due to presence of solid alginate pieces in the core 
of the capsules, they have been noted to display enhanced strength properties for use in 
mammalian cell cultures (Brequet et al., 2007). Various authors have investigated 
mechanisms for increased liquid core APA capsule strength including: coating the capsules 
with alginate of higher molecular weight (Koch et al., 2003); increased number of PLL layers 
(Koch et al., 2003; Leick et al., 2011); higher concentrations of PLL for increased 
crosslinking with alginate for thicker membranes (Koch et al., 2003); reduced capsule sizes 
(Zhang et al., 2007); and more novel methods utilising different forms of PLL (poly-D-lysine, 
poly-L-ornithine, ε-PLL) (Castro et al., 2005; Ma et al., 2012) or the inclusion of vinyl 
monomers and a photoinitiator allows to diffuse into pre-formed calcium alginate beads 
(Wang et al., 2005). The results however have been varied in the significance of 
improvements in capsule stability over time (Castro et al., 2005). 
In order for the work to progress and for a full analysis of the effects of both increased 
colonisation and the application of a controlled-fed perfusion mode of cultivation on 
recombinant protein quality, the work progressed with option (II). As the encapsulated CHO 
DP-12 cell line had not yet been characterised under a batch mode of cultivation in a 1 L 
Erlenmeyer shake flask platform, it was first necessary to investigate the comparability of the 
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activities of encapsulated cells in the 1.7L minifors and 1 L Erlenmeyer shake flask platform. 
In this way any alterations which would occur in encapsulated cell activities after application 
of the control-fed perfusion strategy to the 1 L Erlenmeyer shake flask could be concluded to 
be as a direct effect of the application of the feeding strategy and not due to the scale down of 
the cultures. In Chapter 4, alterations in cellular activities were reported in the scale-up of 
suspension cells.  
No significant difference in cellular growth rates or maximum viable cell number attained 
(cells/mlcapsules and cells/mlreactor) were noted between encapsulated cells cultured in both 1 L 
Erlenmeyer shake flask and 1.7 L minifors reactor platforms. Cell specific production rates 
and maximum IgG1 concentrations reached were comparable between both culture platforms. 
Cell specific and volumetric rates of glucose and glutamine consumption and lactate 
production were also comparable between the two culture platforms. There was a reduction in 
the specific ammonia production rate in the 1 L Erlenmeyer shake flask platform in 
comparison to the 1.7 L minifors reactor cultures. This resulted in an overall reduced 
maximum ammonia concentration of 31 % in the 1 L Erlenmeyer shake flask cultures, which 
gave rise to a reduction in the yield of ammonia on glutamine of 35 %. As well as alterations 
in ammonia production, there were alterations in the quality of the protein harvested from the 
1 L Erlenmeyer shake flask cultures in comparison to the 1.7 L minifors reactor cultures. 
These are related to changes in the glycans occurring over time in the 1 L Erlenmeyer shake 
flask culture, as no differences were noted in the glycoform profile of IgG1 harvested from 
cultures performed at the end of the exponential phase in both platforms.  
There were changes in the relative % of 4 of 8 the glycans detected on IgG1 harvested from 1 
L Erlenmeyer shake flask cultures at the end of the exponential and stationary growth phases. 
Between the two growth phases there was a 12 % decrease in the non-complex F(6)A2 
glycan, a 42 % and 22 % increase in the relative % of the complex glycans F(6)A2[6]G(4)1 
and F(6)A2G2, respectively, and a 22 % increase in the relative % of A2G2. The only glycan 
noted to increase over time in the encapsulated cultures performed in the 1.7 L minifors 
reactor was the M5 glycan, which increased by 2.7-fold. M5 did also increase over the culture 
period in the 1L Erlenmeyer shake flask culture, however by the smaller degree of 51 %.  
The main aim of the study was not to investigate the alterations in the glycosylation profile of 
recombinant IgG1 overtime when harvested from encapsulated cultures performed in a 1 L 
Erlenmeyer shake flask. Although the findings are of interest, the study sought to determine if 
the quality of the protein harvested at the end of the culture period from encapsulated cultures 
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performed in 1 L Erlenmeyer shake flasks was comparable to that harvested from 
encapsulated cultures performed in 1.7 L Erlenmeyer shake flasks. The relative % of M5 
glycan was 39 % lower at the end of the stationary phase in 1 L Erlenmeyer shake flask 
cultures in comparison to 1.7 L minifors reactor cultures. The relative % of the glycan 
F(6)A2G2S1 was 53 % and 63 % higher in the 1 L Erlenmeyer shake flask culture at the end 
of the exponential and stationary growth phases, respectively.  
Heterogeneity studies investigating alterations in recombinant glycoprotein glycosylation 
during a cultivation period have been examined by various authors. An investigation by 
Wong et al., 2010 focused on the up- and down-regulation of 21 different glycosylation genes 
as a possible cause for reduced sialyation levels present interferon-γ (IFN-γ) over the course 
of a fed-batch culture. Various authors have investigated the impact of limiting glucose and 
glutamine concentrations on glycan heterogeneity throughout a culture period (Hooker et al., 
1995; Xie et al., 1997; (Wong et al., 2005). Cell viability and the subsequent release of 
glycosidase enzymes as a result of cell apoptosis have also been noted to be responsible for 
changes in glycan heterogeneity over a culture period (Wong 2005; Yang and Butler 2000; 
Xie et al., 1997). All of these studies report on decreases in the relative % of specific glycans 
over time in a culture. This current study has identified increases in the relative % of glycans 
over time for IgG1 harvested from encapsulated cell cultures performed in 1 L Erlenmeyer 
shake flask platforms.  
A possible reason for a lower increase of M5 over time in the 1 L Erlenmeyer shake flask 
culture in comparison to the 1.7 L minifors reactor culture are linked to the fact that in the 1 L 
Erlenmeyer shake flask encapsulated culture, glucose was not completely distinguished at the 
end of the stationary growth period. On day 8 of the culture period, the glucose concentration 
was in the range of 1.5 mM in the shake flask culture. In the encapsulated minifors reactor 
culture, all of the glucose was depleted at the end of day 7. Banik and Heath (1995) had 
stated that when glucose is limiting it may be utilised for nucleotide sugar synthesis (i.e. 
anabolic reactions as oppose to catabolism). It is therefore possible to suggest that the 
availability (low concentration) of glucose in the 1 L Erlenmeyer shake flask culture would 
have resulted in a higher intracellular pool of UTP, a precursor for the formation of UDP-
GlcNAc, which is required for the transfer of GlcNAc and GalNAc residues onto the 
emerging glycan chain on the recombinant protein.(This could not occur in the 1.7 L 
Erlenmeyer shake flask culture as the glucose was not limiting but rather depleted by day 7). 
Therefore a decreased accumulation of M5 glycan, coupled with an increasing relative % of 
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more complex glycans over time may have been attributed to the availability of glucose in the 
1 L Erlenmeyer shake flask culture right up until the culture was ceased. 
It is important to note that glutamine was limited in both the shake flask and minifors reactor 
cultures after the exponential growth period. In the GFAT network glutamine is required for 
the formation of N-Acetlyglucosamine 1-P which together with UTP forms the UDP-GNAc 
nucleotide sugars. This statement therefore assumes that the intracellular content of N-
Acetlyglucosamine 1-P was sufficient after the glutamine was depleted. It is clear that 
glutamine metabolism was of an efficient nature during the exponential growth phase, noted 
by the decrease in the specific ammonia production rate the 1 L Erlenmeyer shake flask 
culture in comparison to the 1.7 L minifors reactor culture. The increases in sialyation noted 
in the 1 L Erlenmeyer shake flask encapsulated culture and that of the 1.7 L minifors reactor 
culture may also be due to the increased levels of UDP-GNAc present in the cells cultured in 
the shake flasks due to the availability of glucose. As noted above, UDP-GlcNAc is utilised 
to some extent in the formation of ManNAc leading to increases in sialyation. The theory 
used to suggest that the prevalence of a low glucose concentration in the 1 L shake flasks in 
comparison to the 1.7 L minifors reactor cultures is responsible for lower levels of M5 glycan 
in the shake flask culture is verified by statements made in Chapter 4 in which differences in 
quality between two different scales of culture could be attributed to altered metabolism at 
these scales. 
Although alterations were noted in the glycosylation profile of IgG1 harvested from batch 
encapsulated cultures performed in 1 L Erlenmeyer shake flasks and 1.7 L minifors reactor 
cultures, the main aim of the study was to also to determine if the 1 L shake flask platform 
holds potential for increased microcapsules stability suitable for the application of a control-
fed perfusion culture and increased culture longevity. Analysis of the mechanical resistance 
data obtained from Texture Analyser analysis of capsules from both conditions did indicate 
that there was a similar decreasing trend in mechanical resistance, irrelevant of the culture 
platform used. However, the time taken for the microcapsules in 1 L Erlenmeyer shake flasks 
to reach the same low level of mechanical resistance, 0.07 g/capsule, displayed in 1.7 L 
minifors reactors was lengthened by ~ 2 days. Ideally it would have been optimal if the 
mechanical resistance of microcapsules in shake flasks did not reach such a low level at any 
stage during the culture period. However it may be hypothesised that the less harsh 
conditions provided by a shake flask may allow the capsule to maintain integrity for the 
duration of a control-fed perfusion culture. 
298 
 
 
Having compared and contrasted all encapsulated cellular activities between 1 L Erlenmeyer 
shake flask and 1.7 L minifors reactor platforms, it was then necessary to go back to the 
original aims of the work. An investigation was conducted as to whether the control-fed 
perfusion strategy could lead to increased capsule colonisation, resulting in real increases in 
viable cell number per mlvessel for encapsulated cells cultured in the 1 L Erlenmeyer shake 
flask culture. From the initial control-fed perfusion studies performed in the 1.7 L minifors 
reactor, increased capsule colonisation was possible. Control-fed perfusion cultures have 
been not been applied to cells cultured in microcapsules to the best of our knowledge. 
However studies carried out with CHO cells in suspension have noted on the beneficial 
effects of such a strategy of perfusion in relation to increased cell numbers being attained 
(Teng et al., 2011; Yang et al., 2000). The control-fed perfusion strategy was first applied to 
encapsulated cells cultured in non-vented shake flasks as this is directly comparable to the 
batch encapsulated shake flask cultures. The application of the control-fed perfusion strategy 
to these encapsulated culture, termed “control-fed perfusion non-CO2 cultures”, resulted in a 
< 2-fold increase in capsule colonisation with a capsule colonisation of  over 11 % at 
maximum viable cell density. Exponential growth at the maximum specific growth rate 
typically ceased on day 5 of an encapsulated batch culture. The increase in capsule 
colonisation noted in the control-fed perfusion non-CO2 culture was due to an extended 
growth period beyond day 5 in which the growth rate was determined to be half the value of 
the maximum growth rate observed during the exponential growth period (days 1-5). This 
extended growth period ended on day 8 and was possibly linked to a lack of aeration for these 
higher cell densities due to the unvented nature of the shake flasks. In perfusion cultures 
employing full cell retention systems it has been reported how when all other parameters are 
optimal, the only factor which may limit the cell density may be the level of dissolved 
oxygen (Hiller et al., 1993). The control-fed perfusion strategy applied in this study caused 
what are known as “pulse additions” of substrates resulting in subsequent “pulse” increases in 
metabolite concentration. Such a mode of cultivation has been noted to cause increases in the 
specific oxygen consumption rate displayed by hybridoma cells (Hiller et al., 1993). 
Increased metabolite concentrations usually result in increased TCA cycle activity and thus 
an increased oxygen uptake rate (OUR) (Banik and Heath, 1995).  The available oxygen may 
have been limited in the non-vented shake flask studies. Glucose and glutamine were not 
limiting during the point at which the extended growth period ended and a stationary growth 
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phase commenced. The fact that the cells were growing at a lower rate in the extended 
growth period than that observed in the exponential phase may indicate that there was an 
aeration limitation. The control-fed perfusion strategy did perform well in the prevention of a 
depletion of the two main metabolites over the cultivation period. 
Due to the possibility of low mass transfer of air limiting the control-fed culture, the 
experiment was repeated, in a 5 % CO2 incubator in vented shake flasks. The overall result 
was again an extended growth period from the time at which perfusion started (day 5) until 
day 9. In order to confirm that the extended growth period was due to the feeding strategy 
applied, a batch culture was later carried out in the 5 % CO2 incubator under similar 
conditions (data not shown). The results of the batch study did confirm a cessation in cell 
growth on day 5, and all growth characteristics were similar to that observed for the batch 
cultures carried out in the non-CO2 incubator. For the control-fed perfusion culture carried 
out in the CO2 incubator, the maximum exponential growth rate was maintained in the 
extended growth period and the degree of capsule colonisation was determined to be 27 %. 
The maximum viable cell density cells/mlreactor was 5- fold higher and 2.5- fold higher than 
that observed in the batch and control-fed perfusion non-CO2 cultures, respectively. Increased 
cell yields have been reported through the application of similar feeding strategies to 
mammalian cell lines. Yang et al., (2000) reported a 8- and 1.8- fold increase in maximum 
viable cell density achieved under a control-fed perfusion strategy in comparison to cells 
cultured under batch and perfusion modes for an Sp2/0-Ag 14 cell line. Increased cell yields 
brought about by increased culture longevity as oppose to increases in cellular growth rate are 
consistent with those observed by others in the application of control-fed perfusion strategies. 
Teng et al., (2011) applied a control-fed perfusion strategy to a CHO cell line culture and 
reported a 3.3- fold increase in maximum viable cell density achieved in comparison to batch 
cultures. The increased cell yield, in the study by Teng et al., (2011), was not due to an 
increase in the specific growth rate displayed by the cells. The increases in cells/mlcapsule did 
translate into cells/mlvessel with negligible capsule breakup being observed over the 12 day 
control-fed perfusion non-CO2 and 14 day control-fed perfusion CO2 culture period. The 
strength of the microcapsules was not influenced by the application of the perfusion strategy. 
Brequet et al., (2007) did report how the operation of a perfusion mode of cultivation may 
further compromise the mechanical resistance of already fragile liquid core APA 
microcapsules by the necessity for the capsules to constantly equilibrate with the fresh 
medium being added to the culture. The microcapsules did reach the low mechanical 
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resistance level (0.07 g/capsule) observed in other encapsulated studies in both minifors 
reactors and shake flasks. However, due to the less harsh shear environment of the shake 
flasks, the capsules did remain intact for the duration of the control-fed perfusion cultures in 
the 1 L Erlenmeyer shake flasks. 
The cellular growth patterns which were noted in the two control-fed perfusion cultures may 
be characterised into 4 distinct phases, as explained by Breguet et al., (2007).In the study a 
CHO cell line was cultured in APA liquid core microcapsules under a perfusion mode of 
operation. The growth of the encapsulated cells followed the pattern of (1) an exponential 
growth phase during the time period which the culture operated as a batch culture (i.e. before 
perfusion is initiated) (2) a second semi-exponential growth phase with continuous medium 
supple (3) a stationary phase (4) a death phase. This is the typical growth pattern of 
encapsulated cells under conditions of a constant perfusion rate with full retention (Gugerli, 
2003). The perfusion rate in this current control-fed perfusion study also remained constant 
over the growth periods. These observed results suggest that the fortification of the perfusion 
medium with nutrients as required by the cells did not have an effect on the growth pattern 
which is typically displayed by cells which are cultured under a constant perfusion rate with 
full cell retention. Gugerli (2003) described the advantages of using microcapsules as 
effective retention devices for a perfusion system due to the principle of space limitation. It 
was understood that if the entire capsules were to become colonised, a feasible mechanism 
for maintaining cell numbers constant and achieving steady state would essentially be 
provided. However under conditions of full cell retention maintenance of steady state is 
difficult since mammalian cells follow a grow/die cycles, especially at 37 °C. This would 
explain the rapid decline in cell numbers present after the stationary period. In order to avoid 
the negative effects of the grow/die cell cycle in a perfusion culture other studies have 
investigated coupling a biphasic approach to a perfusion culture. When the maximum viable 
cell density is achieved, the culture temperature is essentially lowered to 33 °C in order to 
slow down cell growth, apoptosis, and nutrient uptake and to reach a steady state without cell 
bleeding (Ryll et al., 2000). It has been reported that in perfusion cultures, an abrupt fall in 
CHO cell viability typically occurs, which may not be attributed to the exhaustion of any 
essential amino acid or concentration of a by-product. Altamirano and Gòdia (2001) 
investigated the addition of a concentrated perfusion medium with the hypothesis that the 
inevitable onset of cell death could be avoided. The untimely onset of cell death was not in 
this case avoided. A possible explanation could be a limitation in oxygen due to the low 
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aeration capacity of shake flask environments. Mammalian cells have relatively low demands 
for oxygen and consequently require lower specific power input, this being typically between 
1-10 Wm
-3
 (Zhang et al., 2010). However typical cell densities achieved in shake flasks are in 
the range of 2.5-4 * 10
6
 cells/ml (Muller et al., 2004) when conditions have been optimised. It 
is therefore possible that the high density cultures performed in shake flasks, both non-vented 
and vented, would have eventually become limited by a lack of air.  
In any case, when cells are grown at high specific growth rates, a limiting condition will be 
reached, which is why the biphasic approach (Ryll et al., 2000) would be a favourable step 
forward for these control-fed perfusion cultures in shake flask. When perfusion cultures are 
operated under conditions of no cell bleeding, cell viability does become a limiting factor as 
under steady state conditions the cellular growth rate will equal the cell death rate. In a 
review investigating optimal bleed rate for a processes, emphasis was placed on investigating 
the importance of cell viability on the recombinant protein production and quality. If low 
viabilities should be avoided then the bleed rate should be chosen higher (Chon and Zarbis-
Papastoitsis). 
Due to the increased cell numbers (cells/mlreactor) in the control-fed perfusion cultures, it 
would be expected that increases in volumetric productivity to the same degree would be 
achieved over the culture periods. The volumetric productivity was higher in the two control-
fed perfusion cultures than the batch culture, however not to the same degree as the cell 
numbers. Over the extended growth period, the specific production rate remained unchanged 
in the non-CO2 culture. The specific production rate was however was found to decrease by 
23 % over the extended growth period in the CO2 culture. Over the stationary growth period 
the specific productivity displayed by the cells in the control-fed perfusion (non-CO2) and 
(CO2) reduced by 36 % and 29 %, respectively, in comparison to that observed over the 
exponential growth period. The cumulative amount of IgG1 produced in these cultures at the 
end of the stationary phase in the (non-CO2) culture (day 11) and the (CO2) culture (day 13) 
was 41 % and 2.65- fold higher, respectively, than that observed at the end of the stationary 
phase in the batch cultures (day 8), indicating that overall the application of the control-fed 
perfusion strategies was successful in achieving higher recombinant protein in total. These 
increases in volumetric productivities were however lower than expected given the fact that 
there was a 2- fold higher cell number in the non-CO2 culture and a 5- fold higher cell 
number in the CO2 during the stationary phase in comparison to the maximum cell number 
achieved in the batch cultures. Studies which have previously applied control-fed perfusion 
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feeding strategies have reported on increased volumetric production of recombinant proteins. 
Yang et al., (2000) reported on an increased mAb production in the range of 10- and 2.5- fold 
higher than that observed in batch and perfusion cultures in comparison to the control-fed 
perfusion culture. Teng et al., (2011) reported on a 2.24- fold increase in volumetric 
productivity in a control-fed perfusion culture in comparison to a batch culture. It is typical 
for the concentration of a protein in a perfusion culture to remain lower than the 
concentration typically found in batch or fed-batch cultures under the same conditions (Hu et 
al., 2011). This is however due to the overflow of medium during spent medium removal. 
Ryll et al., (2000) reported protein concentrations in a CHO cell perfusion culture to be 20 to 
80 % that observed in a batch or fed-batch processes. However the overall yield of 
recombinant protein was 2- to 12-fold higher than that observed in batch of fed-batch 
processes. Seifert and Philips (1999) have reported on increases in specific protein production 
when immobilised hybridoma cells are cultured under perfusion mode of cultivation in 
comparison to a batch mode. Goldman et al., (1998) reported that for CHO cells immobilised 
on microcarriers and cultured under a perfusion mode of cultivation, specific IFN-γ 
production was double that observed in batch cultures. Wang et al., (2002) have reported an 
increased specific EPO production rate for cells cultured immobilised on microcarriers under 
a perfusion mode of cultivation in comparison to batch or continuous cultures. Increasing 
EPO specific productivity in the perfusion culture did eventually level off and become stable. 
However none of these authors have reported on a decreased specific recombinant protein 
production rate. Kong et al., (1998) is only of the only studies noted to report no alterations in 
the specific productivity between batch and perfusion cultures using CHO cells immobilised 
on microcarriers. In the discussion section in Chapter 5 it was reported how in many 
instances cell immobilisation may induce increases specific productivities in the cells due to a 
number of factors to consider; stress associated enhanced specific growth brought about by 
impurities in encapsulation polymers (Selimoglu and Elibol 2010), initial stresses brought 
about by the immobilisation procedure (Selimoglu et al., 2011), a reduced growth rate 
enhancing production stability (Yamaguchi et al., 1997), and higher local concentrations of 
growth stimulating endocrine factors, (Lee et al., 1993). Even low dissolved oxygen 
concentrations due to mass transfer limitations in microcapsules may bring about 
circumstances for enhanced specific production (Ray et al., 1990). A plausible explanation 
for the reduced specific consumption rate across the extended growth phase in the CO2 
culture and the stationary growth phase in both the CO2 and non-CO2 cultures cannot be 
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attributed solely to the increased colonisation of the microcapsules. Firstly it is generally 
assumed that increased concentrations of cells in the capsules would result in locally higher 
concentrations of autocrine factors stimulating productivity. There was also no decrease in 
the specific productivity noted when increased capsule colonisation was achieved in the 1.7 L 
minifors reactor platform through the application of the control-fed perfusion strategy. It is 
more so possible that the perfusion rate was not at a sufficient level to support both growth 
and productivity of high cell numbers/mlvessel. Commercially available cell culture media 
usually consists of over 30 essential nutrients, vitamins etc (Xie and Wang 2006). Over the 
course of the perfusion cultures it was necessary to increase the concentration of glucose to a 
level higher than that which is typically present in the medium. It is also possible that the 
concentration of other nutrients in the medium was not sufficient in the volume of medium 
used to perform the perfusion, and so cell performance at the production level was 
compromised. Meuwly et al., (2004) did see alterations in the volumetric productivity of in a 
CHO cell culture operated under a perfusion mode of cultivation in a packed bed bioreactor. 
Volumetric productivity was noted to decrease with decreasing perfusion rates. Yamaguchi et 
al., (1997) does state that the high specific productivities are simply brought about by 
adjusting the culture conditions so that they can be maintained at the optimum conditions. 
Low oxygen levels, beyond the requirements of the cells, may also a possible cause for a loss 
in specific productivity (Link et al., 2004). It was stated above how a possible aeration 
limitation was responsible for the suppressed growth rate of cells in the non-CO2 incubated 
cultures during the extended growth rate. However during this timeframe of possible limited 
aeration, the specific productivity of the cells had not yet decreased. It may therefore be 
proposed that the decrease in specific productivities initially noted was not due to a limitation 
in the level of aeration provided by the shake flask model. It is however possible that during 
the stationary phase (i.e. the period of time at which cells are at their maximum 
concentration), a limit in aeration may have eventually come into play, as the specific 
productivity of the cells did decrease again for cells cultured in both CO2 and non-CO2 
environment over the stationary growth period. It is important to point out that assumptions 
being made in relation to limited oxygen availability are based on the limitations of the shake 
flask platform to provide adequate air supply for high cell densities cultures. It is less likely 
that actual diffusional limitations inside the capsules occurred for either oxygen or 
metabolites. Gugerli, (2003) reported that for 800 μm diameter capsules, and ~ 20 % 
colonisation, no diffusion limitations of metabolites or oxygen occurs.  
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Throughout the completion of the shake flask encapsulated cultures, the spectroscopic 
method for analysis of the permeability of the microcapsules to fluorescent dextrans of 
varying molecular weight (10-500 kDa) was optimised. The study suggested that in all 3 
culture conditions, batch, control-fed perfusion non-CO2 and control-fed perfusion CO2, the 
microcapsules were permeable to dextrans of the same molecular weight of the IgG1 protein 
being produced by the cells, 150 kDa. Throughout the culture period the permeability of the 
capsules increased permitting the diffusion of the 250 kDa dextran. Towards day 9 in the 
control-fed perfusion cultures, some diffusion of the 500 kDa dextran was permitted, 
however the situation were free diffusion was possible was never reached for this dextran. 
The true molecular weight cut-off of the microcapsules was not determined; however an 
indication of the permeability of the microcapsules over time was achieved. Other have 
authors have also investigated the permeability of APA microcapsules without determining 
the true molecular weight cut-off point (Wang et al, 2005; Leick et al., 2011). Ma et al., 
(2012) investigated the permeability of such microcapsules to fluorescently labelled BSA (67 
kDA). Microcapsule permeability was correlated as the ratio of fluorescence intensity of BSA 
in microcapsules to that of the bulk solution. The principle behind such analysis is similar to 
that completed in this current work. Gugerli (2003) did however outline a method by which 
the actual value for the molecular weight cut-off point of APA microcapsules may be 
determined. In brief, the method involves incubating 1 ml of microcapsules with 1 ml of a 0.1 
% (w/v) dextran polymer standard solution (ranging molecular weights 12, 50, 80, 150 and 
270 kDA) in a 0.9 % NaCl w/v solution. An aliquot of liquid is withdrawn immediately from 
the capsule/dextran solution. A second aliquot is withdrawn following incubation with 
agitation for ~ 2 hours. Dextran concentrations in the solutions may be determined using 
HPLC analysis using an RI detector following injection onto a Shodex SB-804 HQ column. 
The maximal diffusion of dextran into the microcapsules corresponds to a decrease of 37 % 
of the initial peak height. The molecular weight cut-off of the microcapsules is defined as the 
lowest molar mass (Mn) of dextran for which diffusion was less than 5 % after 2 hours. 
In regards to cell metabolism both control-fed perfusion strategies, (non-CO2) and (CO2) 
incubated, did perform well. Glucose and glutamine were not entirely depleted at any point 
during the culture period. The concentration of metabolic by-products were maintained at 
levels consistent with that observed in the batch cultures, even though additional 
concentrations of glucose and glutamine were added, beyond levels observed in typical batch 
cultures. Some alterations in cellular metabolism did occur after perfusion was begun on day 
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5 in both the (non-CO2) and (CO2) cultures. In the non-CO2 culture, the specific glucose 
consumption rate was noted to decrease by 32 % over the extended growth period (days 5-8). 
However during this culture period, the specific lactate production rate remained unchanged 
in comparison to that observed over the exponential growth period. An unfavourable shift in 
glucose metabolism occurred over this time point resulting in an overall yield of lactate from 
glucose over the entire culture period 24 % higher than that observed in the batch culture. It 
was stated in the results section how the concentration of glucose added in the first perfusion 
was over-estimated due to a 50 % decrease in the growth rate over the extended growth 
period in comparison to the exponential growth period. The cells were essentially over-fed, 
similar to that which occurred when the control-fed perfusion strategy was applied in the 1.7 
L minifors reactor culture. Under conditions of high glucose concentration, it has been 
estimated that over 90 % of the glucose will enter glycolysis and is subsequently converted to 
lactate It has been reported that, for initial glucose concentrations at or below 0.5 mM, at 
least half of the glucose used by rat hepatoma cells was incorporated into nucleotides; but at 
higher glucose concentrations 5 mM, 90 % of the glucose was converted to lactate (Miller et 
al., 1989). An investigation as to why the specific glucose consumption rate would decrease 
in this culture may suggest that the previously assumed lack of adequate aeration due to the 
non-vented shake flasks may have inhibited entry of glucose into the TCA cycle, which 
requires oxygen (Banik and Heath, 1995). 
It was obvious that the some factor was limiting in the culture during this time point, verified 
by the reduced growth rate (-50 %) observed in this culture from days 5-8 in comparison to 
that observed during the exponential growth period. There was no significant difference in 
the specific glutamine consumption rate over the extended growth period, in comparison to 
that observed over the exponential growth period. This coupled with a decreased ammonia 
specific production rate (40 %) over the extended growth period signifies a shift to more 
efficient glutamine metabolism during this time period. The overall yield of ammonia on 
glutamine over the entire culture period was 25 % lower than that observed in batch cultures. 
It has been reported that at lower growth rates (which were observed over the extended 
growth period), significantly less ammonia may be produced per mole of glutamine 
consumed. (Hiller et al., 1993). This would account for the decreased specific ammonia 
production rate over the extended growth period in comparison to the exponential growth 
period.  
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In the (CO2) culture the specific glucose consumption rate declined by 50 % over the 
extended growth period (days 5-9) in comparison to that observed during the exponential 
phase, this is verified by the utilisation of ~ 50 % of the glucose added during perfusion on 
day 5 by day 6. This was coupled with a decrease in the specific lactate production rate by 60 
% over the extended growth period. The overall yield of lactate on glucose during the entire 
culture period was 26 % lower in the CO2 culture in comparison to that observed in the non-
CO2 culture. A decrease in glucose conversion to lactate over time has been noted to occur 
for other control-fed perfusion strategies applied to mammalian cell lines. The fact that the 
cells were also over-fed with glucose to the same extent as the non-CO2 culture, but the same 
unfavourable glucose metabolism was not noted serves to prove the point made above that 
the cells cultured in the non-CO2 incubator where limited by the lack of aeration in the 
unvented shake flask. Miller et al., (1989) reported that it is normal for hybridoma cells to see 
similar shifts in lactate specific consumption as those seen in glucose consumption after 
addition of 8.5 mM glucose in one step. There was also a decrease in the specific glutamine 
consumption rate, 60 %, over the extended growth period, in comparison to that observed 
during the exponential growth period in the CO2 culture. Similar to that observed in the non-
CO2 culture the specific ammonia production rate also decreased over the extended growth 
period. The reduction was however more profound in the CO2 culture, as it 3.6- fold decrease 
in the rate was noted. Hiller et al., (1993) reported that for CHO cells cultured in suspension 
under perfusion conditions employing total cell retention, specific glutamine and ammonia 
consumption and production rates are reduced due to a shift in glutamine metabolism 
yielding ammonia. Goldman et al., (1998) found that for CHO cells immobilised on 
microcarriers and cultivated under a perfusion conditions, the presence of a direct 
relationship between nutrient consumption and by-product production, which was noted in 
the CO2 culture, suggests a constant metabolic flux in the culture. Due to the more profound 
decrease in the specific ammonia production rate in the CO2 incubated cultures, the yield of 
ammonia on glutamine throughout the culture period was 30 % lower than that observed in 
the non-CO2 incubated cultures. For perfusion cultures using hybridoma cells, it was found 
that overall substrate metabolism became more efficient at high cell densities and low 
specific growth rates (Banik and Heath 1995). In this case, low specific growth rates were not 
present over the extended growth period, but higher cell densities were. Kong et al., (1998) 
have stated that transition to lower specific consumption and production rates does indicate 
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the movement to a stable perfusion environment with efficient nutrient metabolism. This was 
for anchorage dependent CHO cell line on microcarriers, no bleed. 
As noted above there were alterations in the growth, metabolic and production profiles for the 
encapsulated CHO DP-12 cells cultured under batch and control-fed perfusion conditions. 
Differences were noted in the same cellular activities between the control-fed perfusion 
cultures carried out in both the non-CO2 and CO2 incubators. All of such parameters had the 
possibility to alter the quality of the IgG1 protein in terms of the profile of N-linked glycan 
structures attached and also the aggregated state of the protein. 
It was noted above how there was a slight increase in complexity of the glycoform profile 
over the stationary growth period in the batch encapsulated culture, attributed to the lack of 
depletion of glucose over this growth phase, which prevents a depletion of nucleotide sugar 
donors UDP-GlcNAc at the intracellular level (Nyberg et al., 1999). The application of the 
control-fed perfusion strategy to a culture under comparable conditions (non-CO2 incubated) 
to the batch culture on day 5 resulted in increases and decreases in the relative % of glycans 
present on the IgG1 protein. Such increases and decreases were noted to occur primarily over 
the extended growth period (days 5-8), in which the cells continued to grow, but at a 50 % 
lower rate than that observed over the exponential growth period (days 1-5). The majority of 
the changes which occurred in the batch culture did so over the stationary growth period. In 
the control-fed batch culture only two glycans increased in relative % of the stationary phase, 
including M5 and F(6)A2G2. Some of the changes which did occur in the control-fed batch 
culture over time were more profound than those which occurred in the batch culture. The 
relative % of each type of glycan present on the IgG1 was compared and contrasted at the end 
of the stationary phase in the batch and control-fed perfusion cultures. It was found that the 
relative % of M5 was 2-fold higher than that observed in the batch. The complex glycan 
F(6)A2G2 was 30 % higher in the control-fed culture than the batch and the non-complex 
glycan F(6)A2 was 13 % higher in the batch culture than the control-fed perfusion culture. 
Therefore regardless of M5 increases, a further degree in complexity of the glycans was 
found in the control-fed perfusion culture in comparison to the batch. This can be associated 
with the prevented depletion of nutrients, glucose and glutamine, which are key precursors 
for nucleotide sugar donors involved in glycan chain extension (Nyberg et al., 1999). As 
reported in the study so far, M5 appears to be the glycan which increases over time in all 
encapsulated culture conditions tested. So far in this thesis, increases in M5 have been noted 
to occur to the greater extent when glucose or glutamine have been limiting. This was the 
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proposed explanation made above for the higher relative % of M5 present in 1.7 L batch 
encapsulated cultures, in comparison to that observed in the 1 L Erlenmeyer batch 
encapsulated shake flask cultures. However a lack of metabolites is not a possible explanation 
for the higher relative % of M5 present in the control-fed perfusion culture in comparison to 
the batch culture.  A possible cause for the notably higher levels of this glycan in the control-
fed perfusion cultures at the end of the stationary phase in comparison to the batch cultures (1 
L shake flask and 1.7 L minifors reactor platforms) may be associated with an increase in 
osmolality in the culture environment brought about by the addition of fresh culture media. 
For a control-fed perfusion culture, Teng et al., (2011) reported an increase in osmotic 
pressure over the course of the culture period. Pacis et al., (2011), investigated how 
increasing osmotic pressures in a cell culture environment could result in increased mannose 
levels on recombinant IgG proteins. They reported an increase in M5 levels for protein 
harvested from cultures with increasing osmolalities. IgG from 4 cell lines which typically 
has low levels of M5 were tested under increased osmolality conditions. The overall result 
was an increase in M5 as osmolality was increased. Overall though in regards to protein 
quality it must be stressed that the levels of M5 present would be considered low levels for all 
culture conditions tested (batch or control-fed perfusion). It is however important to note that 
a prolonged control-fed perfusion culture could result in higher levels of this glycan. Pacis et 
al., 2011 highlighted that the main concern regarding high mannose level, in that the 
bioactivity of a therapeutic antibody may be adversely affected. 
For the majority of cases in which the effect of a perfusion strategy on recombinant protein 
quality was investigated, an investigation of the effect the strategy may have on protein 
integrity and function was performed. Ryll et al., (2000) has reported on the effectiveness of a 
perfusion strategy in reducing proteolysis and maintaining protein integrity throughout the 
process. A similar report was made by Link et al., (2004). Werner et al., (2002) reported on 
the maintenance of protein functionality when changing from a batch to a perfusion mode of 
production. In regards to the impact of perfusion culture modes on protein glycosylation, 
Wang et al., (2002) reported no significant differences in the glycosylation pattern present on 
recombinant proteins in comparison to proteins harvested from batch culture conditions for 
CHO cells immobilised on microcarriers producing erythropoietin (EPO). Alternatively for 
an IFN-γ producing CHO cell line immobilised on microcarriers, a more complex 
glycosylation profile was achieved under a perfusion mode of cultivation in comparison to a 
batch mode (Goldman et al., 1998). They reported on a higher level of doubly galactosylated 
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glycans, similar to the findings in this current study, and increases sialyation in the perfusion 
culture in comparison to the batch culture. 
The quality of IgG harvested from the 5 % CO2 incubated culture was compared and 
contrasted to that harvested from the non-CO2 incubated culture. As noted above there were 
alterations in cellular behaviour noted between the CO2 and non-CO2 incubated control-fed 
perfusion cultures. They were notably a higher growth rate (~50 %) in the CO2 culture over 
the extended growth period (days 5-9), a lower specific production rate over the extended 
growth period, 43 %, and over the stationary growth period, of 16 %. Cellular metabolism 
was also deemed to be more favourable in the 5 % CO2 incubated culture in comparison to 
the non-CO2 incubated culture due to the lower yields of waste products on metabolites 
noted. It has been extensively reported how increased cellular growth rates may have 
negative effects on protein glycosylation, as it reduces the time in which the recombinant 
protein is exposed to the glycosyl transferase enzymes present in the endoplasmic reticulum 
(ER) and golgi apparatus (GA), as review by (Butler, 2006). Alternatively reduced specific 
protein production rates are thought to be beneficially in increasing the time the protein 
spends in the ER and GA compartments exposed to the glycosyl transferase enzymes 
(Hooker et al., 1999). Efficient glucose and glutamine metabolism is associated with overall 
good cellular metabolic performance allowing for such metabolites to be utilised for the 
production of nucleotide sugar precursors (Nyberg et al., 1999). The glycosylation of the 
IgG1 protein harvested from both the control-fed perfusion cultures was compared and 
contrasted at time points after the extended growth period, (day 8 for the non-CO2 incubated 
culture and day 9 for the CO2 incubated culture). Protein samples were also harvested at the 
end of the stationary growth phases in both cultures for comparison of protein quality, (day 
11 for non-CO2 incubated culture and day 13 for CO2 incubated culture). By the end of the 
extended growth period, the glycoform profile of IgG1 from both cultures was almost 
identical. This indicates that the alterations in growth rate, specific production rate and 
metabolic profiles did not impact on the quality of the protein harvested from both culture 
conditions investigated. The main exception was that the relative % of F(6)A2G2 which only 
increased by 59 % over the extended growth period in the CO2 culture, in comparison to the 
79 % increase observed in the non-CO2 culture. This greater increase did not however result 
in a significant difference being present in the relative % of this glycan between the two 
culture conditions at the end of the extended growth period. 
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It may therefore appear that the 5 % CO2 control-fed perfusion culture was more beneficial in 
achieving higher cell numbers, higher volumetric productivity without impacting on the 
quality of a recombinant protein. However a comparison of glycosylation profile of the IgG1 
harvested from the non-CO2 and 5 % CO2 cultures at the end of the stationary phase did 
indicate that the quality of the protein was compromised over time in the CO2 culture. As 
noted above only significantly low changes in the relative % of two glycans, M5 (+15 %) and 
F(6)A2G2 (+ 11 %), occurred over the stationary growth phase in the non-CO2 culture. It is 
common to see an increase in M5 over time. This is not considered detrimental to protein 
quality unless a subsequent decrease in the relative % of a complex glycan also occurs, which 
did not happen in this case. For the 5 % CO2 culture extreme increases in non-complex 
glycans (F(6)A1/A2, F6A2 and M5) were reported and were coincided with extreme 
decreases in complex types glycans (F(6)A2[6]G(4)1, F(6)A2[3]G(4)1, F(6)A2G2, A2G2 and 
F(6)A2G2S1). Such alterations signify the action of glycosidase enzymes which are released 
from cells brought about by cellular apoptosis. Goldman et al., (1998) reported a concomitant 
reduction in the sialic acid content of IFN-γ during the death phase. Wong et al., (2005) 
found that when culture viability decreased, the sialic acid content of the produced 
recombinant protein IFN-γ also decreased. It is also important to note that no pH control was 
utilised in these shake flask cultures. Sialadase activity is likely to increase as the pH 
decreases (Gramer and Goochee (1993)). However the same study did also report sialadase 
activity at optimal culture pH around 7. As the culture was conducted in a CO2 environment, 
the culture may have become more acidic than the non-CO2 culture resulting in enhanced 
sialidase activity. The viability of the cells was lower in the perfusion CO2 culture than that 
observed in the perfusion (non-CO2), but did still remain above 63 % on day 13. However it 
is important to note that as the total cell number was higher in the control-fed perfusion CO2 
culture, than the non-CO2 culture, the total number of dead cells releasing glycosidase 
enzymes would have been higher than present in the non-CO2 culture, even if the % viability 
was not dramatically lower in the CO2 culture. Other authors have reported on the 
effectiveness of a perfusion strategy for the removal of proteases and glycosidase which 
impact on protein quality (Ryll et al., 2000). In the case of the control-fed perfusion CO2 
culture, the perfusion rate was increased to two medium changes per day after day 9. 
However this increased rate was not sufficient to alleviate the activity of the glycosidase 
enzymes. It is well known that when a perfusion culture is operated with no bleed, cell 
viability does become a limiting factor in the process as under steady state conditions the cell 
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death rate must equal the cell growth rate eventually. When determining the ideal bleed rate 
for a given perfusion process it should first be established whether viability is an important 
parameter with respect to product quality, otherwise the bleed rate should be chosen as low as 
possible. If low viabilities are should be avoided the bleed rate should be chosen higher, 
depending on the viability desired. To obtain the highest volumetric productivity the feed rate 
should be set at such a rate that the cells are just in the non-nutrient limited range (Chon and 
Zarbis-Papastoitsis, 2011). 
 
6.4: Conclusion 
 The final chapter of the thesis did allow for the overall aim of the project to be met 
which is “High cell density CHO cultures: improved productivity and product quality”. The 
application of the control-fed perfusion strategy to encapsulated shake flask cultures 
performed in a 5 % CO2 incubator has led to ~5–fold improvements in comparison to batch 
encapsulated shake flask cultures and <10- fold improvements in comparison to batch 
suspension cultures in the  maximum viable cell density achieved (cells/mlshakeflask). Increased 
productivity has been brought about in regards to volumetric concentrations reached. The 
control-fed perfusion culture performed in the 5 % CO2 incubator brought about –2.6 fold 
increases in total IgG1 produced in comparison to that achieved for batch encapsulated 
cultures. Product quality was also improved denoted by the increases in relative % of 
complex glycans which occurred in the two control-fed perfusion cultures over the extended 
growth period, in comparison to that in the batch cultures for the entire culture period. In the 
achievement of such high quality protein titres, the aggregation of the protein was not noted 
to be affected. 
The work has highlighted the requirement for stricter control of cell viability in encapsulated 
perfusion cultures. Due to the lack of dead cell removal from the cultures, protein quality did 
become compromised over the stationary phase in the high density control-fed perfusion 
cultures performed in the 5 % CO2 incubator. Under conditions of full cell retention, using 
microcapsules, complex glycan structures present on recombinant proteins are subjected to 
glycosidase cleavage. This study has therefore outlined a limitation in the application of 
microcapsules as retention devices for perfusion cultures. Although the viability of the 
culture was noted not be particularly low (~63 %), the fact that the culture was a high density 
culture did result in a higher number of total dead cells than would have been noted over the 
stationary phase in any of the other culture conditions tested.  
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Possible solutions to the aforementioned problem would include introducing a cell bleed by 
removing capsules with spent media from the culture. This would serve to reduce the number 
of dead cells in the culture environment. However this would also compromise the high cell 
density/mlvessel achieved in these cultures. Another possible step forward could include 
lowering the seeding density by reducing the capsule inoculum volume. Such efforts may 
lead to enhanced capsule colonisation and also reduce the cells/mlreactor. The number of dead 
cells would be reduced due to the decreased cells/mlreactor in the shake flask environment. 
A much more attractive step forward would be to move the control-fed perfusion cultures 
back to the minifors reactor platform. Such platforms allow for tighter control and monitoring 
of cell numbers, viabilities and nutrient requirements as the platform facilitate the use of 
various Process Analytical Technologies (PAT) tools which enable online, continuous 
monitoring of cell growth and nutrient requirements. Should cell viabilities not however be 
enhanced through stricter control and monitoring, a second benefit of the reactor platform is 
in the feasibility it provides for the continuous addition and removal of fresh and spent media 
respectively. The residence time in which the protein (present in spent media) spend in the 
culture environment is thus reduced, reducing the overall time the protein is exposed to 
glycosidase enzymes. The minifors reactor platform model is also capable of supporting 
higher cell densities than the shake flask model due to better aeration and agitation. Shake 
flasks models are associated with low cell titre applications (2-4 * 106 cells/ml). In this study 
we have pushed the boundaries of the shake platform for cell numbers attainable.  Moving 
back to the minifors reactor platform would also alleviate any diffusional limitations 
associated with high density shake flask cultures which could have 2 benefits. There is the 
potential to enhance cell viability. Also a second limitation was noted in both of the control-
fed perfusion shake flask cultures which were the reduced specific production rate over the 
stationary phases attributed to the incapability’s of the shake flask design to support such 
high cell densities. 
A movement back to a minifors reactor platform does however require one major limitation 
to be overcome and that is the stability of the APA microcapsules. It is only in recent 
publications that efforts have been noted to be made for enhanced stability of APA 
microcapsules, and which have been discussed in this Chapter. Possibilities for enhancement 
in microcapsule strength are associated with increased poly-L-lysine concentrations, number 
of layers and also different forms of poly-L-lysine have been investigated. The quality and 
viscosity of alginate used also has potential for effecting APA microcapsule strength. 
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Microcapsule size has been noted to potential influence the mechanical resistance of APA 
microcapsules. 
Once such stability limitations have been overcome, this current work illustrates the potential 
for encapsulation as a cultivation technique to achieve high cell densities (+ 10- fold) and 
higher volumetric productivities in comparison to suspension. Mainly this work has 
demonstrated the potential for enhanced glycan complexity in such cultures once tighter 
control of cell viability, or increased perfusion rates have been achieved. 
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Chapter 7: Overall Thesis Conclusions and Outlooks 
Abbreviations 
CHO        Chinese hamster ovary 
CPP        critical process parameter 
CQA        critical quality attribute 
FDA        food and drug authority 
L-GLN       L-glutamine 
IgG1        Immunoglobulin 1 
IR        Infrared spectroscopy 
mAb        monoclonal antibody 
PAT        Process analytical technology 
STR        stirred tank reactor 
 
 A recent review by Butler and Meneses-Acosta (2012), outlined that the specific 
productivity of recombinant glycoproteins from Chinese hamster ovary (CHO) cell lines can 
be expected to be above 50 pg/cell/day giving rise to culture systems with titres of around 5 
g/L with the application of suitable culture platforms (e.g. fed-batch platforms). This is a 
substantial increase in comparison to 10 pg/cell/day noted from such cell lines a decade ago. 
Improvements in bioprocessing have seen cell numbers in a typical culture rise from an 
estimated 1 million cells/ml over a 7 day culture period to 10 million cells/ml with culture 
periods being extended to 21 days for enhanced volumetric productivity. The 
biopharmaceutical sector competes well with all other sectors in the pharmaceutical industry 
with reported sales of biologics reported at US$120 billion for 2011 and expected to reach 
$150 billion by 2015. Global sales of monoclonal antibodies (mAbs) alone are expected to 
reach US$58 billion by 2016. 
Such expected increases in the bioprocessing industry result in a persistent demand for the 
optimisation of upstream mammalian cell culture processes, with the aim of identifying 
critical process parameters (CPP’-s) affecting cell growth and productivity and subsequently 
developing effective tools to be put in place for both the monitoring and control of these 
CPP’-s. The process analytical technology (PAT) framework initiative introduced by the food 
and drugs authority (FDA) in 2001, outlines requirements for the identification of CPP’-s and 
subsequent monitoring and controlling enabling the production of recombinant proteins of 
315 
 
defined and consistent qualities. The critical quality attributes (CQA) determining the quality 
of a protein include both the glycosylated and aggregated states of the protein. Taking into 
account the constant need for increased cell and product yields, while keeping in mind the 
impact of alterations in process conditions on protein quality, the project entitled “High 
density CHO cell cultures: improved productivity and product quality” was designed. 
The project set about to firstly identify possible growth limiting substrates for the in-house 
CHP DP-12 cell line producing the recombinant protein Immunoglobulin 1 (IgG1) (Chapter 
3). The substrate of interest for the study was the amino acid L-glutamine (L-GLN). This 
amino acid and it’s by-product ammonia are considered CPP’s affecting cell growth, 
productivity and outwardly product quality. The inefficient energy metabolism of mammalian 
cells in culture is something which is known to be limiting the optimisation of upstream 
processes. A dynamic study was therefore designed allowing for the growth, metabolic 
activity, productivity and product quality over a range of L-GLN concentrations (0-12 mM) 
in small scale, 1 L Erlenmeyer shake flask studies to be determined. This initial work 
successfully identified the requirement for L-GLN in mammalian cell cultures. The absence 
of L-GLN resulted in a decreased cell yield and specific productivity rate of 45 % and 2.2- 
fold respectively in comparison to cultures containing L-GLN. The quality of the protein was 
compromised by a lack of L-GLN characterised noted by the occurrence of significantly 
higher levels of the non-complex high mannose glycan M5 and lower level of the complex 
galactosylated and sialyated glycan F(6)A2G2S1. The study identified that at a concentration 
of 4 mM L-GLN, exponential cell growth ended with the depletion of this nutrient. Although 
an increased initial L-GLN concentration of 12 mM did not enhance the culture longevity or 
maximum cell yields beyond that achieved in the 4 mM L-GLN culture, this study did 
demonstrate that the increased yield of ammonia (13 mM) over the culture period in the 12 
mM L-GLN culture did not have a negative effect on cell growth, productivity or product 
quality in comparison to the results observed for the 4 mM L-GLN culture (in which the yield 
of ammonia was ~5 mM). These results were important as at later stages in the project it was 
predicted that if higher cell densities were to be achieved, than those noted in the 4 mM L-
GLN culture, the concentration of L-GLN in the media may have to be increased in order to 
meet the specific requirements of a higher cell density. It may be argued that this work is not 
novel due to the vast amount of publications already acknowledged focusing on the effect of 
ammonia on the glycosylation or recombinant proteins. However in starting a project which 
would lead onto more novel work, i.e. identifying CPP’s in high density encapsulated 
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cultures affecting product quality, it was firstly necessary to identify our window for 
optimisation of cell growth and productivity through the manipulation of culture components. 
The vast array of literature on this subject concerning the effects of L-GLN and ammonia on 
cell behaviour does state that all of the effects of L-GLN and ammonia can be found to be 
cell line specific. Although the work was not novel in its own right, an interesting observation 
was made in the dynamic study which was conducted. In previous reports focusing on 
ammonia as a critical culture component effecting cellular activities and product quality, 
experiments were conducted by spiking cultures with high initial ammonia concentrations. A 
comparison made in this study between cellular activities in cultures in which high levels of 
ammonia accumulates and high levels of ammonia are initially present (5-15 mM), found  an 
over-estimation of the negative impact of ammonia on all cellular activities in cultures 
containing high initial ammonia concentrations in what was previously reported. For example 
there was a 50 % lower level of sialyated glycans present on protein harvested from the 15 
mM ammonia culture, in comparison to the 12 mM L-GLN culture. The study also identified 
that should ammonia later become a problem in high cell density cultures, switching to less 
ammoniagenic substrates, such as glutamate would hamper cell growth (3.25- fold decrease), 
product quality (increased accumulation of non-complex glycans) in comparison to cells 
cultured in the presence of L-GLN. 
Having completed these initial studies at small scale it was then necessary to up-scale 
cultures to a 1.7 L minifors reactor platform (Chapter 4). The previous studies were 
completed at small scale due to the ease at which efficient identification of effects of L-GLN 
and ammonia could be conducted and the feasibility of performing such a dynamic study at 
small scale platform. Upscaling was completed due to a general understanding that stirred 
tank reactor platforms allow for better aeration, agitation and also that shake flasks are 
associated with low yields and cell titres. The upscaling of 4 mM L-GLN cultures from shake 
flasks to minifors reactors had a negative effect in the movement towards achieving higher 
cell densities and productivities. The maximum cell number achieved and specific production 
rate displayed by the cells were both 27 % lower than that observed in shake flasks. In 4 mM 
L-GLN shake flasks cultures, a cessation in cell growth was noted to occur when the L-GLN 
was depleted. However in minifors reactor experiments there was a shift in cellular 
metabolism with glucose being depleted earlier on in the culture in an unfavourable 
metabolism which saw increased yields of lactate. Product quality was subsequently 
negatively affected with a 32 % decrease in the level of complex double galactosylated 
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glycans from protein harvested from 1.7 L minifors reactor cultures in comparison to shake 
flask cultures. It was identified that the cells were stressed in some way in this environment 
in comparison to the shake flask environment which does not incorporate such high levels of 
shearing mechanical agitation and aeration in comparison to a stirred tank bioreactor.  
In moving forward to achieve high density cell cultures and identify impacts of productivity 
and product quality, there were two options from this study: (I) optimise conditions in reactor 
through manipulation of process parameters such as agitation and aeration. However prior 
research surrounding the topic suggested that the results of previous investigations had 
limited success. Therefore a second option, (II), encapsulation of the cells in a gelled core 
surrounded by a shear protecting matrix of alginate-poly-L-lysine (APA), seemed to 
demonstrate much more potential. The theory of immobilisation/entrapment/encapsulation of 
cells inside of a gelled matrix was first developed with the aim of offering protection to cells, 
Encapsulation of the CHO DP-12 cell line in APA microcapsules would potentially prove 
beneficial as a step forward from Chapter 4 due to the it’s shear protecting potentials. There 
is also a second benefit of cell encapsulation which adheres to the overall title of the thesis of 
high cell density. The microcapsules environment provides a 3-D structure for the growth of 
cells in close proximity enhancing cell to cell communication and increased local 
concentrations of growth and productivity promoting autocrine factors. Almost all 
publications focusing on cell encapsulation or immobilisation are coupled with the phrase 
“High cell density” referring to a situation in which higher cell densities for cell lines may be 
achieved, greater than that which occurs in suspension. For the particular CHO DP-12 cell 
line used in this study encapsulation brought about 3.7- and 4.8- fold increases in cell and 
product yield in comparison to cells cultured in suspension in the minifors reactor platform. 
Although encapsulation of cells for enhanced growth and productivity has been reported 
previously for various mammalian cell lines, the novelty in this chapter came in the 
identification of the effect of this culture method on protein quality. With regards to the 
identification of important parameters for monitoring and controlling, altered metabolic 
profiles for glucose and glutamine were noted between the suspension and encapsulated cells. 
With regards to product quality, a more profound increase in the level of non-complex glycan 
M5 was noted to occur over the stationary phase in encapsulated cultures in comparison to 
suspension cultures. This was attributed to the increased stationary phase in encapsulated 
cultures and subsequently the increased time frame over which cells were producing protein 
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in a state of L-GLN depletion. The depletion of L-GLN as an issue was attributed to the batch 
nature of the culture. 
An step forward from the encapsulated cultures was to design a feeding strategy which would 
eliminate the problems associated with nutrient depletion in batch cultures and facilitate the 
enhanced colonisation of the microcapsule above the level reported in the batch cultures (5 
%) (Chapter 6). After an analysis of various feeding strategies, a control-fed perfusion 
strategy was designed mainly due to the benefits associated with perfusion in that the 
residence time of the protein in the reactor was reduced. Also looking forward to potential 
monitoring and control of cultures, a perfusion strategy would allow for the ease of control of 
nutrient and by-product concentrations through the addition and removal of media. 
Successful efforts were made using a control-fed perfusion strategy and colonisation was 
enhanced to 11 % and the degree of M5 was reported to be lower at the end of the control-fed 
perfusion culture than that reported for the batch culture in 1.7 L minifors reactor platforms. 
It was however also at this stage in the project that the first limitation was met, namely the 
instability of the microcapsules as cell retention devices. Loss of capsules integrity due to 
break up was noted to a degree of 58 % between days 7 and 9 in the control-fed perfusion 
cultures. Steps forward from the first study in Chapter 6 did not focus on making stronger 
capsules. The overall aim of the thesis was to promote high cell densities and to investigate 
the implications on productivity and product quality. Therefore a decision was made to take 
the encapsulated experiments back to the shake flask model, in which the characteristically 
weak capsules could possibly withstand reduced shear forces in a shake flask platform. The 
overall aim of the thesis was met with dramatic increases in cell and product yields through 
application of the control-fed perfusion strategy to encapsulated cells in shake flasks. The 
degree of colonisation in the final control-fed perfusion encapsulated study in the CO2 
incubator resulted in a degree of colonisation of 27 %. Table 7.1 below details the increased 
cell yields achieved over time scales of the experiment. Although a decrease in specific 
productivity was reported in control-fed shake flasks cultures, particularly over the stationary 
growth phase, increased volumetric product yields did increase over the timescale of the 
experiments conducted. 
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Table 7.1: Overview of enhancements in maximum viable cell number attained and degree of 
capsule colonisation over the entire timescale of the project. 
Max VCD % Capsule
Timescale (*10
6
 cells/ml) colonisation
Chapter 3 4.30 +/- 0.19
Chapter 4 3.12 +/- 0.27
Chapter 5 11 +/- 1.35 5
Chapter 6 18.5 +/- 1.33 11
Chapter 6 44.9 +/- 2.54 22.7
Control-fed
perfusion (non-CO2)
Control-fed
perfusion (CO2)
1 L Erlenmeyer shake
flask (encapsulated)
(encapsulated)
1 L Erlenmeyer shake
flask (encapsulated)
Culture mode
Batch
Batch
Batch
Culture
1 L Erlenmeyer shake
flask (suspension)
1.7 L minifors reactor
(suspension)
1.7 L minifors reactor
 
 The control-fed perfusion strategy was also noted to be beneficial in regards to protein 
quality as increases which occurred in complex glycans throughout the extended growth 
period (days 5-8/9) in the control-fed perfusion cultures, were greater than those which 
occurred in the batch cultures when encapsulated cultures were conducted in shake flasks. 
This is attributed to the constant supply of nutrients for the synthesis of nucleotide sugar 
precursors for the supply of glycan sugars. The control-fed perfusion cultures in shake flasks 
did not reduce the level of the high mannose non-complex M5 glycan in comparison to levels 
observed in the batch cultures. However it was pointed out that the relative % of M5 in 
regards to other glycans present on the protein was considered relatively low. It is something 
that would have to be monitored should the process time be extended through further 
optimisation due to the tendency to increase over time. Therefore it may be concluded that 
irrespective of M5, the control-fed perfusion encapsulated cultures did result in a higher level 
of glycan complexity by the end of the extended growth period in comparison to the batch 
cultures. 
It was however in the stationary growth period (day 9 onwards) in the control-fed perfusion 
culture in the CO2 incubator that complexity of the glycans were adversely effected by 
apparent glycosidase activity resulting in the increase in the relative % of non-complex 
glycans coupled with a similar decrease in complex glycans. A second limitation in the study 
was thereby identified. This was attributed to the ability of the capsules to allow for complete 
cell retention. In continuous cultures, the bleeding of cultures is beneficial in removing dead 
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cells from the reactor whose released enzymes pose a threat to product integrity and quality. 
Microcapsules as retention devices do not permit the bleeding of cells from a perfusion 
system. Even though the viability of the cells was similar to that of the control-fed perfusion 
culture conducted in the non-CO2 incubator during the stationary phase, the total (live + 
dead) cell number was higher in the CO2 culture and so there was a higher number of dead 
cells releasing glycosidase enzymes. A recommendation could be that that total number of 
cells in the culture be reduced by engaging in cell bleed through means of removing some 
capsules in spent media. An ideal time to engage in this activity would be at the beginning of 
the stationary phase. The number of dead cells present in the culture would be reduced over 
the stationary phase, which was a critical time point for the protein quality. This would 
however reduce the beneficial effect of increased cell density (cells/mlreactor) which was noted 
in this control-fed perfusion CO2 culture. However it was noted in this culture that the 
specific productivity did during the stationary growth phase and that both productivity and 
product quality are more favourable over the extended growth period before stationary phase 
is reached. 
A more attractive step forward however would be to return the control-fed perfusion 
encapsulated cultures to a stirred tank reactor (STR) platform. Such platforms enable the 
application of elaborative, online and continuous controlling and monitoring PAT tools which 
specialise in both cell growth and viability monitoring, through dielectric spectroscopy, and 
also nutrient concentration monitoring, through the application of Infrared spectroscopy (IR). 
As this project was completed in a shake flask, online monitoring and control of cell growth 
and viability was not possible. This project has identified the need for online monitoring of 
cell viability through PAT technology so as that product harvest time or capsule removal 
(dead cell bleeding) may be optimised in favour of product quality. The cells in the control-
fed perfusion cultures displayed the typical growth and death cycle characteristics displayed 
by mammalian cells in a fully retained perfusion environment. The use of the PAT 
technologies in a controlled larger scale STR environment would enable stricter control of the 
perfusion strategy and also the application of a strategy with continuous removal and addition 
of media, in which the concentration of nutrients may be monitored online continuously to 
meet the cellular demands. The result of such an application may extend the time period over 
which the quality of the protein is not affected by cell viability, as further metabolic 
optimisation of the cells would be enabled. It is also important to point out that the continual 
removal of spent media, which an STR facilitates, reduces the residence time of the protein in 
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the bioreactor environment. Therefore if similar losses in cell viability did occur, even with 
the application of stricter metabolic control, the timeframe for which the protein would be 
exposed to glycosidases would be dramatically reduced with continuous spent medium 
removal. An STR environment would also serve to alleviate any diffusional limitations which 
are associated with the shake flask environment, traditional used for low volumetric and low 
cell titre applications (2-4 * 10
6
 cells/ml). This project has essentially pushed the boundaries 
of the shake flask model (cell densities achieved ~ 4.5 * 10
7
 cells/mlreactor) and generated 
some promising results in regards to the possibility of not only increased cell and product 
yields but also higher product quality by means of encapsulation and designed feeding.  
Before going back to an STR model, the initial limitation in this project concerning capsule 
instability must first be addressed. There is great potential to increase capsule stability and 
this work has provided the basis for a new PhD project currently being conducted with the 
overall aim to identify possible mechanisms to either (i) enhance the stability of the 
traditional APA microcapsule and/or (ii) also to develop new microcapsules using polymers 
that have been noted for enhanced stability and biocompatibility for mammalian cell culture. 
Possible mechanisms to enhance the stability of the APA microcapsules have been outlined 
in Chapter 6 and include: 
 Smaller sized capsules: for enhanced stability (Zhang et al., 2007)  
 Movement from liquid core to gelled core: Brequet et al., (2007) reported on the 
increased strength associated with semi-liquid core alginate microcapsules. Such 
microcapsules may be formed through the elimination of the incubation in 0.05 M 
sodium citrate step. Other authors have also reported on the enhanced stability of solid 
core microcapsules in comparison to liquid core. Both solid and semi-liquid core 
microcapsules were eliminated from this current study which aimed to investigate 
high cell density. Increased colonisation may have been inhibited in these capsules 
due to space limitation due to the presence of solid alginate in the core.  
 Increasing the concentration of poly-L-lysine and incubation time: Reports have 
suggested an increased in concentration of poly-L-lysine increases capsule stability 
(Leick et al., 2011) or incubation time could enhance capsule strength and subsequent 
integrity. Brequet et al., (2007) found that smaller capsules lost resistance faster, 
however this was attributed to the fact that they were incubated for shorter time 
periods than larger ones in poly-L-lysine. 
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 Increasing the number of layers of poly-L-lysine surrounding the bead: Brequet et al., 
(2007). 
 Different types of poly-L-lysine including poly-D-lysine, poly-L-ornithine (Castro et 
al., 2005) and poly-ε-lysine (Ma et al., 2012) 
 Increasing the viscosity of alginate in the 0.03 % outer layer 
 Inclusion of calcium ions in cell culture media 
 Additional polymers (Wang et al., 2005) 
It is important to point out that at no point during this project was protein aggregation 
considered an issue. This is attributed to the fact that the APA microcapsules noted to permit 
the diffusion of the IgG1 protein. Further development of microcapsules in an effort to 
enhance stability could have an effect on the molecular weight cut-off of the microcapsule to 
a recombinant protein of interest and result in high concentrations of protein inside 
microcapsules leading to concentration induced protein aggregation. Therefore as part of 
microcapsule stability optimisation it is important that there is no trade off in the non-
aggregated production of a rIgG protein. 
The majority of the references listed above are within the last 5 years and therefore suggest 
that the application of APA microcapsules is becoming increasingly attractive, aside from the 
benefits observed in this project. The results of this project are of commercial interest. It was 
stated above that industrial cell lines are expected to grow in the range of 10 * 10
6
 cells/ml. 
This project has demonstrated the possibility to achieve an ~ 11- fold increase in cell number 
for a cell line which typically grew to 4 * 10
6
 cells/mlvessel. It is therefore feasible to suggest 
that the application of the methods used in this project to industrial cell lines could in turn 
result in cell concentrations upwards of 110 * 10
6
 cells/ml.  The fact that such achievements 
were made without the application of novel and advanced control and monitoring tools really 
does demonstrates the advantages of the cultivation methods investigated in this project. 
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Appendices 
Appendix A: Calculation of maximum shear stress exerted on cells cultured in 1.7 L 
minifors reactor (Chapter 4) 
 
Table A1: Values for all parameters of the 1.7 L minifors reactor, required for the calculation 
of maximum shear stress on cells cultured in the reactor. 
Parameter Value 
Working volume (VL) 1.2 L 
Vessel diameter (DT) 10.5 cm 
Air flowrate 0.06 L/min 
  
Impeller diameter (Di) 6.7 cm 
Impeller thickness (Ti) 0.13 mm 
Impeller width (Wi) 6.9 cm 
Agitation rate (N) 100 rpm 
  
Culture medium density (ρ) 1.005 g/ml 
Culture medium kinematic viscosity (υ) 0.0092 cm2/s 
 
Theoretical values of maximum shear stress under stirred conditions, max  (dyn/cm
2
), can be 
determined through the evaluation of Equation (A1). 
  2/1max )..(.33.5  t     (A1) 
where  denotes fluid density and v  denotes the kinematic viscosity. t  is the total energy 
dissipated per unit mass and in sparged conditions is defined by equation (2.2.2.1.2) as 
described by Fernandes-Platzgummer et al., (2014). 
  Sist         (A2) 
S is the energy dissipation rate from the sparging given by: 
gSS .        (A3) 
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where S  denotes the superfacial gas velocity (cm/s) and g is the gravitational constant (981 
cm/s
2
). S  is determined by the following equation: 
  
2
4
i
air
S
D
Q

        (A4) 
where airQ  is the air flow rate (cm
3
/min) and iD in the impeller diameter. 
For the minifors reactor experiments: airQ  = 0.06 L/min, which is 6 * 10
-5
 m
3
/min 
1 m
3
/min = 1 000 000 cm
3
/min, therefore 6 * 10
-5
 m
3
/min = 60 cm
3
/min 
2
3
)7.6(
min)/60(4
cm
cm
S

   = 
)89.44(
)/1(4
2
3
cm
scm

=0.0284 cm/s  
From above gSS .   therefore )/981(*)/0284.0(
2scmscmS  =24.32 cm
2
/s
3
 
S  is often described as W/kg which is the same as m
2
/s
3
. 
1 W/kg = 1 m
2
/s
3
 so therefore we must convert 24.32 cm
2
/s
3
 to m
2
/s
3
. 
24.32 cm
2
/s
3
 = 0.0024 m
2
/s
3
 or 0.0024 W/kg 
  εS = 24.32 cm
2
/s
3
 or 0.0024 W/kg 
iS is the energy dissipation rate from the impeller under sparged conditions given by: 
  


L
S
iS
V
P
       (A5) 
where LV is the working volume of the reactor and  is the fluid density. SP is the power 
consumption under sparged conditions and may be determined from the following equation: 
  53 iSS DNNpP       (A6) 
where N  is the agitation rate (s
-1
). SNp  is the dimensionless power number under sparged 
conditions. As described by Fernandes-Platzgummer et al., (2014), NpNpS   for air 
flowrates typically used in mammalian cell culture. The power number Np can be calculated 
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from Nagata correlations (Sen et al., 2002), as described by Fernandes-Platzgummer et al., 
(2011). 
  
4
66.03
66.03
2
1
Re.2.310
)Re.2.110(
.
Re
K
K
K
Np 







   (A7) 
where, 
  














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




 1856.0.670.14
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t
i
t
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D
D
D
W
K   (A8) 
where, 
  3102
K
K        (A9) 
  











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t
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D
D
D
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K .14.15.0.43.1
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3   (A10) 
  
42
4 75.0.5.2.41.1 


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
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


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t
i
D
W
D
D
D
W
K  (A11) 
where iW is the impeller width, tD is the vessel diameter and Re is the Reynolds number. 
  

NDi .Re
2
       (A12) 
In the equation for A12, N = 100 rpm 
100 rpm = 10.47 rads/s 
We know that 1 rads/s = 0.159155 hz 
10.47 rads/s = 1.67 hz or 1.67 s
-1
 
 
Therefore 
scm
scm
/0092.0
)67.1.()7.6(
Re
2
12 
 = 8148.51  
PN  is subsequently determined by the evaluation of 4321 ,,, andKKKK from equations A8 - 
A11 from above. 
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



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From Equation A6: 
 )/005.1.()7.6.()67.1).(11.1( 531 mlgcmsPS
 = 70147 (cm5).(s-3).(g/ml) 
 
Therefore 


L
S
iS
V
P
 = 
)/005.1).(1200(
)/).()((54.70147 35
mlgml
mlgscm 
 
   17.58IS (cm
5
).(s
-3
)/(ml) 
Therefore  17.58IS (cm
5
)(s
-3
)/(cm
3
) or 58.17 cm
2
/s
3
 
  IS  = 58.17 cm
2
/s
3
 =  0.0058 W/kg  
 
t  from equation (A2): 
 kgWkgWkgWt /0082.0/0058.0/0024.0   
 
Now the maximum shear stress can be determined 
 2/1max )..(.33.5  t       (A.1) 
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mg
  
 = 4.5 g.cm/s
2
.cm
2
                 
1 dyn = g.cm/s
2
 and so the answer becomes 
 4.5 dyn/cm
2
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Appendix B: 
Table B1: Chapter 4: Raw data for relative % of glycans present on rIgG1 harvested from 1 L Erlenmeyer shake and 1.7 L minifors reactor 
suspension cultures 
F(6)A1/A2 F6A2 M5 F(6)A2[6]G(4)1 F(6)A2[3]G(4)1 F(6)A2G2 A2G2 F6A2G2S1
1 L erlenmyer shake flask culture
End of exponential phase 2.52 +/- 0.39 50.23 +/- 0.57 0.99 +/- 0.13 31.44 +/- 0.16 8.43 +/- 0.17 5.46 +/- 0.11 0.67 +/- 0.04 0.26 +/- 0.02
End of stationary phase 4.01 +/- 0.87 50.12 +/- 1.20 1.76 +/- 0.37 29.8 +/- 0.09 8.04 +/- 0.27 5.42 +/- 0.23 0.62 +/- 0.05 0.22 +/- 0.01
1.7 L minifors reactor culture
End of exponential phase 2.93 +/- 0.51 57.64 +/- 2.72 1.28 +/- 0.17 25.72 +/- 1.71 7.67 +/- 0.57 3.77 +/- 0.53 0.72 +/- 0.1 0.25 +/- 0.02
End of stationary phase 4.18 +/- 0.39 56.74 +/- 2.77 2.15 +/- 0.70 24.55 +/- 1.54 7.44 +/- 0.66 3.71 +/- 0.45 0.96 +/- 0.1 0.27+/- 0.01  
 
Table B2: Chapter 5: Raw data for relative % of glycans present on rIgG1 harvested from 1.7 L minifors reactor suspension cultures and 1.7 L 
minifors reactor encapsulated cultures 
F(6)A1/A2 F6A2 M5 F(6)A2[6]G(4)1 F(6)A2[3]G(4)1 F(6)A2G2 A2G2 F6A2G2S1
Suspension cells
End of exponential phase 2.93 +/- 0.51 57.64 +/- 2.72 1.28 +/- 0.17 25.72 +/- 1.71 7.67 +/- 0.57 3.77 +/- 0.53 0.72 +/- 0.1 0.25 +/- 0.02
End of stationary phase 4.18 +/- 0.39 56.74 +/- 2.77 2.15 +/- 0.70 24.55 +/- 1.54 7.44 +/- 0.66 3.71 +/- 0.45 0.96 +/- 0.1 0.27+/- 0.01
Encapsulated cells
End of exponential phase 2.77 +/- 0.49 59.27 +/- 3.95 0.94 +/- 0.04 25.5 +/- 2.71 7.46 +/- 0.81 3.32 +/- 0.74 0.55 +/- 0.74 0.24 +/- 0.04
End of stationary phase 3.16 +/- 0.08 54.09 +/- 5.45 2.71 +/- 0.17 27.28 +/- 4.90 7.38 +/- 1.03 4.18 +/- 1.41 0.93 +/- 1.41 0.3 +/- 0.03  
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Table B3: Chapter 6; Results Section 6.1: Raw data for relative % of glycans present on rIgG1 harvested from 1.7 L minifors reactor 
encapsulated batch and control-fed perfusion cultures 
F(6)A1/A2 F6A2 M5 F(6)A2[6]G(4)1 F(6)A2[3]G(4)1 F(6)A2G2 A2G2 F6A2G2S1
Encapsulated cells
perfusion minifors reactor
End of exponential phase 2.75 59.73 0.91 24.27 8.25 3.44 0.47 0.18
End of stationary phase 3.27 56.92 1.2 24.56 9.16 3.87 0.69 0.34
Encapsulated cells
batch minifors reactor
End of exponential phase 2.77 +/- 0.49 59.27 +/- 3.95 0.94 +/- 0.04 25.5 +/- 2.71 7.46 +/- 0.81 3.32 +/- 0.74 0.55 +/- 0.74 0.24 +/- 0.04
End of stationary phase 3.16 +/- 0.08 54.09 +/- 5.45 2.71 +/- 0.17 27.28 +/- 4.90 7.38 +/- 1.03 4.18 +/- 1.41 0.93 +/- 1.41 0.3 +/- 0.03  
Table B4: Chapter 6; Results section 6.2: Raw data for relative % of glycans present on rIgG1 harvested from 1 L Erlenmeyer shake flask batch 
encapsulated cultures and 1.7 L minifors reactor batch encapsulated cultures 
F(6)A1/A2 F6A2 M5 F(6)A2[6]G(4)1 F(6)A2[3]G(4)1 F(6)A2G2 A2G2 F6A2G2S1
2.96 +/- 0.22 54.19 +/- 0.55 1.09 +/- 0.1 27.83 +/- 0.16 8.77 +/- 0.30 4 +/- 0.13 0.78 +/- 0.03 0.39 +/- 0.02
3.35 +/- 0.14 47.77 +/- 1.25 1.65 +/- 0.13 31.06 +/- 0.58 9.1 +/- 0.14 5.66 +/- 0.25 0.95 +/- 0.06 0.46 +/- 0.04
2.77 +/- 0.49 59.27 +/- 3.95 0.94 +/- 0.04 25.5 +/- 2.71 7.46 +/- 0.81 3.32 +/- 0.74 0.55 +/- 0.74 0.24 +/- 0.04
3.16 +/- 0.08 54.09 +/- 5.45 2.71 +/- 0.17 27.28 +/- 4.90 7.38 +/- 1.03 4.18 +/- 1.41 0.93 +/- 1.41 0.3 +/- 0.03
Encapsulated cells
End of exponential phase
End of stationary phase
batch minifors reactor
Encapsulated cells
batch shake flask
End of Exponential phase
End of Stationary phase
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Table B5(i): Chapter 6; Results Section 6.3: Raw data for relative % of glycans present on rIgG1 harvested from 1 L Erlenmeyer shake flask 
control-fed perfusion culture in non-CO2 incubator. 
F(6)A1/A2 F6A2 M5 F(6)A2[6]G(4)1 F(6)A2[3]G(4)1 F(6)A2G2 A2G2 F6A2G2S1
2.95 +/- 0.07 54.59 +/- 0.60 1.05 +/- 0.03 27.93 +/- 0.20 8.48 +/- 0.18 3.9 +/- 0.11 0.74 +/- 0.03 0.37 +/- 0.04
4.94 +/- 0.55 43.25 +/- 0.73 2.83 +/- 0.24 31.86 +/- 0.90 8.91 +/- 0.33 6.73 +/- 0.27 1.01 +/- 0.05 0.46 +/- 0.04
5.25 +/- 0.05 41.49 +/- 0.61 3.27 +/- 0.08 32.3 +/- 0.45 8.76 +/- 0.16 7.45 +/- 0.20 1.03 +/- 0.03 0.45 +/- 0.03
Perfusion encapsulated cells
shake flask (non-CO2)
Beginning of perfusion
End of increasing cell number
End of stationary phase  
Table B5(ii): Chapter 6; Results Section 6.3: Raw data for relative % of glycans present on rIgG1 harvested from 1 L Erlenmeyer shake flask 
control-fed perfusion culture in 5 % CO2 incubator. 
F(6)A1/A2 F6A2 M5 F(6)A2[6]G(4)1 F(6)A2[3]G(4)1 F(6)A2G2 A2G2 F6A2G2S1
3.32 +/- 0.17 52.58 +/- 0.48 1.27 +/- 0.07 28.61 +/- 0.29 8.92 +/- 0.14 4.20 +/- 0.15 0.74 +/- 0.04 0.36 +/- 0.03
5.42 +/- 0.22 41.42 +/- 0.69 3.3 +/- 0.11 32.43 +/- 0.57 9.21 +/- 0.10 6.66 +/- 0.24 1.08 +/- 0.05 0.47 +/- 0.03
11.35 +/- 0.47 61.33 +/- 1.09 3.50 +/- 0.16 16.42 +/- 0.62 4.75 +/- 0.22 2.05 +/- 0.13 0.46 +/- 0.04 0.15 +/- 0.02End of stationary phase 
Perfusion encapsulated cells
shake flask (CO2)
Beginning of perfusion
End of increasing cell number
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